Acute Pancreatitis by Rodrigo Sáez, Luis Ricardo
ACUTE PANCREATITIS 
 
Edited by Luis Rodrigo 
 
   
 
 
 
 
 
 
 
 
Acute Pancreatitis 
Edited by Luis Rodrigo 
 
 
Published by InTech 
Janeza Trdine 9, 51000 Rijeka, Croatia 
 
Copyright © 2011 InTech 
All chapters are Open Access distributed under the Creative Commons Attribution 3.0 
license, which allows users to download, copy and build upon published articles even for 
commercial purposes, as long as the author and publisher are properly credited, which 
ensures maximum dissemination and a wider impact of our publications. After this work 
has been published by InTech, authors have the right to republish it, in whole or part, in 
any publication of which they are the author, and to make other personal use of the 
work. Any republication, referencing or personal use of the work must explicitly identify 
the original source. 
 
As for readers, this license allows users to download, copy and build upon published 
chapters even for commercial purposes, as long as the author and publisher are properly 
credited, which ensures maximum dissemination and a wider impact of our publications. 
 
Notice 
Statements and opinions expressed in the chapters are these of the individual contributors 
and not necessarily those of the editors or publisher. No responsibility is accepted for the 
accuracy of information contained in the published chapters. The publisher assumes no 
responsibility for any damage or injury to persons or property arising out of the use of any 
materials, instructions, methods or ideas contained in the book. 
  
Publishing Process Manager Vedran Greblo 
Technical Editor Teodora Smiljanic 
Cover Designer InTech Design Team 
Image Copyright Sebastian Kaulitzki, 2011. Used under license from Shutterstock.com 
 
First published December, 2011 
Printed in Croatia 
 
A free online edition of this book is available at www.intechopen.com 
Additional hard copies can be obtained from orders@intechweb.org  
 
 
Acute Pancreatitis, Edited by Luis Rodrigo  
    p. cm.  
978-953-307-984-4  
  
free online editions of InTech 
Books and Journals can be found at
www.intechopen.com
 
 
 
 
 
 
 
Contents 
 
Preface IX 
Part 1 Etiology 1 
Chapter 1 Acute Biliary Pancreatitis 3 
Mehmet Ilhan and Halil Alıs 
Chapter 2 Acute Pancreatitis Induced by Drugs 17 
Karel Urbánek, Ilona Vinklerová, 
Ondřej Krystyník and Vlastimil Procházka 
Chapter 3 Obesity and Acute Pancreatitis 35 
Davor Štimac and Neven Franjić 
Chapter 4 Acute Pancreatitis During Pregnancy 47 
Tea Štimac and Davor Štimac 
Chapter 5 Pancreatitis in Children 55 
Alfredo Larrosa-Haro, Carmen A. Sánchez-Ramírez 
and Mariana Gómez-Nájera 
Chapter 6 Pancreatitis in Cystic Fibrosis and CFTR-Related Disorder 67 
Michael J. Coffey and Chee Y. Ooi 
Chapter 7 Diabetes or Diabetes Drugs: 
A Cause for Acute Pancreatitis 91 
Leann Olansky 
Part 2 Pathogenesis 99 
Chapter 8 Role of Peritoneal Macrophages on Local and Systemic 
Inflammatory Response in Acute Pancreatitis 101 
Marcel Cerqueira Cesar Machado 
and Ana Maria Mendonça Coelho 
Chapter 9 Molecular Biology of Acute Pancreatitis 109 
Francisco Soriano and Ester C.S. Rios 
VI Contents 
 
Chapter 10 Oxidative Stress and Antioxidative 
Status in the Acute Pancreatitis 117 
Andrzej Lewandowski, Krystyna Markocka-Mączka,  
Maciej Garbień, Dorota Diakowska and Renata Taboła 
Chapter 11 Microcirculatory Disturbances in 
the Pathogenesis of Acute Pancreatitis 141 
Dirk Uhlmann 
Part 3 Diagnosis 171 
Chapter 12 Endoscopic Retrograde 
Cholangiopancreatography-Related Acute 
Pancreatitis – Identification, Prophylaxis and Treatment 173 
Alejandro González-Ojeda, Carlos Dávalos-Cobian, 
Elizabeth Andalón-Dueñas, Mariana Chávez-Tostado, 
Arturo Espinosa-Partida and Clotilde Fuentes-Orozco 
Chapter 13 Endoscopic Retrograde Cholangiopancreatography 
(ERCP) Related Acute Pancreatitis 197 
Zoltán Döbrönte 
Chapter 14 Nutrition Assessment and 
Therapy in Acute Pancreatitis 215 
Vanessa Fuchs-Tarlovsky and Krishnan Sriram 
Part 4 Treatment 233 
Chapter 15 Changes in the Management 
of Treatment in Acute Pancreatitis Patients 235 
Juraj Bober, Jana Kaťuchová and Jozef Radoňak 
Chapter 16 Hypertriglyceride Induced Acute Pancreatitis 259 
Joshua Lebenson and Thomas Oliver 
Chapter 17 The Role of Percutaneous Drainage in 
the Treatment of Severe Acute Pancreatitis 
on the Basis of the Modified Atlanta Classification 279 
Zsolt Szentkereszty, Róbert Kotán and Péter Sápy 
 
 
 
   
 
 
 
 
 
 
Preface 
 
It is a great pleasure r to be the editor of this interesting book about Acute Pancreatitis, 
written by an international group of experts, doctors, university professors, and 
investigators, experienced in this field. 
Acute pancreatitis is one of the more commonly encountered etiologies in the 
emergency setting and its incidence is rising. Presentations range from a mildself-
limiting condition which usually responds to conservative management,to one with 
significant morbidity and mortality in its most severe forms. While clinical criteria are 
necessary to make the initial diagnosis, contrast-enhanced CT is the mainstay of 
imaging and has a vital role in assessing the extent and evolution of the disease and its 
associated complications.  
Disease severity is best predicted from a number of clinical scoring systems which can 
be applied at diagnosis in association with repeated clinical assessment, measurement 
of acute inflammatory markers, and CT. 
Establishing a biliary etiology in acute pancreatitis is clinically important because of 
the potential need for invasive treatment, such as endoscopic retrograde 
cholangiopancreatography. The etiology of acute biliary pancreatitis (ABP) is 
multifactorial and complex. Passage of small gallbladder stones or biliary sludge 
through the ampulla of vater. seems to be important in the pathogenesis of ABP. Other 
factors such as, anatomical variations associated with an increased biliopancreatic 
reflux, bile and pancreatic juice exclusion from the duodenum, and genetic factors, 
might contribute to the development of ABP. A diagnosis of a biliary etiology in acute 
pancreatitis is supported by both laboratory and imaging investigations. An increased 
serum level of alanine aminotransferase (>1.0 microkat/l) is associated with a high 
probability of gallstone pancreatitis (positive predictive value 80-90%). Confirmation 
of choledocholithiasis is most accurately obtained using endoscopic ultrasonography 
or magnetic resonance cholangiopancreatography. 
Prophylactic antibiotics are not effective in reducing the incidence of (peri)-pancreatic 
infection in patients with severe disease (or even documented necrotizing 
pancreatitis). The only rational indication for antibiotics is documented infection. 
X Preface 
 
Recurrent acute pancreatitis is a common clinical problem. Most cases of pancreatitis 
are identified by a careful history and physical examination. Despite advanced 
evaluation, the cause is not apparent in about 10% of cases. The etiology of recurrent 
acute pancreatitis appears to be multifactorial, with genetic and environmental 
influences playing a significant role. The strength of evidence for certain etiologies is 
highly variable, and natural history data is limited. Controversy exists regarding the 
most appropriate diagnostic and therapeutic approach. Recurrent acute pancreatitis 
often represents a continuum with chronic pancreatitis. 
Although most cases of acute pancreatitis are uncomplicated and resolve 
spontaneously, the presence of complications has significant prognostic importance. 
Necrosis, hemorrhage, and infection convey up to 25%, 52%, and 80% mortality, 
respectively. Other complications such as pseudocyst formation, pseudoaneurysm 
formation, or venous thrombosis, increase morbidity and mortality to a lesser degree. 
 
Luis Rodrigo PhD 
HUCA, 
Spain 
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Acute Biliary Pancreatitis 
Mehmet Ilhan and Halil Alıs 
Ministry of Health Bakırkoy, Dr Sadi Konuk Training and 
Research Hospital General Surgery, Istanbul, 
Turkey 
1. Introduction  
Acute pancreatitis is an inflammatory disease of the pancreas. The etiology and 
pathogenesis of acute pancreatitis have been intensively investigated for centuries 
worldwide. It can be initiated by several factors, including gallstones, alcohol, trauma, 
infections and hereditary factors. About 75% of pancreatitis is caused by gallstones or 
alcohol.  In this chapter we discuss the causes, diagnosis, imaging findings, therapy, and 
complications of acute biliary pancreatitis. 
2. Anatomy and physiology 
The pancreas is perhaps the most unforgiving organ in the human body, leading most 
surgeons to avoid even palpating it unless necessary. Situated deep in the center of the 
abdomen, the pancreas is surrounded by numerous important structures and major blood 
vessels. Surgeons that choose to undertake surgery on the pancreas require a thorough 
knowledge of its anatomy. However, knowledge of the relationships of the pancreas and 
surrounding structures is also critically important for all surgeons to ensure that pancreatic 
injury is avoided during surgery on other structures. 
The pancreas is a retroperitoneal organ that lies in an oblique position, sloping upward from 
the C-loop of the duodenum to the splenic hilum. In an adult, the pancreas weighs 75 to 100 
g and is about 15 to 20 cm long. The fact that the pancreas is situated so deeply in the 
abdomen and is sealed in the retroperitoneum explains the poorly localized and sometimes 
ill-defined nature with which pancreatic pathology presents.  
Surgeons typically describe the location of pathology within the pancreas in relation to four 
regions: the head, neck, body, and tail. The head of the pancreas is nestled in the C-loop of 
the duodenum and is posterior to the transverse mesocolon. 
Most of the pancreas drains through the duct of Wirsung, or main pancreatic duct, into the 
common channel formed from the bile duct and pancreatic duct. (Figure 1) The length of the 
common channel is variable. In about one third of patients, the bile duct and pancreatic duct 
remain distinct to the end of the papilla, the two ducts merge at the end of the papilla in 
another one third, and in the remaining one third, a true common channel is present for a 
distance of several millimeters. 
The main pancreatic duct is usually only 2 to 3 mm in diameter and runs midway between 
the superior and inferior borders of the pancreas, usually closer to the posterior than to the 
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anterior surface. Pressure inside the pancreatic duct is about twice that in the common bile 
duct, which is thought to prevent reflux of bile into the pancreatic duct. The main pancreatic 
duct joins with the common bile duct and empties at the ampulla of Vater or major papilla, 
which is located on the medial aspect of the second portion of the duodenum. The muscle 
fibers around the ampulla form the sphincter of Oddi, which controls the flow of pancreatic 
and biliary secretions into the duodenum. Contraction and relaxation of the sphincter is 
regulated by complex neural and hormonal factors.   
 
 
Fig. 1. Pancreas and biliary system anatomy 
The exocrine pancreas accounts for about 85% of the pancreatic mass; 10% of the gland is 
accounted for by extracellular matrix, and 4% by blood vessels and the major ducts, whereas 
only 2% of the gland is comprised of endocrine tissue.  
The pancreas secretes approximately 500 to 800 mL per day of colorless, odorless, alkaline, 
isosmotic pancreatic juice. Pancreatic juice is a combination of acinar cell and duct cell 
secretions. The acinar cells secrete amylase, proteases, and lipases, enzymes responsible for 
the digestion of all three food types: carbohydrate, protein, and fat. The acinar cells are 
pyramid-shaped, with their apices facing the lumen of the acinus. Near the apex of each cell 
are numerous enzyme-containing zymogen granules that fuse with the apical cell 
membrane. 
Pancreatic amylase is secreted in its active form and completes the digestive process already 
begun by salivary amylase. Amylase is the only pancreatic enzyme secreted in its active 
form, and it hydrolyzes starch and glycogen to glucose, maltose, maltotriose, and dextrins. 
 
Acute Biliary Pancreatitis 
 
5 
These simple sugars are transported across the brush border of the intestinal epithelial cells 
by active transport mechanisms. Gastric hydrolysis of protein yields peptides that enter the 
intestine and stimulate intestinal endocrine cells to release cholecystokinin (CCK)-releasing 
peptide, CCK, and secretin, which then stimulate the pancreas to secrete enzymes and 
bicarbonate into the intestine. 
The proteolytic enzymes are secreted as proenzymes that require activation. Trypsinogen is 
converted to its active form, trypsin, by another enzyme, enterokinase, which is produced 
by the duodenal mucosal cells. Trypsin, in turn, activates the other proteolytic enzymes. 
Trypsinogen activation within the pancreas is prevented by the presence of inhibitors that 
are also secreted by the acinar cells. Chymotrypsinogen is activated to form chymotrypsin. 
Elastase, carboxypeptidase A and B, and phospholipase are also activated by trypsin. 
Trypsin, chymotrypsin, and elastase cleave bonds between amino acids within a target 
peptide chain, and carboxypeptidase A and B cleave amino acids at the end of peptide 
chains. Individual amino acids and small dipeptides are then actively transported into the 
intestinal epithelial cells. Pancreatic lipase hydrolyzes triglycerides to 2-monoglyceride and 
fatty acid. Pancreatic lipase is secreted in an active form. Colipase is also secreted by the 
pancreas and binds to lipase, changing its molecular configuration and increasing its 
activity. Phospholipase A2 is secreted by the pancreas as a proenzyme that becomes 
activated by trypsin. Phospholipase A2 hydrolyzes phospholipids and, as with all lipases, 
requires bile salts for its action. Carboxylic ester hydrolase and cholesterol esterase 
hydrolyze neutral lipid substrates like esters of cholesterol, fat-soluble vitamins, and 
triglycerides. The hydrolyzed fat is then packaged into micelles for transport into the 
intestinal epithelial cells, where the fatty acids are reassembled and packaged inside 
chylomicrons for transport through the lymphatic system into the bloodstream. 
The centroacinar and intercalated duct cells secrete the water and electrolytes present in the 
pancreatic juice. About 40 acinar cells are arranged into a spherical unit called an acinus. 
Centroacinar cells are located near the center of the acinus and are responsible for fluid and 
electrolyte secretion. These cells contain the enzyme carbonic anhydrase, which is needed 
for bicarbonate secretion.  
The acinar cells release pancreatic enzymes from their zymogen granules into the lumen of 
the acinus, and these proteins combine with the water and bicarbonate secretions of the 
centroacinar cells. The pancreatic juice then travels into small intercalated ducts. Several 
small intercalated ducts join to form an interlobular duct. Cells in the interlobular ducts 
continue to contribute fluid and electrolytes to adjust the final concentrations of the 
pancreatic fluid. Interlobular ducts then join to form about 20 secondary ducts that empty 
into the main pancreatic duct. Destruction of the branching ductal tree from recurrent 
inflammation, scarring, and deposition of stones eventually contributes to destruction of the 
exocrine pancreas and exocrine pancreatic insufficiency. 
There are nearly 1 million islets of Langerhans in the normal adult pancreas. Alpha cells that 
secrete glucagon, Beta cells that secrete insulin, Delta cells that secrete somatostatin, Epsilon 
cells that secrete ghrelin, and PP cells that secrete PP.[1] 
3. Incidence 
Acute pancreatitis is a relatively common disease that affects about 300,000 patients per 
annum in America with a mortality of about 7%. Acute pancreatitis is mild and resolves 
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itself without serious complications in 80% of patients, but it has complications and a 
substantial mortality in up to 20% of patients despite the agressive intervention[1]. The 
incidence of alcoholic pancreatitis is higher in male, and the risk of developing acute 
pancreatitis in patients with gallstones is greater in male. However, more women develop 
this disorder since gallstones occur with increased frequency in women[2].  
4. Etiology and pathophysiology 
The pathogenesis of acute pancreatitis has not been fully understood. The general belief 
today is that pancreatitis begins with the activation of digestive enzymes inside acinar cells, 
which cause acinar cell injury. The Factors in Acute Pancreatitis can be classified as: 
Metabolic 
Alcoholism 
Hyperlipoproteinemia 
Hypercalcemia 
Drugs (e.g., thiazide diuretics) 
Genetic 
Scorpion poison 
Mechanical 
Trauma 
Gallstones 
Iatrogenic injury 
Perioperative injury 
Endoscopic procedures with dye injection 
Pancreas divisium 
Pancreatic duct obstruction( tumors, ascariasis, ampullar stenosis) 
Pancreatic duct bleeding 
Duodenal obstruction 
Vascular 
Shock 
Atheroembolism 
Vasculitis (Polyarteritis nodosa) 
Infectious 
Viral 
Mumps 
Coxsackievirus 
EBV 
HIV (Human Immunodeficiency Virus) 
Bacterial  
Mycoplasma pneumonia 
Campylobacter 
Legionella 
Parasites 
Ascaris 
Clonorchis sinensis 
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Of note, 10% to 20% of patients with acute pancreatitis have no known associated processes. 
Although this condition is currently termed idiopathic.  
The underlying reason of gallstone disease and other conditions causing acute pancreatitis is 
ductal hypertension resulting from ongoing exocrine secretion into an obstructed pancreatic 
duct. Elevated intraductal pressure, due to ongoing exocrine secretion, causes rupture of the 
smaller ductules and leakage of pancreatic juice into the parenchyma. Pancreatic tissue 
favors activation of proteases when transductal extravasation of fluid occurs.  
In the normal pancreas, the inactive digestive zymogens and the lysosomal hydrolases are 
found separately in discrete organelles. However, in response to ductal obstruction, 
hypersecretion, or a cellular insult, these two classes of substances become improperly 
colocalized in a vacuolar structure within the pancreatic acinar cell. Coalescence of zymogen 
granules with lysosome vacuoles resulting in intrapancreatic activation of proteolytic 
enzymes. Small amounts of trypsin can be countered by endogenous pancreatic trypsin 
inhibitor. However, large amounts of trypsin release can overwhelm the serological defense 
mechanism (α-1-antitrypsin and α-2-macroglobulin) and activate other enzymes resulting in 
destruction of acinar cells, local and systemic complications commonly seen in the course of 
the disease. Activation of the enzyme phospolipase A2 has important consequences like 
destruction of pulmonary surfactant that can result in ARDS and liberation of 
prostaglandins and leucotriens that may be important in the pathogenesis of the systemic 
inflammatory response which can lead to multi organ failure. More than that, inflammatory 
mediators may be used as predictors of disease severity in the near future. Also, trypsin 
activates and complements kinin, kallikrein, possibly playing a part in disseminated 
intravascular coagulation, shock, renal failure and vascular instability. [3], [4].  
5. Diagnosis 
A detailed history and careful physical examination are the first step towards making the 
diagnosis. The diagnosis of gallstone pancreatitis should be suspected if the patient has a 
prior history of biliary colic. (5], (6] Acute pancreatitis typically presents with severe upper 
abdominal pain which may radiate through to the back and be associated with nausea and 
vomiting.  
On physical examination, the patient may show tachycardia, tachypnea, hypotension, and 
hyperthermia. The temperature is usually only mildly elevated in uncomplicated 
pancreatitis. Voluntary and involuntary guarding can be seen over the epigastric region. The 
bowel sounds are decreased or absent. There are usually no palpable masses. The abdomen 
may be distended with intraperitoneal fluid. There may be pleural effusion, particularly on 
the left side. With increasing severity of disease, the intravascular fluid loss may become 
life-threatening as a result of sequestration of edematous fluid in the retroperitoneum.  
6. Biochemical markers 
Due to the destruction of acinar cells, the levels of the enzymes that they contain (e.g., 
amylase, lipase, trypsinogen, and elastase) are found elevated in the serum of most 
pancreatitis patients. Serum amylase concentration increases almost immediately with the 
onset of disease and peaks within several hours. It remains elevated for 3 to 5 days before 
returning to normal. There is no significant correlation between the magnitude of serum 
amylase elevation and severity of pancreatitis. [7,8] 
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Lipase is more specific for pancreatitis. Serum lipase has a longer half life than amylase and 
therefore tends to remain elevated for longer. 
Urinary clearance of pancreatic enzymes from the circulation increases during pancreatitis; 
therefore, urinary levels may be more sensitive than serum levels. 
Several tests can help differentiate biliary pancreatitis from other causes of pancreatitis. 
Aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl 
Transpeptidase  (GGT ), alkaline phosphatase and serum bilirubin are the so-called liver 
function tests; they should be reviewed before making a confident diagnosis. 
Several recent research studies have suggested additional markers that may have prognostic 
value, including C-reactive protein (CRP), alpha2-macroglobulin, polymorphonuclear 
neutrophil–elastase, alpha1-antitrypsin, and phospholipase A2. [9],[10] Although CRP 
measurement is commonly available, many of the others are not. Therefore, at this time, 
CRP seems to be the marker of choice in clinical settings. The measurement of IL-6 has 
recently been shown to distinguish patients with mild or severe forms of the disease. 
Another prognostic marker under evaluation is urinary–trypsinogen activation peptide 
(TAP). It has a good correlation between the severity of pancreatitis and concentrations of 
TAP in urine.  
Currently, these new markers have limited clinical availability, but there is significant 
interest in better understanding markers of immune response and pancreatic injury because 
these could be valuable tools for reliably predicting the severity of acute pancreatitis and 
supplementing imaging modalities. [10],[11],[12] 
7. Radiologic imaging 
Ultrasound: Abdominal ultrasound (US) examination is the best way to confirm the 
presence of gallstones in suspected biliary pancreatitis. It also can detect extrapancreatic 
ductal dilations and reveal pancreatic edema, swelling, and peripancreatic fluid collections. 
But abdominal ultrasonography seldom visualizes the pancreas in patients with acute 
pancreatitis due to air in the distended loops of the small bowel. [13]  (Figure 2) 
Computed Tomography Scan (CT): A CT allows identification of pancreatic edema, fluid or 
cysts, and the severity of pancreatitis to be graded, detects complications including 
development of pseudocysts, abscess, necrosis, hemorrhage, and vascular occlusion. The 
finding of gallstones and dilatation of the extra-hepatic biliary tree on cross-sectional 
abdominal imaging further support to the diagnosis of gallstone pancreatitis. [14] 
Currently the best method to stage the acute pancreatitis is CT. Specific CT findings can be 
categorized into pancreatic and peripancreatic changes. Pancreatic changes include diffuse 
or focal parenchymal enlargement, edema, or necrosis with liquefaction. Peripancreatic 
involvement includes blurring or thickening of the surrounding tissue planes. An 
approximate correlation exists between the degree of CT abnormalities and the clinical 
course and severity of acute pancreatitis. 
An early discrimination between mild edematous and severe necrotizing forms of the 
disease is of the utmost importance to provide optimal care to the patient.  CT has become 
the gold standard for detecting and assessing the severity of pancreatitis. Although clinically 
mild pancreatitis is usually associated with interstitial edema, severe pancreatitis is 
associated with necrosis. The presence of air bubbles on a CT scan is an indication of 
infected necrosis or pancreatic abscess. [15] 
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Fig. 2. Ultrasound image of the gallbladder  demonstrates multiple dependent gallstones 
(curved arrow) with acustic shadowing (straight arrows). The patient had elevated 
pancreatic enzyme levels and underwent cholecystectomy because of gallstone 
pancreatitis.  
Magnetic Resonance Cholangiopancreatography (MRCP): MRCP has been found to be as 
accurate as contrast-enhanced CT in predicting the severity of pancreatitis and identifying 
pancreatic necrosis but is less sensitive for detection of small stones.  
Endoscopic Ultrasonography: It is useful in obese patients and patients with ileus, and can 
help determine which patients with acute pancreatitis would benefit most from therapeutic 
ERCP. [16], [17] 
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Fig. 3. Acute biliary pancreatitis with a thickened pancreas and an effusion around the 
pancreatic tail and around the spleen - CT scan 
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Fig. 4. Sigmoid configuration of the main pancreatic duct with distal dilation of both main 
and dorsal ducts, suggesting the presence of an obstructive condition at the level of both 
major and minor papillae. 
ADMISSION INITIAL 48 HOURS 
Gallstone Pancreatitis   
Age > 70 yr Hct fall >10 
WBC >18,000/mm3 BUN elevation >2 mg/100 mL 
Glucose > 220 mg/100 mL Ca2+ <8 mg/100 mL 
LDH >400 IU/L Base deficit >5 mEq/L 
AST >250U/100 mL Fluid sequestration >4 L 
Nongallstone Pancreatitis   
Age >55 yr Hct fall >10 
WBC >16,000/mm3 BUN elevation >5 mg/100 mL 
Glucose >200 mg/100 mL Ca2+ <8 mg/100 mL 
LDH >350 IU/L PaO2 <55 mm Hg 
AST >250U/100 mL Base deficit >4 mEq/L 
  Fluid sequestration >6 L 
Adapted from Ranson JHC, Rifkind KM, Roses DF, et al: Prognostic signs and the role of operative 
management in acute pancreatitis. Surg Gynecol Obstet 139:69-81, 1974; and Ranson JHC: Etiological 
and prognostic factors in human acute pancreatitis: A review. Am J Gastroenterol 77:633, 1982. ( AST, 
aspartate transaminase; BUN, blood urea nitrogen; Ca2+, calcium; Hct, hematocrit; LDH, lactic 
dehydrogenase; PaO2, arterial oxygen; WBC, white blood cell count.) 
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8. Scoring systems in acute pancreatitis 
A variety of scoring systems have been proposed for accurate assessment of the severity of 
acute pancreatitis. These include the clinical scoring scales as Ranson criteria, Glasgow 
scales, simplified acute physiology (SAP), score and acute physiology and chronic health 
evaluation II (APACHE II) score. The CT severity index (CTSI) derived by Balthazar grading 
of pancreatitis and the extent of pancreatic necrosis is now widely used in describing CT 
findings of acute pancreatitis and serves as the radiological scoring system. [18] 
Ranson identified a series of prognostic signs for early identification of patients with severe 
pancreatitis. Out of these 11 objective parameters, five are measured at the time of 
admission, whereas the remaining six are measured within 48 hours of admission. 
Morbidity and mortality of the disease are directly related to the number of signs present. It 
is important to realize that Ranson's prognostic signs are best used within the initial 48 
hours of hospitalization and have not been validated for later time intervals. 
Another set of criteria often used to assess the severity of pancreatitis is the acute physiology 
and chronic health evaluation (APACHE-II) score. This grading system assesses severity on 
the basis of quantitative measures of abnormalities of multiple variables, including vital 
signs and specific laboratory parameters, coupled with the age and chronic health status of 
the patient. The main advantage of the APACHE-II scoring system is the immediate 
assessment of the severity of pancreatitis. A score of eight or more at admission is usually 
considered indicative of severe disease. APACHE II, although complicated, ensures the 
highest positive predictive value up to 69%. [19] 
The risk of severe acute pancreatitis is increased at Glasgow's or Ranson's score ≥3 in 48 
hours, APACHE II on admission ≥8, Balthazar's score ≥4.  
In 1985, Balthazar and colleagues introduced a scoring system based on radiological 
findings by means of a 5- grade scale: the presence of pancreatic and peripancreatic 
inflammation and fluid accumulation. [20].  
Grade CT findings: 
Grade A Normal pancreas 
Grade B Pancreatic enlargement 
Grade C Pancreatic inflammation and/or peripancreatic fat 
Grade D Single peripancreatic fluid collection 
Grade E Two or more fluid collections and/or retroperitoneal air. 
A correlation was shown between the grade on CT performed within 10 days of admission 
and the clinical follow-up finding, morbidity, and mortality. Therefore, CT was appreciated 
as a useful prognostic indicator for outcome in Acute pancreatitis. The study showed a 
morbidity of only 4% and no mortality in patients with Acute pancreatitis and a CT grade of 
A, B, or C. In patients with CT grade D or E, the morbidity rate was 54% and the mortality 
14%. The Balthazar radiological prognostic score was easy to assign without the need of 
contrast-enhanced CT. Unfortunately, this score did not assign any value to pancreatic 
necrosis as a prognostic parameter and did not make the distinction between Acute fluid 
collections and pseudocysts vs. post-necrotic fluid collections and walled-off pancreatic 
necrosis. With the introduction of newer CT-based scoring systems, some authors question 
the value of Balthazar’s score in predicting prognosis and severity in Acute Pancreatitis [21]. 
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9. Treatment 
Gallstones are the most common cause of acute pancreatitis worldwide. According to  the 
physical examination, radiological findings and labarotory results the etiology of the acute 
pancreatitis is diagnosed as biliary or non-biliary. The most important initial treatment of 
biliary pancreatitis is conservative intensive care with the goals of oral food and fluid 
restriction, replacement of fluids and electrolytes parenterally as assessed by central venous 
pressure and urinary excretion, and control of pain. [22], [23] 
After stabilizing the patient, specific treatment and timing of the intervention have to be 
planned. The issue of when to intervene for clearance of gallstones is controversial. General 
consensus is either urgent intervention (cholecystectomy) within the first 48 to 72 hours of 
admission, or briefly delayed intervention (after 72 hours, but during the initial 
hospitalization) to give an inflamed pancreas time to recover. Cholecystectomy and 
common duct clearance is the best treatment of biliary acute pancreatitis. Patients who have 
persistent impacted stone in the distal common bile duct or ampulla should have 
confirmation by radiologic imaging (CT, magnetic resonance cholangiopancreatography, or 
endoscopic ultrasonography) before intervention. If common duct stone are diagnosed, 
stones are cleared and endoscopic sphincterotomy is done by ERCP  and then laparoscopic 
cholecystectomy is performed.[24] 
Routine ERCP for examination of the bile duct is discouraged in cases of biliary pancreatitis, 
as the probability of finding residual stones is low, and the risk of ERCP-induced 
pancreatitis is significant. But in the case of acute biliary pancreatitis in which analytical 
studies suggest that the obstruction persists after 24 hours of observation, emergency ERCP 
has to be done to prevent biliary sepsis. 
Although ERCP with Endoscopic Sphincterotomy (ES) and stone extraction has been shown 
to be useful for early treatment of severe biliary pancreatitis, the incidence of bile duct 
stones at elective surgery is low and most of these ERCP are unnecessary. For this reason 
accurate predictors of common bile duct stones are required; studies have shown that the 
sensitivity of preoperative abdominal US for predicting common bile duct stones is 42% and 
specificity is 86% [25]. Furthermore, an endoscopic approach is unable to fully resolve the 
patient’s biliary pathology with one procedure and one anesthesia. This adds substantial 
risk of morbidity and even mortality. Concern remains also regarding the potential long-
term risks of ES. Although the immediate complications of ES are well documented, the 
long-term effects are less defined. Stricture formation and stone recurrence account for 
nearly all longterm complications. Although most of the authors prefer the endoscopic to 
the surgical treatment of CBD stones, there is still some minor discussion on it[26]. 
Timing of laparoscopic surgery in acute biliary pancreatitis depends upon the severity of the 
disease. In the case of mild pancreatitis it doesn’t matter when, within 1 week, laparoscopic 
cholecystectomy is performed. However, in patients with severe pancreatitis, laparoscopic 
cholecystectomy, when performed within the 1st week after the onset of symptoms, as other 
authors have observed [27], places patients at increased risk of operative morbidity and 
technical complications. In these patients, the management of complications of pancreatitis 
is strongly advisable before cholecystectomy. 
Delaying surgery for more than a week after hospitalization, in our experience, does not 
adversely affect technical difficulty. Delaying surgery for several weeks in severe acute 
pancreatitis allows acute inflammation to settle down and might allow stones in the 
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common bile duct to clear spontaneously. However, studies showed that approximately 
one-quarter of patients have symptomatic recurrence within 6 weeks if gallstones are 
untreated, and it increases with time [28], [29] 
Cholangiogram of good quality during laparoscopic cholecystectomy, since the risk of 
common bile duct stones is 14–20% . [30] This strategy minimizes the need for common bile duct 
exploration and still achieves the goal of a limited hospital stay and the prevention of 
recurrence of pancreatitis. If common bile duct stones are found at cholangiogram they should 
be treated laparoscopically if at all possible. In most instances, it should be possible to retrieve 
the stones via the cystic duct, since acute pancreatitis is usually caused by the migration of 
small stones. If this is not feasible, one alternative is to perform a laparoscopic 
choledochotomy. These cases have a rather long hospital stay and delayed return to work, but 
their level of  pain is diminished. Our current impression is that this procedure is possible 
though technically demanding. In case of failure, traditional  exploration is mandatory. 
In severe acute pancreatitis, or when signs of infection are present, most experts recommend 
broad-spectrum antibiotics (e.g., imipenem) and careful surveillance for complications of the 
disease. 
10. Complications of acute pancreatitis 
Acute pancreatitis complications may be divided as systemic and local. Pancreatic 
phlegmon, pancreatic abscess, pancreatic pseudocyst, pancreatic ascites and involvement of 
adjacent organs, with hemorrhage, thrombosis, bowel infarction, obstructive jaundice, 
fistula formation, or mechanical obstruction are local complications. Systemic complications 
are classified as hematologic (Hemoconcentration, Disseminated intravascular 
coagulopathy), cardiovascular (Hypotension, Hypovolemia, Sudden death, Nonspecific ST-
T wave changes, Pericardial effusion), pulmonary (Pneumonia, atelectasis, Acute respiratory 
distress syndrome, Pleural effusion), renal (Oliguria, Azotemia, renal artery/vein 
thrombosis), metabolic (Hyperglycemia, Hypocalcemia, Hypertriglyceridemia, 
Encephalopathy, Sudden blindness (Purtscher's retinopathy), central nervous system 
(Psychosis, Fat emboli, Alcohol withdrawal syndrome), gastro intestinal system (Peptic 
ulcer, Erosive gastritis, Portal vein or splenic vein thrombosis with varices) 
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1. Introduction 
Drug-induced acute pancreatitis (DIP) is generally considered to be a rare disease. Indeed, 
the incidence of cases caused by medication use is much lower than of those caused by 
biliary disorder or alcohol. On the other hand, the total incidence of acute pancreatitis in 
developed countries continues to rise as does the exposition of general population to 
medication. The disease was almost unknown before the 1960s. Probably the first two cases 
were reported in the late 1950s: by Zion et al. in 1955 and Johnston & Cornish in 1959. From 
that time, the number of reported cases has increased steadily until these days. A further 
increase in the incidence of drug-induced acute pancreatitis may be expected and seems to 
be actually present in recent scientific papers on the topic. 
For a proper understanding of the disease, we must regard it not simply as one of many 
other types of acute pancreatitis, but primarily as an adverse drug reaction (ADR). A recent 
definition describes an ADR as “an appreciably harmful or unpleasant reaction, resulting 
from an intervention related to the use of a medicinal product, which predicts hazard from 
future administration and warrants prevention or specific treatment, or alteration of the 
dosage regimen, or withdrawal of the product” (Edwards & Aronson, 2000).  
 
Type of 
ADR 
Mnemonic Dose dependence / 
Predictability 
Characteristics 
A Augmented Dose-related, predictable Most usual; frequent 
B Bizarre Dose-unrelated, 
unpredictable 
Immunity-mediated reactions or 
idiosyncrasies; rare 
C Continuous Related to a cumulative 
dose and time 
Effect of chronic use, late toxicity 
D Delayed Related to time Long time from drug cessation 
E End of use Related to drug 
withdrawal 
Immediately after withdrawal 
Table 1. Types of adverse drug reactions 
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The vast majority of the reported DIP cases seem to have an idiosyncratic character (see 
Table 1). This also means that it is nearly impossible to obtain sufficiently large cohorts with 
similar patient characteristics. From that point of view, every case of drug-induced 
pancreatitis should be documented as well as possible, and also reported to a 
pharmacovigilance system for further evaluation. 
2. Epidemiology 
It is usually estimated that drug use accounts for 2% of all the causes of acute pancreatitis. It 
must be pointed out that the diagnosis might be underestimated, particularly for the 
difficulties in diagnosing this etiology. The overall incidence varies in different studies from 
0.1 to 2% with a tendency to increase over time (Balani et al, 2008).  
There are three sources of information on the DIP incidence: data from clinical studies on 
acute pancreatitis, individual or serial case reports published in medical journals, and data 
on spontaneous reports from pharmacovigilance databases. Another possible source – data 
from clinical testing of new drugs – is not very useful because of an idiosyncratic character 
of DIP. The B-type of adverse drug reactions occurs with a frequency lower than 1:10,000, so 
their record in the first three phases of clinical drug investigation is almost impossible. 
The number of cases reported to pharmacovigilance databases and of published case reports 
is increasing so rapidly that any number will be obsolete by the time it manages to be 
printed. According to Lancashire et al., the WHO database of ADRs listed 2,479 episodes 
suspected of being caused by 529 different drugs from 1968 to 1993. An analysis of the DIP 
cases reported to the Danish Committee on Adverse Drug Reactions from 1968 to 1999 
(Andersen et al., 2001) showed an increasing number of reports in time and a predominance 
of women, but estimating the proportion of DIP in total acute pancreatitis incidence is 
clearly improper. The mortality of 9% among the cases analyzed shows a tendency to report 
the most severe cases, whilst the majority of mild-to-moderate cases remain unreported. On 
the other hand, an information bias, due to more frequent notification of a drug already 
known to cause a specific ADR, is limiting the validity of spontaneous reporting. A Medline 
search of the English literature revealed 1,214 case reports with 120 suspected drugs 
between 1955 and 2006 (Badalov et al., 2007). The weakness of estimating DIP incidence 
from these sources is in preferential publication of the case reports describing ADRs of new 
– therefore more “attractive” – agents rather than of older ones in which the risk is 
considered to be well-known. 
In a multicenter study by Gullo et al., published 2002, in which the etiology and mortality of 
acute pancreatitis were studied, the proportion of drug injury was almost negligible: only 
0.2% (2 patients) out of 1,068 cases. It is worth noting that three out of the seven centers 
involved in this study (providing 581 AP cases for the study) were surgical departments; 
moreover, 139 (13%) cases of acute pancreatitis in this study were classified as idiopathic. 
We believe that the incidence of DIP in this study may be somewhat underestimated. As 
will be discussed below, establishing the diagnosis of DIP often requires a re-evaluation and 
knowledge of the patient's post-episode history. 
On the other hand, at least two published studies showed a significantly higher incidence of 
DIP in retrospective analysis. A study by Mennecier et al., published 2007, found an 
incidence of drug-induced cases of 8.3 % among a total of 108 acute pancreatitis cases 
hospitalized in hepatogastroenterology and intensive care units of a French hospital over a 
9-year period. Our study, published in 2010, included 170 acute pancreatitis cases 
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hospitalized in a tertiary hospital during a period of two years. The proportion of DIP in this 
cohort was 5.3% (Vinklerová et al., 2010). Obviously, the incidence found in these studies is 
higher than in the general population. If DIP occurrence depends on the use of specific 
drugs, in tertiary hospitals as centers for the treatment of specific diseases (e.g. Crohn's 
disease or malignancies) it must be higher.  
The discrepancy in the published results demonstrates, in particular, the fact that the 
importance of drug-induced pancreatic injury will be different in the general population 
than among the cases reported in surgical or medical departments. It is also clearly 
improper to suppose that this disease can have similar incidence in all countries because of 
its dependence on the consumption of causative drugs and, secondarily, the dependence on 
the incidence of diseases treated with these medications. 
Studies with very low report of DIP are usually characterized by a high number of 
idiopathic acute pancreatitis cases. Clinicians sometimes forget that there is no such thing as 
an “idiopathic” disease. The word “idiopathic” means that we are not able to establish the 
actual cause of the disease – and a not insignificant number of idiopathic cases of acute 
pancreatitis might be caused by xenobiotics, including medication. The only way how to 
determine the real incidence of drug-induced acute pancreatitis is to perform prospective 
multicenter studies targeted at the etiology of non-alcoholic, non-biliary acute pancreatitis. 
3. Etiology 
The pathogenesis of acute pancreatitis is probably very uniform differing only by the initial 
injury mechanism. It consists of three steps: (i) premature activation of trypsin in acinar 
cells; (ii) intrapancreatic inflammation; and (iii) extrapancreatic inflammation (Banks & 
Freeman, 2006).  The mechanisms by which drugs initiate a cascade of damaging events 
remain shrouded in mystery. However, it should be borne in mind that the same is true for 
the vast majority of responses independent of drug dose. 
3.1 Mechanisms of injury 
Mechanism of medication's action against pancreas remains unknown. Two possible 
mechanisms of pancreatic injury caused by drugs are usually recognized, but in our 
opinion, at least three more possible mechanisms should be also mentioned: 
a. Direct toxic effect on pancreatic tissue; 
b. Idiosyncratic reaction; 
c. Influence of medication on the bile flow; 
d. Amplification of direct toxic effect of ethanol on pancreatic tissue; 
e. Secondary pancreatic damage. 
Simple direct toxic injury of pancreatic tissue, similar to the hepatic injury caused by some 
drugs or their metabolites (e.g. paracetamol), seems very unlikely in the majority of reported 
DIP cases. This (A-type) pattern of ADR is dose-dependent, irrespective of the patient's 
response, reproducible and usually occurs in much higher numbers than usual in DIP. 
Although acute pancreatitis sometimes develops under the condition of an overdose of 
some drugs, its incidence remains so rare that an underlying predisposition must play a role 
in these cases. Genetic differences in metabolism are usually supposed to be the most 
probable predisposing factor here. Only several drugs are reported as causing DIP by 
overdose: paracetamol (or acetaminophen), erythromycin and carbamazepine. We had an 
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opportunity to describe DIP in a patient overdosed on mycophenolate (Vinklerová et al., 
2001). Some kind of cumulative dose-dependent effect of toxic metabolites is also sometimes 
hypothesized in drugs showing a consistent long latency (more than 30 days) at the onset of 
the first episode of DIP. It is supposed mainly in valproate, but possibly also in didanosine, 
tamoxifen, chlorothiazide and estrogens. This would correspond to the C-type (continuous) 
of ADR, but other mechanisms can also explain the late onset of DIP in these agents. 
The definition of an idiosyncratic adverse drug reaction (B-type) best matches the actual 
characteristics of DIP. A strong correlation with some immune disorders (mainly Crohn's 
disease and HIV infections) implicates an immune-mediated reaction as a chief causative 
factor of the disease. Often, the latency between initiation of the drug and the onset of DIP is 
one week to one month, but later rechallenge led to a second episode in one to three days. 
The frequently mentioned lack of hypersensitivity symptoms (rash, fever, 
lymphadenopathy and eosinophilia) is of no major importance as it is rare in the majority of 
immune-mediated organ damage and cannot be considered pathognomic. An immune-
mediated process is undoubtedly the pathogenetic nature of many rare ADRs also 
connected with the drugs mentioned here, such as drug-induced pericarditis, lupus-like 
syndrome and, moreover, some types of drug-induced liver injury. It is possible that all 
these reactions have a common immune-mediated nature and the specific organ is injured in 
fact “accidentally” as a current locus minoris resistentiae. Unfortunately, there is as little 
evidence available for this hypothesis as there is for the others. This should lead us to study 
these rare ADRs more in terms of patient characteristics than those of individual drugs.  
The latter three mechanisms may not be as irrelevant as it might seem. Several drugs 
involved in acute pancreatitis have been implicated as causing cholestatic liver injury, e.g. 
azathioprine, cytarabine, estrogens and erythromycin. Codeine, morphine and possibly 
some other drugs can cause spasm of sphincter of Oddi. An interesting relationship between 
rofecoxib-induced cholestatic hepatitis and acute pancreatitis was observed (Sato et al, 2006). 
Human leukocyte antigen haplotype HLA-A33/B44/DR6 is involved in both these reactions 
reported simultaneously in several patients. Cholestatic hepatitis caused by this haplotype 
may induce secondary pancreatitis. Also, the occurrence of drug-induced pancreatitis in 
alcoholic patients has been described, but this issue has not been given much attention. 
Secondary (off-target) injury of pancreatic tissue is also possible in some drugs.  Known 
potential indirect effects of drugs on the pancreas comprise ischemia (azathioprine, 
diuretics), hypercalcemia (thiazide diuretics), thrombosis of pancreatic blood vessels 
(estrogens), and an increase in pancreatic juice viscosity (diuretics, pentamidine). 
3.2 Predispositions 
Several populations at higher risk have been identified during research in drug-induced 
pancreatitis. Predisposing demographic characteristics are female gender and younger age. 
The male-to-female ratio is inversed in comparison to other acute pancreatitis types, at least 
to 1:1.3. DIP is also more commonly reported in younger patients, not exceptionally in 
children. An increased risk in older patients with polypharmacy seems to be a bias: the risk 
is in the use of many drugs by a large segment of this population rather than old age itself. 
Three types of diseases were recognized as the most frequent predisposing health factors: 
inflammatory bowel diseases, HIV infection and cancer treated by combined chemotherapy. 
In patients with advanced HIV infection (CD4 counts < 200 cells/mm3), treated with 
antiretroviral drugs, an incidence of 14% was found, but incidence of up to 40% is also 
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mentioned (Trivedi et al., 2005). In an anticancer chemotherapy, the risk is also higher, but 
sometimes it is difficult to decide which of the multiple medications have caused the 
disease. The use of dexamethasone or cytarabine seems to be of the highest risk. 
The etiology of acute pancreatitis in patients with Crohn's disease was evaluated in a 
targeted study (Moolsintong et al., 2005). Among the 48 patients treated for Crohn's disease 
who had acute pancreatitis between 1976 and 2001, an ADR was the cause in 17% of cases 
with the vast majority being caused by purine analogs – azathioprine and 6-mercaptopurine. 
The most common etiologies of AP – biliary and alcoholic – were found only in 21% and 
15%, respectively. A higher risk of induction of AP in Crohn's disease was also proven by 
evidence in a study by Weersma et al. in which the risk was significantly higher in patients 
treated for Crohn's disease compared to the risk of those treated for autoimmune diseases or 
organ transplant. Also, a similar study performed by Bajaj et al. supports these findings. In 
ulcerative colitis, the risk is probably increased, but lower than in Crohn's disease. On the 
other hand, in a Danish population-based case-control study (1,590 incident cases of acute 
pancreatitis and 10 controls per case), a nearly four-fold increased risk of acute pancreatitis 
in patients with Crohn's disease and a 1.5-fold increased risk for ulcerative colitis were 
found, but the use of mesalazine or sulfasalazine was not associated with an increased risk 
(Munk et al., 2004). We suppose that this can be explained by the low proportion of DIP in 
the etiology of acute pancreatitis. In the population with a significantly increased risk, the 
number of medication-associated cases cannot influence the total risk. 
3.3 Experimental findings 
The obvious aim of experimental models is to mimic as closely as possible the conditions in 
an organism suffering from acute pancreatitis. Some of those models were based on the 
systemic administration of an exogenous substance. They are not considered to be best 
available for many reasons, but they can help in further research on DIP pathophysiology.  
Cerulein is a ten amino acid oligopeptide, similar to cholecystokinin, that stimulates gastric, 
biliary, and pancreatic secretion and also contraction of certain smooth muscles. It has been 
used by intravenous (as well as intraperitoneal or subcutaneous) route to cause acute 
pancreatitis in mice, rats, hamsters and dogs. Within one hour from application, cerulein 
causes pancreatic interstitial edema reaching a maximum in 12 hours. The supposed 
mechanism of action is the upregulation of NF-κB (nuclear factor κ-light-chain-enhancer of 
activated B cells) leading to activation of ICAM-1 protein and promotion neutrophil 
adhesion onto pancreatic acinar cells. An increase in digestive enzyme production and 
activation of NADPH oxidase could be supporting mechanisms. Pancreatitis caused by 
cerulein is mild, with negligible mortality (Su et al., 2006). 
L-arginine is one of the most common natural amino acids. If administered 
intraperitoneally, it causes acute pancreatitis in mice and rats. Significantly increased 
plasma amylase levels, pancreatic MPO activity, trypsin activation, and histological changes 
including accumulation of fluid, disruption of histoarchitecture, acinar cell vacuolization, 
extensive acinar cell necrosis, and neutrophilic infiltration have been described. It is 
believed that nitric oxide synthase (NOS), present in acinar cells and metabolizing L-
arginine, might play a role in the initiation of pancreatitis. Induction of NOS by L-arginine 
leads to an interaction of NO and superoxide radicals, which can generate peroxynitrite 
radicals causing cell injury (Dawra et al., 2007). Effects are dose dependent and a higher dose 
can lead to acute pancreatitis within a few hours. 
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It is worth noting that some drugs known to cause human DIP (e.g. azathioprine) are able to 
successfully suppress the development of acute pancreatitis in various experimental models. 
This supports the opinion that host factors (most probably the immune system) are more 
important for the development of DIP than the pharmacodynamic properties of causative 
agents. 
4. Causative drugs 
Several hundreds of chemical substances have been reported to cause acute pancreatitis in 
humans. The majority of these reports remain single with a limited level of evidence. Drugs 
causing pancreatic injury more frequently have been listed in several reviews, some of 
which tried to quantify the risk of individual agents. A comparison of the ability to cause 
drug-induced pancreatitis is very difficult as the probability of an adverse effect is 
conditioned by many population or individual risk factors. 
An interesting attempt to estimate the potential of individual drugs to cause DIP by 
pharmacoepidemiological methods was performed by Lancashire et al. in 2003. They 
examined the data held in the General Practitioner Research Database and compared the 
frequency of intake of different drugs by individuals with and without acute pancreatitis 
(3,673 cases of pancreatitis, 3 controls for each case). Odds ratios were calculated for recent 
(1–90 days before the episode), past (91–360 days before the episode) or continuing 
(prescription in both periods) use. A nine-fold increased risk in recent takers of mesalazine 
was found as well as a ten-fold increased risk in ever-takers of azathioprine in comparison 
to never-takers. Only a moderate risk was found for captopril and valproate. Strikingly 
increased odds ratios were found for recent takers of acid inhibitory drugs without having a 
peptic ulcer diagnosed. Although these drugs can certainly cause DIP, this is clearly a bias 
because their prescription is related to abdominal pain and other GIT symptoms preceding 
the diagnosis of acute pancreatitis. This result also shows the limitation of a study 
performed by using this method – no data on the etiology of acute pancreatitis were used. 
Estimating the risk of drugs to cause a rare ADR also requires a much greater population. 
There is no doubt that some diseases may predispose to the occurrence of acute pancreatitis 
in themselves. To distinguish the impact of this predisposition from the influence of 
medication, it will be necessary to carry out such studies in much larger cohorts. Therefore, 
a classification system based on the number of DIP reports appears to be the most 
appropriate way to assess the risk potential of a drug. 
4.1 Classification systems 
Because the risk potential of individual drugs is difficult to establish, it is generally 
estimated from the absolute numbers of published cases. In earlier critical reviews, the 
potential of a drug to induce AP was evaluated as definite, probable or possible (Mallory & 
Kern, 1980; McArthur, 1996). The current knowledge has recently been summarized and 
used to propose classification systems in papers published by Trivedi and Pitchumoni in 
2005 and Badalov et al. in 2007. 
Trivedi & Pitchumoni classified risk drugs on the basis of the search of the reported cases in 
the National Library of Medicine/Pubmed from 1966 to 2004. Drugs were indexed into 
Classes I-III: Class I drugs were medications implicated in greater than 20 reported cases of 
acute pancreatitis with at least one documented case following re-exposure; Class II 
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involved medications implicated in more than ten cases of acute pancreatitis; and Class III 
drugs were all other medications reported to be associated with pancreatitis.  
Also, Badalov et al. reviewed Medline reports of drug-induced AP from 1955 to 2006. The 
authors classified reported medications into four classes based on the published weight of 
evidence for each agent and the pattern of clinical presentation. Class I included 
medications in which at least one case was proven by a re-challenge with the drug. Class II 
included drugs with a consistent latency in 75% or more of the reported cases. Class III 
included drugs that had two or more case reports published, but neither a re-challenge nor a 
consistent latency period. Class IV drugs were similar to class III drugs, but only one case 
report had been found. 
An apparent weakness of all existing drug classifications is the lack of the knowledge on the 
relationship between the incidence of drug-induced AP and population exposure to the 
causative drugs. Quantifying this relationship is a challenge for pharmacoepidemiology. In 
addition, regular updating of existing classifications appears necessary because every year 
new cases of DIP occur, which may result in a reclassification of the drugs included. 
4.2 Drugs commonly associated with drug-induced pancreatitis 
Among several hundreds of drugs reported as causative for drug-induced pancreatitis, only 
a few have a sufficiently strong evidence base to be clearly associated with this rare adverse 
drug reaction. These agents are listed in Table 2. At least some of them also deserve more 
detailed mention, which can be found in following sections.. 
4.2.1 Azathioprine 
Azathioprine is a purine analog used in low doses as immunosuppressant. It is a pro-drug 
metabolized into the active 6-mercaptopurine, itself a purine synthesis inhibitor. Enzyme 
thiopurine S-methyltransferase (TPMT) deactivates 6-mercaptopurine. The most severe 
adverse effect of azathioprine is bone marrow suppression, especially in TPMT genetic 
polymorphism. Its adverse effects on the pancreas are well documented, so it is classified 
into class I according to the risk of induction of DIP by both classification systems. A 
significantly higher risk of azathioprine-induced acute pancreatitis was demonstrated in 
patients with Crohn's disease compared to all the others, including those with ulcerative 
colitis. Consistent latency of the DIP onset with an average of 25 days has been found. This 
adverse effect is neither dose related nor associated with myelotoxicity or the defect of 
TPMT. It is believed that the cause may be an immune-mediated response based on a 
genetic predisposition common to that predisposing to Crohn's disease. 
4.2.2 Mesalazine 
Mesalazine (mesalamine, 5-aminosalicylic acid) is an anti-inflammatory drug used to treat 
the inflammation of the digestive tract in ulcerative colitis and Crohn's disease. The 
mechanism of action remains unknown, but is limited to the intestine as the agent is not 
absorbed systemically in significant amounts. Therefore, systemic adverse reactions, e.g. 
interstitial nephritis and lupus-like syndrome, are uncommon and immune-mediated. 
Mesalazine belongs to drugs with the best documented association (Class I) with drug-
induced acute pancreatitis. Acute pancreatitis induced by mesalazine usually occurs during 
the first days or weeks of treatment; however, an occurrence following prolonged use has 
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also been sporadically reported. No dose dependence has been observed and the symptoms 
usually disappear within 10 days after drug withdrawal.  
 
Drug class Drug name Risk class 
Trivedi 
Risk class 
Badalov 
Usual onset 
latency 
Analgesics codeine* I Ia 1 day 
 paracetamol II II 1 day 
 sulindac I Ia > 30 days 
     
Anesthetics propofol III II 1 day 
     
Antidiabetics exenatide* - -  
 sitaglipin* - -  
     
Anti-infectives     
Antivirals didanosine I II > 30 days 
 lamivudine II Ib  
Antibacterials cotrimoxazole I Ia 1 – 30 days 
 erythromycin II II  1 day 
 tetracycline I Ia  
Antiparazitic agents pentamidine I Ib 1 – 30 days 
 stibogluconate* I Ia 1 – 30 days 
     
Anticonvulsants valproate I I and II > 30 days 
     
Antineoplastic agents asparaginase I II 1 – 30 days 
 cytarabine I Ib 1 – 30 days 
     
Cardiovascular drugs     
ACE inhibitors* enalapril II Ia > 30 days   
Diuretics furosemide I Ib  
Statins* pravastatin III Ia > 30 days 
     
Gastrointestinal drugs mesalazine I Ia 1 – 30 days 
 omeprazole III Ib > 30 days   
     
Steroid hormones estrogens* I Ib > 30 days 
 glucocorticoids* I Ib 1 – 30 days 
     
Immunosuppressants azathioprine  I Ib and II 1 – 30 days 
 sulfasalazine I Ia 1 – 30 days 
 
Table 2. Drugs commonly associated with drug-induced pancreatitis (* class effect probable) 
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4.2.3 Valproate 
Valproic acid is an anticonvulsant, acting as an inhibitor of GABA transaminase in the CNS 
and blocking the neuronal voltage-gated sodium channels and T-type calcium channels. 
Tens of DIP cases caused by its use have been reported, with 75% of them being observed in 
children. There is a long latency of the first episode onset (3–17 months) and a short one in 
rechallenge (6–12 weeks). Although usually mild, valproate-induced pancreatitis may have 
a severe course with associated complications such as necrosis or even death. 
4.2.4 Propofol 
Propofol is an intravenously administered general anesthetic with several proposed 
mechanisms of action, mainly the potentiation of GABAA receptor activity and blockade of 
neuronal sodium channels. The nature of an agent used as an anesthetic results in an 
immediate onset of drug-induced pancreatitis following a single use. At least 20 cases of 
propofol-associated acute pancreatitis have been reported in the literature with subsequent 
discussions on the possible role of drug formulation in the oil-in-water emulsion. Elevated 
serum lipids do not seem to be a reason for this ADR; the rarity of the ADR suggests an 
idiosyncratic nature (Jawaid et al., 2002). 
4.2.5 Enalapril and other ACE inhibitors 
ACE inhibitors belong to the most widely used and most effective cardiovascular drugs. In 
contrast to their wide use, the occurrence of acute pancreatitis caused by these agents is rare. 
The number of reported cases clearly depends on the time from introduction of the specific 
agent and its widespread use; thus, enalapril is the most commonly reported agent (Class II, 
Trivedi; Class Ia, Badalov). Some cases of a second episode of DIP caused by another drug 
with a similar mechanism of action suggest the class effect. The risk of acute pancreatitis in 
patients using cardiovascular drugs has been extensively studied in the European study on 
drug-induced acute pancreatitis. The use of ACE inhibitors has been associated with an 
increased risk of acute pancreatitis (adjusted odds ratio 1.5). The risk increased with higher 
daily doses and was highest in the first six months of therapy (Eland et al., 2006). 
4.2.6 Statins 
HMG-CoA reductase inhibitors are currently the most popular hypolipidemic agents. The 
number of DIP reports related to this drug class exceeded 50, most often concerning 
simvastatin and pravastatin. An odds ratio of 1.41 was found for the risk of acute 
pancreatitis in patients with a past history of exposure to statins (Singh & Loke, 2006). The 
risk appears to increase with the duration of treatment. The ability to cause pancreatitis is 
believed to be a class effect. 
4.3 Controversial issues: Acid-suppressing drugs 
The relationship between drugs suppressing the secretion of gastric acid and acute 
pancreatitis is a frequently discussed issue. Histamine H2 receptor antagonists cimetidine 
and ranitidine have been reported to cause drug-induced pancreatitis in several case reports 
without an evidence of rechallenge or a consistent latency. Some experimental findings also 
indicate the possible causative relationship, whilst others deny it. Also, in much more 
effective drugs with a similar effect, the proton pump inhibitors (PPIs, namely omeprazole), 
the risk of inducing pancreatitis has been described. In the above-mentioned study by 
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Lancashire et al., the odds ratios were extremely high for both H2-receptor inhibitors and 
PPIs. On the other hand, a previous, much larger and better designed study brought no 
evidence for this suspicion (Eland et al., 2000). We therefore believe that the relationship of 
these drugs with DIP is overestimated, perhaps with the exception of cimetidine. 
4.4 Controversial issues: Incretin-related antidiabetics  
Soon after the introduction of a new class of oral antidiabetic agents, stimulating receptors 
for glucagon-like peptide 1 (GLP-1), reports on acute pancreatitis caused by their use began 
to emerge. In a subgroup of direct GLP-1 receptor agonists, eight cases during clinical 
development and 36 cases in postmarketing surveillance were reported for exenatide (the 
first-of-class agent) and another four cases were reported for liraglutide (Anderson & 
Trujillo, 2010). This phenomenon was probably even more pronounced in a newer group of 
agents with similar effects, dipeptidyl peptidase-4 inhibitors. At least 88 cases of acute 
pancreatitis in patients using sitagliptin were reported to FDA until 2010 (Olansky, 2010).  
A considerable effort has been made to refute this connection, which is, of course, in the 
interest of the manufacturers. It has been found that the risk of acute pancreatitis is 
significantly higher in the diabetic compared to the non-diabetic population and that the use 
of drugs affecting the GLP-1 system does not further increase this risk (Garg et al., 2010). 
Here is yet another example of a negative result in a pharmacoepidemiological study. 
Again, the probable reason lies in an extremely small proportion of drug-induced cases in 
total numbers of acute pancreatitis, which of course cannot influence the overall risk in 
high-risk populations. Nevertheless, the number of DIP cases reported in these medications 
is exceptional and supports the hypothesis of an association between the use of these drugs 
and DIP. Only the future will reveal whether this new group of drugs will be more 
beneficial for the treatment of diabetes or for studying the pathogenesis of DIP.  
4.5 Toxins and illicit agents 
Acute pancreatitis caused by animal toxin poisoning has been sporadically described in the 
literature. Probably the best known are the effects of scorpion venom. Available clinical case 
reports or series are usually too outdated to rely on the information contained 
(Bartholomew, 1970), but experimental studies on the effects of scorpion toxin are very 
interesting. Concurrent stimulation of pancreatic secretion and contraction of the sphincter 
of Oddi have been demonstrated in the late 1970s. Recently, it has been proven that the 
venom from the Brazilian scorpion Tityus serrulatus and a purified fraction selectively cleave 
essential SNARE proteins within exocrine pancreatic tissue (Fletcher et al., 2010). Rare 
reports on pancreatitis caused by adder bite (venom containing neurotoxic phospholipase 
A2) or even blue-ringed octopus bite (venom containing tetrodotoxin) have been published.  
Aside from alcohol, another addictive substance often mentioned in association with acute 
pancreatitis is marijuana, abused by smoking. A smaller series of marijuana-induced 
pancreatitis cases was reported by Wargo et al. in 2007. The authors suggest a dose-related 
mechanism of pancreatic injury. Cannabinoid receptors CB1 and CB2 were found in the 
pancreas, so their stimulation might be a trigger of the proinflammatory cascade there. 
Interestingly, stimulation of cannabinoid receptors was found to be a protective mechanism 
during experimental pancreatitis. This is yet another example of ambivalent behavior of 
some xenobiotics towards the pancreatic tissue. The importance of smoking, as a route of 
THC administration, for the initiation of pancreatitis has not yet been reviewed. 
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5. Diagnostics, disease course and management 
Among the reasons why the real incidence of drug-induced acute pancreatitis is still not 
known, the difficulties in diagnosis are probably most important. Milder cases of pancreatic 
injury are often missed because serum amylase and lipase estimations are not part of the 
metabolic profile obtained during a routine health checkup and abdominal pain is often 
attributed to underlying diseases. Many cases of DIP are also erroneously classified as 
alcoholic or biliary in etiology often by default, whether they are causal or innocent 
bystanders. If acute pancreatitis is diagnosed, the treatment invariably includes exclusion of 
oral intake and, thus, also abolishment of causative oral medication and thereby the 
opportunity to diagnose DIP is missed (Trivedi & Pitchumoni, 2005). 
5.1 Diagnosis 
As is usual with the vast majority of idiosyncratic adverse drug reactions, no specific test for 
establishing the diagnosis of drug-induced pancreatitis is available. Therefore, the diagnosis 
is usually based on the following criteria:  
a. Acute pancreatitis occurs during the administration of a drug; 
b. All other common causes are excluded; 
c. Symptoms of acute pancreatitis disappear after drug withdrawal; 
d. Symptoms recur after a re-challenge of the suspected drug. 
These criteria bring some problems in all ADRs, not only in such a difficult one as DIP. The 
first criterion seems to be easy to achieve until we remember that monotherapy in our 
patients becomes more and more scarce. If DIP occurs in the later course of the 
pharmacotherapy, the decision which drug is most suspicious is not easy. Use of the 
classification systems mentioned above may be very useful for that purpose. 
Excluding all other causes of the disease is also not so straightforward in many cases of 
acute pancreatitis. However, modern diagnostic methods have led to a great progress in this 
area. The validity of diagnosis may depend on the equipment available and even more on 
the experience of the medical staff. From this point of view, previously published DIP case 
reports should also be considered since the possibilities of excluding other causes of acute 
pancreatitis are quite different now than they were in the 1970s. 
Disappearance of symptoms following drug withdrawal is also sometimes misleading. 
Discontinuation of oral therapy is a natural part of any management of acute pancreatitis. In 
patients treated by multiple pharmacotherapy, it is impossible to decide which medication 
withdrawal led to a resolution of the symptoms and laboratory findings. A similar problem 
occurs in drugs administered at once, e.g. general anesthetics or anticancer 
chemotherapeutics. In these cases, acute pancreatitis is usually diagnosed within several 
days from drug administration.  
Due to the character of the disease and ethical considerations, deliberate, repeated 
administration of suspect drug to induce a new episode of acute pancreatitis is not possible. 
Re-challenge is usually unintended, mainly if the cause of the first AP episode was not 
properly recognized. An exception is the use of essential drugs in cases where the benefits 
outweigh the risks. In such cases, the patient's written informed consent should be obtained. 
A simplified algorithm for diagnosing drug-induced pancreatitis is given in Figure 1. The 
suspected drug etiology should be considered after the exclusion of more common causes of 
illness. For the above reasons, it seems obvious that it is not always possible to establish a 
definitive diagnosis of drug-induced AP immediately. A "second-look" with the knowledge 
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of the subsequent patient's history may often be necessary. For that purpose, a proper 
documentation of each case is needed. A detailed medication history documentation is 
obvious as well as the determination of suspicious substances. We strongly recommend the 
use of scoring system of ADR probability and classification of suspicious drugs according to 
the DIP risk in the patient's files. 
 
 
Fig. 1. Algorithm for diagnosing drug-induced acute pancreatitis 
5.2 Probability scoring 
For the purposes of future re-evaluation of each DIP case, it is very useful to classify drugs 
involved in the event by the above classification systems. There is no evidence for preferring 
one of these systems, so it is possible to use both, mainly if there is a difference between 
them in classifying a specific suspicious agent. Assigning probability of causation to a 
suspected adverse drug reaction can be best done by using the WHO scoring system (see 
Table 3). Of course, the diagnosis of DIP comes into consideration only in the first three 
degrees of probability: certain, probable or possible. 
Definite diagnosis of acute pancreatitis 
Alcoholic or biliary etiology excluded 
Drugs with known risk used? 
Perform required tests 
NO 
YES 
Perform required tests  
NO 
Drug-induced etiology 
NO 
Other drugs used? 
YES 
Symptoms resolution following drug withdrawal 
YES 
YES 
Drug-induced etiology 
Drug-induced etiology probable 
Rechallenge test positive 
Rechallenge test negative 
Drug-induced etiology certain 
No rechallenge test 
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It is therefore appropriate that a record of the event in the patient's documentation should 
be written as follows: “Acute pancreatitis, drug induced; probability level: probable 
according to WHO scoring system; causative agent: azathioprine, class I according to 
Badalov”. Using these classification systems may improve the quality of information for 
further patient treatment and further processing of the event for scientific or 
pharmacovigilance purposes. 
 
Level of 
probability  
Characteristics 
Certain A clinical event, including a laboratory test abnormality, that occurs in a 
plausible time relation to drug administration, and which cannot be 
explained by concurrent disease or other drugs or chemicals 
 The response to withdrawal of the drug (dechallenge) should be clinically 
plausible 
The event must be definitive pharmacologically or phenomenologically 
using a satisfactory rechallenge procedure if necessary 
Probable A clinical event, including a laboratory test abnormality, with a 
reasonable time relation to administration of the drug, unlikely to be 
attributed to concurrent disease or other drugs or chemicals, and which 
follows a clinically reasonable response on withdrawal (dechallenge) 
 Rechallenge information is not required to fulfill this definition 
Possible A clinical event, including a laboratory test abnormality, with a 
reasonable time relation to administration of the drug, but which could 
also be explained by concurrent disease or other drugs or chemicals 
 Information on drug withdrawal may be lacking or unclear 
Unlikely A clinical event, including a laboratory test abnormality, with a temporal 
relation to administration of the drug, which makes a causal relation 
improbable, and in which other drugs, chemicals, or underlying disease 
provide plausible explanations 
Conditional / 
unclassified 
A clinical event, including a laboratory test abnormality, reported as an 
adverse reaction, about which more data are essential for a proper 
assessment or the additional data are being examined 
Unassessable / 
unclassifiable 
A report suggesting an adverse reaction that cannot be judged, because 
information is insufficient or contradictory and cannot be supplemented 
or verified 
Table 3. Causality assessment of suspected ADRs (Edwards & Aronson, 2000) 
5.3 Disease severity, management and secondary prevention 
It is believed that drug-induced pancreatitis usually has a mild course. Lankisch et al. in 1995 
showed that the disease course was usually favorable in patients with drug-induced AP, but 
more recent greater studies strongly suggest that the etiology of acute pancreatitis generally 
does not determine the severity (Gullo et al., 2002). Also, a number of deaths from DIP were 
reported, for example, in a Danish analysis of spontaneous reports, four (9%) out of 47 DIP 
episodes led to death (Andersen et al., 2001). Of course, severe cases tend to be more often 
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reported both in the literature and in spontaneous pharmacovigilance reports. Sometimes it 
may be rather difficult to decide to what extent DIP contributed to the death, especially in 
the presence of a severe, often end-stage underlying disease such as HIV infection or 
disseminated tuberculosis (Ksiądzyna, 2001). 
In the disease management, there are no specific issues concerning drug-induced 
pancreatitis, with an exception of an immediate withdrawal of the suspected drug. The 
treatment does not differ from other types of acute pancreatitis. A difficult question is how 
to reintroduce medication if the causative agent is not unambiguously identified. We 
recommend not introducing all withdrawn drugs at the same time to distinguish the cause 
of a possible flare-up. An agent with the lowest risk should be reintroduced first. The most 
suspected drugs should be substituted by their analogs with a different chemical structure. 
Secondary prevention consists of avoiding the drug which caused the episode of acute 
pancreatitis. Rechallenge of such an agent is justified only if its benefits outweigh the risks, 
as discussed above. 
The relationship between acute DIP and chronic pancreatitis is not known. Trivedi & 
Pitchumoni in their above cited paper hypothesized – on the basis of a known sequence in 
the pathogenesis of chronic pancreatitis – that prolonged use of a causative drug in a patient 
who experienced an episode of DIP may lead to chronic pancreatitis by causing repeated 
clinical or subclinical episodes of DIP but no evidence is available for this suggestion to date. 
6. Future research 
Given how inadequate the current state of knowledge on drug-induced pancreatic injury is, 
the area for further research in this field is remarkably wide. The majority of the knowledge 
on the topic has been obtained from case reports or their series. These will remain a major 
source of information, so it is necessary to improve their informative value substantially. 
The following recommendations for processing case reports on DIP were proposed by 
Balani & Grendell in 2008. Published case reports should: 
a. Provide the age and sex of the patient, along with the indication for treatment with a 
drug; provide the dose and frequency of medication;  
b. Document a definite case of pancreatitis based on current diagnostic guidelines;  
c. Provide information on the time course between initiation of drug and onset of 
pancreatitis;  
d. Exclude the most common causes of pancreatitis; document a positive response to 
withdrawal of medication;  
e. Provide the response to a rechallenge, if available. 
Higher level of knowledge may be obtained by performing multicenter studies targeted at 
the etiology of non-alcoholic, non-biliary pancreatitis. Several thousands of acute 
pancreatitis cases must be involved in these studies to reveal the actual occurrence of drug-
induced pancreatitis. Better cooperation between gastroenterologists and 
pharmacoepidemiologists is also needed to assess the actual risk of DIP for individual 
drugs. Any new pharmacoepidemiological study on this topic would be useful, but to 
improve the validity of its outcomes, substantially better input data are required. For this 
purpose, it would be optimal that each single case of acute pancreatitis included in such a 
study be documented according to the above principles. 
Integration of the research in different disciplines would also be very useful for studying the 
causes of DIP. An obvious field for this research is the issue of diseases with a high 
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incidence of this disorder. Identifying the genetic differences predisposing to pancreatic 
injury caused by medication in patients suffering from Crohn's disease or AIDS would be 
the most axiomatic target. Another issue is the experimental pharmacological research of 
mechanisms by which xenobiotics can damage the pancreatic tissue as well as the common 
mechanisms of immune-mediated tissue injury caused by drugs. Any substantial progress 
in this research can contribute to a progress in two scientific challenges: recognizing the 
nature of more frequent causes of acute pancreatitis and also recognizing the cause and 
pathogenesis of idiosyncratic adverse drug reaction. 
7. Conclusion 
Drug-induced injury is a rare cause of acute pancreatitis. Epidemiological studies show a 
very wide range of its incidence, but at least the absolute number of its cases is undoubtedly 
increasing. We are able to identify the drugs with the greatest risk and populations at risk, 
but the absolute risk for medication users is still very low. On the other hand, the 
pathogenesis of the disease remains completely unknown. A better understanding of drug-
mediated pancreatic injury can also help to understand the etiology of more common types 
of acute pancreatitis. Research in drug-induced acute pancreatitis is both a challenge and an 
opportunity to improve the collaboration of gastroenterology and clinical pharmacology. 
8. Acknowledgment 
Supported by grants IGA UPOL LF_2011_005 and MSM 6198959216. 
9. References 
Andersen, V; Sonne, J.  & Andersen, M. (2001) Spontaneous reports on drug-induced 
pancreatitis in Denmark from 1968 to 1999. European Journal of Clinical Pharmacology, 
Vol. 57, No. 6-7, (September 2001), pp. 517-21, ISSN 0031-6970. 
Anderson, S.L. & Trujillo, J.M. (2010) Association of pancreatitis with glucagon-like peptide-
1 agonist use. The Annals of Pharmacotherapy, Vol. 44, No. 5, (May 2010), pp. 904-
909, ISSN 1060-0280. 
Badalov, N.; Baradarian, R.; Iswara, K.; Li, J.; Steinberg, W. & Tenner, S. (2007) Drug-
induced acute pancreatitis: an evidence-based review. Clinical gastroenterology and 
hepatology, Vol. 5, No. 6, (June 2007), 648-61. ISSN 1542-3565. 
Bajaj, J.S; Saeian, K; Varma, R.R; Franco, J; Knox J.F; Podoll, J; Emmons, J; Levy, M. & Binion, 
D.G. (2005) Increased rates of early adverse reaction to azathioprine in patients 
with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center 
experience. The American Journal of Gastroenterology; Vol. 100, No. 5, (May 2005), pp. 
1121-5, ISSN 0002-9270. 
Balani, A.R. & Grendell, J.H. (2008) Drug-Induced Pancreatitis. Incidence, Management 
and Prevention. Drug Safety, Vol. 31, No. 10, (October 2008), pp. 823-37, ISSN 
0114-5916. 
Banks, P.A. & Freeman, M.L. (2006) Practice Parameters Committee of the American 
College of Gastroenterology. Practice guidelines in acute pancreatitis. The 
 
Acute Pancreatitis 
 
32
American Journal of  Gastroenterology, Vol. 101, No. 10 (October 2006), pp. 2379-400, 
ISSN 0002-9270. 
Bartholomew C. (1970) Acute scorpion pancreatitis in Trinidad. British Medical Journal, Vol. 
5697, No. 1, (March 1970), pp. 666-8, ISSN 0007-1447. 
Dawra, R; Sharif, R; Phillips, P; Dudeja, V; Dhaulakhandi, D. & Saluja, A.K. (2007) 
Development of a new mouse model of acute pancreatitis induced by 
administration of L-arginine. American journal of physiology. Gastrointestinal and liver 
physiology, Vol. 292, No. 4, (April 2007), G1009-18, ISSN 0193-1857. 
Edwards, I.R. & Aronson, J.K. (2000) Adverse drug reactions: definitions, diagnosis, and 
management. Lancet, Vol. 356, No. 9237 (October 2000), pp. 1255-9, ISSN 0140-
6736. 
Eland I.A; Alvarez C.H; Stricker B.H. & Rodríguez, L.A. (2000) The risk of acute pancreatitis 
associated with acid-suppressing drugs. British Journal of Clinical Pharmacology, Vol. 
49, No. 5, (May 2000), pp. 473-478, ISSN 0306-5251. 
Eland, I.A; Sundström, A; Velo, G.P; Andersen. M; Sturkenboom, M.C; Langman, M.J; 
Stricker, B.H. & Wiholm, B. (2006) Antihypertensive medication and the risk of 
acute pancreatitis: the European case-control study on drug-induced acute 
pancreatitis (EDIP). Scandinavian Journal of Gastroenterology, Vol. 41, No. 12, 
(December 2006), pp-1484-1490, ISSN:0036-5521. 
Fletcher, P.L.Jr; Fletcher, M.D; Weninger, K; Anderson, T.E. & Martin, B.M. (2010) Vesicle-
associated membrane protein (VAMP) cleavage by a new metalloprotease from the 
Brazilian scorpion Tityus serrulatus. The Journal of Biological Chemistry, Vol. 285, No. 
10, (March 2010), pp. 7405-16, ISSN 0021-9258. 
Garg, R; Chen, W.  & Pendergrass, M. (2010) Acute pancreatitis in type 2 diabetes treated 
with exenatide or sitagliptin: a retrospective observational pharmacy claims 
analysis. Diabetes Care, Vol. 33, No. 11, (November 2010), pp. 2349-2354, ISSN 0149-
5992. 
Gullo, L; Migliori, M; Oláh, A; Farkas, G; Levy, P; Arvanitakis, C; Lankisch, P. & Beger, H. 
(2002) Acute pancreatitis in five European countries: etiology and mortality. 
Pancreas, Vol. 24, No. 3, (April 2002), pp. 223-7, ISSN 0885-3177. 
Jawaid, Q; Presti, M.E; Neuschwander-Tetri, B.A. & Burton F.R. (2002) Acute pancreatitis 
after single-dose exposure to propofol: a case report and review of literature. 
Digestive Diseases and Sciences; Vol. 47, No.3, (March 2002), pp. 614-8, ISSN 0163-
2116. 
Johnston, D.H. & Cornish, A.L. (1959) Acute pancreatitis in patients receiving 
chlorothiazide. Journal of the American Medical Association, Vol. 170, No. 17 (August 
1959), pp. 2054-6, ISSN 0002-9955. 
Ksiądzyna, D. (2011) Drug-induced acute pancreatitis related to medications commonly 
used in gastroenterology. European Journal of Internal Medicine, Vol. 22, No. 1, 
(February 2011), pp. 20-25, ISSN 0953-6205. 
Lancashire, R.J; Cheng, K.  & Langman, M.J. (2003) Discrepancies between population-based 
data and adverse reaction reports in assessing drugs as causes of acute pancreatitis. 
Alimentary Pharmacology and Therapeutics, Vol. 17, No. 7, (April 2003), pp. 887-93, 
ISSN 0269-2813. 
 
Acute Pancreatitis Induced by Drugs 
 
33 
Lankisch, P.G; Droge, M. & Gottesleben, F. (1995) Drug induced acute pancreatitis: 
incidence and severity. Gut, Vol. 37, No. 4, (October 1995), pp. 565-7, ISSN:0017-
5749. 
Mallory, A. & Kern, F. Jr. (1980). Drug-induced pancreatitis: a critical review. 
Gastroenterology, Vol.78, No.4, (April 1980), pp. 813-20, ISSN 0016-5085.  
McArthur, K.E. (1996). Review article: drug-induced pancreatitis. Alimentary Pharmacology 
and Therapeutics, Vol.10, No.1, (February 1996), pp. 23-38. ISSN 0269-2813. 
Mennecier, D; Pons, F; Arvers, P; Corberand, D; Sinayoko, L., Harnois, F.; Moulin, O; 
Thiolet, C; Nizou, C & Farret, O. (2007) Incidence and severity of non alcoholic and 
non biliary pancreatitis in a gastroenterology department. Gastroentérologie clinique 
et biologique; Vol. 31, No. 8-9, (August-September 2007), pp. 664-667, ISSN 0399-
8320.  
Moolsintong, P; Loftus, E.V., Jr; Chari, S.T, Egan, L,J; Tremaine, W.J. & Sandborn, W.J. (2005) 
Acute pancreatitis in patients with Crohn's disease: clinical features and outcomes. 
Inflammatory Bowel Diseases, Vol. 11, No. 12, (December 2005), pp. 1080-1084, ISSN 
1078-0998. 
Munk, E.M; Pedersen, L; Floyd, A; Nørgård, B; Rasmussen, H.H. & Sørensen, H.T. (2004) 
Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment 
and risk of acute pancreatitis: a population-based case-control study. The American 
Journal of Gastroenterology, Vol. 99, No. 5, (May 2004), pp. 884-888, ISSN 0002-9270. 
Olansky, L. (2010) Do incretin-based therapies cause acute pancreatitis? Journal of 
Diabetes Science and Technology, Vol. 4, No. 1, (January 2010), pp. 228-229, ISSN 
1932-2968. 
Sato, K; Yamada, E; Uehara, Y; Takagi, H. & Mori M. (2006) Possible role for human 
leukocyte antigen haplotype in rofecoxib-associated acute pancreatitis and 
cholestatic hepatitis. Clinical Pharmacology and Therapeutics, Vol. 80, No. 5, 
(November 2006), pp. 554-555, ISSN 0009-9236. 
Singh, S. & Loke, Y.K. (2006) Statins and pancreatitis: a systematic review of observational 
studies and spontaneous case reports. Drug Safety, Vol. 29, No. 12, (December 2006), 
pp. 1123-1132, ISSN 0114-5916. 
Su, K.H; Cuthbertson, C. & Christophi. C. (2006) Review of experimental animal models of 
acute pancreatitis. HPB: the official journal of the International Hepato-Pancreato-Biliary 
Association, Vol. 8, No. 4, (2006), pp. 264-86, ISSN 1365-182X. 
Trivedi, C.D. & Pitchumoni, C.S. (2005) Drug-induced pancreatitis: an update. Journal of 
Clinical Gastroenterology; Vol. 39, No. 8, (September 2005), pp. 709-716. ISSN 0192-
0790.  
Vinklerová, I; Procházka, M; Procházka, V. & Urbánek, K. (2010) Incidence, severity, and 
etiology of drug-induced acute pancreatitis. Digestive Diseases and Sciences, Vol. 55, 
No. 10 (October 2010), pp. 2977-81, ISSN 0163-2116. 
Wargo, K.A; Geveden, B.N. & McConnell, V.J. (2007) Cannabinoid-induced pancreatitis: a 
case series. Journal of the Pancreas, Vol. 8, No. 5, (September 2007), pp. 579-83, ISSN 
1590-8577. 
Weersma R.K; Peters F.T; Oostenbrug L.E; van den Berg A.P; van Haastert M; Ploeg R.J; 
Posthumus M.D; Homan van der Heide J.J; Jansen, P.L. & van Dullemen, H.M. 
 
Acute Pancreatitis 
 
34
(2004) Increased incidence of azathioprine-induced pancreatitis in Crohn's disease 
compared with other diseases. Alimentary Pharmacology and Therapeutics, Vol. 20, 
No. 8, (October 2004), pp. 843-50, ISSN 0269-2813. 
Zion, M.M; Goldman, B. & Suzman, M.M. (1955) Corticotrophin and cortisone in the 
treatment of scleroderma. The Quarterly Journal of Medicine, Vol. 24, No. 95, (July 
1955), pp. 215-27, ISSN 0033-5622. 
3 
Obesity and Acute Pancreatitis 
Davor Štimac and Neven Franjić 
Division of Gastroenterology, Department of Internal Medicine, 
University Hospital Rijeka, Rijeka, 
Croatia 
1. Introduction  
Evidence accumulated for the past two decades leads to the conclusion that obesity 
enhances the development of acute pancreatitis and worsens its clinical course. Is this true? 
We will try to give an answer to this issue by presenting the scientific data accumulated thus 
far. 
“Obesity is a medical condition in which excess body fat has accumulated to the extent that 
it may have an adverse effect on health, leading to reduced life expectancy and/or increased 
health problems.“ (World Health Organization, 2000) The main problem with obesity is 
determining the best (and easiest) way to measure it. According to the definition, one 
should calculate the total amount of body fat a person has and deduct the “normal” amount 
of fat from it. Several methods have been developed, each with its strengths and 
weaknesses. (Kamel et al, 2000; Browning et al, 2011) 
Body mass index or BMI is the basic method used to determine obesity. It is a measure 
obtained by dividing the patient’s weight (in kilograms) with the square of his/her height 
(in meters); obesity is defined as BMI > 30 kg/m2.  The method is based on the presumption 
that a person’s excess weight predominantly consists of fat. The advantage of this method is 
its application simplicity, namely the lack of complicated procedures needed to determine it 
as well as the fact that it has been globally accepted. The disadvantages are the 
consequences of the above mentioned presumption namely that a person’s excess weight 
predominantly consists of fat as well as the lack of body composition in the equation: a 
person who gains weight due to a component other than fat will have a falsely increased 
BMI, e.g. athletes have muscle hypertrophy; patients with ascites (liver cirrhosis) and 
peripheral edema (renal failure, heart failure) accumulate water, etc. 
Other methods used to determine obesity measure the amount of subcutaneous fat tissue. 
These methods are based on the fact that the amount of subcutaneous fat tissue correlates 
well with the amount of excess fat tissue. The methods include the measurement of skin fold 
thickness, waist diameter and waist-to-hip ratio. As is the case for BMI, these methods are 
simple, requiring only a meter or a simple measuring instrument and the results are easily 
interpreted. The limiting factor for these methods is the presence of edema in the 
investigated areas (liver cirrhosis, heart and kidney diseases). 
The method that is not affected by the presence of excess water is dual-energy X-ray 
absorptiometry (DEXA). It is used to measure body composition based on the difference in 
the absorption of X-rays in different types of tissues (bone, fat, muscle, water). Compared to 
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other methods, DEXA is rather expensive, requires radiological equipment and a radiology 
specialist to interpret the results; also, it uses radiation (X-rays), which makes it potentially 
harmful for the patients. 
After two decades of tedious work in finding the best method for estimating the amount of 
body fat in acute pancreatitis, scientists offer no clear answers. Although some data suggest 
that waist diameter and waist-to-hip ratio have the best correlation with the occurrence of 
complications in acute pancreatitis, BMI is still widely used as the standard procedure. The 
following sections offer a detailed insight into the best methods for estimating the amount of 
body fat in acute pancreatitis. 
2. Epidemiology, etiology and pathogenesis 
2.1 Epidemiology and etiology 
The epidemiology of acute pancreatitis indicates that the incidence of acute pancreatitis 
during the last decades has been increasing. (Satoh et al, 2011) Although definitive data are 
not available, the authors suspect that the main reasons for this are linked to the rise of the 
underlying causes of pancreatitis – increased alcohol consumption and gallstones. Each 
cause is responsible for approximately 40% of cases of acute pancreatitis. (Lowenfels et al, 
2009; Spanier et al, 2008; Goldacre & Roberts, 2004) 
Whether obesity has direct consequence on the increased incidence of acute pancreatitis is 
not clear. Only few epidemiological studies have tried to establish a direct link between 
obesity and the onset of acute pancreatitis, but the studies’ findings are contradictory. 
(Blomgren et al, 2002; Lowenfels et al, 2005, 2009) The main problem with this theory is the 
fact that obesity is a well-known risk factor for biliary calculi and consequently for acute 
biliary pancreatitis. Therefore, it is hard to determine whether or not obesity has a direct 
impact on the onset of acute pancreatitis.  
Another factor taken into consideration when analyzing obesity’s effect on the onset of acute 
pancreatitis is weight distribution. Analyses show that there is no difference in the weight 
distribution of patients suffering acute pancreatitis and the general population. The reason 
for this lies in the fact that while patients with biliary pancreatitis tend to be overweight (as 
obesity is a risk factor for biliary stones), patients suffering alcoholic pancreatitis tend to be 
lean or even malnourished. 
2.2 Pathogenesis 
The increased interest in obesity is the consequence of the epidemiological boom of obese 
people and children in post-industrial societies. Since obesity is linked to acute pancreatitis, 
there have been many speculations about the pathogenetic links between the two. (Bastard 
et al, 2006; Fuentes et al, 2010; Frossard et al, 2009) 
Ever since the discovery of adipokines, hormones synthesized and excreted by the cells 
residing in the adipose tissue, the endocrine function of adipose tissue has become even 
more intricate. Adipokines once included only biologically-active substances secreted by the 
adipocytes, but today they refer to all biologically-active substances produced by the 
adipose tissue. 
The principal anti-inflammatory substance secreted by the adipocytes is adiponectin. It is a 
30-kDa protein with plasma levels ranging from 5 to 30 mg/L in lean subjects. Adiponectin 
has many potentially beneficial effects in acute pancreatitis (Zyromski et al, 2008): it 
enhances insulin-sensitivity (Yamauchi et al, 2002), modulates endothelial adhesion 
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molecules (Ouchi et al, 1999), alters macrophage and lymphocyte action (Ouchi et al, 2001; 
Wolf et al, 2004) and modulates the balance of cytokines in favor of anti-inflammatory 
cytokines (Ouchi et al, 2000; Huang et al, 2008; Masaki et al, 2004) 
Leptin, a pro-inflammatory adipokine synthesized in the adipocytes, is on the opposite side 
of the spectrum. Leptin acts pro-inflammatory by regulating cytokine production in favor of 
pro-inflammatory cytokines (Fantuzzi & Faggioni, 2000; Santosa et al, 2007) and by 
enhancing leukocyte activity (Loffreda et al, 1998; Lord et al, 1998). On the other hand, a 
study performed by Matyjek et al. showed an inhibitory effect of leptin on cholecystokinin-
related secretion of pancreatic enzymes. (Matyjek et al, 2003) 
Resistin is another adipokine, a 12.5 kDa protein produced mainly by monocytes and 
macrophages. Its effects include increased insulin resistance and dyslipidemia. (Steppan et 
al, 2001; Trayhurn & Wood, 2004) 
According to modern conceptions, obese people are in a state of chronic inflammation. 
Studies have shown that excess adipose tissue generates more leptin and resistin, and less 
adiponectin. This, in turn, leads to the prevalence of pro-inflammatory over anti-
inflammatory cytokines, resulting in a state of constant inflammation of the adipose tissue. 
(Frossard et al, 2009) The residing macrophages are affected as well. Normal fat tissue 
contains a balance of the so-called M1 or pro-inflammatory macrophages and the so-called 
M2 or anti-inflammatory macrophages. In obesity, the scale is tipped in favor of M1 
macrophages; the net-result is a constant over-production of various pro-inflammatory 
cytokines, like interleukin-1 (IL-1), interleukin-6 (IL-6) or tumor necrosis factor-alpha (TNF-
alpha). 
The pro-inflammatory effect of excess adipose tissue varies throughout the body and 
depends on the place where excess fat is stored. The worst place it can be stored is the 
intraabdominal compartment; visceral adipose tissue is metabolically the most active 
adipose tissue and the most “pro-inflammatory oriented”. (Clement & Langin, 2007) 
Because the veins of the visceral adipose tissue drain into the portal system, the hormonal 
products and free-fatty acids (FFAs) produced by the visceral adipose tissue directly 
influence the liver and cause central insulin resistance. This is the pathogenetic pathway by 
which the central obesity causes cardiovascular diseases as well as diabetes. Free-fatty acids, 
however, act through toll-like receptors (TLRs) inducing an inflammatory response in 
macrophages, adipocytes and muscle-cells.  
The central dogma of the acute pancreatitis etiopathogenesis is the uncontrolled 
intrapancreatic conversion of trypsinogen into trypsin. In theory, it is rather easy to imagine 
how an altered pro-inflammatory cytokine milieu could trigger the activation of 
trypsinogen, leading to the onset of acute pancreatitis. Clinical data are, however, 
inconclusive. Therefore, we must be overlooking some important factors in the development 
of acute pancreatitis. 
3. Clinical course 
The clinical course of acute pancreatitis follows two discrete patterns. It can be a mild 
disease, resulting in edematous interstitial inflammation of the pancreas and resolving 
without consequences within a week. On the other hand, it can be a severe, debilitating 
disease, manifested by pancreatic and peripancreatic necroses and resulting, in turn, in local 
and systemic complications. Can obesity influence the course of the disease? 
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Obesity is a chronic subclinical inflammatory disorder that, in theory, can influence the 
clinical course of acute pancreatitis. There is evidence that obese patients have elevated 
levels of pro-inflammatory cytokines circulating in their blood. (Clement & Langin, 2007) 
This, in turn, can affect the course of the disease by enhancing inflammation and increasing 
the chance of necrosis. 
The second way excess fat can influence the course of acute pancreatitis is by increasing the 
risk of pancreatic infection and the severity of inflammation. In the course of acute 
pancreatitis, the inflammation affects peri-pancreatic adipose tissue as well. The risk of 
complications is proportional to the amount of excess fat tissue in the peri-pancreatic area, 
which is a component of the visceral adipose tissue. (Frossard et al, 2009) On the other hand, 
excess peripancreatic fat could be a protective factor by separating the pancreatic tissue from 
the retroperitoneal structures thus localizing the necrotizing process. 
The third, and often neglected problem in obese patients with acute pancreatitis is (chronic) 
insulin resistance. It is a common denominator of obesity and carries the burden of type II 
diabetes development. Insulin resistance is a system-wide problem which affects both the 
vasculature and the immune system and can give rise to microcirculatory problems which 
can cause pancreatic ischemia. (Mentula et al, 2007) Insulin resistance (acute) is actually a 
physiological reaction accompanying acute immune reactions and stress. The body needs 
energy and nutrients, i.e. glucose, amino-acids and free-fatty acids. In order to meet its 
needs, the body must inhibit nutrient uptake and reverse the process: cells which are not 
needed degrade its proteins, carbohydrates and lipids in order to produce the above-
mentioned nutrients. That way the body fuels up the immune reactions and makes healing 
possible. When the healing (reconvalescence period) is complete, the body lowers insulin 
resistance to normal levels. The problem is when this state persists for a long time, as in the 
case of obesity. As a result, the body is not able to adequately react to the traumatic 
experience (acute pancreatitis) and prolonged healing follows. 
Although all the proposed mechanisms seem logical, clinical data have failed us once again. 
Some of the studies do show a statistical significance in the outcomes of obese and non-
obese pancreatitis patients; however, other studies do not confirm these findings. Even in 
some studies, which support the idea that obese patients tend to have a more complicated 
course of acute pancreatitis, the confidence interval is rather wide, indicating possibly 
biased data. A possible explanation is that the measure of obesity used in the studies is not 
the real measure of obesity. 
Unfortunately, as with many other topics covering acute pancreatitis, we still await an 
unequivocal conclusion. 
4. Obesity measures 
Various obesity measurements are used in everyday practice. However, modern tendencies 
are to simplify disease management and at the same time be cost-effective. Complex 
measurements are performed in high-volume hospitals and university hospitals; smaller 
hospitals employ simplified methods more suited to smaller budgets. Body-mass index 
(BMI) and waist diameter are the methods which fulfill the mentioned criteria. 
4.1 BMI 
As mentioned before, BMI is calculated by dividing the patient’s weight (in kilograms) with 
the square of his/her height (in meters). Patients with BMI above 25 kg/m2 are defined as 
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overweight; above 30 kg/m2 are obese. These are, again, divided into three subcategories: 
type I obesity ranging from 30 to 35 kg/m2, type II or severe obesity ranging from 35 to 40 
kg/m2 and type III or morbid obesity with BMI levels above 40 kg/m2. 
Several studies have tried to substantiate the idea that obesity predisposes a person for the 
development of acute pancreatitis. Suazo-Barájona et al. in 1998 found a significant 
difference in the occurrence of severe acute pancreatitis between patients with BMI≥25 
kg/m2 (overweight and obese), and those with BMI<25 kg/m2 (lean). The differentiation of 
the overweight and the obese into separate groups is performed only graphically. The graph 
shows a tendency of patients with higher BMI to develop severe acute pancreatitis more 
often. (Suazo-Barájona et al, 1998) Johnson et al. modified the APACHE II score by adding 
BMI into the scoring system. A value of 1 or 2 is added to the “classic” APACHE score 
depending on the value of BMI. (Johnson et al, 2004) The study, along with a study from 
Papachristou et al two years later, showed a positive correlation between the BMI and the 
disease’ severity, though in the second study the APACHE-O score did not perform better 
than the original APACHE II score. (Papachristou et al, 2006) In 2006, a meta-analysis was 
performed by Martinez et al in order to determine the effect of BMI on the occurrence of 
local complications, systemic complications and mortality. The meta-analysis included 739 
patients and clearly showed an increased incidence of local and systemic complications, as 
well as increased mortality. However, with respect to mortality, the odds ratio (OR) for the 
obese patients was 2.1, but with a 95% confidence interval (CI) ranging from 1.0 to 4.8 
(figure 1). This implies an increased mortality risk in obese patients suffering acute 
pancreatitis, but it should be taken into careful consideration. (Martinez et al, 2006) In the 
period after 2006, several studies negating the effect of BMI on disease severity have been 
published. (Mentula et al, 2007; Stimac et al, 2007) The last meta-analysis published in 2011 
(Wang et al, 2011) included 8 studies with 939 patients. The meta-analysis showed that the 
incidence rates of severe acute pancreatitis, local complications and mortality were all 
increased in overweight patients (OR 2.48, 2.58 and 3.81, respectively). The last meta-
analysis did not show correlation between BMI and systemic complications, though. 
 
 
 
Fig. 1. The results of the meta-analysis performed by Martinez et al. (Martinez et al, 2006) 
The influence of obesity on the mortality in patients suffering acute pancreatitis is shown in 
the forest plot with a calculated pooled odds ratio (OR). O = Obese; NO = Nonobese 
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4.2 Waist diameter and waist-hip ratio  
Waist diameter or circumference is the measurement of the shortest abdominal distance, 
halfway between the lower rib margin and the iliac crest. Men with a waist diameter <94 
cm, 94-101.9 cm and ≥102 cm are defined as lean, overweight and obese. Similarly, in 
women the values are <80 cm, 80-87.9 cm and ≥88 cm, respectively. 
 Waist-to-hip or waist-hip ratio is calculated by dividing the waist diameter with the hip 
diameter. The hip diameter is acquired by measuring the abdominal diameter at the level of 
the hips. Again, the distribution is <0.90, 0.90-0.99 and ≥1.00 for lean, overweight and obese 
men. In women, the cut-off values are 0.80 and 0.85 (<0.80, 0.80-0.84 and ≥0.85). 
The mentioned ranges are reference ranges defined for the European population. 
Differences exist among different populations. The American societies define the ranges 
somewhat higher, while the Asian societies tend to lower the ranges, mirroring the normal 
distribution of waist diameter and waist-hip ratio in the respective populations. 
The idea of analyzing waist diameter and waist-hip ratio as a predictive factor in acute 
pancreatitis has emerged as early as in the 90’s, but only several studies have been 
performed thus far. In 1999, Martinez et al. showed that waist diameter was greater in 
patients with severe acute pancreatitis than in patients with the mild form. (Martínez et al, 
1999) A second study in which Torgerson et al. tried to determine the impact of obesity on 
the occurrence of gallstones, gallbladder disease and pancreatitis was limited by the small 
number of patients suffering acute pancreatitis. (Torgerson et al, 2003) The latest study 
published in 2010 by Duarte-Rojo et al. showed that waist diameter, waist-hip ratio and 
waist-thigh ratio all correlated well with the severity of acute pancreatitis. The study also 
showed that waist diameter correlated best with the subcutaneous abdominal fat, while the 
waist-hip ratio showed a similar correlation with intra-abdominal fat. (Duarte-Rojo et al, 
2010) 
Fluid sequestration in the retroperitoneal compartment affects both the BMI and the 
abdominal obesity measures. With fluid retention, the measures become inaccurate in 
assessing obesity as they tend to overestimate the amount of body fat, and become more 
accurate in predicting disease severity (the more the fluid is sequestered the more severe the 
course of the disease). That is perhaps the reason why some studies have shown a good 
correlation between obesity measures and disease severity, while others did not. In the case 
of fluid retention, abdominal measures should theoretically have a greater prognostic 
significance than BMI; one should note that this does not imply obesity as well. (Beger & 
Rau, 2007)  
Whether BMI or abdominal measures are the best disease severity predictors still remains to 
be seen. Studies comparing the two are needed. 
5. Treatment differences 
Current approach to acute pancreatitis management depends mostly on the course the 
disease will follow. Specific therapy for acute pancreatitis does not exist, as medications 
which could impede the development of the disease or change its course have not been 
found yet. Therefore, the only therapy is symptomatic and depends on the patient’s status. 
In mild edematous pancreatitis, fluid resuscitation and oral food intake prohibition will 
enhance the patient’s recovery. Even the lack of therapy would yield a similar result, as in 
this case the disease is self-limited. For this type of pancreatitis there are no differences in 
the management of obese and non-obese patients. 
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Severe necrotizing pancreatitis is the therapeutic nightmare for every gastroenterologist and 
intensivist. In the acute phase of the disease (within 7 days from onset), the main problem is 
organ failure. Obese patients tend to have more local and systemic complications, and 
respiratory failure is among the more common ones. Therefore, in the management of obese 
patients, aggressive fluid resuscitation with a special concern for respiratory function is of 
utmost importance. Since obesity carries the risk of type II diabetes, and glucose intolerance 
is rather often found in the acute phase of acute pancreatitis, insulin is usually added to 
glucose or Ringer solutions in order to maintain glucose levels under 10 mmol/L (180 
mg/dL). (Di Carlo et al, 1981; Pisters & Ranson, 1992) 
The main problem in the subacute phase of acute pancreatitis is the elevated risk of 
infection. Insulin resistance can impede the normal function of the immune system and lead 
to serious infections. (Turina et al, 2005) Therefore, antibiotic prophylaxis should be given in 
order to prevent this setting from taking place. 
Since the predilection of obese patients for local and systemic complications is still under 
revision, the measures are opinion-based and not substantiated with evidence from RCTs. 
However, common sense dictates us to monitor such patients more closely in order to try to 
prevent the worst from happening. 
6. Nutritional support 
As obesity is (usually) a nutritional disorder, nutritional support in acute pancreatitis is 
separated from other therapeutic interventions. (Ionnanidis et al, 2008) 
Due to the lack of specific therapy, the modern mainstay of therapy of acute pancreatitis is 
“pancreatic rest”. (Cassim & Allardyce, 1974) This means that the pancreas should be 
stimulated as little as possible in order to enable it to contain the inflammation and give it 
time to heal itself. Again, the treatment approach for patients with mild pancreatitis differs 
from those suffering severe pancreatitis. 
In mild pancreatitis food is withheld for several days, after which the patient is given oral 
food, first in the form of water and tea, followed by the so-called “pancreatic” diet (food rich in 
carbohydrates and scarce in fats). If the patient cannot tolerate oral intake, enteral or even 
parenteral feeding should be administered. Obese patients are treated the same way. 
In severe pancreatitis, the approach is more invasive. Patients are fed enterally through a 
naso-jejunal tube. If they cannot tolerate enteral feeding, or enteral feeding is inadequate, 
parenteral feeding is added. Obese patients should be fed according to ideal weight and not 
the actual one. The target energy requirements include 25-35 kcal/kg of ideal body weight, 
with 1.2-1.5 g of nitrogen per kg of ideal body weight. (Choban & Dickerson, 2005; Elamin, 
2005) One should note that this means that obese patients are ‘permissively underfed’. In 
their case, weight reduction can have beneficial effects on insulin resistance and the overall 
status of the patient. (Martindale et al, 2009) 
Plasma glucose levels should be monitored at least twice a day, more intensively in case of 
offset values. High glucose values (above 10.0 mmol/L) should be corrected with 
subcutaneous administration of insulin. 
7. Treatment 
The treatment of acute pancreatitis in obese patients is summarized in table 1. 
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Mild pancreatitis 
 food restriction (depending on clinical severity) 
 fluid resuscitation (depending on laboratory values) 
   
Severe pancreatitis 
 enteral nutrition, parenteral 
if needed 
(amount calculated according to ideal weight) 
 aggressive fluid 
resuscitation 
(up to 4-6 L daily, depending on the state of the 
cardiovascular system) 
 insulin according to plasma glucose levels 
 oxygen therapy depending on oxygen saturation 
 antibiotic prophylaxis (carbapenems, ciprofloxacin, metronidazole) 
Table 1. Therapeutic approach in obese patients with acute pancreatitis 
8. Conclusion 
In the end, we will talk about the future and what it holds for obese patients suffering from 
acute pancreatitis. 
Scientists and clinical practitioners are presently searching for new and better ways to help 
patients suffering from acute pancreatitis and are exploring ways to overcome and combat 
the disease.  
In the field of diagnostics, most researches are battling with the issue of identifying 
prognostic factors for severe acute pancreatitis. The goal is to find a diagnostic tool that 
could predict and determine the course of the disease at admission. This is especially 
important for obese patients, as they tend to have a more complicated disease. 
In the field of therapy, most researches are concentrated on finding a medication that could 
alter the course of the disease. A number of substances have been investigated in order to 
achieve this, but to no avail. Specific therapy would reduce the number of complications 
and mortality to ppm levels. 
Finally, scientists are trying to find the best possible methods and interventions to treat 
acute pancreatitis complications. Again, it is an issue of utmost importance for the obese, as 
interventions are more difficult in these patients and carry out a greater risk of procedural 
complications and mortality. 
Although the mentioned investigations are related to acute pancreatitis, there are a number 
of options available for implementing effective interventions for treating obesity. Will these 
obesity treatment procedures have positive effects on and will they become a part of acute 
pancreatitis treatment procedures, only time will show! 
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1. Introduction  
Acute pancreatitis is rare and serious complication during pregnancy, estimated to occur in 
1/1000 to 1/12000 pregnancies (Ramin et al., 1995). Discrepancy in incidence is because of 
the rarity of disease and because studies span different decades and countries. Acute 
pancreatitis appears to be more prevalent with advanced gestational stage, occurring more 
commonly in the second and the third trimester (Hernandez et al., 2007; Ramin et al., 2001). 
Ramin and al. noted that 19% of acute pancreatitis occurs in the first, 26% in the second, 53% 
in the third and 2% in the postpartum period, while others reported most of cases, 56%, in 
the second trimester (Hernandez et al., 2007; Ramin et al., 1995).  
The most frequent etiology of acute pancreatitis in pregnancy is biliary caused by gallstones 
or sludge (Wang et al., 2009). Other causes are hyperlipidemia and alcohol abuse. Rarely it 
could be, also, caused by hyperparathyroidism, connective tissue diseases, abdominal 
surgery, infections (viral, bacterial or parasitic), blunt abdominal injuries or could be 
iatrogenic caused by medications (diuretics, antibiotics, antihypertensive drugs) (Wang et 
al., 2009; Ramin et al., 1995).  
In pregnancy gallstones and sludge induce most of the cases of acute pancreatitis, they cause 
duct obstruction with pancreatic hyperstimulation that increases pancreatic duct pressure, 
trypsin reflux and activation of trypsin in the pancreatic acinar cells. This leads to enzyme 
activation within pancreas and causes autodigestion of the gland, followed by local 
inflammation. Pregnancy does not primarily predispose the pregnant woman to 
pancreatitis, but it does increase the risk of cholelithiasis and biliary sludge formation 
(Ramin et al., 1995). Theoretical reasons for the association of pregnancy and biliary tract 
diseases include increased bile acid pool size, decreased enterohepatic circulation, decreased 
percentage of chenodeoxycholic acid, and increased percentage of cholic acid and 
cholesterol secretion and bile stasis (Scott, 1992). Moreover, the steroid hormones of 
pregnancy decrease gallbladder motility (Ramin et al., 1995). Progesterone is a smooth 
muscle cell inhibitor that provokes gallbladder volume increase and slows emptying (Ramin 
et al., 1995). Estrogens increase cholesterol secretion and minimally alter gallbladder 
function ( Ramin et al., 1995). Also in the third trimester when the acute pancreatitis is most 
frequent, the uterus is enlarged and intrabdominal pressure on the biliary ducts is increased 
(Berk et al., 1971). 
 
Acute Pancreatitis 
 
48
2. Clinical features 
Acute pancreatitis presents essentially in the same way during pregnancy as in the non-
pregnant state. However, it is difficult to diagnose acute pancreatitis by history and physical 
examination because of similarity to many acute abdominal illnesses.  
2.1 Symptomatology 
Acute pancreatitis in pregnancy is mainly related to gallbladder disorders and correlates with 
cholelithiasis and biliary sludge (muddy sediment, precursor to gallstone formation) as the 
most likely predisposing causes (Ramin et al., 1995). The symptoms of gallbladder disease can 
be present or can precede the clinical presentation of acute pancreatitis. The symptoms include 
abdominal pain (colicky or stabbing) which may radiate to the right flank, scapula and 
shoulder. Onset of pain is rapid, with maximal intensity in 10 to 20 minutes. Pain is steady and 
moderate to severe. Band-like radiation of the pain to the back occurs in half of patients. Other 
symptoms of gallbladder disease include anorexia, nausea, vomiting, dyspepsia, low-grade 
fever, tachycardia and fatty food intolerance (Ramin et al., 1995).  
2.2 Physical examination 
Physical findings vary with the severity of illness, in moderate to severe pancreatitis the 
patient appears acutely ill and is found lying in the “fetal position” with flexed knees, hips 
and trunk. Abdominal tenderness is often found; in diffuse peritonitis muscle rigidity can be 
present. Bowel sounds, secondary to paralytic ileus, are usually hypoactive or absent. In 
severe pancreatitis the general physical examination may reveal abnormal vital signs if there 
are third-space fluid losses and systemic toxicity. Due to hypovolemia tachycardia up to 
150/min and low blood pressure could be found. Also, because of severe retroperitoneal 
inflammatory process temperature may increase. Dyspnea, tachypnea and shallow 
respirations resulting with hypoxemia may be present. Altered maternal acid-base status 
can adversely affect fetal acid-base status. Acute fetal hypoxia activates some compensatory 
mechanisms for redistribution of blood that enable fetus to achieve a constancy of oxygen 
consumption in the fetal cerebral circulation and in fetal myocardium. Redistribution of 
blood to vital organs enable fetus to survive for moderately long period of limited oxygen 
supply, but during more severe or sustained hypoxemia, these responses were no longer 
maintained and decompensation with fetal tissue damage and even fetal death may occur 
(Crisan et al., 2009; Date et al., 2008).  
Some physical findings point to a specific cause of acute pancreatitis: jaundice in biliary 
origin, spider angiomas in alcoholic or xanthomas and lipemia retinalis in hyperlipidemic 
pancreatitis.     
3. Diagnosis 
Acute pancreatitis in pregnancy is diagnosed by symptoms already described, by laboratory 
investigations and imaging methods.  
3.1 Laboratory diagnosis  
Laboratory investigations are the same as in non-pregnant and relies on at least a three-fold 
elevation of serum amylase and lipase levels in the blood. The total serum amylase level 
rises within 6 to 12 hours of onset of the disease, usually remain elevated for three to five 
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days. However, there are several conditions (i.e. pathologic processes in salivary glands, 
fallopian tubes, bowel obstruction, cholecystitis, hepatic trauma, perforative dudoenal ulcer, 
hyperamylasemia on familial basis...) that may result in elevation of serum amylase.  Serum 
lipase is elevated on the first day of ilness and remains elevated longer than the serum 
amylse. Specificity of serum lipase is greater than amylase, lipase level is normal in salivary 
gland disorder, tumors, gynecologic conditions and familial macroamylasemia. Calculation 
of an amylase to creatinine clearence ratio may be helpful in pregnancy,  ratio greater than 
5% suggests acute pancreatitis (Augustin&Majerovic, 2007).  
3.2 Imaging methods 
Imaging in pregnancy remains a controversial issue with concern of the effect of radiation on 
the developing fetus. Abdominal ultrasound (US) is the ideal imaging technique for detection 
of dilated pancreatic ducts and pseudocysts and focal accumulations larger than 2 to 3 cm.  US 
has no radiation risk to the fetus, but is limited by operator skill, patient obesity and bowell 
dilatation. Computed tomography (CT) should be avoided, especially during the first 
trimester, because of radiation exposure to the fetus, but has to be performed when benefits 
out-weighed the risk. When a common bile duct stone is suspected, endoscopic ultrasound 
(EUS) has a high positive predictive value nearing 100%, even for small stones  ≤ 2mm or 
sludge (Pitchumoni & Yegneswaran, 2009). EUS is considering to be the best imaging study to 
evaluate common bile duct, but requires expensive equipment, intravenous sedation and 
technical expertise. It is superior to magnetic resonance cholangiopancreatography (MRCP), an 
imaging method providing multi – planar large field of view images of the bilopancreatico-
ductal system. There are some concerns about the safety of MRCP in the first trimester of 
pregnancy because radiofrequency pulses result in energy deposition and could potentially 
result in tissue heating (Leyendecker et al., 2004). MR procedures are indicated in pregnancy if 
other non-ionizing forms of diagnostic imaging studies are inadequate, or if the examination 
provides information that would otherwise require exposure to ionizing radiation. Endoscopic 
retrograde cholangiopancreatography (ERCP) as a diagnostic tool lost its value because of the 
risk of radiation and the availability of safer procedures (i.e. EUS or MRCP).  ERCP should be 
used only as a therapeutic option in selected cases with confirmed bile duct stones. In cases of 
severe acute biliary pancreatitis (SABP) with or without cholangitis, early ERCP, preferably 
within 24 hours, is recommended (Banks&Freeman, 2006). Decompression  of the common 
bile duct and removal of gallstones with subsequent papillotomy could prevent complications 
and reduce mortality in SABP. Before proceeding to therapeutic ERCP, a less-invasive 
diagnostic method such as MRCP or EUS should  be performed.  In pregnancy it is necessary 
to minimise radiation exposure during ERCP, the procedure should be carried out only by a 
very experienced endoscopic and radiologic team and the fetus should be shielded all the time 
(Chong & Jalihal, 2010; O'Mahony, 2007). With the advent of ERCP and MRCP, the need for 
IOC (intraopeartive cholangiogram) is minimal, although there have been no reports 
investigating the safety of IOC during pregnancy (Date et al., 2008). Laparoscopic US scan 
appears to be alternative to retained common bile duct stones (Date et al., 2008). 
4. Treatment  
4.1 Conventional treatment measures 
The initial management of acute pancreatitis during pregnancy is similar to management in 
non-pregnant patients. Treatment consists of fluid restoration, oxygen, analgetics, 
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antiemetics and monitoring of vital signs. Important additional measures during pregnancy 
include fetal monitoring, attention to the choice of medications and positioning of the 
mother to avoid inferior vena cava constriction.  
Mild  pancreatitis treated conservatively usually resolves within 7 days. Ten percent of 
patients have severe course, and they are best managed in an intensive care unit. The third 
space fluid sequestration is the most serious hemodynamic disorder leading to hypovolemia 
and organ hypoperfusion resulting in multiple organ failure. In volume-depleted patients 
the essential treatment modality is initial infusion of 500 to 1000 mL of fluid per hour 
(Gardner et al., 2008). Monitoring of hydration, cardiovascular, renal and respiratory 
functions is important for early detection of volume overload and electrolyte disturbances 
(Forsmark & Baillie, 2007). 
Many pharmacological agents (somatostatin, octreotide, n-acetyl-cystein, gabexate mesylate, 
lexipafant and probiotics) have been investigated in acute pancreatitis, but because most of 
them have failed to show a positive effect they should be avoided in pregnancy. 
Cessation of oral feeding has been thought to suppress the exocrine function of pancreas, 
and to prevent further pancreatic autodigestion. Bowel rest is associated with increased 
infectious complications, and total parenteral nutrition (TPN) and enteral nutrition (EN) 
have an important role in the management of acute pancreatitis.  Keeping the patients "nil 
by mouth" with the use of TPN has been for years a traditional treatment of acute 
pancreatitis, but carries a significant risk of infections and metabolic distress. EN is 
physiological, helps the gut flora maintain the gut mucosal immunity, reduced translocation 
of bacteria, while simulataneously avoiding all the risks of TPN.  
Mild cases of acute pancreatitis do not need nutritional support, as the clinical course is 
usually uncomplicated and a low-fat diet can be started within 3 to 5 days. 
Treatment of severe necrotising pancreatitis should include enteral feeding by nasojejunal 
tube and if needed, should be supplemented by parenteral nutrition (Meier et al., 2006). 
Prophylactic use of antibiotics is very controversial and the choice of antibiotic in pregnancy 
is difficult. There are concerns with regarding to the antibiotic being tranplacentally 
transferred to the fetus with a risk of teratogenicity. Antibiotics have no role in the treatment 
of mild acute pancreatitis. The use of prophylactic antibiotics in severe acute pancreatitis 
remains controversial. The available evidence demonstrates that antibiotic prophylaxis 
might have a protective effect against non-pancreatic infections, but failed to show a benefit 
on reduction of mortality, infected necrosis and need for surgical intervention (Bai Y et al., 
2010; Jafri, 2009). Due to the lack of evidence on beneficial effect of antibiotics, an even more 
conservative approach is recommended in pregnancy. 
4.2 Surgical treatment 
Surgical treatment of pancreatitis has two aspects, which include operative intervention for 
the disease itself and surgical management of associated biliary tract disease once acute 
inflammation subsides (Ramin et al., 1995).  
Since, first study published in 1963 (Greene et al., 1963), the dilemma, whether or not to treat 
pregnant patients with gall-stones conservatively, still exists. Risk of conservative treatment 
include risk to the fetus due to recurrent episodes, complications of gallstones, risk of 
malnutrition caused by lack of oral intake. Conversely, surgical treatment carries risk to the 
fetus from surgery and anaesthesia and risk specific to laparoscopic surgery. Laparoscopic 
cholecystectomy (once considered contraindicated during pregnancy) (Gadacz & Talamini, 
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1991), is today, probably, the best treatment for the patients failed to respond to 
conservative management or because of recurrent episodes (Cosenza et al., 1999; SAGES 
Guidelines, 2011). Benefits of laparoscopy during pregnancy appear similar to those non-
pregnant patients including less postoperative pain, less postoperative ileus, significantly 
reduced hospitalization, decreased narcotic use and quick return to a regular diet and faster 
recovery. Other advantages of laparoscopy include less manipulation of the uterus and 
detection of other pathology that may be present and because of early mobility reduced risk 
of postoperative deep vein thrombosis (Date et al., 2008). Cholecystectomy is considered 
safe at all stages of pregnancy, and may be performed in any trimester of pregnancy without 
any increased risk to the mother or fetus (Cosenza et al., 1999; SAGES Guidelines, 2011). 
Historical recommendations to delay surgery until the second trimester or gestational age 
limit of 26 to 28 weeks of pregnancy have been refuted. Laparoscopy in pregnancy was 
conected with the fear of damage to the gravid uterus upon Veress or troacar insertion, 
technical difficulty in performing the surgery with the presence of an enlarged, gravid 
uterus and the concern of fetal acidemia due to decreased uterine blood flow because of 
increased intraabdominal pressure from insufflation and possible fetal carbon dioxide 
absorption (Wang et al, 2009). Also, maternal  venous return secondary to increased 
intraperitoneal pressure from CO2  insufflation could be present. The use of a uterine 
manipulator is contraindicated in pregnancy. At the begining of 2011, The Society of 
American Gastrointestinal and Endoscopic Surgeons (SAGES) updated its guidelines for 
laparoscopy during pregnancy (SAGES Guidelines, 2011). Recent reports suggest that the 
risk of fetal wasting and teratogenicity from gastrointestinal operation during pregnacy is 
minimal (Barone et al., 1999). However, some precautions should be followed: the use of an 
open technique for the insertion of the umbilical port, avoiding high intraperitoneal 
pressures, using of left lateral position to minimize aortocaval compression, avoiding rapid 
changes in the position of the patient and using electrocautery cautiously and away from 
uterus (Date et al., 2008). 
Early cholecystectomy should be performed in patients with mild acute biliary pancreatitis 
while patients with SABP should undergo this procedure within 4 and 6 weeks, 
respectively, after hospital discharge (Forsmark & Baillie, 2007).  
While sterile necrosis is  treated conservatively,  infected necrosis  requires the use of 
antibiotics and surgical necrosectomy. Patients with infected necrosis should be treated 
surgically within 3 to 4 weeks after the onset of symptoms. Minimal invasive surgical 
techniques are new in the management of acute pancreatitis with only a few relatively small 
series reported to date (Van Santvoort et al., 2007). 
A diagnostic and therapeutic alghorytm for acute pancreatitis in pregnancy is proposed in 
Diagramm 1 (Stimac & Stimac, in press) 
5. Outcome 
Prognosis for women with mild disease who respond to conservative management is 
excellent for mother and fetus. However, for more severe form of disease, mother mortality 
and fetal morbidity and mortality rates increase. In 1973 Wilkinson reviewed 98 cases of 
acute pancreatitis during pregnancy, 30 patients died (Wilkinson, 1973). Also, fetal death 
was noted in 60% of cases. Recently, the percentage of fatal outcomes of acute pancreatitis 
has been less than 5% (Talukdar & Vege, 2009) and is similar in pregnancy (Hernandez et al, 
2007). In the past decades high perinatal mortality rate, up to 50% (Wilkinson, 1973) 
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secondary to acute pancreatitis resulted from neonatal deaths after preterm delivery, but 
improvements in neonatal intensive and supportive care play important role in premature 
babies' survival. The mechanisms of demise include, also, placental abruption and profound 
metabolic disturbance, including acidosis. This highlights the importance of regular fetal 
monitoring and consideration of delivery if the maternal disease is deteriorating. 
 
 
 
 
 
Diagramm 1. Diagnostic and therapeutic alghorithm - acute pancreatitis in pregnancy 
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6. Conclusions 
Acute pancreatitisis is a rare entity in pregnancy,  mainly caused by gallbladder disorders, 
in which symptoms of cholelithiasis and biliary sludge in many cases precede the symptoms 
and clinical picture of acute pancreatitis. Diagnosis is based on clinical presentation, 
laboratory investigations and imaging methods performed  with precaution because of 
potential radiation risk  to the fetus. 
General management of mild AP in pregnancy is conservative and supportive, while severe 
AP deserves hospitalisation in intensive care unit and endoscopic or surgical interventions.  
The most common in pregnancy - biliary pancreatitis, can be resolved with urgent ERCP 
sphincterotomy and laparoscopic cholecystectomy preferably in second trimester, when 
technical conditions are optimal and  risk for fetus and pregnant woman minimized. 
Although treatment of acute pancreatitis during pregnancy is similar to general approach in 
acute pancreatitis patients, a multidisciplinary team consisting of gastroenterologist, gastro-
intestinal surgeon, radiologist and obstetrician should be included in the treatment and 
follow up of these patients. 
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1. Introduction 
Decades ago acute pancreatitis was thought to be an unusual disease in children; therefore 
the diagnosis was delayed or even misdiagnosed. Recent published information regarding 
its incidence, etiological factors and clinical characteristics suggest two important issues: its 
prevalence and incidence seem to increase in the last decade and the concept of a benign 
entity has been challenged by the high proportion of cases with necrotic-hemorrhagic 
lesions demonstrated by image studies and the relatively frequent occurrence of relapses 
(1,2). It is not clear if these published data mean an actual increasing incidence or reflect the 
fact that pediatricians are testing more frequently for this disease. An increase in the number 
of cases of pancreatitis in children has been demonstrated by authors in the USA (2-8), 
Australia (9), Poland (10), México (11-13), and Taiwan (14). 
2. Definition  
The National Library of Medicine defines pancreatitis as an inflammatory disorder of the 
pancreas (http://www.ncbi.nlm.nih.gov).  In order to diagnose pancreatitis at least two of 
the following criteria are required: 1) an increase in serum amylase >3 normal (>330 U/L) or 
in serum lipase >3 normal (>900 U/L); 2) clinical signs and symptoms consistent with the 
diagnosis (abdominal pain, vomiting, ileus and other signs like fever and jaundice); and 3) 
evidence of edema or hemorrhage and necrosis of the pancreas by ultrasonography and/or 
computed tomography (CT) (15). According to its evolution, pancreatitis may be classified 
as acute when it lasts days or a few weeks and is a reversible process. The term recurrent is 
used when more than one episode of acute pancreatitis occurs. Chronic pancreatitis implies 
the presence of pancreatic morphologic changes and losses of the exocrine and endocrine 
function that are not reversible. 
3. Pathophysiology and etiology 
Pancreatitis results from injury and inflammation of the pancreas that may be extended to 
peri-pancreatic tissues and remote organs. The process requires an initiating event that 
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triggers the acinar cells and activates the intracellular trypsinogen and other digestive 
enzymes. The resultant acinar cell damage produces pancreatic edema and a local 
inflammatory response associated with the release of inflammatory mediators (6,15-17). 
In most cases of pancreatitis more than one etiological factor may be indentified; from this 
point of view pancreatitis is better defined as a complex multifactorial disease (Figure 1).  
 
 
Fig. 1.  Etiologic factors associated to pancreatitis. AP: acute pancreatitis; RP: recurrent 
pancreatitis; CP: chronic pancreatitis. 
Studies performed in adults have described that the prevalence of the etiological factors 
have changed with time: the frequency of alcoholic induced chronic pancreatitis has 
decreased, biliary tract disease accounts for a higher percentage and etiologies as 
autoimmune and particularly hereditary/genetic pancreatitis are reported with increasing 
frequency (17-19). 
In children, the spectrum of factors associated to pancreatitis is very broad. The etiological 
factors identified in some pediatric series are described in Table 1; the most common are 
biliary tract disease (cholelitiasis, lithogenic bile, choledocal cyst, sphincter of Oddi 
dysfunction), abdominal trauma, drug ingestion and viral infections. The family history of 
pancreatitis is an important etiological factor that has to be asked, since hereditary 
pancreatitis may be defined as two patients with history of pancreatitis within one 
generation or more than two patients in more than one generation (20). In 7.2 to 37.6% of 
children with acute pancreatitis, no etiological factors are identified and these cases are 
classified as idiopathic (3-5,9,10,14,21-25).  
Another issue regarding etiology is the genetics of pancreatic disease. Recent evidence 
suggests that a significant proportion of cases with idiopathic pancreatitis, particularly 
recurrent and chronic, may be associated to mutations. The first pancreatitis susceptibility 
gene discovered was PRSS1 (protease, serine 1). Mutations in PRSS1, which encodes cationic 
trypsinogen, were discovered in families with hereditary pancreatitis (26-28) and the most 
common PRSS1 mutation  results in an Arg122 His substitution, which eliminates the key 
autolysis site that allows for rapid trypsin self-destruction in solutions with a low calcium 
concentration, such as inside the acinar cell (Whitcomb, 1996). This means that trypsin 
activation and prolonged survival inside the acinar cell leads to pancreatitis due to a 
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premature trypsinogen activation and persistent trypsin activity as being key initiators of 
pancreatic injury, because all of the zymogens are activated by trypsin and thereby increase 
susceptibility to acute and chronic pancreatitis (29).  
 
Author Year n Biliary Anatomic Family history Trauma 
Drug 
ingestion Metabolic Infectious 
Sistemic 
disease Genetic Idiopathic 
Mao-Meng 
Tiao 2002 61 11.4  - 45.9 6.6  1.6 14.7 - 19.7 
López 2002 274 10 - - 19 5 - - 53 - 17 
Pezilli 2002 50 28 - 6 10 2 2 12 6 - 34 
De Banto 2002 202 6.4 2.5 6.9 14.4 10.4 3.5 2.5 6.4 2.5 37.6 
Werlin 2003 180 12.2 3.3 - 13.9 12.2 6.1 7.2 13.9 2.8 7.2 
Choi 2003 56 29 2 - 11 30 -  9 - 12 
Alvarez 2003 31 16.1 3.2 - 6.5 9.7 3.2 19.3 6.5 - 35.5 
Sobczynska-
Tomaszewska 2006 92 10.9 15.2 27.2 5.4 - 8.7 2.2 4.3 33.7 29.3 
Nydegger 2007 279 5.4 - - 36.3 3.2 5.8 2.2 22.2 - 25.1 
Kandula 2008 87 5.7 - - 8.0 8 - 21.8 34.5 - 21 
Sánchez- 
Ramírez 2011 92 25 4.3 14.1 20 18.5 17.4 3.3 12 9.8 36.8 
Table 1. Etiologic factors in 11 series of children with pancreatitis. Results are presented as 
percentages. 
If trypsinogen becomes prematurely activated, a small fraction is directly inhibited by a 
pancreatic secretory trypsin inhibitor (PSTI), which is also known as serine protease 
inhibitor Kazal-type 1 (SPINK1). The importance of this specific trypsin inhibitor is that 
patients with mutated SPINK1 develop recurrent acute and chronic pancreatitis.(30-32). 
Another gene associated to the development of pancreatitis is the cystic fibrosis 
transmembrane conductance regulator (CFTR), which is a regulated anion channel that is 
located at the luminal surface of the duct cell and the key molecule in the pancreatic duct 
responsible for fluid secretion. The loss of bicarbonate secretion in the duct caused by CFTR 
mutations confers a less alkaline pancreatic juice that does not inhibits activated trypsin by 
interfering with the transition between trypsinogen and trypsin (33-35) and the ability to 
flush active enzymes out of the duct may be lost. The CFTR also protects the pancreas by 
quickly sweeping zymogens out of the pancreas. In 1998, two groups (34,35) demonstrated 
that CFTR mutations were also common in idiopathic and alcoholic chronic pancreatitis, 
which indicates that some of the 1,250 known CFTR gene sequence variants cause 
pancreatitis, particularly ∆F508 in which a three-base pair deletion causes loss of 
phenylalanine 508 and represents about 70% of CFTR mutations worldwide (36). The 
detection of mutations in the genes associated to pancreatitis is important since it has been 
demonstrated by other authors that the interaction of environmental and genetic factors (i.e. 
N34S + alcohol or PRSS1 + smoking) further increased the probability of a disease (20). 
The majority of the cases with mutations in genes associated to pancreatitis get ill in 
childhood. However, in a significant number of cases the definite signs of chronic 
pancreatitis may be found only after a long follow-up period. Keim describes that 
 
Acute Pancreatitis 
 
58
approximately 80% of patients with SPINK1 mutations showed at least one of the definite 
signs of chronic pancreatitis after a follow-up time of 15 to 20 years. In 50% of the patients 
with a PRSS1 mutation, chronic pancreatitis may be diagnosed after 25 years of follow up. In 
addition, it has been demonstrated a geographical variation regarding etiology, particularly 
genetic variants.  
The genetic variants (20) performed in pediatric population are very few compared to the 
studies performed in adult population. The mutations associated to pancreatitis that have 
been identified in some pediatric series are described in Table 2. There is a trend of a higher 
proportion of mutations in patients with RP and CP than in AP, although most of the 
studies included only patients with RP and CP and not cases with AP (10,31,37,38). 
In a pediatric series of 92 children with AP and RP attended at the Hospital of Pediatría 
(Guadalajara, México), we identified mutations (R122H and N34S) in a group of AP 
exclusively; this represented a 13-fold increased risk of having AP compared with the 
general population in which we did not identified these mutations. The SPINK1 N34S 
mutation was identified in 3/58 cases with AP, none in the group of RP nor in general 
population and it was found that the cases bearing the SPINK1 N34S G allele exhibited a 10-
fold increased risk of developing AP compared with the general population, suggesting that 
the SPINK1 N34S mutation represents an etiological risk factor for the development of AP in 
our pediatric patients (25).  
It is important to highlight that genetic testing in children with pancreatitis is not only 
useful for diagnosis but also as a predictive factor as it helps to identify individuals at risk 
for a more severe course of the disease. 
4. Clinical, laboratory and image data 
A summary of studies that report the frequency of the symptoms and signs in children with 
pancreatitis is presented in Table 3. The most common symptoms were abdominal pain 
followed by vomiting; in our series, ileus reached almost one-half of the cases studied 
(1,39,40). Abdominal pain is less commonly observed in children younger than 2 years, since 
it may be manifested by irritability (24,41). 
In pediatric series with pancreatitis an elevation of serum amylase has been reported in 83.6 to 
85.5% of the cases and of serum lipase in 82 to 90% (1,5,14). Although it has a relatively low 
sensitivity and specificity (75 to 92% and 20 to 60%, respectively), serum amylase remains as 
the test most frequently used to confirm pancreatitis. Serum amylase begins to increase 2 to 12 
hours after the pancreatic insult and peaks at 12 to 72 hours after the onset of symptoms. 
Sensitivity and specificity of serum lipase is 86-100% and 50-99% respectively. By increasing 
the cutoff level to greater than three times the upper normal limit, sensitivity may increase to 
100% and specificity to 99%. Lipase level remains elevated for a longer period of time in the 
plasma than amylase; increase occurs within 4 to 8 hours after symptom onset, peaks at 24 
hours and decreases over 8 to 14 days. By using serum amylase and lipase determinations 
together, clinical sensitivity for the diagnosis of pancreatitis increases to 94% (15). 
Imaging studies are a crucial tool to perform the diagnosis of pancreatitis. Ultrasound (US) 
is the primary imaging modality. However, the pancreas size is age-dependent and its 
echogenicity is variable; its reliability to identify pancreatitis seems to be higher in children. 
The US sensitivity in adults is 62-67% for acute and 50-80% for chronic pancreatitis, 
respectively (42). To our knowledge, in children there are no studies assessing the accuracy 
of US in the diagnosis of pancreatitis. The computed tomography (CT) provides additional 
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information about potential etiologies besides the presence of necrosis and other 
complications (6); however, it involves radiation exposure and has poor sensitivity in 
detecting ductal abnormalities (6,43). The CT with IV contrast is useful to identify necrotic-
hemorrhagic areas, fluid collections and peri-pancreatic inflammation; as pancreatic necrosis 
occurs 24 to 48 hour after the symptom onset it is recommended to perform the CT 48 to 72 
hours after pain or vomiting appeared. In two pediatric series, CT identified abnormalities 
more frequently than US (1, 14).  
 
Study Year Patients 
(n) 
Clinical signs and symptoms (%) 
Abdominal 
pain 
Vomiting Ileus Fever Jaundice 
Mao-Meng Tiao, et al. 2002 61 95 37.7 - 29.5 |3.2 
Pezzilli et al. 2002 50 96 - - - - 
Alvarez, et al. 2003 31 90 38 - 9.6 - 
Werlin, et al. 2003 214 67.8 44.9 - - - 
Sánchez-Ramírez, et al. 2007 55 94.5 85.5 47.3 27.3 9.1 
Table 2. Mutations associated to acute (AP), recurrent (AR) or chronic (CP) pancreatitis in 
624 children from different countries. Results are presented in percentages. 
 
Author (year) Country n 
SPINK (%) PRSS1 (%) 
AP RP or CP AP RP or CP 
Witt (2000) Germany and Austria 96 - 19.6 - 6.2 
Witt (2001) Germany and Austria 164 - 20.7 - 4.2 
Sobczynska-
Tomaszewska (2006) Poland 92 - 8.7 - 9.2 
Werlin (2003) USA 180 0.6 1.2 - 1.1 
Sanchez-Ramírez (2011) México 92 5.2 - 1.7 - 
Table 3. Clinical characteristics in 411 children with pancreatitis from five pediatric series. 
Values of clinical signs and symptoms are presented as percentages. 
The magnetic resonance cholangio-pancreaticography is non-invasive and do not expose the 
patients to radiation. It may provide a comprehensive morphological description of the 
biliary and pancreatic duct, making the endoscopic retrograde cholangio-pancreaticography 
(ERCP) unnecessary for diagnostic purposes (43). 
5. Disease spectrum 
Acute pancreatitis should be thought as an event and chronic pancreatitis as a process (16). 
Recurrent pancreatitis could be considered as a transition state until definite signs of chronic 
pancreatitis are detectable (20).The disease spectrum of pancreatitis is variable, ranging from 
mild edematous to severe fulminant pancreatitis, with potentially devastating complications.  
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DeBanto et al. (4) proposed a scoring system to predict the severity of pancreatitis in 
children. This scoring may permit to estimate the probability of having or not a severe 
disease; children who have a score of ≥3 on admission should be sent to a "step down" unit 
for close monitoring; if they reached the 48-h point with a score of ≤2, they would be 
transferred to a regular ward bed. 
This scoring system has eight parameters, four to be scored on admission and four by 48h. 
The criteria for admission to an intensive care unit from the emergency room are: age <7 yr, 
weight <23 kg, white blood cell count >18,500 and lactic dehydrogenase >2,000. The 48h 
criteria are calcium <8.3 mg/dL, albumin <2.6 g/dL, fluid-sequestration >75 ml/kg/48 h 
and a rise in blood urea nitrogen >5 mg/dL. 
6. Treatment 
Once the diagnosis of acute pancreatitis has been confirmed, the approach during the acute 
phase is initially directed to maintain the homeostasis by means of an IV fluid, electrolyte 
and glucose infusion according to the patients needs for age, hydration status and 
electrolyte balance. An adequate hemodynamic condition will prevent ischemia and 
pancreatic necrosis. The cases with abdominal CT suggestive of severe hemorrhagic 
pancreatitis should be admitted to an intensive care unit; the DeBanto’s score system on 
admission and at 48 hours may help the clinician to decide the admission to intensive care. 
A nasogastric tube with drainage by gravity will help to decompress the bowel and may 
improve the abdominal pain as well as the vomiting; in patients with ileus the nasogastric 
drainage will have intestinal or even fecal aspect (42,44,45).  
Antibiotics are not recommended in all cases of children with acute pancreatitis. They 
should be used in the presence of biliary obstruction, pancreatic abscesses or in selected 
cases of necrotic-hemorrhagic pancreatitis. However, these recommendations have been 
outlined from adult series with pancreatitis; these criteria have been used somehow in 
children although systematic pediatric data are lacking (42,44,45). Management of 
abdominal pain is crucial as this symptom may be associated to an adverse outcome; 
narcotics are not recommended due to its potential effect on Oddi’s sphincter (45). 
Surgery may be indicated at least three weeks after the acute episode in patients with severe 
pancreatitis associated to extra-pancreatic fluid collections, abscesses and large pseudocysts 
(14,42). The surgical approach should be considered in particular cases. 
The core goals of treatment are to support the involution of the pancreatic inflammation and 
to prevent the activation of the pancreatic enzymes. A logical way to achieve this goal is to 
avoid the physiologic stimulus of pancreatic secretion, namely the presence of 
macronutrients in the stomach and in the proximal duodenum (46). In children, this 
approach implies parenteral or enteral nutritional support. 
Children with acute pancreatitis are at risk of acute malnutrition due to two conditions: a) 
an increase in energy and nutrient requirements related to their catabolic disease; and b) 
iatrogenic or spontaneous oral food restriction (47). The nutritional risk is inversely 
proportional to age as growth speed and energy/nutrient requirements are higher in 
younger children; this is a physiologic condition between catabolic states in children versus 
adults. 
Fasting in adults with mild acute pancreatitis is not recommended and oral feedings may be 
initiated when pain stops. No benefit of enteral  or parenteral nutrition has been 
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demonstrated in these patients (48). Parenteral or enteral nutrition have been widely used 
for more than two decades in adult patients when fasting must be prolonged beyond one 
week because the pancreatic inflammation persists or in the presence of hemorrhagic 
pancreatitis. Although these two modalities of nutritional intervention have shown their 
efficacy, evidence related to the advantages of enteral nutrition has gradually accumulated. 
The rationale for using enteral nutrition is that nutrient infusion ahead the duodenum 
diminishes or avoids the secretion of cholecystokinin, secretin and pancreozymin and 
consequently maintains a low pancreatic exocrine activity. However, there is controversy 
regarding the infusion site in the GI tract. Some authors have demonstrated that nasogastric 
infusion is a secure and well tolerated alternative although their data relate more to non-
severe pancreatitis (49-53). There are no published data regarding enteral nutrition with a 
nasogastric infusion in pediatric patients with pancreatitis. 
The European Society for Clinical Nutrition and Metabolism recommends initiating oral  after 
abdominal pain has disappeared, when amylase and lipase concentration are almost 
normal, gastric emptying is normal and complications were solved out (48,53). A non-
randomized study in adults with acute pancreatitis identified that 21% of patients presented 
a pain relapse and 12 day delay between onset of symptoms and oral refeeding. In a 
retrospective study in children with acute pancreatitis, 15.4% and 10.3% had recurrence of 
pain and amylasemia when oral feedings were started before the days 7th and 10th 
respectively (52,54,55). 
An elemental diet or formulas with oligopeptides seem the best options to achieve a 
maximum suppression of the pancreatic enzyme secretion (48,53); however, a recent meta-
analysis states that polymeric diets have similar efficacy in the nutritional support of adults 
with acute pancreatitis. In the last two decades a number of children with mild or severe 
pancreatitis have been managed with naso-jejunal enteral nutrition using an elemental diet 
with low recurrence and complication rates (54-57).   
Adults with pancreatitis have increased energy and protein requirements; this has been 
estimated between 30 to 50% above normal daily requirements (Meier 2006). In children with 
pancreatitis this increased needs have been assumed for parenteral or enteral nutrition during 
the disease. In a series of children with pancreatitis managed with home enteral nutrition and 
energy intake of about 80% of the daily energy requirements an actual loss of weight was 
observed along the 14th to the 21th day of the intrevention (55). In a recent open clinical trial in 
17 children with acute pancreatitis managed with enteral nutrition, an enteral energy supply of 
130% of daily energy requirements led to a stable weight along the trial and to a significant 
increase in serum albumin (57) . 
Enteral nutrition prevents the systemic inflammatory response, luminal stasis, bacterial 
overgrowth and bacterial translocation (58). Besides maintaining the “pancreatic rest”, 
enteral nutrition reduces the length and costs of hospitalization and the frequency of sepsis 
(59,60). In prospective studies it has been demonstrated that the early onset of enteral 
nutrition –within 48 hours after admission- actually prevents the severity of the pancreatic 
damage, maintains enteral function and improve oral tolerance.  
The proposal of nutritional intervention in children with acute pancreatitis is supported in 
several facts: a) prevents acute malnutrition; b) provides nutrients for tissue healing; and c) 
modulates the systemic inflammatory response and thus prevents multiple organic failure 
(59). Published data related to nutritional support in children with acute pancreatitis are 
scanty. In the experience of the authors of this chapter in dealing with children with acute 
pancreatitis for about two decades, some facts may be underlined: a) children with mild or 
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edematous pancreatitis managed NPO and IV saline/glucose solutions do present acute 
malnutrition with a loss of more than 1 standard deviation of weigh for height or triceps 
skinfold (13,39,54); b) fasting for less than 7 days has an increased risk of recurrence of 
abdominal pain, raise in amylase levels >3x and recurrence of US abnormalities in around 
20% of cases (13,54); c) sepsis is almost inexistent in children managed with enteral 
nutrition; d) it is feasible to handle home enteral nutrition even with families with parents 
with mid educational level (55); e) decrease in amylase levels and symptomatic 
improvement are similar in children managed with total parenteral nutrition versus enteral 
nutrition (55); d) acute malnutrition may be prevented with the infusion of ~ 130% of the 
daily recommended intake of energy and macronutrients (56,57). 
The suggested nutritional intervention protocol for children with acute pancreatitis is 
presented in Table 4. The enteral infusion may be initiated once the ileum is resolved (the 
nasogastric drainage is clear, peristalsis is normal and the patient is passing gas and stools), 
even in the presence of abdominal pain. The enteral tube must be located in the jejunum and 
the infusion should be continuous for 24 hours if the patient remains hospitalized or 
discontinued for six hours (from 24 PM to 6 AM) if the patient is managed at home. The 
energy target is 130% of daily recommended intake of energy for age and sex and the 
recommended formula is an elemental diet; the authors do not have experience with the 
management of semi-elemental or polymeric formulas. The large amount of fluids required 
to reach this goal are tolerated quite well (56-57).  
 
 
Enteral tube Naso-jejunal feeding tube (2-way, radio-opaque tube) 
Infusion site placed ahead the angle of Treitz (verify tube placement 
with abdomen X-ray) 
Tube marked with permanent ink at the nostril fixation level 
Enteral formula Elemental formula (free amino-acids, glucose polymers and essential 
fatty acids). 80g of formula = carbohydrate 63g, protein 12.6g and fat 
0.81g. 
Enteral infusion 24-hour continuous infusion in hospitalized patients, 18-hour 
infusion in home enteral nutrition.  
Initial infusion: 100% of DRI of energy for age and sex; increase 15% 
daily to a target of  130% 
Re-feeding Oral refeeding; edematous pancreatitis 7 days and severe pancreatitis 
14 days after de symptom onset (in absence of abdominal pain and 
serum amylase and lipase not higher than 2x)  
Re-feeding diet: Diet high in carbohydrate and moderate in fat and 
protein starting with 70% of energy DRI and increasing 10% daily to 
reach 100% DRI. 
DRI: Daily recommended intake 
Table 4. Enteral nutrition recommendations in children with acute pancreatitis. 
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1. Introduction  
Named after the pathologic changes seen in the pancreas, cystic fibrosis (CF) is the most 
common lethal genetic disease in Caucasians, occuring in around 1 in 3000 live births. CF is 
uncommon among Asians (1 in 31,000 live births) and African Americans (1 in 15,000 live 
births) (Maitra & Kumar, 2005). It is caused by disease-causing mutations on both cystic 
fibrosis transmembrane conductance regulator (CFTR) alleles. Acute, recurrent-acute  and 
chronic pancreatitis in association with CFTR mutations can develop in the setting of either 
CF disease or CFTR-related pancreatitis, which belong within the spectrum of disorders 
associated with CFTR dysfunction.  
2. Cystic fibrosis (mucoviscidosis)  
Cystic fibrosis was historically considered to be a multi-system disease which manifested 
clinically either at birth (with intestinal obstruction due to meconium ileus) or in 
infancy/early childhood (with failure to thrive due to pancreatic insufficiency and 
recurrent/chronic sino-pulmonary disease). Our understanding of this disease has changed 
in recent times, particularly after the discovery of the CFTR gene. Any one, or all of the 
manifestations of CF can occur at any point, from before birth through to childhood, 
adolescence and even in adulthood. 
The CFTR gene responsible for CF is located on chromosome band 7q31.2, and encodes for a 
cyclic adenosine monophosphate (cAMP)-dependent chloride channel (Fig. 1). This 
particular chloride channel is located in the apical membrane of secretory and absorptive 
epithelium of the pancreas, intestine, liver, airway, vas deferens and sweat glands. The 
manifestations of CF generally arise from ductal and glandular obstruction due to an 
inability to hydrate macromolecules within the ductal lumen.  
3. Pancreatic diseases associated with CF and CFTR-related diseases 
Immunohistologic and pathologic studies have identified localisation of CFTR protein at the 
apical domain of the pancreatic ductal cells. Obstruction of proximal intralobular ducts by 
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inspissated protein plugs (obstructive tubulopathy) has been shown as early as during the 
in-utero period in CF (Oppenheimer & Esterly, 1976). The susceptibility of the pancreas to 
intraductal obstruction resulting from CFTR dysfunction is thought to be due to the high 
macromolecule concentration of the secretions and the dependence on the CFTR chloride 
(and bicarbonate) channel for maintaing fluid balance. Progressive ductal obstruction and 
fibrosis of acinar tissue presents as pancreatic insufficiency either at birth or in early 
childhood (Waters et al. 1990). Complete pancreatic exocrine deficiency is the seen in 85% to 
90% of patients with CF (Durno et al., 2002; Ooi et al., 2011a).  
 
 
 
 
Fig. 1. Schema illustrating the processing, structure and function of the CFTR protein. The 
classes of genetic mutations (discussed later) and their effects on the CFTR 
processing/function are illustrated. The CFTR protein consists of two transmembrane 
domains, two nucleotide-binding domains (NBD), and a regulatory R domain. Normal 
functioning involves an agonist such as acetyl-chloine binding to epithleial cells, resulting in 
an increase in cAMP, which activates protein kinase A (PKA). PKA phosphorylates the 
CFTR protein at the R domain, thus resulting in opening of the chloride (Cl¯) channel. ATP, 
adenosine triphosphate; c-AMP, cyclic adenosine monophosphate; CFTR, cystic fibrosis 
transmembrane conductance regulator. 
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The majority of CF patients carrying functionally severe mutations on both alleles (Class I-III 
and VI) have a pancreatic insufficient (PI) phenotype (85% to 90%). A small proportion (2-
3%) of patients carrying severe mutations on both alleles are pancreatic sufficient (PS) at 
diagnosis, but most experience gradual transition from PS to PI (Waters et al.,1990; 
Wilschanski & Durie, 2007). It is well established that PS-CF patients, who are often 
diagnosed at an older age, with more subtle disease manifestations, have mean sweat 
chloride values that are significantly lower than the current diagnostic reference criteria of 
60 mmol/L (Farrell et al., 2008; Gilljam et al., 2004). Without sufficient enzyme activity (or 
enzyme replacement), PI patients suffer from malabsorption of proteins, fats and fat-soluble 
vitamins, and to a lesser extent, carbohydrates. Clinical manifestations of PI include: 
steatorrhoea, failure to thrive/poor weight gain, abdominal distension, a reduction in 
subcutaneous fat and muscle tissue, and fat-soluble vitamin deficiencies. In adolescents, 
absence of a pubertal growth spurt and delayed maturation may occur (Rosenstein, 2006).  
With the increasing life expectancy of CF patients, it has become recognised that a 
significant proportion of PI-CF patients develop glucose intolerance, and up to 32% of 
patients over 25 years of age progress to insulin-requiring CF-related diabetes mellitus 
(Moran et al., 1999; Rosenstein, 2006). CF-related diabetes is characterised by an insidious 
onset and mild clinical course (e.g. gradual weight loss).  
4. Pancreatitis in CF and CFTR-related disease: Pathogenesis 
Pancreatitis is a well-known but uncommon manifestation in CF disease. This is not 
surprising as the majority of patients who carry functionally severe mutations on both 
alleles are PI. Since the presence of residual pancreatic acinar tissue is necessary for 
pancreatitis to occur, symptomatic pancreatitis does not (or rarely) occur in PI patients, but 
is not uncommon in PS-CF patients. Approximately 20% of PS-CF patients develop 
pancreatitis (Ooi et al., 2011a). Several studies have shown that individuals with idiopathic 
recurrent-acute or chronic pancreatitis have an increased incidence of mutations in the CFTR 
gene (Bishop et al., 2005; Cohn et al., 1998; Sharer et al.,1998). Bishop et al. (2005) showed 
that 43% and 11% of patients with idiopathic recurrent-acute or chronic pancreatitis carried 
at least one, and two CFTR mutations (and/or variants), respectively; the diagnostic criteria 
of CF could be fulfilled in 21% of these patients.  
Whilst obstructive tubulopathy of the pancreas due to CFTR dysfunction is thought to be 
primary pathogenic factor, the exact mechanism of pancreatitis associated with CFTR 
mutations is still unknown. Based on murine models, CFTR dysfunction may also affect 
pancreatic acinar cells by impairing apical endocytosis through diminished ductal 
bicarbonate secretion and subsequently reduced alkalinization of the acinar lumen 
(Freedman et al., 2001). A recent study also suggests an important role of pH dysregulation 
in the development of pancreatitis.  Co-release of protons (H+) with proteins from secretory 
granules of acinar cells during pancreatic secretion was demonstrated (Behrendorff et al., 
2010). Acidification of the pancreatic lumen led to a loss of tight junction integrity, which 
allowed the leakage of zymogens into the interstitial fluid. Abberant activation of calcium 
channels may also occur and result in the release and premature activation of zymogens, 
thus causing tissue damage and inflammation. The findings of this study fits with the 
development of pancreatitis in the setting of CFTR mutation(s) or CFTR dysfunction; 
reduced CFTR function impairs entry of bicarbonate into the ducts, and results in a more 
acidic and dehydrated pancreatic lumen. These studies support the complex interactions 
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that exist between the ductular and acinar components of the pancreas in the development 
of pancreatitis. 
Parodoxically, CFTR genotypes associated with otherwise mild phenotypic effects have a 
greater risk of causing pancreatitis, when compared with genotypes associated with 
moderate to severe disease phenotypes. Patients with enough functional CFTR to confer a 
phenotypically functional pancreas have an increased risk of pancreatitis, as sufficient 
pancreatic acinar tissue is required for obstructive ductal lesions to cause disease (Fig. 2).  
 
 
Fig. 2. Risk of pancreatitis in relation to severity of CFTR dysfunction. **The gradient within 
the pancreatitis curve reflects the relative risk of pancreatitis. A delicate balance between the 
degree of residual acinar tissue present and severity of ductal obstruction exists, and this 
balance correlates to the risk of pancreatitis. A. Patients with severe CFTR dysfunction have 
minimal/no risk of developing clinical pancreatitis despite severe ductal obstruction, as 
there is insufficient residual pancreatic acinar tissue. B. The risk of pancreatitis increases 
with decreasing CFTR dysfunction and is highest when there is adequately pathogenic 
ductal obstruction and sufficient residual acinar tissue present. C. With further increases in 
CFTR function, the degree of ductal obstruction is minimal, thus the risk of pancreatitis is 
low despite large amounts of pancreatic acinar tissue. The exception to this is when non-
CFTR modifier factors play a role. CFTR, cystic fibrosis transmembrane conductance 
regulator; Duct Obst., degree of ductal obstruction; f(acinii), residual acinar function; PI, 
pancreatic insufficient.  
5. CFTR mutations 
Since the discovery of the CFTR gene in 1989, advances in molecular analysis techniques 
have identified > 1800 CFTR mutations (Dorfman, 2011). Mutation in this context simply 
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refers to a molecular alteration in the DNA sequence of a gene, with no inference made 
concerning the effect of this alteration on gene expression, protein function and, therefore, 
clinical phenotype. For many of the CFTR mutations which have been identified, the effect 
of the mutation on gene expression or function of the protein product is unknown. This is 
especially true for missense mutations (a base pair substitution in the DNA sequence) which 
represent approximately 40% of the identified mutations. To explain the use and 
interpretation of CFTR mutation analysis in clinical practice, the European Cystic Fibrosis 
Society (ECFS) published a consensus paper in 2008 which categorised mutations into four 
groups based on their predicted clinical consequences: (i) CF-causing mutations, (ii) 
mutations associated with CFTR-related disease, (iii) mutations with no known clinical 
consequence, and (iv) mutations with unknown clinical relevance (Castellani et al., 2008). 
Mutations which are associated with both PS and PI phenotypes are listed in Table 1. Note 
the more conservative list of mutations which are included on the recommended panel of 
CF-causing mutations for population screening developed by the American College of 
Medical Genetics (Farrell et al., 2008). This list is not entirely exhaustive, as other mutations 
can be predicted to be CF-causing if the molecular alteration results in a change in amino 
acid sequence that: severely affects CFTR synthesis and/or function; introduces a premature 
termination signal; or alters invariant nucleotides of intron splice sites. However, the vast 
majority of known mutations do not fulfill the accepted criteria for CF-causing mutations 
(Castellani et al., 2008; Farrell et al., 2008). 
In CF, disease-causing mutations are often identified on newborn screening panels. In recent 
times, several diseases that resemble CF at an organ-specific level (e.g. pancreatitis,  
bronchiectasis and obstructive azoospermia) have also been found to be strongly associated 
with mutations in the CFTR gene (Ooi et al., 2010b). The functional consequence(s) of many 
CFTR gene alterations is unknown and unable to be determined. This is due to the interplay 
of mild and severe mutations, as well as the variation in genotype-phenoytpe expression, 
which is affected by non-CFTR modifiers (genetic and/or environmental).  
The complex and heterogenous presentation of CF disease and CFTR-related disorders is 
associated with a continuous spectrum of CFTR dysfunction. A clear relationship between 
the number and functional severity of CFTR gene alterations, with the range of CFTR-
mediated ion channel abnormalities has been established (Bishop et al., 2005; Wilschanski, 
2006). This observation has helped develop our understanding of the threshold of CFTR-
mediated ion channel function that is required for disease pathogenesis and diagnosis. 
A 5-class classification system for CFTR mutations was originally developed to categorize 
the molecular characteristics of different mutations (Fig. 3) (Tsui, 1992). On the basis of its 
molecular defect, mutations in Classes I-III could be predicted to have severe functional and 
phenotypic consequences. Conversely, Classes IV-V may confer residual CFTR function and 
thus, be predicted to be associated with milder phenotypic consequences. Remarkably, 
genotype-phenotype studies demonstrated an excellent correlation between Classes I-III 
with a PI phenotype, and Classes IV-V with a PS phenotype (Ahmed et al., 2003; Kristidis et  
al.,1992). A 6th mutation class has subsequently been proposed which is also associated with 
severe functional and phenotypic consequences. In general, patients homozygous or 
compound heterozygous for severe mutations (class I-III, and VI) will be PI. Alternatively, 
patients with at least one mild mutation (class IV or V), will often be PS, as the milder of the 
two mutations confers a dominant phenotypic effect. In very young infants, CFTR genotype 
may not be closely associated with pancreatic phenotype; particularly those identified by 
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newborn screening. This is almost certainly due to the fact that some infants carrying severe 
mutations on both alleles have some residual exocrine pancreatic function at birth. 
However, almost all of the patients who are homozygous or compound heterozygous for 
severe mutations will develop PI within the first two years of life (Waters et al., 1990). 
 
CFTR mutations and their associated clinical consequences 
Association Mutations Phenotype 
CF-causing F508del* 
R553X* 
R1162X* 
R1158X 
2184delA* 
2184insA 
3120+1G>A* 
I507del* 
1677delTA 
6542X* 
G551D* 
W1282X* 
N1303K* 
621+1G>T* 
1717-1G>A* 
1898+1G>T* 
R560T* 
G85E* 
711+1G>T* 
1898+1G>A 
S549N 
E822X 
1078delT 
2789+5G>A* 
3659delC* 
Usually 
PI 
A455E* 
R334W* 
R347P* 
711+3A>G 
3849+10kbC>T* 
R117H-T5* 
D1152H 
L206W 
TG13-T5 
Usually 
PS 
CFTR-related 
disease 
R117H-T7* 
D1152H 
TG13-T5 
D565G 
TG12-T5 
S997F 
R297Q 
L997F 
G576A 
TG11-T5 
R74W-D1270N 
R668C-G576A-
D443Y 
M9521 
Usually 
PS 
No clinical 
consequences 
I148T 
R75Q 
875+40A/G 
M470V 
E528E 
T854T 
P1290P 
2752-15G/C 
I807M 
1521F 
F508C 
I506V 
TG11-T5 
- 
Unknown or 
uncertain clinical 
consequence 
Mainly missense mutations with subclinical molecular 
consequences (e.g. M470V), which may co-segregate on 
the same chromosome and exert a more potent, 
cumulative phenotypic effect. 
- 
Table 1. List of CFTR mutations with their associated clinical consequence(s) and pancreatic 
exocrine phenotype(s). Adapted from Castellani et al., 2008. Underlined are the mutations 
associated with both PS and PI phenotypes. * The CFTR mutations included on the 
recommended panel of CF-causing mutations for population screening (Farrell et al., 2008). 
CF, cystic fibrosis;  CFTR, cystic fibrosis transmembrane conductance regulator; PI, 
pancreatic insufficient; PS, pancreatic sufficient.  
Although this class system is useful as a conceptual framework, it does have several 
limitations which include (Ooi et al., 2010b): (i) molecular changes of different mutations 
within the same class (especially classes IV and V), may have varying functional 
consequences, (ii) mutations may have overlapping molecular defects which may be 
assigned to more than one class, (iii) the molecular consequences of the majority of rare 
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CFTR mutations, particularly missense alterations are unknown or cannot be predicted, and 
(iv) inferred properties of many mutations remain to be confirmed by functional studies. 
 
Normal 
 Normal CFTR protein function 
I 
Defective protein synthesis: Nonsense or frameshift mutations 
associated with a complete lack of CFTR protein at the apical 
membrane (e.g. G542X, 394delTT and 1717-1G>A) 
II 
Abnormal protein folding, processing, and trafficking: 
Misfolded functional CFTR protein is largely degraded 
intracellularly, so there is a complete lack of CFTR protein at the 
apical membrane (e.g. F508del and N1303K) 
III 
Defective regulation: Mutations prevent channel activation by 
inhibiting binding and hydrolysis of ATP at one of the two 
nucleotide-binding domains. Thus the CFTR protein on the apical 
surface is nonfunctional (e.g. G551D) 
IV Decreased conductance: Abnormal anion conductance results in impaired protein function (e.g. R117H and R347P) 
V 
Reduced abundance: Abnormal splicing, promoter mutations or 
inefficient trafficking results in a reduced number of normally 
functioning protein at the apical membrane (e.g. A455E and 
3849+10kbC>T) 
VI 
Decreased stability or altered regulation of separate ion 
channels: Mutations which cause inherent lability of the CFTR 
protein or alter regulation of other ion channels 
Fig. 3. Classes of CFTR mutations according to the functional consequences of the gene 
product with respect to chloride regulation. Severe mutations (classes I-III and VI) confer 
little or no functional CFTR at the apical membrane, whilst mild mutations (classes IV and 
V) confer some partial CFTR function. Adapted from Tsui, 1992; Wilschanski & Durie, 
2007.CFTR, cystic fibrosis transmembrane conductance regulator. 
A new surrogate measure for the severity of CFTR mutations, known as the Pancreatic 
Insufficiency Prevalence (PIP) score, was recently developed and validated (Dorfman et al., 
2010; Ooi et al., 2011a). The PIP scoring system permitted a more refined classification of the 
functional severity of CFTR mutations, and in a far greater number of patients than previous 
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methods of classification. The PIP score is based upon a direct assessment of the effect of 
each genotype on exocrine pancreatic phenotype; which had been objectively determined in 
a large population-based CF database. This classification system is based on several 
premises: (i) the well-established correlation between severity of CFTR mutations and 
exocrine pancreatic function, (ii) the dominant phenotypic effect conferred by the milder of 
the 2 CFTR mutations, and (iii) the availability of a comprehensive database containing large 
numbers of CF patients, with stringent determination of clinical diagnosis and exocrine 
pancreatic status. Ooi et al. (2011a) described how mutations can be classified as either mild 
(≤0.25) or moderate-severe (>0.25) on the basis of the PIP score (Table 2). 
 
Pancreatic Insufficiency Prevalence (PIP) Scores for Common, Well-Defined  
CFTR Mutations 
Mutation Class Total PI Total PI + PS PIP Score Phenotype 
R117H 
3849+10kbC>T 
R334W 
IV-V 
IV-V 
IV-V 
1 
2 
1 
25 
22 
10 
0.04 
0.09 
0.10 
Mild 
2789+5G>A 
A455E 
G85E 
G551D 
R1162X 
N1303K 
W1282X 
1717-1G>A 
F508del 
G542X 
I507del 
R553X 
711+1G>T 
621+1G>T 
IV-V 
IV-V 
I-III,VI 
I-III,VI 
I-III,VI 
I-III,VI 
I-III,VI 
I-III,VI 
I-III,VI 
I-III,VI 
I-III,VI 
I-III,VI 
I-III,VI 
I-III,VI 
6 
18 
16 
59 
12 
45 
19 
20 
1276 
74 
11 
24 
36 
96 
16 
37 
22 
67 
13 
48 
20 
21 
1324 
75 
11 
24 
36 
96 
0.38 
0.49 
0.73 
0.88 
0.92 
0.94 
0.95 
0.95 
0.96 
0.99 
1.00 
1.00 
1.00 
1.00 
Moderate-
severe 
Table 2. PIP scores for common, well-defined CFTR mutations based on the prevalence of PI 
in a large and well-defined cohort of Canadian CF patients (n=2481) (Ooi et al., 2011a). The 
PIP score for a specific mutation is the ratio between the PI patients carrying the mutation 
(Total PI), and all PI and PS patients (Total PI + PS) carrying the same mutation when in a 
homozygous state or heterozygous combination with F508del, G551D or class I mutations 
(bona fide severe mutations). For example, a ratio of 1.00 indicates that all patients with 
621+1G>T are PI. Similarly, a ratio of 0.1 demonstrates that 10% of subjects with R334W are 
PI. CFTR, cystic fibrosis transmembrane conductance regulator; PI, pancreatic insufficient; 
PIP, pancreatic insufficiency prevalence; PS, pancreatic sufficient.  
Using the PIP score, a relationship between severity of CFTR genotypes with risk of 
pancreatitis was observed among PS-CF patients. Patients with genotypes associated with 
mild phenotypic (PIP score ≤ 0.25) effects have a greater risk of developing pancreatitis than 
patients with genotypes associated with moderate-severe phenotypes (PIP score > 0.25); 
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among the patients who developed pancreatitis, 70% had a mild genotype, while 30% 
carried a moderate-severe genotype (P = 0.004) (Ooi et al., 2011a). The genotype associated 
with mild PIP scores had a hazard ratio of 2.4 for pancreatitis (95% confidence interval, 1.3-
4.5; P = 0.006). Furthermore, there was a gradation of risk of developing pancreatitis 
according to severity of each allele carried: highest risk seen in CF patients who carried 2 
mild mutations (mild/mild) followed by those who carried 1 mild mutation 
(mild/moderate-severe), compared with those who carried functionally moderate-severe 
mutations on both alleles (Fig. 4). Thus, this is the first systematic study to date, 
demonstrating an association between higher risks of pancreatitis with different degrees of 
genotype mildness (based on the PIP score). 
 
 
Fig. 4. Survival curves (Kaplan-Meier estimate) comparing time to pancreatitis in patients 
grouped according to severity of both CFTR alleles (mild/mild vs. mild/moderate-severe vs. 
moderate-severe/moderate-severe). The survival table (below the curve) indicates the 
number of patients/“survivors“ at risk of pancreatitis at 0, 10, 20, 30, 40 and 50 years 
respectively. Adapted from Ooi et al., 2011a. * Log-rank test CFTR, cystic fibrosis 
transmembrane conductance regulator; Mod-Sev, moderate-severe. 
All classification systems are limited by the fact that the heterogenous CF disease spectrum 
is not just explained by CFTR genotype, but is also influenced by environmental and other 
genetic modifying factors. Genes such as cationic trypsinogen (PRSS1), anionic trypsinogen 
(PRSS2), pancreatic secretory trypsin inhibitor (SPINK1), and chymotrpsinogen C (CTRC) 
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have been demonstrated to be involved in the regulation of trypsinogen autoactivation and 
also play a role in cases of idiopathic recurrent-acute and chronic pancreatitis (Ooi et al., 
2010a). The interactions with environmental factors such as cigarette smoking, alcohol and 
diet are also highly complex, and are only beginning to unravel.  
6. The spectrum of CFTR dysfunction 
The notion of a spectrum of CFTR dysfunction is supported by the observation that CF may 
manifest at different ages, in different organs and with variable severity. Cystic fibrosis and 
CFTR-related disorders comprise of pancreatic exocrine insufficiency, pancreatitis, chronic 
sinopulmonary disease, intestinal diseases, hepatobiliary disease, and obstructive 
azoospermia in men.  
Individuals who carry one or two CFTR gene mutation(s) show an overlapping clinical 
spectrum, ranging from no clinical disease at one extreme, through those with CFTR-related 
disorders, to those with CF disease (with/without sufficient pancreatic function) at the other 
extreme (Fig. 5). 
 
 
 
Fig. 5. Spectrum of disorders associated with the level of CFTR function and the 
respective severity/risk of disease. * Severe CF liver disease with cirrhosis ± portal 
hypertension. CBAVD, congenital absence of the vas deferens; CF, cystic fibrosis; CFTR, 
cystic fibrosis transmembrane conductance regulator; PI, pancreatic insufficient; PS, 
pancreatic sufficient.  
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There is considerable debate and difficulty on where to draw the diagnostic line between CF 
disease and CFTR-related disorder. Although they can be divided into two entities, they 
form part of a continuous spectrum of diseases associated with CFTR dysfunction. Similarly, 
ion channel measurements in the sweat gland (sweat test) and nasal epithelium (nasal 
potential difference test) show a continuum of values with overlap, and no clear delineating 
point between individuals without CF (healthy controls and obligate heterozygotes) and 
patients with CF (pancreatic sufficient and insufficient). Consequently our ability to 
establish or exclude CF disease has become increasingly problematic. 
The subset of clinically heterogeneous patients who are diagnosed with CF in adolescence 
and adulthood, who do not resemble the typical clinical presentation in infancy or early 
childhood are discussed later in this chapter. 
7. Pancreatitis in CF and CFTR-related disorder: Clinical presentation and 
diagnosis  
The initial clinical presentation of acute, recurrent-acute and chronic pancreatitis due to 
CFTR dysfunction can be indistinguishable from idiopathic pancreatitis. The clinical 
features and diagnostic criteria for pancreatitis are covered by companion chapter(s) in this 
textbook. 
The most recent United States Cystic Fibrosis Foundation (USCFF) consensus report (Farrell et 
al., 2008), agreed that a diagnosis of CF can be made in individuals who present with a 
characteristic clinical phenotype or a history of CF in a sibling, in the presence of an abnormal 
sweat chloride value ≥ 60 mmol/L and/or two CF-causing mutations. It is important to note 
that a diagnosis of CF cannot be made based on the identification of CFTR mutations on both 
alleles alone, especially when one or both are not designated as disease-causing mutations. 
Due to the vast array of phenotypes associated with CFTR mutations, the diagnosis of 
patients with CF disease has become increasingly difficult, and the demarcation line 
between those with CF and those not classified as having CF by current diagnostic criteria 
has blurred. To deal with the spectrum of disease, the USCFF consensus report stated that 
the classification of this disease should be limited to two terms (Farrell et al., 2008): (i) CF 
disease, to describe patients who fulfil the currently accepted diagnostic criteria, and (ii) 
“CFTR-related disorder,” to describe individuals with a CF phenotype in at least one 
affected organ plus evidence of CFTR dysfunction, but insufficient to fulfil the diagnostic 
criteria for CF disease (e.g. borderline sweat test and/or 1 – 2 non-CF causing mutation(s)). 
Using this terminology, patients with recurrent-acute or chronic pancreatitis due to CFTR 
dysfunction , may receive a diagnosis of CF pancreatitis or CFTR-related pancreatitis. 
Individuals with a CFTR-related disorder are recognised to be at risk for developing CF disease 
(Farrell et al., 2008). Therefore, a diagnosis of CFTR-related pancreatitis may precede a 
diagnosis of CF, as it may be the initial manifestation of CFTR dysfunction, or it may be 
associated with other CFTR-related disorders at the time of presentation (e.g. infertile males 
with pancreatitis) or later on. Consequently, if repeat sweat chloride values remain in the 
intermediate range (40-59 mmol/L), further assessment has been recommended at a CF care 
center to clarify the diagnosis. Further assessment may include: clinical assessment, 
expanded genetic testing, exocrine pancreatic function testing, and respiratory tract culture 
for CF-associated pathogens. Depending on the clinical presentation, assessment may also 
include ancillary tests, such as pulmonary function testing and urogenital evaluation in 
males (genital examination, rectal ultrasound, and sperm analysis). It is important to 
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emphasise that treatment should be dependent on the disease presentation, and not on 
presence or absence of a diagnostic label. 
7.1 Sweat chloride testing 
The sweat chloride test has been in clinical use for over 50 years, and it still remains the 
principal test for the confirmation of the diagnosis of CF in the genomic era (Gibson & 
Cooke, 1959). Although the test is now commonly available in most diagnostic laboratories, 
appropriate performance of the sweat test in accordance to recommended standards is 
crucial for accurate diagnosis. The sweat test involves transdermal administration of 
pilocarpine by iontophoresis to stimulate sweat gland secretion, followed by collection and 
quantitation of sweat onto gauze or filter paper, or into a Macroduct coil. The reference 
ranges for sweat chloride concentration which we use today, were defined using studies of 
CF patients presenting with classical symptoms of CF at an early age (most were PI); there 
were no “truly healthy” controls, and the technical aspects of the sweat test methodologies 
would not meet currently accepted guidelines (Farrell et al., 2008; Shwachman & 
Mahmoodian, 1967). Furthermore, there has also been no study to accurately determine the 
reference ranges for sweat chloride values in infants and young children less than 5 years of 
age (Farrell et al., 2008). Several studies have also reported patients being diagnosed with 
CF (PS and PI), who have sweat chloride values < 60mmol/L (Desmarquest et al., 2000; 
Highsmith et al., 1994; Stewart et al., 1995). This is especially true among the well described 
CF disease-causing mutations associated with normal or intermediate sweat chloride values 
(e.g. 3849+10kbC>T).  
Sweat chloride values are traditionally interpreted categorically. Due to the aforementioned 
limitations, it is not surprising that the reference values for the various sweat chloride 
categories are not universally agreed upon. According to the USCFF consensus guideline, 
sweat chloride values can be categorised as the following among individuals > 6 months old: 
normal ≤ 39 mmol/L, intermediate 40-59 mmol/L, or abnormal ≥ 60 mmol/L; the 
intermediate range is extended to 30-59 mmol/L in infants up to 6 months old (Farrell et al., 
2008). This differs from the reference ranges recommended by the ECFS: normal ≤ 29 mmol/L, 
intermediate 30-60 mmol/L, and abnormal > 60 mmol/L, for all ages (De Boeck et al., 2006).  
There is preliminary data to suggest that the individual sweat chloride value, taken into 
account with the clinical context, is of more value to the clinician than categorical 
interpretation (Ooi et al., 2011b). This study evaluated the diagnostic performance of sweat 
testing in the general population and in patients with idiopathic pancreatitis who were 
referred to a gastroenterology (GI)-CF clinic. This study raised an important point that 
sweat test parameters and results are dependent on the patient population and disease 
incidence in each population. When comparing the general population to symptomatic 
pancreatitis patients in a GI-CF clinic: the pre-test probability for CF is 1 in 3608 vs. 10%; the 
carrier rate is 4% vs. 50%; and the PI:PS CF ratio is 8:1 vs. all patients with pancreatitis being 
PS (Bishop et al., 2005; Castellani et al., 2010; Dupuis et al., 2005; Durno et al., 2002). It has 
also been reported that a diagnosis of CF can be made in 10% of idiopathic pancreatitis 
patients (referred to a GI-CF clinic), based on sweat testing and/or genotyping, however the 
diagnosis may be equivocal in up to 20% of patients (Bishop et al., 2005; Ooi et al., 2010a). As 
expected, there were vast differences in the diagnostic performance of sweat chloride testing 
in the two populations (Table 3).  
An important observation from this study is the dramatic increase in the positive predictive 
value (PPV) of sweat chloride values ≥ 55 mmol/L in the general population, and the not 
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clinically insignificant high PPV in those who present with symptomatic pancreatitis and 
have sweat chloride values ≥ 40mmol/L (Fig. 6). These results demonstrate how the 
individual sweat chloride result (whilst also taking in to account the clinical context of the 
patient), may be more valuable to the clinician than using the traditional categorical 
interpretation.  
 
 
Fig. 6. PPV of sweat chloride testing in the general population and patients with idiopathic 
pancreatitis referred to a GI-CF clinic (Ooi et al., 2011b).CF, cystic fibrosis; CFTR, cystic 
fibrosis transmembrane conductance regulator; PPV, positive predictive value.  
 
Sw Cl 
(mmol/L) 
General Population GI-CF Clinic 
Sens Spec PPV NPV Sens Spec PPV NPV 
20 100 54 0.1 100 98 48 17 100 
30 99 83 0.2 100 94 77 31 99 
40 98 97 0.9 100 81 91 51 98 
50 97 99 2 100 77 96 70 97 
55 97 100 25 100 73 99 92 97 
60 96 100 100 100 64 100 100 96 
Table 3. Diagnostic performance parameters for various sweat chloride values in a general 
population and patients at a GI-CF clinic. (Ooi et al., 2011b). CF, cystic fibrosis; GI, 
gastroenterology; NPV, negative predictive value; PPV, positive predictive value; Sens, 
sensitivity; Spec, specificity; Sw Cl, sweat chloride.  
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7.2 Genotyping 
Despite the considerable optimism that genotyping would supersede the traditional sweat 
test, there remains considerable misunderstanding of the role of CFTR genotyping as a 
diagnostic aid in CF. In patients with a suspected, but unproven diagnosis of CF, mutation 
testing (including complete sequencing of the CFTR gene) appears to be the least helpful 
diagnostic tool and may be potentially misleading. In fact, carefully performed sweat 
chloride testing has been reported to be more sensitive and specific than complete 
sequencing in patients presenting with a single organ manifestation of CF including 
pancreatitis (Bishop et al., 2005; Gilljam et al., 2004; Wilschanski, 2006). In a cohort of 46 CF 
patients diagnosed in adulthood, only 15 (33%) fulfilled the diagnostic criteria of CF based 
on genotyping alone; all except one of the 15 (6.7%) had an abnormal sweat test > 60 
mmol/L. Sweat testing alone diagnosed CF in 30 (65%) subjects and when sweat testing was 
combined with genotyping, the diagnostic sensitivity only improved slightly to 67% (n=31) 
(Gilljam et al., 2004).  
If a clinician decides to assess a patient’s genotype, it is important to consider that most 
patients presenting in adolescence and adulthood and/or those who present with single-
organ disease, frequently carry one or more rare CFTR mutations which are often not 
included in screening panels. However, extensive genotyping or complete sequencing of the 
CFTR gene has major limitations also. The majority of mutations have unknown functional 
consequences, while some are considered to be benign polymorphisms with no pathogenic 
potential. Furthermore, some mutations are known  to form complex alleles i.e. > 1 mutation 
occurs only on one allele and hence, may be mis-interpreted as the presence of mutations on 
both alleles. With all these variables, there is a potential risk of informing a patient with 
pancreatitis that they have CFTR mutations, and implying they have CF. Misinterpretation 
of genotyping results carries enormous psychosocial and medical implications, as well as 
affecting potential insurability. In a study reporting the outcomes from a commercially 
available extensive CFTR mutation test, 84% of patients identified with 2 CFTR mutations 
were incorrectly labeled as having CF (Keiles & Kammesheidt, 2006; Ooi et al., 2010a). 
7.3 Transepithelial nasal potential difference testing 
The transepithelial nasal potential difference (NPD) test is an electrophysiological test that 
assesses CFTR activity by measuring transepithelial potential difference of the nasal 
epithelium. This test is based on the characteristic bioelectric properties of amiloride-
dependent sodium (Na+) absorption (via ENaC) and CFTR-mediated Cl¯ diffusion (Schuler 
et al., 2004). NPD has been used in CF research for decades but due to a lack of validated 
reference values and standardisation, it has only been cautiously applied in clinical practice 
as an adjunctive test to assist in clarifying the diagnosis of CF, especially for individuals 
with intermediate sweat chloride values (Farrell et al., 2008). 
NPD is measured between a fluid-filled exploring bridge positioned on the nasal respiratory 
mucosa, and a reference bridge inserted into the subcutaneous space. Both bridges are 
linked by Ag/AgCl electrodes (or saturated calomel half-cells) to a high-impedence 
voltmeter. An otoscope is used to help place the tip of the exploring catheter on the 
respiratory mucosa inferior to the concha nasalis inferior. A basal potential difference is 
established once consistent baseline NPD measurements are obtained. Different 
solutions/drugs can be administered via the exploring catheter, and the changes in 
transepithelial potential difference as a response to superfusion can be measured. The 
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findings of a high potential difference during baseline measurements, followed by an absent 
or very low voltage response to zero-chloride plus isoproterenol perfusion, are indicative of 
CF (Knowles et al., 1995).  
Patients who have equivocal sweat chloride results and/or CFTR mutation analysis may 
also have equivocal NPD measurements, and a consensus of what constitutes a borderline 
result is lacking (Ooi et al., 2010b). In addition, the procedure is complex to perform, labour 
intensive, and operator dependent. Although NPD testing has been reported in infants and 
young children, the accurate performance of this test requires undivided cooperation from 
the subject. False positives can occur with incorrect placement of the measuring catheter, 
minor perturbations of nasal epithelium, allergies, respiratory infections, and smoking 
(Cantin et al., 2006).  
7.4 Intestinal ion channel measurement 
Intestinal ion channel measurement (ICM) is an ex vivo test performed in an Ussing 
chamber using a freshly obtained rectal biopsy and measuring its electrical response to a 
series of secretagogues. Intestinal epithelia of CF subjects have been evaluated by two 
different laboratory methods (circulating vs. continuously perfused) (De Jonge et al., 2004; 
Mall et al., 2004). The common finding of both approaches demonstrates absent or 
diminished chloride secretion after stimulation with agonists that act via intracellular cAMP.  
Intestinal ICM has been reported to be useful in clarifying the diagnosis of CF in cases of 
uncertainty, but again the absence of standardisation and well-established reference values 
limits its use in clinical practice (Farrell et al., 2008).  
7.5 Imaging in CF and CFTR-related pancreatitis 
The typical changes of the pancreas on imaging in patients with CF are neither specific nor 
diagnostic for CF and CFTR-related pancreatitis. In CF, fatty replacement of the pancreatic 
parenchyma, with or without glandular atrophy (56-93%) is the most common finding at 
imaging in adult patients, and the mean age of fatty replacement is 17 years (Robertson et 
al., 2006; Shanbhogue et al., 2009). Other radiological findings include pancreatic 
calcifications (7%); cyst formation (pancreatic cystosis); and abnormalities of the pancreatic 
duct, including strictures, beading, dilatation, and obstruction (Shanbhogue et al., 2009). The 
pancreatic duct can be poorly demonstrated with ultrasonography (US) in CF patients with 
pancreatic atrophy and fatty replacement, and is best demonstrated with magnetic 
resonance cholangiopancreatography (MRCP) or endoscopic retrograde 
cholangiopancreatography (ERCP) (Robertson et al., 2006). Imaging has no role in 
monitoring of exocrine pancreatic function but has a yet to-be-defined role in surveillance 
for pancreatic adenocarcinoma.  
8. Management of pancreatitis in CF and CFTR-related disorder 
The management of pancreatitis associated with CF or CFTR mutations per se, is currently 
no different to other forms of pancreatitis (covered in companion chapters). Affected 
patients however should be referred to a CF clinic or gastroenterologist with 
interests/expertise in CF for a thorough evaluation. The main considerations in these 
patients are a progression from PS to PI, and the risk of developing CF disease and/or 
disease in other CF-affected organs (e.g. bronchiectasis) (Gilljam et al., 2004; Ooi et al., 
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2011a). In addition, there are increasing concerns of an increased risk of pancreatic 
adenocarcinoma among those with CF and CFTR-related pancreatitis. 
8.1 Pancreatic function testing 
The exocrine pancreas has a large reserve capacity and requires between 90% and 99% of 
enzyme secretory capacity to be lost before a subject develops clinical manifestations of PI. It 
is recommended that patients with PS-CF and CFTR-related pancreatitis have their 
pancreatic exocrine function assessed. Individuals who have sufficient pancreatic function at 
presentation need to be assessed periodically, or when new symptoms suggestive of PI 
develop, as some may progress to PI (Gilljam et al., 2004; Ooi et al., 2011a). Progression of PI 
is dependent on the following factors: (1) the carriage of moderate-severe mutations on both 
alleles, and (2) the development of symptomatic pancreatitis. PS-CF patients with mild 
genotypes (i.e. those otherwise expected to remain PS) who develop pancreatitis are at an 
increased risk of progressing from PS to PI (odds ratio = 5.5) (Ooi et al., 2011a).  
Exocrine pancreatic function can be measured through non-invasive and invasive methods. 
Currently, non-invasive pancreatic function tests are commonly utilised for defining the 
exocrine pancreatic phenotype. The 72-hour faecal fat balance test, expressed as the 
coefficient of fat absorption (CFA), is considered the gold standard as far as non-invasive 
tests are concerned (Ooi et al., 2010b). However, the test is inconvenient and not well 
tolerated by patients or laboratory staff. Faecal elastase-1 is an alternative indirect stool 
marker for pancreatic function, as elastase (an endogenous pancreatic secretion enzyme) is 
resistant to gastrointestinal degradation. Using a cut-off of 200 μg/g stool, the sensitivity for 
mild, moderate, severe and all patients with PI, was reported to be 63%, 100%, 100% and 
93% respectively, whilst the specificity was 93% (Loser et al., 1996). Because of its ease of 
use, faecal elastase-1 is recommended for evaluating pancreatic function at diagnosis and for 
follow-up monitoring. Currently, a value of < 100 μg/g in individuals over the age of 2 to 3 
years is considered indicative of PI. Values from 100 μg/g to 200 μg/g are associated with 
significant loss of pancreatic function, although not necessarily of sufficient severity to 
confer PI, and warrant the need for pancreatic enzyme supplementation (Farrell et al., 2008). 
In addition, there are differences in the diagnostic performance parameters (sensitivity and 
specificity) between monoclonal and polyclonal assays for faecal elastase; the monoclonal 
assay is superior due to less cross-reactivity and can be used whilst patients are on 
pancreatic enzyme therapy (Pezzilli et al., 2005). False positivity can occur due to 
malabsorption from an intestinal cause, particularly if there is stool dilution from severe 
diarrhoea (Beharry et al., 2002). Other indirect methods for assessing pancreatic function 
include the measurement of faecal concentrations of the pancreatic enzymes, trypsin and 
chymotrypsin. However, both faecal trypsin and chymotrypsin are prone to intestinal 
degradation and faecal chymotrypsin cross-reacts with exogenously administered enzyme 
therapy. 
Serum trypsinogen has been used for newborn screening for more than two decades, and has 
been shown to help define pancreatic functional status in CF patients older than 7 years of age 
(Durie et al., 1986). This test has the added benefit of being able to predict the progression of 
pancreatic status from PS to PI (Couper et al., 1995). Serum trypsinogen is also capable of 
identifying the presence of pancreatic disease and dysfunction (loss of pancreatic reserve or 
pancreatitis) in individuals with a CFTR-related disorder (Ooi et al., 2010b).  
Alternatively, the invasive direct pancreatic stimulation test allows assessment of both 
pancreatic acinar (enzyme) and ductular (electrolyte and fluid) status. There is currently no 
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standardized methodology for direct pancreatic stimulation testing and various techniques 
are used throughout the world. Measurements and diagnosis of exocrine pancreatic status 
based on pancreatic stimulation testing warrants careful interpretation and can be 
misleading if not performed accurately. The quantitative pancreatic stimulation test that 
uses perfusion markers with multiple sampling periods is sensitive, highly specific, and 
capable of evaluating the entire range of pancreatic function (Groman et al., 2004). This 
technique is regarded as the true gold standard in direct pancreatic stimulation testing. 
Nevertheless, this test is time consuming, technically complex to perform and not routinely 
available. Consequently, alternative and simpler direct pancreatic stimulation techniques 
(non-quantitative), are used at many clinical centers. These generally utilise a single-lumen 
duodenal tube or endoscope to aspirate duodenal pancreatic secretions, either as a spot 
sample and/or over a timed sampling period (Choi et al., 2001; Monaghan et al., 2004; 
Rohlfs et al., 2002; Suaud et al., 2007). Despite their popularity, non-quantitative techniques 
have a high false positive rate for misdiagnosing PI and have not been proven superior over 
non-invasive indirect pancreatic function tests. In fact, Schibli et al. (2006) demonstrated that 
these techniques carry the greatest risk of misclassifying a PS patient as PI, especially among 
PS patients with a secretory capacity between the threshold of PI and the lower limit of 
normal (Grody et al., 2001; Schibli et al., 2006). 
8.2 Referral to a CF care centre 
As mentioned previously, CF and CFTR-related disease may manifest with variable 
severity, in single or multiple organs, and at different ages. For the clinician at hand dealing 
with a patient with pancreatitis associated with borderline or abnormal sweat test results 
and/or CFTR mutations, a more detailed assessment of other affected organ systems may be 
necessary. The phenotypic features of CF which should be kept in mind are summarised in 
Table 4. Furthermore, other organs affected by CFTR dysfunction may not be clinically 
evident at the time of diagnosis, thus overall assessment and routine follow-up is crucial. 
Referral should be made to a multidisciplinary CF care centre that can provide 
comprehensive diagnostic testing, determination of involvement of all affected organs (e.g. 
pulmonary disease), timely intervention, disease-specific counseling (e.g. fertility and 
smoking cessation for pancreatitis and lung disease), genetic counseling, and monitoring. 
Beyond the well-established phenotypic features of CF, cystic-fibrosis-related diabetes 
(CFRD) should also be tested for and monitored, particularly among those confirmed as 
having CF and who progress to PI.  
8.3 Prognosis 
Data from the Canadian CF registry shows that the median survival age in patients with CF 
has risen from 29.1 years in 1988 to 46.6 years in 2008 (Canadian Cystic Fibrosis Foundation, 
2008). Similar improvements have occurred in other countries, but differences in survival 
persist (Fogarty, 2000). End-stage lung disease is the primary cause of morbidity and 
mortality in CF, but discussions on the respiratory aspects of CF are beyond the scope of this 
chapter. For patients with CFTR-related pancreatitis, the long-term outcomes are unknown.  
A recent study reported an association between CFTR mutations and a higher risk of 
pancreatic adenocarcinoma (OR 1.82; 95% CI, 1.14-2.94; P = 0.011) (McWilliams et al., 2010). 
Carriers of CFTR mutations were seen to be diagnosed at a younger age than non-carriers, 
with the effect exclusively seen in ever-smokers (median 60 years vs. 65 years; P = 0.028).  
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Phenotypic Features of CF 
Gastrointestinal 
Abnormalities 
i. Pancreatic: PI, recurrent-acute pancreatitis, chronic pancreatitis 
ii. Intestinal: meconium ileus, distal intestinal obstruction syndrome, 
rectal prolapse 
iii. Hepatic: prolonged neonatal jaundice, chronic hepatic disease (focal 
biliary cirrhosis or multilobular cirrhosis) 
iv. Nutritional: failure to thrive, hypoproteinemia and oedema, fat-
soluble vitamin deficiency syndromes 
Male Genital 
Tract Disease 
i. Obstructive azoospermia due to congenital absence of the vas 
deferens 
Chronic 
Sinopulmonary 
Disease 
i. Persistent colonisation/infection with typical CF pathogens 
(Staphylococcus aureus, nontypeable Haemophilus influenza, 
mucoid and nonmucoid Pseudomonas aeruginosa, 
Stenotrophomonas maltophilia, and Burkholderia cepacia) 
ii. Chronic cough and sputum production 
iii. Persistent chest radiographic findings (e.g bronchiectasis, 
atelectasis, infiltrates, and hyperinflation) 
iv. Airway obstruction, with wheezing and air-trapping 
v. Nasal polyps 
vi. Digital clubbing 
Table 4. Phenotypic features of CF. (Adapted from Farrell et al., 2008). CF, cystic fibrosis; PI, 
pancreatic insufficiency.  
9. Areas for future research 
Greater understanding of the true prevalence of CFTR-related disorders, including CFTR-
related pancreatitis is much needed, and long-term studies in these patients are lacking.  
Despite CF being a monogenic disease, the development of pancreatitis in CF and CFTR-
related disorder is dependent on complex interactions with non-CFTR genetic, 
environmental and anatomic factors. Future research is needed to investigate the complex 
interaction between CFTR, other known (e.g. PRSS1 and SPINK1 mutations) and unknown 
genetic factors, and their interplay with environmental factors. Future studies are needed to 
determine the risk and protective modifier factors (genetic and environmental) that lead to 
the different single organ phenotypes in CFTR-related disorders (i.e. “why do individuals 
with the same combinations of CFTR mutations present heterogeneously?”). This in turn 
may also lead to additional therapeutic potentials.  
One such therapeutic potential in the pipeline are small molecule therapies, known as CFTR 
correctors and potentiators. These therapies may have a role in not only patients with CF, 
but also those with CFTR-related pancreatitis; in view of our recent increased understanding 
of the relationship between CFTR dysfunction and risk of pancreatitis (Ooi et al., 2011a). A 
recent study of a CFTR mutation-specific potentiator reported improvement in CFTR 
function (measured using NPD and sweat chloride testing) and lung function in affected CF 
patients with a G551D mutation (Accurso et al., 2010). 
With increased longevity of patients with CF, the relatively infrequent condition of 
pancreatic adenocarcinoma is anticipated to become more clinically relevant. In view of its 
 
Pancreatitis in Cystic Fibrosis and CFTR-Related Disorder 
 
85 
associated high mortality rates, future studies into optimal screening regimens and 
modalities in patients with genetic causes of chronic pancreatitis are needed. 
10. Conclusion 
There has been a vast expansion in our understanding of the wide range of phenotypes 
associated with CFTR dysfunction since the discovery of the CFTR gene. Pancreatitis is one 
such phenotype, which is almost exclusively seen in patients who are PS. In addition, a 
relationship between the severity of CFTR genotypes and the risk of pancreatitis has been 
established. Paradoxically, genotypes associated with otherwise mild phenotypic effects 
have the greater risk for causing pancreatitis; compared with genotypes associated with 
moderate to severe disease phenotypes.  
Idiopathic acute, recurrent-acute and chronic pancreatitis may be the initial manifestation of 
CF and CFTR-related disorder. However, diagnosing CF or CFTR-related disorder can be 
challenging. Sweat chloride testing is the principal diagnostic test and effectively diagnoses 
CF patients with the severe PI phenotype but it may have a limited ability to conclusively 
establish or exclude a diagnosis of CF disease. Careful interpretation of sweat chloride 
values and repeated testing may be necessary. CFTR genotyping for investigation of 
idiopathic pancreatitis has a limited diagnostic yield, may be misleading and may have 
uncertain “real life” consequence(s). Referral to a tertiary CF centre for further assessment is 
recommended, and periodical reassessment may be necessary to detect, monitor and 
intervene in treatable co-morbidities, even if the diagnostic criteria for CF cannot be fulfilled. 
Development of symptomatic pancreatitis is a strong risk factor for progressive decline in 
exocrine pancreatic function in patients with cystic fibrosis and possibly also in CFTR-
related pancreatitis; thus, it is important to monitor for the development of exocrine 
pancreatic insufficiency over time. 
11. References 
Accurso, F.J.; Rowe, S.M.; Clancy, J.P.; Boyle, M.P.; Dunitz, J.M.; Durie, P.R.; et al. (2010). 
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. New 
England Journal of Medicine, Vol.363, No.21, (November 2010), pp. 1991-2003, ISSN 
0028-4793 
Ahmed, N.; Corey, M.; Forstner, G.; Zielenski, J.; Tsui, L.; Ellis, L.; et al. (2003). Molecular 
consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in 
the exocrine pancreas. Gut, Vol.52, No.8, (August 2003), pp. 1159-1164, ISSN 0017-
5749 
Beharry, S.; Ellis, L.; Corey, M.; Marcon, M. & Durie, P. (2002). How useful is fecal pancreatic 
elastase 1 as a marker of exocrine pancreatic disease?. Journal of Pediatrics, Vol.141, 
No.1, (July 2002), pp. 84-90, ISSN 0022-3476 
Behrendorff, N.; Floetenmeyer, M.; Schwiening, C. & Thorn, P. (2010). Protons released 
during pancreatic acinar cell secretion acidify the lumen and contribute to 
pancreatitis in mice. Gastroenterology, Vol.139, (November 2010), pp. 1711-1720, 
ISSN 0016-5085 
Bishop, M.D.; Freedman, S.D.; Zielenski, J.; Ahmed, N.; Dupuis, A.; Martin, S.; et al. (2005). 
The cystic fibrosis transmembrane conductance regulator gene and ion channel 
 
Acute Pancreatitis 
 
86
function in patients with idiopathic pancreatitis. Human Genetics, Vol.118, No.3-4, 
(December 2005), pp. 372-381, ISSN 0340-6717 
Canadian Cystic Fibrosis Foundation (Ed.). (2008). Canadian Cystic Fibrosis Patient Data 
Registry Report 2008, In: Cystic Fibrosis Canada, 08.06.2011, Available from: 
http://www.cysticfibrosis.ca/assets/files/pdf/CPDR_ReportE.pdf  
Cantin, A.M.; Hanrahan, J.W.; Bilodeau, G.; Ellis, L.; Dupuis, A.; Liao, J.; et al. (2006). Cystic 
fibrosis transmembrane conductance regulator function is suppressed in cigarette 
smokers. American Journal of Respiratory and Critical Care Medicine, Vol.173, No.10, 
(May 2006), pp. 1139-1144, ISSN 1073-449X 
Castellani, C.; Macek, M.Jr.; Cassiman, J.J.; Duff, A.; Massie, J.; ten Kate, L.P.; et al. (2010). 
Benchmarks for cystic fibrosis carrier screening: a European consensus document. 
Journal of Cystic Fibrosis, Vol.9, No.3, (May 2010), pp. 165-178, ISSN 1569-1993 
Castellani, C.; Cuppens, H.; Macek, M.; Cassiman, J.J.; Kerem, E.; Durie, P.; et al. (2008). 
Consensus on the use and interpretation of cystic fibrosis mutation analysis in 
clinical practice. Journal of Cystic Fibrosis, Vol.7, No.3, (May 2008), pp. 179-196, ISSN 
1569-1993 
Choi, J.Y.; Muallem, D.; Kiselyov, K.;Lee, M.G.; Thomas, P.J. & Muallem, S. (2001). Abberant 
CFTR-dependent HCO3- transport in muations associated with cystic fibrosis. 
Nature, Vol.410, No.6824, (March 2001), pp. 94-97, ISSN 0028-0836 
Cohn, J.A.; Friedman, K.J.; Noone, P.G.; Knowles, M.R.; Silverman, L.M. & Jowell, P.S. 
(1998). Relation between mutations of the cystic fibrosis gene and idiopathic 
pancreatitis. New England Journal of Medicine, Vol.339, No.10, (September 1998), pp. 
653-658, ISSN 0028-4793 
Couper, R.T.; Corey, M.; Durie, P.R.; Forstner, G.G. & Moore, D.J. (1995). Longitudinal 
evaluation of serum trypsinogen measurement in pancreatic-insufficient and 
pancreatic-sufficient patients with cystic fibrosis. Journal of Pediatrics, Vol.127, No.3, 
(September 1995), pp. 408-413, ISSN 0022-3476 
De Boeck, K.; Wilschanski, M.; Castellani, C.; Taylor, C.; Cuppens, H.; Dodge, J. & 
Sinaasappel, M. (2006). Cystic Fibrosis: terminology and diagnostic algorithms. 
[Review]. Thorax, Vol.61, No.7, (July 2006), pp. 627-635, ISSN 0040-6376 
De Jonge, H.R.; Ballmann, M.; Veeze, H.; Bronsveld, I.; Stanke, F.; Tummler, B. & 
Sinaasappel, M. (2004). Ex vivo CF diagnosis by intestinal current measurements 
(ICM) in small aperture, circulating Ussing chambers. Journal of Cystic Fibrosis, Vol.3 
Supplement 2, (August 2004), pp. 159-163, ISSN 1569-1993 
Desmarquest, P.; Feldman, D.; Tamalat, A.; Boule, M.; Fauroux, B.; Tournier, G. & Clement, 
A. (2000). Genotype analysis and phenotypic manifestations of children with 
intermediate sweat chloride test results. Chest, Vol.118, No.6, (December 2000), pp. 
1591-1597, ISSN 0012-3692 
Dorfman, R. (April 2011). Cystic Fibrosis Mutation Database, 08.06.2011, Available from: 
http://www.genet.sickkids.on.ca/cftr 
Dorfman, R.; Nalpathamakalam, T.; Taylor, C.; Gonska, T.; Keenan, K.; Yuan, X.W.; et al. 
(2010). Do common in silico tools predict the clinical consequences of amino-acid 
substitutions in the CFTR gene?. Clinical Genetics, Vol.77, No.5, (May 2010), pp. 464-
473, ISSN 0009-9163 
 
Pancreatitis in Cystic Fibrosis and CFTR-Related Disorder 
 
87 
Dupuis, A.; Hamilton, D.; Cole, D.E. & Corey, M. (2005). Cystic fibrosis birth rates in 
Canada: a decreasing trend since the onset of genetic testing. Journal of Pediatrics, 
Vol.147, No.3, (September 2005), pp. 312-315, ISSN 0022-3476 
Durie, P.R.; Forstner, G.G.; Gaskin, K.J.; Moore, D.J.; Cleghorn, G.J.; Wong, S.S. & Corey, 
M.L. (1986). Age-related alterations of immunoreactive pancreatic cationic 
trypsinogen in sera from cystic fibrosis patients with and without pancreatic 
insufficiency. Pediatric Research, Vol.20, No.3, (March 1986), pp. 209-213, ISSN 0031-
3998 
Durno, C.; Corey, M.; Zielenski, J.; Tullis, E.; Tsui, L. & Durie, P. (2002). Genotype and 
phenotype correlations in patients with cystic fibrosis and pancreatitis. 
Gastroenterology, Vol.123, No.6, (December 2002), pp. 1857-1864, ISSN 0016-5085 
Farrell, P.M.; Rosenstein, B.J.; White, T.B.; Accurso, F.J.; Castellani, C.; Cutting, G.R.; et al. 
(2008). Guidelines for diagnosis of cystic fibrosis in newborns through older adults: 
Cystic Fibrosis Foundation consensus report. The Journal of Pediatrics, Vol.153, No.2, 
(August 2008), pp. S4-S14, ISSN 0022-3476 
Fogarty, A. (2000). International comparison of median age at death from cystic fibrosis. 
Chest, Vol.117, No.6, (June, 2000), pp. 1656-1660, ISSN 0012-3692 
Freedman, S.D.; Kern, H.F. & Scheele, G.A. (2001). Pancreatic acinar cell dysfunction in 
CFTR(-/-) mice is associated with impairments in luminal pH and endocytosis. 
Gastroenterology, Vol.121, No.4, (October 2001), pp. 950-957, ISSN 0016-5085 
Gibson, L.E. & Cooke, R.E. (1959). A test for concentration of electrolytes in sweat in cystic 
fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics, Vol.23, 
No.3, (March 1959), pp. 545-549, ISSN 0031-4005 
Gilljam, M.; Ellis, L.; Corey, M.; Zielenski, L.; Durie, P. & Tullis, D.E. (2004). Clinical 
manifestations of cystic fibrosis among patients diagnosed in adulthood. Chest, 
Vol.126, No.4, (October 2004), pp. 1215-1224, ISSN 0012-3692 
Grody, W.W.; Cutting, G.R.; Klinger, K.W.; Richards, C.S.; Watson, M.S.; Desnick, R.J. & 
Subcommittee on Cystic Fibrosis Screening, Accreditation of Genetic Services 
Committee, ACMG. American College of Medical Genetics. (2001). Laboratory 
standards and guidelines for population-based cystic fibrosis carrier screening. 
Genetics in Medicine, Vol.3, No.2, (March-April 2001), pp. 149-54, ISSN 1098-3600 
Groman, J.D.; Hefferon, T.W.; Casals, T.; Bassas, L.; Estivill, X.; Des Georges, M.; et al. (2004). 
Variation in a repeat sequence determines whether a common variant of the cystic 
fibrosis transmembrane conductance regulator gene is pathogenic or benign. 
American Journal of Human Genetics, Vol.74, No.1, (January 2004), pp. 176-179, ISSN 
0002-9297 
Highsmith, W.E.; Burch, L.H.; Zhou, Z.; Olsen, J.C.; Boat, T.E.; Spock, A.; et al. (1994). A 
novel mutation in the cystic fibrosis gene in patients with pulmonary disease but 
normal sweat chloride concentrations. New England Journal of Medicine, Vol.331, 
No.15, (October 1994), pp. 974-980, ISSN 0028-4793 
Keiles, S. & Kammesheidt, A. (2006). Identification of CFTR PRSS1 and SPINK1 mutations in 
381 patients with pancreatitis. Pancreas, Vol.33, No.3, (October 2006), pp. 221-227, 
ISSN 0885-3177 
 
Acute Pancreatitis 
 
88
Knowles, M.R.; Paradiso, A.M. & Boucher, R.C. (1995). In vivo nasal potential difference – 
techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. 
Human Gene Therapy, Vol.6, No.4, (April 1995), pp. 445-455, ISSN 1043-0342 
Kristidis, P.; Bozon, D.; Corey, M.; Markiewicz, D.; Rommens, J.; Tsui, L.C. & Durie, P. 
(1992). American Journal of Human Genetics, Vol.50, No.6, (June 1992), pp. 1178-1184, 
ISSN 0002-9297 
Loser, C.; Mollgaard, A. & Folsch, U.R. (1996). Faecal elastase 1: a novel, highly sensitive, 
and specific tubeless pancreatic function test. Gut, Vol.39, No.4, (October 1996), pp. 
580-586, ISSN 0017-5749 
Maitra, A. & Kumar, V. (2005). Diseases of Infancy and Childhood, In: Robbins and Cotran 
Pathologic Basis of Disease (7th ed.), Kumar, V.; Abbas, A. & Fausto, N. (Eds.), 469-
508, Elsevier Saunders, ISBN 978-0-7216-0187-8, Phildelphia, USA 
Mall, M.; Hirtz, S.; Gonska, T. & Kunzelmann, K. (2004). Assessment of CFTR function in 
rectal biopsies for the diagnosis of cystic fibrosis. Journal of Cystic Fibrosis, Vol.3 
Supplement 2, (August 2004), pp. 165-169, ISSN 1569-1993 
McWilliams, R.R.; Petersen, G.M.; Rabe, K.G.; Holtegaard, L.M.; Lynch, P.J.; Bishop, M.D. & 
Highsmith, W.E.Jr. (2010). Cystic fibrosis transmembrane conductance regulator 
(CFTR) gene mutations and risk for pancreatic adenocarcinoma. Cancer, Vol.116, 
No.1, (January 2010), pp. 203-209, ISSN 0008-543X 
Monaghan, K.G.; Highsmith, W.E.; Amos, J.; Pratt, V.M.; Roa, B.; Friez, M.; et al. (2004). 
Genotype-phenotype correlation and frequency of the 3199del6 cystic fibrosis 
mutation among I148T carriers: Results from a collaborative study. Genetics in 
Medicine, Vol.6, No.5, (September-October 2004), pp. 421-425, ISSN 1098-3600 
Moran, A.; Hardin, D.; Rodman, D.; Allen, H.; Beall, R.; Borowitz, D.; et al. (1999). Diagnosis, 
screening and management of CF related diabetes mellitus: a consensus conference 
report. Diabetes Research & Clinical Practice, Vol.45, No.5, (August 1999), pp. 61-73, 
ISSN 0168-8227 
Ooi, C.Y.; Dorfman, R.; Cipolli, M.; Gonska, T.; Castellani, C.; Keenan, K.; et al. (2011). Type 
of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. 
Gastroenterology, Vol.140, No.1, (January 2011), pp. 153-161, ISSN 0016-5085 
Ooi, C.Y.; Dupuis, A.; Keenan, K.; Tullis, E. & Durie, P.R. (2011). Role of sweat testing in 
patients with idiopathic pancreatitis. Gastroenterology, Vol.140, No.5, Supplement 1, 
(May 2011), pp. S-854-S-855, ISSN 0016-5085 
Ooi, C.Y.; Gonska, T.; Durie, P.R. & Freedman, S.D. (2010). Genetic Testing in Pancreatitis. 
Gastroenterology, Vol.138, No.7, (June 2010), pp 2202-2206, ISSN 0016-5085 
Ooi, C.Y.; Tullis, E. & Durie, P. (2010). Diagnostic Approach to CFTR-related Disorders, In: 
Cystic Fibrosis. Lung Biology in Health and Disease Series, Allen, J.; Rubenstein, R. & 
Panitch, H. (Eds.), 103-122, Informa Healthcare, ISBN 978-1-4398-0182-6, New York, 
USA 
Oppenheimer, E.H. & Esterly, J.R. (1976). Pathology of cystic fibrosis: review of the literature 
and comparison with 146 autopsied cases. Perspectives in Pediatric Pathology, Vol.2, 
(n.d. 1976), pp. 241-278, ISSN 0091-2921 
Pezzilli, R.; Morselli-Labate, A.M.; Palladoro, F.; Campana, D.; Piscitelli, L.; Tomassetti, P. & 
Corinaldesi, R. (2005). The ELISA fecal elastase-1 polyclonal assay reacts with 
 
Pancreatitis in Cystic Fibrosis and CFTR-Related Disorder 
 
89 
different antigens than those of the monoclonal assay. Pancreas, Vol.31, No.2, 
(August 2005), pp. 200-201, ISSN 0885-3177 
Robertson, M.B.; Choe, K.A. & Joseph, P.M. (2006). Review of the abdominal manifestations 
of cystic fibrosis in the adult patient. Radiographics, Vol.26, No.3, (May-June 2006), 
pp. 679-690, ISSN 0271-5333 
Rohlfs, E.M.; Zhou, Z.; Sugarman, E.A.; Heim, R.A.; Pace, R.G.; Knowles, M.R.; et al. (2002). 
The I148T CFTR allele occurs on multiple haplotypes: a complex allele is associated 
with cystic fibrosis. Genetics in Medicine, Vol.4, No.5, (September-October 2002), pp. 
319-323, ISSN 1098-3600 
Rosenstein, B.J. (2006). Cystic Fibrosis, In: Oski’s Pediatrics (4th ed.), McMillan, J.A.; Feigin, 
R.D.; DeAngelis, C. & Jones, M.D. (Eds.), 1426-1438, Lippincott Williams & Wilkins, 
ISBN 0-7817-3894-6, Philadelphia, USA 
Schibli, S.; Corey, M.; Gaskin, K.J.; Ellis, L. & Durie, P.R. (2006). Towards the ideal 
quantitative pancreatic function test: analysis of test variable that influence validity. 
Clinical Gastroenterology and Hepatology, Vol.4, No.1, (January 2006), pp. 90-97, ISSN 
1542-3565 
Schuler, D.; Sermet-Gaudelus, I.; Wilschanski, M.; Ballmann, M.; Dechaux, M.; Edelman, A.; 
et al. (2004). Basic protocol for transepithelial nasal potential difference 
measurements. [Review]. Journal of Cystic Fibrosis, Vol.3 Supplement 2, (August 
2004), pp. 151-155, ISSN 1569-1993 
Shanbhogue, A.K.; Fasih, N.; Surabhi, V.R.; Doherty, G.P.; Shanbhogue, D.K. & Sethi, S.K. 
(2009). A clinical and radiologic review of uncommon types and causes of 
pancreatitis. Radiographics, Vol.29, No.4, (July-August 2009), pp. 1003-1026, ISSN 
0271-5333 
Sharer, N.; Schwarz, M.; Malone, G.; Howarth, A.; Painter, J.; Super, M. & Braganza, J. 
(1998). Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. 
New England Journal of Medicine, Vol.339, No.10, (September 1998), pp. 645-652, 
ISSN 0028-4793 
Shwachman, H. & Mahmoodian, A. (1967). Pilocarpine ionophoresis sweat testing results of 
seven years‘ experience. Bibliotheca Paediatrica, Vol.86, (n.d. 1967), pp. 158-182, ISSN 
0301-357X 
Stewart, B.; Zabner, J.; Shuber, A.P.; Welsh, M.J. & McCray, P.B.J. (1995). Normal sweat 
chloride values do not exclude the diagnosis of cystic fibrosis. American Journal of 
Respiratory and Critical Care Medicine, Vol.151, No.3 Pt 1, (March 1995), pp. 899-903, 
ISSN 1073-449X 
Suaud, L.; Yan, W. & Rubenstein, R.C. (2007). Abnormal regulatory interactions of I148T-
CFTR and the epithelial Na+ channel in Xenopus oocytes. American Journal of 
Physiology. Cell Physiology, Vol.292, No.1, (January 2007), pp. C603-611, ISSN 0363-
6143 
Tsui, L. (1992). The spectrum of cystic fibrosis mutations. Trends in Genetics, Vol.8, No.11, 
(November 1992), pp. 392-398, ISSN 0168-9525 
Waters, D.L.; Dorney, S.F.; Gaskin, K.J.; Gruca, M.A.; O’Halloran, M. & Wilcken, B. (1990). 
Pancreatic function in infants identified as having cystic fibrosis in a neonatal 
screening program. New England Journal of Medicine, Vol.322, No.5, (February 1990), 
pp. 303-308, ISSN 0028-4793 
 
Acute Pancreatitis 
 
90
Wilschanski, M. & Durie, P.R. (2007). Patterns of GI disease in adulthood associated with 
mutations in the CFTR gene. Gut, Vol.56, No.8, (August 2007), pp. 1153-1163, ISSN 
0017-5749 
Wilschanski, M. (2006). Mutations in the cystic fibrosis transmembrane regulator gene and 
in vivo transepithelial potentials. American Journal of Respiratory and Critical Care 
Medicine, Vol.174, No.7, (October 2006), pp. 787-794, ISSN 1073-449X 
7 
Diabetes or Diabetes Drugs: 
A Cause for Acute Pancreatitis 
Leann Olansky 
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USA 
1. Introduction 
About a decade ago, a question was raised about glyburide, a widely used sulfonylurea, as a 
possible cause for acute pancreatitis (Blomgren). Since then, several systemic reviews reveal 
the incidence of acute pancreatitis in patients with type 2 diabetes 1.5 to 3-fold increase risk 
compared to non-diabetic subjects in each of 3 large health data bases (Noel, Garg, Girman). 
Five years after the concern was raised about glyburide and soon after the first of the 
incretin based, exenatide, had gained a significant market share, reports of pancreatitis 
again began to surface. This was followed by a similar concern when the first in class of the 
next new class of diabetes agents, the dipeptyl depeditidase-4 inhibitor (DPP-4 inhibitor), 
sitagliptin had achieved a significant market share. Exenatide is a glucagon like peptide one 
(GLP-1) agonist and DPP-4 inhibitors increase to action of endogenous GLP-1 by slowing 
the degradation of endogenous GLP-1, as well of other gut derived hormones, so a common 
etiology was implied. Examination of two different insurance data bases, again reveal no 
real increase over other agents used to treat type 2 diabetes. Review of the incidence of acute 
pancreatitis from the adverse event data from the clinical trials of the two GLP-1 agonists 
and the three DPP-4 inhibitors available currently on the US market reveals similar rates of 
acute pancreatitis with each agent and with the comparators during blinded clinical trials, 
providing more evidence that it is the disease state, not the agent causing the increase in 
incidence. 
This chapter will cover the wide variety of drugs that have been associated with acute 
pancreatitis as well as the studies that substantiate increase in acute pancreatitis in type 2 
diabetes.  The rate of acute pancreatits in incretin based agents and other agents as 
mentioned above seems the same as the rate in the population of type 2 diabetic as a whole.  
The rates of acute pancreatitis from clinical trial data of the five agents available in the US 
and the comparators afford the best prospective data on this subject.  
2. Background 
In 2002 Blomgren reported the association of acute pancreatitis with obesity and glyburide 
therapy in type 2 diabetic subjects (Blomgren). The first of a new class of incretin-mimetic 
agents, exendatide (Byetta) was introduced for the treatment of diabetes in 2005 and by 2006 
the first report of acute pancreatitis was made by Denker (Denker) and soon others began to 
immerge. In 2007, the first of the dipeptyl depeditidase-4 (DPP-4) inhibitors (Januvia) 
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entered the US market and by 2009 there were 88 reports of acute pancreatitis in patients 
treated with this agent (FDA). These agents shared a common pathway in improving 
metabolic control in diabetes by increasing the occupancy of GLP-1 receptors. The incretin-
mimetic agents are synthetic agonists for the gut hormone, glucagon like peptide 1 (GLP-
1)receptors, and the DPP-4 inhibitors extend the action of endogenous incretin hormones 
including GLP-1 and also gastric inhibitory peptide (GIP) as well other gut derived 
hormones by delaying their degradation. Perhaps, the fact that the pathway involved with 
each of these new types of agents has the potential to affect the gastrointestinal tract, there 
was concern that this might be responsible for precipitating acute pancreatitis. 
Acute pancreatitis in the general population appears to be increasing in Western countries 
with 70–80% attributed to alcohol or gallstones but at least 20% has no clear etiology. 
Diabetic comorbidities of hypertriglyceridemia and obesity may increase their risk for acute 
pancreatitis. New etiologies continue to be described as evidenced by the report by Frulloni 
and colleagues of an autoimmune pancreatitis identified by a novel antibody directed at an 
epitope homologous to a protein from Helicobacter pylori (Frulloni). Type 2 diabetes is 
associated with obesity and hyperlipidemia, each of which has been considered a risk factor 
for pancreatitis (Trivedi, Blomgren). It is estimated that 2-5% of cases of acute pancreatitis 
are drug-induced. Many drugs have been associated with acute pancreatitis, yet these 
include drugs from varied classes, with very different modes of action and metabolic 
degradation pathways without any uniform explanation. Only alcohol, which both 
stimulates exocrine pancreatic secretion and contraction of the outlet sphincter (of Oddi) can 
be explained. In a 2005 review, Trivedi reported that, of the top 100 prescribed drugs in the 
United States, 44 have been associated with acute pancreatitis (Trivedi). These include over-
the-counter agents such as acetaminophen, common antibiotics such as trimethoprim/ 
sulfamethoxazole and erythromycin, commonly used agents such as furosamide, 
glucocortiods, statins, angiotensin conversion inhibitors as well as agents used to treat 
human immunodeficiency virus acquired immunodeficiency syndrome, and oncologic 
agents. No clear pathophysiologic basis connects the various agents. 
3. Diabetes and acute pancreatitis 
The association of diabetes and acute pancreatitis was noticed at least a century ago and 
reported by Korte (Korte). His data was included in a large review by Shumacker along with 
many of Shumacker’s own observations (Shumacker). Korte＇s observation preceded any 
pharmacologic agents for diabetes and at a time of Schumacker’s reports, only insulin was 
available to treat diabetes. While the emphasis of Shumacker’s paper appears to be acute 
pancreatitis causing diabetes, he does report some patients who were known to have 
diabetes prior to the episode of acute pancreatitis. Schumacker also noted cholelithiasis 
and/or cholecystitis in patients with acute pancreatitis. Gall bladder disease is known to be 
increased in diabetes as well as a cause for acute pancreatitis (Pagliarulo). K. Warren made a 
similar case for pancreatitis causing diabetes in five cases (Warren 1950). However, S. 
Warren reported acute pancreatitis in 12 patients 6 months to 13 years after the diagnosis of 
diabetes in a pathology text dealing with pathology of diabetes (Warren 1952). Root 
reported 5 cases of acute pncreatitis with diabetes, four of which were shown at autopsy to 
have fatty livers, which suggests type 2 diabetes with accompanying insulin resistance 
(Root). Bossak’s report seemed to be the first to emphasize acute pancreatitis complicating 
diabetes mellitus rather than causing diabetes (Bossak,). She noted 3 cases of acute 
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pancreatitis in hospitalized patients with previously diagnosed diabetes which prompted an 
examination of the records of 103 patients admitted to Mount Sinai Hospital, New York City 
between 1936 and 1954. She found 5 more cases of acute pancreatitis in patients with pre-
existing diabetes. Again, these observations were made in an era prior to any anti-diabetic 
therapies other than insulin. As more recent reports of acute pancreatitis have been 
published in association with agents used to treat diabetes, the earlier association of acute 
pancreatitis in the diabetic patient has not been acknowledged. Since these early twentieth 
century reports have been primarily in the way of case reports of acute pancreatitis in 
subjects with diabetes on a particular agent used in the treatment of diabetes or its 
comorbidities. Drugs such as metformin, ACE inhibitors and statins have been reported. The 
only series is that by Blomgren suggesting glyburide could increase the risk of acute 
pancreatitis and the relationship of that agent and the other agents has been primarily 
circumstantial (Balani, Blomgren, Jeandidier, Singh). The most common etiologies of acute 
pancreatitis accounting for 70-80% of cases are alcohol and gallstones.  Chapman reported in 
1996 a higher prevalence of gallstone disease based on ultrasound examination or report of 
cholecystectomy in diabetics (32.7%) compared to controls (20.8%, p<0.001) (Chapman, 
1996).  The difference was even greater for females were prevalence was 41.8% for female 
diabetic compared to controls 23.1% (p<0.001). 
 
Drug Class Agents 
Cardiovascular  
ACE Inhibitors Captopril, Enalopril, Lisinopril, Ramipril 
Angiotensin Receptor Blocker Losartan 
Centrally acting Metyldopa 
Loop diuretic Furosemide 
Thiazide diuretic Chlorothiazide, hydrocholthiazide 
HMG-CoA reductase 
inhibitors 
Simvastatin, pravastatin, fluvastatin, atrovastatin, 
rosuvastatin 
Fibrate Benzafibrate 
  
Antidiabetic Metformin, glyburide, exenatide, sitagliptin 
Table 1. Common Agents used in treating diabetic patients with reports of acute pancreatitis 
The increased prevalence of gall bladder disease in subjects with diabetes has been addressed 
more recently in the medical literature than the association with acute pancreatitis. In 1990 
Haffner reported an increased incidence of gallbladder disease in non-insulin dependent 
diabetes mellitus (NIDDM, now referred to as type 2 diabetes) patients compared to those 
without diabetes in San Antonio Heart Study (Haffner). The relative risk was 1.6, 95% CI 1.08-
2.37. There was an even greater risk in Mexican-American women compared to non Hispanic 
white women where the relative risk was 2.21, 95% CI 1.50-3.28.  The San Antonio Heart Study 
was a landmark study that early on identified the insulin resistance with an increased risk for 
cardiovascular disease. The increased risk for gallbladder disease as well as cardiovascular 
disease in this population known to have resistance to insulin suggests that insulin resistance 
might be the common thread. Jorgensen failed to find an increased prevalence of gall stones in 
diabetic subjects in a Danish population after adjusting for obesity in a population not known 
for insulin resistance (Jorgensen). Chapman, in contrast, found an increased risk for gallstones 
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in female diabetic subjects in New Zealand but no statistically increase in male diabetics after 
controlling for other know risk factors of BMI, HDL cholesterol, and TG, common 
comorbidities associated with type 2 diabetes (Chapman, 1996). Chapman reported increased 
gallbladder volume in type 2 diabetic subjects even without stones not seen in type 1 diabetics 
(Chapman 1998). It has been suggested that this reflects stasis or poor gallbladder emptying 
that could predispose to stone formation. Ruhl examined 5,653 adults as part of the third 
Unites States National Health and Nutrition Examination Survey (NHANES 1988-1994) a cross 
section of the US population, using ultrasound examinations, fasting glucose and insulin levels 
in a population not known to have diabetes (Ruhl). After controlling for other known risks for 
gall bladder disease, she found that women with undiagnosed diabetes (fasting blood glucose 
above 126 mg/dl (>7 mmole/L)) were at an almost 2-fold risk for gall stones (1.91, 95% CI 
1.29-2.83). This risk increased as the fasting serum insulin increased comparing the highest to 
lowest quintiles. She suggested that it was the insulin resistance rather than diabetes that 
accounted for the increase in gall bladder disease even though this relationship was not seen in 
those who only had impaired fasting glucose (fasting glucose 110-125 mg/dl (6.1-6.9 
mmole/L)). Boland reported gallbladder disease severe enough to lead to hospitalization in 
the Atherosclerosis Risk in Communities (ARIC) study of 3.8 per thousand person years 
increasing with an increase in BMI (Boland 2002). She also noted association to 
hyperinsulinemia, low HDL, hypertriglyceridemia and hormone replacement in diabetic 
women. Noel examined a US insurance data base for comorbidities of type 2 diabetes, acute 
pancreatitis and gall bladder disease and found relative risk for gall bladder disease to be quite 
similar to the investigators above (Noel). Girman examined health records covering 2003- 2007 
from the General Practice Research Database (GPRD) in the UK and found rates that were not 
dissimilar (Girman). It is not a great leap to infer that increased rates of acute pancreatitis relate 
to the greater risk for gall bladder disease, a known risk factor for acute pancreatitis as 
suggested by Pagliarulo (Pagliarulo). 
 
Author  Population RR 95% CI P value 
Haffner San Antonio Heart Study (all) 1.6 1.08-2.37  
 Mexican American vs Non Hispanic 
Women 
2.21 1.50-3.82  
Jorgensen Denmark NS   
Chapman New Zealand Women DM vs Non DM 1.8  <.001 
                   Women  Type 2 DM vs Non DM 2.10  <0.001 
                   Women  Type 1 DM vs Non DM 1.57  <0.05 
                   Men Type 2 DM vs Non DM 1.83     <0.05 
                   Men Type 1 vs Non DM 0.86      ns 
Ruhl USA Women DM vs Non DM         1.91 1.29-2.83  
Noel US Type 2  DM vs Non DM 1.91 1.81-1.99  
Girman UK Type 2 DM vs Non DM Adjusted 1.49 1.31-1.70  
Table 2. Risk of gall bladder disease in diabetic subjects. 
The examine more directly the relative risk for acute pancreatitis in subjects with type 2 
diabetes three separate large health data bases, two in the USA and one in United Kingdom, 
have been examined. Noel reported a 2.83 fold risk of acute pancreatitis as well as 1.91 fold 
risk for biliary tract disease in type 2 diabetic members by examining a large US health care 
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claims database covering more than 100,000 person-years over the period from 1999-2005, a 
period predating GLP-1 or DPP4 therapies (Noel).  Garg and Girman each examined other 
large health databases, Garg a US database and Girman one from the UK (Garg, Girman). 
Garg reports a 2.1 (95 % CI: 1.7-2.5) fold increase in acute pancreatitis in type 2 patients. 
Girman examined data from the (GPRD) found that 0.2% of type 2 diabetic subjects 
experienced acute pancreatitis from 2003 to 2007.  Girman reports a similar increased risk for 
acute pancreatitis in type 2 diabetes of 2.89 (95% CI: 2.56-3.27) but after correction for age, 
gender and obesity the relative risk was 1.49 (95% CI:1.31-1.70).  Only Girman made 
adjustment for obesity. 
It is likely that the increase in acute pancreatitis in type 2 diabetic subjects is secondary to 
the gallbladder dysfunction. The increase in gallbladder disease is attributed to the secretion 
of lithogenic bile in the setting of obesity, insulin resistance and dyslipidemia. Which of 
these is primary is not known but studies by Grundy of bile composition in Pima Indian 
women, a group known to have a high risk for both type 2 diabetes and gallbladder disease, 
demonstrated an increase secretion of cholesterol and a reduced secretion of bile salts 
compared to non-stone forming Caucasian women and compared to Pima Indian men 
(Grundy, Sampliner). Lithogenic bile develops in the setting of inadequate bile salts or 
phospholipids to maintain cholesterol in solution (Dowling). Stones or sludge form due to 
supersaturation with cholesterol. Patients can have symptoms of gallbladder dysfunction 
even when no stones are present, a situation known as acalculous gallbladder disease 
presumably from this sludge (Fink-Bennett). The relationship of gallbladder disease risk to 
lipid metabolism in highlighted by Boland’s finding in the ARIC study that Apo E4/E4 
genotype subjects had a reduced risk to be hospitalized for gallbladder disease compared to 
all the other genotypes (Boland 2006). Apo E regulate metabolism of triglyceride rich lipid 
particles. The enzyme CYP7A1 appears to be key to the regulation of cholesterol conversion 
to bile salts (Pandak). CYP7A1 is regulated by LXR alpha, the nuclear oxysterol receptor liver 
X receptor alpha (Goodwin) and that regulation is complex but it has been shown that LXR 
alpha null mice feed a high cholesterol diet accumulate cholesterol in the liver and 
eventually die of liver failure. The relationship to insulin resistance and type 2 diabetes has 
yet to be elucidated but this may be a model for non-alcoholic liver disease seen with 
increasing frequency in obese type 2 diabetic subjects with dyslipidemia. 
4. Diabetes and incretin-based antidiabetic therapies 
The association acute pancreatitis with diabetes and with exenatide and sitagliptin usage 
has been examined systematically by Dore as well as Garg (Dore, Garg). Dore examined 
similar large health data base covering 2005 to 2008 and was able to compare the risk of 
acute pancreatitis in over 27,000 exenatide users and matched metformin or glyburide users 
and found the relative risk for acute pancreatitis was 1.0 (95% CI: 0.6-1.7). He compared over 
16,000 sitagliptin users with matched metformin or glyburide users and found the relative 
risk for acute pancreatitis to be 1.0 (95% CI 0.5-2.0). Garg examined another large US health 
claims database of 786,656 patients and found the incidence of acute pancreatitis to be 1.9 
per 1000 patients years in non-diabetic control group compared to 5.6 per 1000 patient years 
in the diabetic control group. Exenatide users incidence for pancreatitis was 5.7 and for 
sitagliptin users 5.6 cases per 1000 patient years. This data is retrospective. 
Is there any prospective data that is relevant to this subject? If we examine the adverse event 
reporting from the clinical trials that lead to approval of incretin based therapies, we see very 
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similar incidence rates. These were fairly large trials with balanced patient demographics and 
fairly complete data collection as these event were undoubtedly Severe Adverse Events (SARs) 
requiring extensive follow-up reporting to the FDA. Exenatide: Examination of the clinical 
trial data deposited with the FDA shows that in the exenatide development program, six cases 
of acute pancreatitis were observed in about 3,489 subject-years of exposure (1.7 per 1,000 
subject-years), compared with one case in about 336 subject-years with placebo (3.0 per 1,000 
subject-years) and one case in about 497 subject-years (2.0 per 1,000 subject-years) with insulin 
(FDA.gov/Drugs/DrugSafey). Liraglutide: The second GLP-1 agonist to market, showed a 
similar risk of acute pancreatitis, with seven cases in 3,900 patients receiving liraglutide 
compared with one case in a patient taking comparator diabetes agents. Liraglutide incidence 
was similar to that seen in exenatide clinical trials but the control goup had fewer than 
expected, suggesting an ascertainment bias or that comparison groups might have been 
underreported. Sitagliptin. The pooled analysis of controlled clinical trials revealed incidence 
rates to be (0.8 events vs. 1.0 events per 1000 patient-years for comparators. Saxagliptin the 
second DPP-4 inhibitor to reach the US market. reported an incidence of acute pancreatitis of 
0.2% in 3,422 patients receiving saxagliptin and 0.2% in 1,066 controls  in mostly shorter 
termed trials. Linagliptin, the most recent addition to the US DPP-4 inhibitor agents showed 
0.2% incidence of acute pancreatitis (1 case in 538 person years and 0 in 433 patient-years in the 
comparators). The risk of acute pancreatitis in each of these trials is similar to that found by 
Noel, Garg and Girman during periods predating most of these agents (Noel, Garg, Girman). 
Despite this reassuring data, the FDA requires warnings for each product and continues post-
marketing surveillance for acute pancreatitis. As new antidiabetic agents enter the market and 
their use becomes common, we expect similar rates of acute pancreatitis to be reported, just as 
was reported in by Blomgren in 2002 for glyburide as it was reaching peak popularity 
(Blomgren). 
 
 
Fig. 1. Pathophysiology of gallbladder disease and acute Pancreatitis in type 2 diabetes. 
Liver produces lithogenic bile that forms stones or sludge. The occlusion of the common bile 
duct obstructs the pancreatic duct leading to acute pancreatitis. 
5. Discussion 
The medical literature over the past century reflects an increase in gallblader disease and 
acute pancreatitis in patients with diabetes, particularly those with type 2 diabetes. These 
patients are often obese, with dyslipidemia. The association of dyslipidemia with lithogenic 
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bile may be the explanation for the increased incidence of gallbladder disease in type 2 
diabetic subjects and this is the likely explanation for the increase in acute pancreatitis as 
illustrated in Figure 1. If any agent would be predicted to be associated with an increase in 
gallbladder disease and acute pancreatitis, it might be colesevelam, a bile sequesterant with 
glucose lowering action, due to the loss of bile salts but no reports of an increase in acute 
pancreatitis with this agent have immerged. It is unlikely that any one class of medications 
used to treat diabetes has significantly altered this risk. It would be helpful if the risk for 
acute pancreatitis associated with type 2 diabetes were more generally known so that as 
each new agent is not accused of causing the problem when it achieves a significant level or 
use. 
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1. Introduction 
Severe acute pancreatitis is a serious disease with high morbidity and mortality.1,2 Despite 
many experimental and clinical studies its pathophysiology is yet not completely 
understood. It is well accepted that activation of enzymes within the pancreatic tissue is the 
initial event in acute pancreatitis followed by a cascade of events that modify not only the 
local process but also affect distant organs and systems.3 Indeed, previous studies have 
demonstrated that acute pancreatitis is associated with an increase in inflammatory 
mediators that induce the systemic inflammatory response syndrome (SIRS) and are 
associated with distant organ dysfunction being responsible for the morbidity and mortality 
related to disease.4,5 Acute pancreatitis is characterized by release of proteolytic enzymes 
from the pancreas and activation of several signaling pathway in macrophages resulting in 
the releasing of TNF-α.6,7  
2. Macrophages 
Macrophages are released from bone marrow migrate to many tissues and undergo to final 
differentiation into specific type of resident macrophages. Macrophages are concentrated in 
lungs, spleen, liver (Kupffer cells), lymphnodes, and in the serosal membrane of pleural and 
peritoneal cavity. Activation of macrophages by different insults may result in the 
production of many substances that interfere in the immune response. Inflammation 
lymphocytes activation and secretion of various cytokines are some of the many function of 
macrophages.  
The degree of macrophages activation seems to be an important factor determining the 
severity of acute pancreatitis.8-10 In the pancreatic tissue, besides enzymatic activation, and 
acinar cells production of TNF-α, macrophages and monocytes are the main inflammatory 
cells involved in the pathogenesis of local and systemic inflammation. The production of 
proinflammatory substances by these cells results in amplification of the inflammation to 
distant organs as liver, lungs kidneys intestines and might result in multi organs failure.11-13  
Following pancreatic inflammation several organs like liver, spleen and lungs with a large 
population of macrophages function as important source of cytokines production further 
amplifying the inflammatory response.14 In spite the production of cytokines macrophages 
also induce the activation of enzymes as inducible nitric oxide synthase (iNOS) or 
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cyclooxygenase 2 (COX-2) involved in the production of nitric oxide and arachdonic acid.15 
The severity of acute pancreatitis seems to be related to the levels of proinflammatory 
cytokines as IL-1, IL-6, IL-8, and TNF-α, PAF, and C-reactive protein.3,16 Administration of 
agents that antagonize or diminish the production of TNF-α is associated with decreasing of 
the systemic effects of acute pancreatitis.17,18 
In a previous study we have showed that treatment of rats with acute pancreatitis by 
administration of hypertonic saline solution reduces the production of inflammation 
markers (inducible nitric oxide synthase, cyclooxygenase 2, TNF-α, and IL-6) in pancreatic 
tissue. The volume of ascitic fluid and level of cytokines in ascitic fluid were also reduced, 
decreasing the systemic inflammatory response in experimental acute pancreatitis.19 In this 
study pancreatic enzymes activation was not reduced in animals receiving hypertonic 
saline, therefore ascitic fluid volume and TNF-α reduction were probably caused by 
decrease of peritoneal macrophages proinflammatory response.20,21 Administration of 
hypertonic saline solution reduces the production of cytokines by these cells and reduces the 
systemic inflammatory response in experimental acute pancreatitis.19  
 
 Pancreatic 
TNF-α 
 
Pancreatic
IL-6 
 
Pancreatic
IL-10 
 
Pancreatic 
IL-10/TNF- α 
ratio 
Control 
(without AP) 
 
AP Non-treated 
 
12,6± 0,9 
 
 
45,0 ± 6,9 * 
9,3 ±1,9 
 
 
44,1 ± 5,6 *
2,7 ± 0,27 *
 
 
14,6 ± 2,1 
0.22 
 
 
0,32 
AP hypertonic saline-treated 23,1 ± 4,2 # 
 
18,7 ± 1,2 #
 
16,4 ± 2,8 
 
0,88* 
 
Pancreatic levels of TNF- α, IL-6; and IL-10 were measured in homogenates of pancreas (pg/mg 
protein). Date are expressed of mean ± SEM  *,  #p<0.05 
Table 1. Effect of hypertonic saline solution on pancreatic inflammation in acute pancreatitis 
(AP). 
 
 COX-2 iNOS 
 
Control 
(without AP) 
 
AP Non-treated 
 
 
100 ± 0 
 
 
329 ± 16 * 
 
 
 
100± 0 
 
 
505 ± 105 * 
 
 
AP hypertonic saline-treated 206 ± 38 # 213 ± 48# 
 
Date are expressed of mean ± SEM  *,  #p<0.05 
Table 2. Effect of hypertonic saline solution on the expression of COX-2 and iNOS (Western 
blot analysis) in the pancreas in acute pancreatitis (AP) 
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 Ascitic Fluid 
Volume (ml) 
Ascitic Fluid 
TNF-α (pg/ml) 
 
Control 
(without AP) 
 
AP Non-treated 
 
 
0 
 
 
1.8 ± 0.3* 
 
 
 
0 
 
 
192 ± 23 * 
 
 
AP hypertonic saline-treated 0.8 ± 0.2 # 64 ± 10# 
 
Date are expressed of mean ± SEM  *,  #p<0.05 
Table 3. Effect of hypertonic saline solution on peritoneal inflammation in acute pancreatitis 
(AP). 
In the early stage of inflammatory response there is activation of macrophages (M1 
macrophages) that release proinflammatory cytokines as TNF-α IL-1β and IL-6.15 Besides M1 
macrophages another population of macrophages was observed (M2a) called alternative 
related to wound healing. This population of macrophages is unable to produce NO and to 
present antigen to T cells. This population of macrophages up regulates mannose receptor 
expression and arginase II 22,23 and seems to act in the production of extracellular matrix. 
There is yet another population of macrophages (M2b) found in the later stages of 
inflammation which are related to the production of IL-10 and TGF beta with inhibition of 
the production of proinflammatory mediators.24  
2.1 Peritoneal macrophages 
Peritoneal macrophages in spite to be a small fraction of the total population seem to 
performing an important role in the defense against infection in the peritoneal cavity and in 
the severity of acute pancreatitis. 
Previous study demonstrated that trypsin stimulates the production of cytokines from 
peritoneal macrophages in vitro and in vivo.25 In acute pancreatitis there is activation and 
leakage of enzymes from the intracellular compartment to pancreatic interstitium, 
peripancreatic tissues and peritoneal cavity26, therefore activating peritoneal macrophages 
and increasing the production of TNF-α25 Peritoneal macrophages from animals with acute 
pancreatitis are more efficient in the production of TNF-α than controls when challenged 
with LPS.27 Indeed some investigators in 1970s  proposed that most of the mediators of 
inflammatory process in acute pancreatitis could be found in the peritoneal cavity and 
should be removed in order to attenuate the systemic inflammatory syndrome associated 
with acute pancreatitis.28 Endotoxin can also increase the production of TNF-α by peritoneal 
macrophages that makes infected pancreatic necrosis extremely dangerous. Many 
investigators demonstrated that pancreatitis associated ascitic fluid has noxious effects on 
mitochondria29, kidney and lungs besides an apoptosis-inducing-factor.30 The key point in 
these studies is to understand the importance of peritoneal macrophages on the systemic 
inflammatory response in acute pancreatitis.31,32 Peritoneal macrophages represent a small 
fraction of the total macrophage population however they are strategically located lining the 
serosal peritoneal membrane. Activated peritoneal macrophages have many activities such 
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as lymphocyte activation, tissue damage and microbiocidal activity through the production 
of several cytokines as TNF-α, IL-1, IL-8 TGF-β1, superoxide and nitric oxide.30  
Overproduction of these substances however, may be dangerous inducing systemic 
inflammatory response. Reducing the production or removal of these substances may have 
beneficial effects on the inflammatory response in acute pancreatitis. Indeed, previous study 
has shown the beneficial effect of peritoneal lavage in acute pancreatitis. 28 
Recently, we have demonstrated that peritoneal lavage in an experimental model of acute 
pancreatitis not only leads to a decrease in serum levels of TNF-α and IL-6 but also results in 
an increase in serum levels of IL-10.33 (Table 4). We have also demonstrated in the pancreatic 
tissue a reduction in cycloxygenase-2 and inducible nitric oxide synthase expression.33  
(Table 5)  
 
 Serum TNF-α 
(pg/ml) 
Serum IL-6 
(pg/ml) 
Serum IL-10 
(pg/ml) 
 
AP Non-treated 
 
32 ± 10 
 
 
258 ± 46 
 
 
39 ± 8 
AP Peritoneal lavage-
treated 
 
7 ± 5* 
 
141 ± 26* 
 
149 ± 46* 
 
Date are expressed of mean ± SEM  * p<0.05 
Table 4. Effect of peritoneal lavage on systemic inflammation in acute pancreatitis (AP). 
 
 COX-2 iNOS 
 
Sham 
 
100 ± 0 
 
 
100± 0 
 
AP Non-treated 454 ± 38 * 
 
609 ± 104 * 
 
AP Peritoneal lavage-treated 304 ± 25 # 410 ± 63 # 
 
Data are expressed of mean ± SEM  *,# p<0.05 
Table 5. Effect of peritoneal lavage on the expression of COX-2 and iNOS (Western blot 
analysis) in the pancreas in acute pancreatitis (AP). 
We concluded that peritoneal lavage has an anti-inflammatory effect in acute pancreatitis. It 
is possible that a special subset of peritoneal macrophages with anti-inflammatory 
properties is preserved or activated during peritoneal lavage.24  
It has been demonstrated that CO2 pneumoperitoneum decreases TNF-α and interleukin IL-
6 production while increasing the production of IL-10.34  
Indeed peritoneal macrophages exposed to CO2 in vitro have a significant decrease of TNF-
α production when stimulated with LPS.35 CO2 pneumoperitoneum pretreatment alters 
acute-phase response36 and increases survival in an experimental model of 
lipopolysaccharide (LPS)-contaminated laparotomy.37  
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It has been suggested that the local tissue acidification due to CO2 pneumoperitoneum 
decreases the production of cytokines by peritoneal macrophages.36 Recently, we have 
demonstrated that CO2 abdominal insufflation decreases pancreatic inflammation and 
systemic inflammatory response in an acute pancreatitis model.38 (Tables 6-8). 
 
 Ascitic Fluid 
(ml) 
TNF-α 
(pg/ml ascitic fluid)
 
Peritoneal cells 
(x106) 
 
AP Non-treated 
 
4.2 ± 0.4 
 
 
534 ± 129 
 
 
21 ± 2 
 
AP CO2-treated 
 
2.4 ± 0.4* 
 
 
188 ± 47* 
 
 
14 ± 2* 
 
Date are expressed of mean ± SEM  * p<0.05 
Table 6. Effect of CO2 insufflation on the peritoneal inflammation induced by acute 
pancreatitis (AP). 
 
 Serum TNF-α 
(pg/ml) 
Serum IL-6 
(pg/ml) 
Serum IL-10 
(pg/ml) 
Serum 
IL-10/TNF- α 
ratio 
 
AP Non-treated 
 
 
AP CO2-treated 
 
228 ±92 
 
 
34 ±16* 
 
92 ±19 
 
 
42 ±12* 
 
40 ±5 
 
 
37 ± 9 
 
0.18 
 
 
1.09* 
Date are expressed of mean ± SEM  * p<0.05 
Table 7. Effect of CO2 insufflation on the systemic inflammation induced by acute 
pancreatitis (AP). 
 
 COX-2 iNOS 
 
Sham 
 
100 ± 0 
 
 
100± 0 
 
AP Non-treated 545 ±159 * 
 
446 ±85* 
 
AP CO2-treated 198 ±31 132 ±5 
 
Data are expressed of mean ± SEM  * p<0.05 
Table 8. Effect of CO2 insufflation on the expression of COX-2 and iNOS (Western blot 
analysis) in the pancreas in acute pancreatitis (AP).   
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In this study we also demonstrated that CO2 abdominal insufflation not only reduces the 
serum levels of proinflammatory cytokines but did not changed the serum levels of IL-10. 
The ratio of IL-10 over TNF-α demonstrates a clear anti inflammatory effect of CO2 
pneumoperitoneum.38 The CO2 pneumoperitoneum also decreases the inflammation in the 
peritoneal cavity reducing the volume of ascitic fluid and the total content of TNF- α.38 It is 
conceivable that if an endoscopic procedure for stone retrieval has to be performed it should 
be done during the laparoscopic cholecystectomy to decrease the inflammatory response 
secondary to acute pancreatitis. These results suggested that peritoneal macrophages play 
an important role on the outcome of acute pancreatitis and should be considered an 
important target for therapeutic management in acute pancreatitis. However, peritoneal 
macrophages are also important in the defense against infection in the peritoneal cavity. In a 
large experience in the surgical treatment of acute pancreatitis we have observed that even 
draining pancreatic abscess through the abdominal cavity we rarely observed bacterial 
peritonitis. It seems that peritoneal macrophages priming by pancreatic enzymes are more 
effective to protect peritoneal cavity from bacterial infection.27 
3. Conclusion 
In spite to be a small fraction of body population peritoneal macrophages have an important 
role in the pathophysiology of acute pancreatitis and should be object of future clinical trials 
and probably a target for the modulation of systemic inflammatory response in acute severe 
pancreatitis. 
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1. Introduction 
In the Acute Pancreatitis the pancreatic enzymes are activated locally, causing a tissue injury 
followed by a pancreatic inflammation, characterized by edema, leucocyte infiltration, 
hemorrhage and necrosis.  
The etiology of the pancreatitis presents as major cause of this disease, the alcoholism and 
the gallstone. These risk factors are common in the actual society and are determining to the 
increase pancreatitis incidence. 
Despite the default in the establishment of the initializing mechanism of the acute 
pancreatitis, experimental studies suggest a disturbance in the intracellular calcium levels as 
a first event of the process.  
Following this idea, a duct obstruction or alcohol exposure could modify the calcium 
release, leading to a migration of exocytosis machinery from the apical area of the 
membrane to the basolateral area. The relocation of the enzyme vesicles and the release of 
the content in the inter membrane space are the starter of pancreatic auto-digestion.  
Experimental pancreatitis studies have shown that the membrane permeability (disruption) 
of the acinar cell is crucial to the calcium disorders and consequent pathologic mechanisms, 
resulting in the release of cytoplasmic proteins. However, the understanding of the 
deficiency remains unclear, i.e., if it is a disturbance of the plasmatic membrane or a delay in 
the calcium-dependent mechanisms for cell membrane resealing. 
Actually, the membrane exocytosis machinery can be disturbed under the exposition to 
different stimulation. It has been reported a blockade apical granule fusion after stimulus 
with cholecystokinin (CCK) and carbachol, for example.  
The fusion of zymogen granules occurs in a very limited apical region of surface membrane 
to increase the effectiveness of pancreatic content delivering. This efficiency is due to the 
protein machinery that control the direct fusion of the zymogen granules with the 
membrane as well as the granule-to-granule fusion of the distant granules to the most 
apically located. This granule-granule fusion remains occurring despite of the apical 
releasing blockade and could be responsible to aggravate the basolateral exocytosis, the 
event possibly responsible by the pancreatitis starting. 
The definition of initial cause of the acute pancreatitis is decisive to the control of late 
complication in this disease. However, the knowledge about the exact mechanism among a 
variety of etiologies still remains controversial.  
Despite the alcoholism be often associated with a chronic pancreatitis, there are several 
reports of bouts of acute pancreatitis resulting of alcohol abuse. This could be due to the 
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association of the raised gut permeability with alcohol intake and the concomitant 
endotoxemia. In other view, the pancreatic stellate cells could be activated by the alcohol 
consumption. The role of these cells in pancreatic injury is similar to the liver injury during 
alcoholism, with the fibrosis establishment. Thence, the mechanism related to these cells is 
more evident in the chronic pancreatitis. 
The molecular mechanism of biliary acute pancreatitis is Ca2+ mediated. Several authors 
suggested that the increase in bile acids preventing reuptake of Ca2+ by a PI3K-dependent 
mechanism. 
The molecular mechanism of gallstone – associated pancreatitis seems to be simpler. The 
pancreatic duct obstruction confine the zymogen and lysosomal granules causing the 
condensing vacuoles and impeding the acinar exocytosis. Consequently, the trypsinogen is 
activated to trypsin and triggers the cascade of enzyme activation leading to the pancreatic 
injury. 
Pancreatitis induced by hypertriglyceridemia is associated to amylase release and the cell 
injury due to the free acids released because its detergent properties. 
2. Molecular biology of multiple organ failure during acute pancreatitis 
The local and systemic complications during pancreatitis aggravate the prognostic of the 
disease. The morbidity and the mortality pancreatitis-associated occur due the systemic 
inflammation and the multiple organ dysfunctions, mainly lung, liver and kidney.  
The intra and extra pancreatic events of the acute pancreatitis are responsible by the 
complexity of the disease. Initially, there is the local activation of the trypsinogen. 
Subsequently, the trypsine activates other enzymes those turn begin to digest the pancreatic 
tissue, whose content leaks into the abdominal cavity, causing cytokine release, activation of 
the immune system, coagulation and fibrinolysis.  
The cytokines activates the inflammatory pathway, resulting in the increase of adhesion 
molecules, neutrophils infiltrate, production of Reactive Oxygen Species (ROS) and several 
inflammatory molecules such as Prostaglandin E2 (PGE2), Tromboxan A2 (TXA2), Platelet 
Activating Factor (PAF). On the other hand, the release of these mediators leads to Systemic 
Inflammation Response Syndrome (SIRS). 
The ascitic fluid released in response to pancreatic inflammation could lead to activation of 
Kupffer Cells that will produce cytokines and others mediators, such protelytic enzymes, 
establishing the hepatic inflammation. The lung is often a target of these mediators and the 
dominant cause of mortality.  
It has been shown that severe acute pancreatitis correlates with the incidence of hepatic 
injury. Although the liver is known to be a primary target of cytokines released in pancreatic 
blood, the liver itself releases inflammatory substances, such as reactive oxygen species, 
thereby leading to the injury of distant organs. 
The oxidative stress is important in the early stages of the systemic inflammation that occurs 
in pancreatitis and the liver is a target of this event. Also, the liver is a source of oxidative 
stress. Multiple hepatic cells, including hepatocytes, Kupffer cells, stellate cells, endothelial 
cells can generate nitric oxide, superoxide, and peroxynitrite. On the other hand, these 
oxygen and nitrogen – derived species might lead to the early Hepatic Stellate Cells (HSC) 
activation, which leads to alteration in the extracellular matrix components and involves as 
much degradation as fibrogenesis. The extracellular matrix degradation could be 
responsible by the amplification of the inflammatory mediators release and the systemic 
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inflammation (Figure 1). Moreover, the oxidative and nitrative stress are responsible by the 
alteration in the mitochondrial respiration and the consequent apoptosis induction. 
 
 
Fig. 1. The hepatic injury involved in the multiple organ failure during pancreatitis. The 
liver is both a source and target of the inflammatory mediators systemically released during 
pancreas inflammation. These mediators activate several hepatic cells causing oxidative 
stress, mitochondrial dysfunction and consequently apoptosis and synthesis of 
inflammatory proteins that will aggravate the involvement of distant organs. 
3. Molecular signaling of the oxidative stress 
Despite the initial cause of pancreatitis, the oxidative stress is the mainly contributing factor 
to the destruction of the pancreatic tissue. Moreover, the dysbalance redox participates of 
hepatocellular injury as well as the pulmonary lesion.  
Among the effects of the pancreatitis in the liver it was demonstrate the reduction of oxygen 
consume by the mitochondria in animals that received samples of ascitic fluid from rats with 
acute pancreatitis.  
Reactive oxygen species (ROS) activates necrosis and modify the production of cytokine and 
adhesion molecules. Furthermore, lipid peroxidation products are chemotactic and might 
lead to amplification of the inflammation process.  
It is known that the Nitric Oxide Synthases exhibit different profiles during the pancreatic 
inflammation. The Reactive Nitrogen Species (RSN), produced constantly, are responsible 
by the regulating the exocrine secretion of the pancreas. At basal levels, RSN protect against 
pancreatitis by increasing microcirculatory flow, inhibiting the leukocyte infiltration and 
suppressing the Catepsine, an important mediator to the activation of trypsinogen.  
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On the other hand, an increase in the Inducible Nitric Oxide Synthase (iNOS) expression 
followed by an exacerbated Nitric Oxide (NO) production during Acute Pancreatitis could 
lead to an activation of the inflammatory pathway, inhibition of the cellular respiration, 
nitrosylation and nitration of proteins, resulting in cell death by necrosis and apoptosis.  
In the mammalian cell, the NO is protective against chemistry agents generating of 
oxidative stress .This anti-oxidant effect could be important to minimize the tissue injury in 
the ROS-associated process. Once the NO is accumulated in its activated form, its 
concentration in the tissues is important to the regulation of immunity by modulation of the 
protein expression and activity. 
Pancreatitis is known to cause a marked increase in superoxide production. The key players 
in the physiology of inflammatory processes are NO and its products. There is great 
controversy in the literature as to whether the effects of NO are protective or harmful. There 
is evidence that NO promotes cell death under conditions of oxidative stress, indicating 
concurrent superoxide production. However, under resting conditions, NO is protective. 
Recent studies have shown an increase of lipid peroxidation, which indirectly indicates the 
release of oxidative products, during pancreatitis. This increase was concomitant to enhance 
the NO production.  
It has been shown that, in the presence of high superoxide levels, peroxynitrite formation 
becomes dependent on NO production. Peroxynitrite can exert its toxic effect through the 
nitration of macromolecules or as a selective oxidant, contributing to either necrosis or 
apoptosis. The formation of nitrotyrosine is a consequence of peroxynitrite activity, and 
increased nitrotyrosine levels have been detected in human diseases associated with 
oxidative stress. There are various ways in which peroxynitrite-induced impairment of 
endothelial function might contribute to the pathogenesis of organ failure due to circulatory 
shock: by exacerbating local vasospasm, increasing local neutrophil adhesion, and 
increasing neutrophil migration into inflamed tissues; by exacerbating platelet activation 
and aggregation; or by promoting hypoperfusion of certain parts of various organs. During 
pancreatitis, it was shown that the hepatocytes around the central vein were apparently the 
most susceptible to aggression. The superoxide anion and NO both react rapidly to form the 
toxic reaction product, the peroxynitrite anion. Pharmacological studies in a variety of 
experimental systems have demonstrated that peroxynitrite is more cytotoxic than is NO or 
superoxide, as well as being able to induce necrosis and apoptosis. Peroxynitrite 
(endogenous or exogenous) is a potent trigger of DNA single-strand breakage, whereas NO 
is not. In turn, DNA single-strand breakage activates the nuclear enzyme poly (adenosine 
diphosphate-ribose) polymerase.  
The concentrations of NO and superoxide determine the formation of peroxynitrite, which 
was demonstrated after pancreatitis induction. This event is correlated to the increase of 
liver injury during pancreatitis.  
4. Molecular biology of cell death in acute pancreatitis 
Acute pancreatitis–associated distant organs injury is mediated by inflammatory cytokines 
that are produced within tissue resident macrophages. These organs, in turn, participate in 
the systemic inflammation releasing several inflammatory mediators leading to 
amplification of the injury of distant organs. Substances released systemically during 
pancreatitis, such as Nitric Oxide (NO) and free radicals can interfere with mitochondrial 
respiration and induce apoptosis. The apoptotic cell death may play a considerable role in 
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affecting mortality and morbidity in severe acute pancreatitis. Apoptosis pathway, by death 
receptors or the mitochondrial pathway, activates the final caspase to cell death. Death 
Receptors signaling has been associated with apoptosis in several hepatic diseases such as 
ethanol-induced liver injury and cholestatic liver disease. Apoptosis related to the severe 
acute pancreatitis injury is known to be triggered through the mitochondrial pathway.  
Cell death has been seen in both apoptotic and necrotic forms, in clinical as well as 
experimental acute pancreatitis. Current evidence suggests that the amount and the balance 
between apoptosis and necrosis influence the severity of acute pancreatitis. 
There are two apoptotic pathways: the extrinsic pathway is activated by death receptors and 
is subjected to caspase-8 activation. The mitochondrial or intrinsic pathway is mediated by 
caspase-9 activation. Both pathways activate the caspase-3, initializing the programmed cell 
death.  
On the other hand, the pancreatitis can activate directly the caspase-9, which forms a 
complex with Activator Protease Factor-1 and cytochrome c, priming the mitochondrial 
pathway.  
The mitochondria are the determining factor to modulation of cell death during pancreatitis, 
defining whether the cell death will occur by necrosis or apoptosis. While the necrosis is 
often observed in severe pancreatitis, apoptosis is more evident in the pancreatitis of 
medium gravity.  
5. Important proteins signaling during acute pancreatitis  
The family of protein associated to the membrane fusion machinery includes receptors 
bind to proteins attachment to N-ethylmaleimide-sensitive fusion proteins and donor 
vesicles. Some isoforms of this multiprotein complex are present in the pancreatic acinar 
cells where they mediated the granule-granule fusion as well as the membrane-granule 
fusion.  
The regulation of these proteins is mediated by other protein family called Munc. Recent 
studies demonstrated molecular interaction of the isoform 18c of Munc and proteins of 
SNARE family during CCK or carbachol stimulation. This interaction is mediated by 
modifying in the calcium release. It is important to mention that this basolateral plasma 
membrane activity is intermediated by protein kinase C family proteins, which are activated 
by carbachol stimulation.  
It was demonstrated that the pancreatitis could induced the Heat Shock Protein (HSP) gene 
transcription and, in contrast, reduce the protein levels. This modulation is important due 
the different physiologic roles of each one of the HSP. HSP60, for example, is involved in 
toll-like receptors activation and necrosis process. On the other hand, the HSP70 is described 
as a tissue protector in several disease models. 
Recently, heat-shock proteins and their cofactors have been revealed associated to apoptotic 
and necrotic pathways .Heat shock proteins are molecular chaperones that stabilize and 
refold damaged intercellular proteins, preventing the intracellular protein aggregation and 
making the cells resistant to stress-induced cell damage. 
In the experimental acute pancreatitis, induced by cholecystokinine, cerulean, arginine and 
taurocholic acid, there is an increase of the Heat Shock Protein (HSP) -70 expression 
concurrent to a reduction of the HSP60. On the other hand, some authors suggest that 
HSP60 could reduce the trypsinogen activation, a basic event to the onset of pancreatitis. 
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During inflammation, neutrophils connect to tissue areas activated. Throughout the 
neutrophylic invasion, there is the release of enzymes responsible by the tissue digestion, 
such as metalloproteinases, which in turn could enhance the injury due the release of 
signaling molecules after the extracellular matrix digestion.  
The local injury during pancreatitis induces the production of proinflammatory cytokines 
such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β). These cytokines are 
released via portal vein and lymph fluid drainage to the circulation. In turn, it occurs the 
vascular endothelium activation and the leukocyte migration. In the acute pancreatitis, the 
increase of pro and anti-inflammatory cytokines was correlated to the reduced human 
leukocyte antigen-DR levels, which characterizes the immunosuppression. This event could 
explain the multiple organ failure often related to the pancreatitis. 
6. Molecular biology in the treatment of the acute pancreatitis 
Currently, the treatment of the acute pancreatitis aims the hemodynamic balance, nutrition, 
control of the pain and complications. However, the major events in the pancreatitis are: 
Systemic Inflammatory Response Syndrome, microcirculatory disturb and translocation of 
bacteria. 
Several experimental studies demonstrate the efficiency of Nitric Oxide, block of 
endothelial receptors, antagonists of the PAF-receptors, antibodies against Intercellular 
Adhesion Molecules. These treatments improved the microcirculatory flow during acute 
pancreatitis.  
 
 
Fig. 2. Molecular effects of the hypertonic solution. The water loss could modify the 
cytoskeleton structure leading to activation of a protein cascade triggering specific gene 
transcription.  
Fluid resuscitation is a necessary therapeutic intervention in severe pancreatitis. Patients 
with pancreatitis present volume extravasation to the peritoneum and retroperitoneum, and 
some have hemodynamic inestability. However, the infusion of large volumes can induce 
pulmonary interstitial edema and can increase intra-abdominal pressure. Fluid 
accumulation in the lungs exacerbates respiratory failure and can make mechanical 
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ventilation necessary. Increased abdominal pressure reduces the venous return to the heart, 
thereby decreasing cardiac output, as well as reducing perfusion of the kidney and gut, all 
of which can provoke organ damage. 
In experimental animal models of pancreatitis, hypertonic saline has been shown to alter 
circulating plasma volume, reduce trypsinogen levels, prevent acinar necrosis, reduce 
inflammatory cytokine levels, and avert pancreatic infection, thereby minimizing injury, 
limiting the local and end-organ and reducing mortality. It has recently been demonstrated 
that administration of hypertonic saline in a rat model of acute pancreatitis reduces systemic 
inflammation rather than protecting local (pancreatic) tissue. Hypertonic saline modulates 
pancreatitis-related injury to the lungs and liver. This effect was attributed to the modulated 
expression and activity of various proteins, such as metalloproteinase, collagen, and 
members of the HSP family. Also hypertonicity could modify the gene transcription, 
expression and function of several proteins, activation of kinases (figure 2), cell adhesion 
and the ROS and cytokines release. This modifying may be due the alteration in the 
cytoskeleton because the cell edema diminishing.  
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1. Introduction  
Acute pancreatitis is the inflammatory condition of a gland, including an invasion into, to a 
lesser or greater extent, the surrounding tissues, and also the contiguous or distant organs 
(Braganza, 2001; Frossard et al., 2008). 
The analysis of the processes, occurring in the course of acute pancreatitis, has made it 
possible to define this disease as the one which comprises of two phases.  
Initially, the hyperstimulation of the immunological system with the excessive local 
activation of the cells of inflammatory focus in the pancreas occurs, and later on, as a result, 
the systemic response, expressed as Systemic Inflammatory Response Syndrome (SIRS), 
develops. 
Compensatory Anti-inflammatory Response Syndrome (CARS) causes early organic 
complications (Gamaste, 1994; Toouli et al., 2002; Yousaf & McCallion, 2003). 
The intensification of an inflammatory response, hypoxia and the occurrence of 
oligovolemic shock may result in the clinical development of Multi-Organ Dysfunction 
Syndrome (MODS), which is defined as the more advanced stage of SIRS. In this period, 
greater susceptibility to bacterial infections and fungal infections and, consequently, an 
increased mortality rate, caused by blood poisoning, is observed. Multi-Organ Dysfunction 
Syndrome requires the application of the powerful methods of supporting the organism of a 
patient (Song et al., 2003).  
Acute pancreatitis is a disease of an unpredictable course. It is, usually, a reversible process, 
in which the pain ailments of the abdomen undergo regression and the activity of pancreatic 
enzymes returns to its normal level.  
In 70 - 75% of cases, this process becomes subjected to the self-limitation and has the 
properties of interstitial inflammation. However, in 5 – 15%, a form characterized by severe, 
necrotic course may develop. 
In this case, local complications and multi-organic complications are alike present 
The morbidity rate in case of acute pancreatitis in Poland is estimated to be at the level of 
240 cases per 1 million in a year. 
The mortality rate amounts to 5 - 10% in total. However, in the cases of severe course, it 
amounts to approximately 35% (Baillie, 1997; Balthazar et al., 2002; Beger et al., 1997; Lund 
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et al., 2006; Munoz, & Katerndahl 2000; Mutinga et al., 2000; Song , 2003). In 
pathomorphology, the oedemic and the necrotic form of acute pancreatitis, which 
constitutes an infavourable development of the oedemic form, or is developing as a separate 
form of the disease from the beginning is observed (Banks & Freeman, 2006; Yousaf et al., 
2003). 
In Atlanta, in 1992 (Bradley, 1993), an obligatory classification of acute pancreatitis was 
drawn up; this classification it assumes the division into: 
- acute pancreatitis of mild course. 
- acute pancreatitis of severe course, which means the occurrence of one of the following 
states: 
- local complications: necrosis, false cyst and abscess, 
- organic dysfunction, 
- meeting 3 or more criteria on the Ranson scale (Ranson, 1997), 
- obtaining 8 or more points on the APACHE II scale II (Lankisch et al., 2002; Song, 2003). 
Acute pancreatitis results in the destruction of the alveolar cells, which results in the 
handicap of the extra-secretory functions of the pancreas. What may also contribute to the 
damage to the alveolar cells and releasing active proteases and other enzymes into the 
parenchyma of the pancreas, is the obstruction of the pancreatic ducts and increase in 
pressure in them connected with that or the intra-cellular activity of chemical substances 
(Braganza, 2000; Sharma & Howden, 1999). 
Nowadays, there is more and more information about the chain of events, occurring after 
the release of active enzymes into the pancreatic parenchyma. However, the mechanism of 
the activation of the zymogens at molecular level still remains unknown (Braganza, 2001; 
Song et al., 2003).   
2. Causes of acute pancreatitis  
The causes of acute pancreatitis may be divided into: mechanical, toxic, metabolic, infection-
related, vascular, genetic and idiopathic (Yadav & Lowenfels, 2006). 
2.1 Mechanical causes  
The most frequent cause of acute pancreatitis is choledocholithiasis and alcohol. 
It is estimated that both of these etiological factors are the cause of as many as 80% of cases 
of the disease. 
In medical literature, the connection between choledocholithiasis and acute pancreatitis was 
a subject of publication for the first time in 1909 (Song et al., 2003).  
Large stones, of the diameter of 20 mm and more, cause increase in the risk of the acute 
inflammation of the gall bladder. 
The risk of acute pancreatitis increases if the diameter of the stones does not exceed 5 mm.  
Their being jammed in the duodenal papillae and the occurrence of acute pancreatitis is also 
made more likely by the shape of concretions if it is similar to that of mulberry fruit. 
In 3 hours after getting jammed in the duodenal papillae, inflammatory changes in the 
pancreas occur. It is assumed upon the basis of estimations that if the obstacle is removed 
within a 24-hour period, acute pancreatitis of severe course occurs in only as few as 6% 
cases.  
The risk increases to 90% if the obstacle is removed later than within a 48-hour period 
(Baron et al., 1996). 
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Damage to the alveolar cells resulting from the inflammatory process of the pancreas, may 
also occur if the bacterial infection of gall coexists with choledocholithiasis. (Liu et al., 1997). 
Bacterial endotoxins cause the release of cytokines and the occurrence of SIRS.  
Pancreas divisum, which means chronic pancreatitis, may be the cause of the acute, 
recurrent inflammations of this organ, particularly in case of children. 
This developmental variety of the pancreas is revealed in case of approximately of 5% 
population. 
The risk of the occurrence of inflammatory changes is connected with the papillary stenosis 
of the smaller duodenal papilla. 
According to estimations, approximately 3% of the cases of acute pancreatitis, described in 
literature, is caused by a tumour on the pancreas or duodenal papillae (Fan et al., 1993). 
Sphincteritis Oddi stenosans, which means the stenotic inflammation of the duodenal 
papilla, by means of handicapping the outflow of biliary juice and pancreatic secretion, may 
result in the occurrence of an incident of acute pancreatitis (Song et al., 2003). 
Into the group of the mechanical causes able to cause acute pancreatitis, may also be 
included penetrative and blunt abdomen injuries. 
Endoscopic retrograde cholangiopancreatography (ERCP) is also a described cause of the 
occurrence of acute pancreatitis. The frequency of such cases reaches 2% (Demols & Deviere, 
2003; Folsch et al., 1997).  
Accidental damage to the Wirsung duct during an operations is a following mechanical 
cause of acute pancreatitis. 
It most frequently occurs during the fixation of the intestine with the stump of the pancreas 
in the course of operative procedures (Golub et al., 1998, Vaquero-Raya & Molero-Richard, 
2005). 
A not very frequent cause of acute pancreatitis may be blocking the pancreatic duct or the 
biliary duct by a lumbricus (Ascaris lumbricoides hominis). 
Duodenal-pancreatic reflux, occurring in the conducting loop syndrome after a resection 
procedure on the stomach with the application of the B2 method, may also be a cause of the 
occurrence of acute pancreatitis (Frossard & Hadengue, 2001, Gamaste, 1994). 
2.2 Toxic causes  
A frequent factor causing acute pancreatitis is ethyl alcohol (Dufour & Adamson, 2003).  
It may cause the oedema of the papillae of Vater, the regurgitation of duodenal contents into 
the pancreatic ducts and increase in the permeability of the pancreatic ducts. 
Ethyl alcohol exerts cytotoxic influence as well because it form the ethyl esters of fat acids, 
which damage the cells of the pancreas, causing acute alcohol-related pancreatitis (Golub et 
al., 1998; Schenker & Montalvo, 1998). 
It is suspected that some kinds of medications are able to induce acute pancreatitis. This 
group encompasses: mesalazinum, sulfasalazinum, furosemide, rifampicin, sulphonamides, 
octreotide, didanozinum, isoniazid, azathioprine, erythromycin, shadowing medications 
administered in ERCP and others. A rare cause of acute pancreatitis is having been bitten by 
animals representing venomous species, e.g. by certain species of scorpions. 
2.3 Infection-related causes 
A cause of the occurrence of acute pancreatitis may be bacterial infection. 
As a result of translocation, bacteria reach the tissue of the pancreas on their way from the 
large intestine. 
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Those bacteria produce endotoxins, which induce releasing pro-inflammatory cytokines, 
which as a result causes damage to the pancreatic cells.  
Viral infection – a virus of epidemic parotid inflammation and HIV is also a described cause 
of the occurrence of acute pancreatitis. 
In case of patients with developed AIDS, the frequency of the occurrence of acute 
pancreatitis is several hundred times larger than in case of healthy population. 
Acute pancreatitis in course of AIDS may be caused by the virus itself, but also the very 
occurrence of opportunistic infections generates inflammatory processes. 
Patients with AIDS frequently come from the backgrounds abusing alcohol and 
psychoactive substances, which is an additional factor, able to case acute pancreatitis 
This is caused by the co-existence of several factors simultaneously.  
Medications administered to patients, for example didanozinum (DDI), may also induce the 
occurrence of acute pancreatitis. 
2.4 Metabolic causes 
Increase in the concentration of triglycerides, particularly above 1000 mg%, may be a factor 
inducing the development of acute pancreatitis. 
Such a state is observed in case of patients, suffering from hyperlipidaemies of type I, IV and 
V. 
Hypercalcaemia connected with the hyperacitivity of the parathyroid glands, uremia and 
the neoplasm of bones also increases the risk of the induction of inflammatory processes in 
the pancreatic gland (Rau et al., 1997; Schoenberg et al., 1995). 
2.5 Vascular causes 
The development of acute pancreatitis may occur after cardiac-surgical operations, 
performed with the use of cardiopulmonary bypass, and after image-based examinations 
with the use of contrast, for example after abdominal aortography (Niederau & Lüthen, 
1997).  
In the literature, there are described cases of acute pancreatitis, occurring as a result of the 
complications of sclerosis such as the block of upper mesenteric artery and the block of the 
celiac trunk. 
In the research conducted in the recent years, changes in pancreatic microcirculation are 
regarded as the cause of the disease in such cases (Sabater et al., 2004). 
The disorders of celiac flow within pancreatic microcirculation occur in the early phase of 
the disease and precede changes in the digestive duct microcirculation. 
The disorders of celiac flow within pancreatic microcirculation are of importance in the 
transformation of mild (oedemic) form in the necrotic-hemorrhagic one. 
Substantial reductions in capillary perfusion and of the saturation of hemoglobin with 
oxygen occur. 
The disorders within pancreatic microcirculation are a complex process, in which the 
dysfunctions of the cells of endothelial vessels occur.  
Free oxygen radicals being released and cytokines participate in this process. 
Important mediators causing the inflammatory reactions are: blood platelet activating 
factor, neoplasm necrosis factor α (TNF–α), cytokines (IL-1, IL- 6, IL-8), interferon γ (INF- γ), 
thromboxane, leukotrienes and prostaglandins (Lewandowski et al., 2007; Osman & Jensen, 
1999; Rau et al. 1997). 
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2.6 Genetic causes 
The course of acute pancreatitis is dependent on one hand on the activity and strength of 
factors, damaging the pancreas, and, on the other hand, on the genetically-conditioned 
response of the immunological system. 
Depending upon the individual properties, the self-limitation of the inflammatory process 
may occur, or, alternatively, its intensification and proliferation may occur. 
Genetic research has differentiated a disease of the genetically-conditioned mechanism of 
development: hereditary pancreatitis – acute pancreatitis occurring within the family. 
The research suggests the existence of mutation N34S in the gene responsible for coding a 
pancreatic inhibitor, trypsin, defined as PSTI (pancreatic secrectory trypsin inhibitor) or 
SPINK1 (serine peptidase inhibitor, Kasal type 1). 
This polypeptide constitutes one of the barriers, safeguarding against self-digestion of the 
cells of the pancreas.  
The mutation of the gene results in the earlier activation of trypsinogen inside the cell and 
its destruction (Karczowski, 2002; Swaroop et al., 2004). 
The premature activation of the pancreatic pro-enzymes is still regarded as the essential 
pathomechanism of self-digestion of the pancreatic gland which occurs in the severe form of 
acute pancreatitis. 
Molecular researches on the mutation of trypsinogen in the course of acute pancreatitis 
occurring within the family have shown the superior role of the trypsin in the premature 
activation of proteolithic enzymes (Niederau & Lüthen, 1997; Swaroop et al., 2004).  
All it takes to activate them is a small amount of free trypsin remaining in balance with the 
complex: trypsin-pancreatic secretory trypsin inhibitor (PSTI) (Karczowski, 2002). 
In 2000, it was found out that the gene for pancreatic trypsin inhibitor (PSTI) may contribute 
to the modification of the risk of pancreatitis, particularly in case of mutation N34N PSTI, 
wherein the risk of the occurrence of acute pancreatitis is increased ten-fold (Karczowski, 
2002). 
In approximately 10% cases, it proves impossible to determine the cause of acute 
pancreatitis. Such cases are defined as idiopathic (Kim et al., 2003; Testoni et al., 2008).  
3. The clinical record of the acute pancreatitis 
Acute pancreatitis of mild course, or, in other words, its oedemic form, does not cause 
complications. 
In some cases, so-called liquid collections of acute phase appear. 
This is the state in which effusion liquid is accumulated in the anatomical spaces of the 
peritoneal cavity. 
The cistern of the acute phase does not have a tissue-connecting capsule and, as a rule, it is 
subject to resorption to four weeks from the beginning of the disease. 
Sometimes, however, it is encysted and causes the formation of false cyst of the pancreas 
(Sabater et al.: 2004, Williford et al., 1983). 
Liquid cysterns of the acute phase may occur in the pancreatitis of mild course and the 
severe one alike (Morgan et al 1997). 
Clinical symptoms of acute pancreatitis depend above all on the form (degree of severity), 
spread of changes and time of the disease duration. 
The main symptom of acute pancreatitis is pain. 
It is described by the patients as: encircling, and sometimes as radiating to the left or to the 
both of shoulder blades, and to the spine. 
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It is frequently felt as the pressure similar to compressing with a girdle. 
Initially, it is the pain of celiac character, but after some time it transforms into somatic-
celiac (mixed) one. 
The individuals are unable to identify its source precisely. 
Celiac pain is formed as a result of the irritation of receptors (nociceptors) in a particular 
organ of the abdominal cavity. 
Its cause is the sudden increase of wall tension or the constriction of the smooth muscles of 
the celiac organs. 
The pain is usually dull, less frequently stabbing, with a location that is difficult to define. 
It radiates to the areas of the same neural segment, which is affected by the pain of the 
disease-changed celiac organ. 
Frequently, it is accompanied by vegetative symptoms, for example acceleration or slowing 
down the heart action, vomiting or decrease in arterial blood pressure. 
The pain is intensified during rest, and weakens during performing movements – the 
individuals are restless and motor-activated. 
Conducting the stimuli of celiac pain is connected with the autonomous nervous system. 
Somatic pain is connected with the irritation of the sensory endings of the core nerves of the 
parietal peritoneum, mesentery, retriperitoneal space or the walls of the abdominal 
integuments. 
This pain is acute or blunt, but constant, easy to describe and clearly-localized. 
It is accompanied by the tension of the muscles, called muscular defense. 
The individuals are calm and they avoid movement.  
The pain accompanying acute pancreatitis may be of constant intensity, but it may, 
alternatively, be getting more intensive (Morgan et al., 1997; Dervenis et al., 1999). 
In the initial period of the disease, nausea and vomiting, which do not bring about relief, 
occur. 
They are the symptoms of the irritation of the pneumogastric nerve. 
These ailments are accompanied by the integuments, excessive hyperhidrosis, increased 
thirst, accelerated breath and, frequently, decrease in arterial blood pressure.  
Disorders for the part of the nervous system, such as anxiety developing into fear, strong 
psycho-motor excitation, and hallucinations may occur (Dervenis et al 1999). 
The position adopted by the individuals and their outsider appearance are frequently 
characteristic of this disease. 
The patients are lying on their side with their lower extremities bent and appear to be 
suffering a lot. 
The initial paleness of the body integuments may be joined by the characteristic erythema of 
the skin of the face – the Loeffler symptom or marbleness of the skin of the abdomen and the 
extremities – Halsted symptom. 
These are the symptoms of vessel-widening activity of mediators of inflammatory state. 
What is also a quite characteristic symptom is abdominal distention, the presence of 
hepatitis or blue disease. 
In case of acute pancreatitis with severe course, as the complication of necrosis of fat 
subcutaneous tissues, lividness of the skin may occur. 
If it is found in the era near the navel, it is described in the literature as Cullen symptom. 
If this is found in lumbar region, this is Grey-Turner symptom (Steinberg & Tenner, 1994).  
Researching abdominal integuments in a palpative manner, we frequently discover 
tenderness, muscular defense, peritoneal symptoms and Blumberg symptom. 
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It is sometimes possible to discover the presence of free liquid in the peritoneal cavity or an 
effusion on the left pleural cavity – Clairmont symptom 
3.1 Diagnostic investigation in the acute pancreatitis  
The most frequently performed examination is determining the activity of amylase in the 
serum. 
In order for it to be possible to diagnose acute pancreatitis, the activity of amylase ought to 
be three-fold larger than the norm. It happens in the course of acute pancreatitis of severe 
course that the activity of amylase is correct, probably as a result of a massive damage to the 
parenchyma of the gland. 
The most sensitive marker of pancreatitis is the increase in the activity of pancreatic lipase. 
This is an enzyme, produced only by the pancreatic gland, and therefore the increase in its 
activity is the most typical of acute pancreatitis. Proinflamatory cytokines play a crucial role 
in the primary activation of the cells of the immunological system as a result of damage to 
the pancreas (Lewandowski et al. 2007). 
In the x-ray chest, it is possible to ascertain the presence of the liquid in the left pleural 
cavity. The plain radiological picture of the abdomen is taken as a routine measure in the 
diagnostics of acute pancreatitis. 
Ultrasonography (USG) – possesses as many as 90% of the tenderness in diagnosing acute 
pancreatitis. It is a non-invasive treatment, which may be repeated several times. 
Ultrasonography pictures the dynamics of the pathological changes course in pancreatic 
parenchyma and in the adjacent tissues 
Computer tomography (CT) is currently regarded as a diagnostic standard the highest is a 
sensitivity in terms of acute pancreatitis, Magnetic resonance imagining (MRI) – is a method, 
alternative to CT. 
Endoscopic retrograde cholangiopancreatography (ERCP) – is the most effective method of 
discovering the cause of acute pancreatitis. It is simultaneously possible to remove the 
triggering factor. 
Endoscopic sphincterotomy performed within the first 24 hours after the occurrence of the first 
symptoms causes alleviating the course of the disease and reduces the risk of complications 
Endoscopic ultrasonography (EUS) is a modern method of imagining of the cause of acute 
pancreatitis, however, without a possibility of procedural intervention.  
4. Oxidative stress and antioxidative status in acute pancreatitis 
Oxidative stress was defined by Sies in 1985 as a state of relative balance in a living 
organism between the prooxidation activity, which means the production of free oxygen 
radicals and antioxidative processes, which means the deactivation of free radicals 
(Braganza et al., 1995; Kikuchi et al., 1997; Sies H & Cadenas, 1985).  
Free oxygen radicals are substances possessing one non-paired electron, or more. 
Such a chemical structure determines high instability of these chemical compositions and 
tendency to become involved in violent biochemical reactions parts, leading to damaging 
cellular structures (Matkovics et al., 1995; Schulz et al., 1999). 
Contemporarily, instead of the notion free oxygen radicals theRreactive Oxygen Form (ROF) 
is more frequently used.  
The best researched ROFs are: hyper-oxygen radical, hydrogen-oxygen radical, hyper-oxide 
radical, hydrogen hyper-oxygen radical and nitrogen oxide (Schulz et al., 1999; Song et al., 
2003; Petrov, 2010).  
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Non-radical form also include non-radical type substances, the derivatives of oxygen, 
displaying similar impact as radicals, e.g. hydrogen peroxide, hypochlorous acid, ozone or 
singleton oxygen (Abu-Zidan et al., 2000; Braganza et al., 1995). 
The sources of ROFs are the reactions of oxidation and reduction, mainly occurring in 
mitochondria and cellular membranes, including the cells of the vessel perithelium. 
The source of ROFs is also the process of oxidizing hypoxanthine by xanthine oxidase, and 
also by the reaction in which the ions of some metals, mainly iron and copper, participate 
(Chmiel et al., 2002). 
The formation of the reactive form of oxygen takes place, among others, in the chain of 
changes of arachidonic acid. 
Large amounts of ROFs are formed in the course of inflammatory processes. 
The source of them are the cells, directly participating in immunological response and 
pathogens, for example bacteria (Park et al., 2003). 
The oxidation of organic substances, such as proteins and lipids, is also the source of the  
ROFs display strong toxic impact in relation to the cells of a human organism. The effect of 
their impact is damaging structural proteins, enzymatic structures, lipids of cellular 
membranes, breaking up the threads of DNA, damage to chromosomes, degeneration of the 
cytoskeleton of the cell, disorders of the synthesis of collagen and neoplasm transformation, 
which consequently leads to the death of a cell, which is preceded by a substantial damage 
and disordering its functions (Winterbourn et al., 2003). 
In the course of inflammatory process in the pancreas, the local accumulation of activated 
phagocytes occurs; these phagocytes are producing chemotactic factors, which cause the 
migration of new leukocytes to the area, invaded by inflammation. 
The activated phagocyte cells release proteolithic enzymes, which damage the tissues and 
are the secondary source of new ROF (Wereszczyńska-Siemiatowska et al., 1998, 2004). 
Pathogenetic factors, causing handicapping of blood flow through the pancreas are the 
cause of ischaemia and hypoxia of the cells of this organ. 
Ischaemia is a reversible and temporary process.  
After this period, reperfusion occurs. 
An increase in the concentration of oxygen in the blood results in the production of a very 
active and cytotoxic hydrogen oxide radical, regarded as the main cause of the damage to 
the cells of the pancreas. 
As a result of reperfusion, occurring after ischaemia, deepening the damage to the 
endothelium of the blood vessels and activation of the components of the complement 
system, the activation of the mast cells, the intensification of the aggregation of blood 
platelets, which consequently leads to the formation of micro-thromboses occur. 
The activated cells of the immunological system secondarily cause the intensified 
production of the reactive form of oxygen, damaging the adjacent tissues (Sweiry & Mann 
1996; Telek et al., 2001). 
In turn, antioxidants counteract the reactive form of oxygen in an organism. 
Their function is to maintain the balance between the processes of oxidation and reduction 
(Curran et al., 2000; Dabrowski et al., 1999; Johnson, 2007; Satinder et al., 2011). 
There are two essential defense mechanisms – non-enzymatic and enzymatic. 
Non-enzymatic defense anti-oxidation system is composed of substances, so-called 
„sweepers”, reacting directly with the reactive form of oxygen. 
They include: vitamin E, vitamin C, beta- carotene, uric acid, ceruloplasmin and glutation. 
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The most important enzymatic anti-oxidants include: hyperoxide dismutase (SOD), the 
system of glutation peroxidases (GPX) and the system of catalases (Tsai et al.; Vaquero-Raya 
&Molero-Richard, 2005). 
The disturbance of balance between the oxidation and anti-oxidation factors in case of 
patients with acute pancreatitis leads to oxidation stress. 
The level of its intensification has a direct influence on the severity of the course of disease, 
the risk of complications and prognosis.  
5. The aim of the work 
The aim of the work was to examine the dynamics of oxidative (8-OhdG) and antioxidative 
status (TAS) in patients with mild and severe form of acute pancreatitis.  
The profiles of exchanged parameters, the degree of the correlation among them and the 
degree of statistical significance can give certain information relating to prognose of the 
course of the acute pancreas, as also he can give therapeutic and prognostic instructions. 
6. The principles of the work 
Forty patients admitted to the clinic with the symptoms of acute pancreatitis were subjected 
to the assessment. 
All patients expressed their consent to perform the research. 
Consent of the Regionale Commission of Research Ethics was obtained. 
In all patients, apart from a routine examination, the following data were determined for the 
blood serum and the urine: 
1. Oxidative activity of peroxide DNA 8- hydroxyl – 2 – deoxyguanosine (8-OhdG) in I, III, 
V, VII day of hospitalization.  
and in the blood serum: 
2. Total antioxidative status in I, III, V, VII day of hospitalization. 
The patients were divided in two groups: with mild and severe form of acute pancreatitis. 
In both of the groups, the dynamics of the processes of oxidation (8-OhdG) and 
antioxidation (TAS) were assessed; moreover, it was assessed, whether there was a 
correlation between separate parameters. 
The obtained results were subjected to statistical analysis and the influence of the disease 
process on the level of the researched parameters was assessed. 
7. Material and methods  
7.1 Clinical material 
Material for the research was obtained by means of collecting the venous blood and urine 
from the patients, admitted to the Department of Gastrointestinal & General Surgery 
Silesian Piasts` University of Medicine in Wrocław and the Department of General Surgery 
Railway Hospital in Wrocław during the emergency service because of acute pancreatitis 
between 2004 and 2006 years.  
The samples of blood and urine were collected in I, III, V and VII day of hospitalization.  
The research on the following parameters: 8-OhdG and TAS included patients with the 
acute pancreatitis of severe course and, randomly selected, with the acute pancreatitis of 
mild course. 
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In all patients, the quantitative markings of 8-OhdG and TAS respectively in I, III, V, VII day 
of stay at the hospital were conducted. 
The patients were qualified into a research group upon the basis of the typical symptoms of 
acute pancreatitis. 
In the group with the mild form, dominated the pain ailments of the abdomen of various 
intensity, bad general mood, nausea, vomiting and other symptoms. 
The ailments abated most frequently after 3-4 days after the application of intravenous 
liquid-based therapy and treatment with analgesic and antispasmodic drugs. 
This group included 20 of thepatients. 
In the group with the severe form, the symptoms were more serious. 
The dominating ones were the pain ailments of the abdomen and the symptoms of Systemic 
Inflammatory Response Syndrome (SIRS), connected with the hyperstimulation of the 
immunological system. 
In the patients, the temperature of the body increased, the action of the heart was 
accelerated, and the level of leukocytosis grew, while the diuresis per hour decreased. 
As a result of the outflow of liquid and protein from the vascular bed, the cardiac-vascular 
failure, kidney failure, the respiratory system failure, necrotic changes in the parenchyma of 
the pancreas (visible thanks to computer tomography), thrombotic complications and 
enzymatic toxemia occurred. 
This group encompassed 20 patients. 
Altogether, 40 patients were researched in the course of the research. 
Among the researched, there were 7 women and 33 men. 
 
 
Fig. 1. Clinical material 
In the group of the patients with the mild course, there were 3 women and 17 men. 
In the group of the individuals with the severe course, there were 4 women and 16 men. 
The oldest group member was 76 years old, whilst the youngest one 26 years old. 
The average age of the patients was 51 years. 
In the researched group with acute pancreatitis, women constituted 17.5%, while men 82.5%. 
In the group with the mild pancreatitis, women constituted 15 %, while men 85%. 
In the group with the severe pancreatitis, women constituted 20 %, whilst men 80%. 
The lowest incidence rate was observed in the age groups 26-35 and 36-45. 
The highest incidence rate was observed in the age groups 46-55 and 66-75. 
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7.2 Laboratory methods 
7.2.1 Marking oxidation activity in the serum and urine in case of the patients with 
acute pancreatitis 
Oxidation activity was marked in the serum and in urine upon the basis of marking 8-
hydroxydeoxyguanosine (8-OhdG) with the Elis method. 
The research was conducted in strict accordance with the procedure, determined by the 
producer – bioxtech 8-OhdG-eia kit-oxis. 
The results were expressed in ng/ml. 
The range of detection rate 8-OhdG in accordance with the applied methods amounted to 
0.125-200 ng/ml. 
The results for 8-OhdG in urine were expressed in relation to creatinine. 
The norms marked in case of 15 healthy volunteers at the age of 19 to 50 years are within the 
range 0.00 – 0.8 ng/ml in serum and between 0,00 – 0,3 ng/ml/g/creatinine in urine.  
7.2.2 Marking total antioxidation ability in the serum in case of the patients with acute 
pancreatitis 
The principle of marking according to the set produced by the Random Laboratories 
Company – the strict application of the regulations of the producer. 
The norm marked in the serum of 30 health volunteers at the age of 20 to 65 years is within 
the range 1.30 – 1.75 mmol/l, and corresponding to the standard of Trolox – a substance 
with antioxidative properties. 
8. The results of the serearch 
8.1 Clinical analisis 
Taking under consideration the aetiological factor in the entire group, the patients with 
biliary acute pancreatitis constituted 50% of the patients (20 patients). 
The patients with alcoholic acute pancreatitis constituted 35% (14 patients). 
In case of 15% (6 patients), it proved impossible to determine the causes of acute 
pancreatitis. 
These cases were diagnosed as idiopathic. 
In the group with the mild pancreatitis, patients with biliary pancreatitis constituted 40% (8 
patients), with alcoholic pancreatitis constituted 35% (7 patients), while with idiopathic 
pancreatitis constituted 25% (5patients). 
In the group with the severe pancreatitis, patients with biliary pancreatitis constituted 60% 
(12 patients), with alcoholic pancreatitis constituted 30%(6 patients), while with idiopathic 
pancreatitis constituted 10% (2 patients). 
The treatment of the patients with acute pancreatitis encompassed actions in accordance 
with established therapeutic 
principles depending on the severity of the course of the disease. 
In case of 20 patients with the mild pancreatitis, conservative treatment was applied. That 
consisted in: fasting, intravenous liquid-based therapy, pumping out the stomach contents 
with a pro-bang, inserted through the nose, treatment of pain, monitoring the activity of the 
kidneys, monitoring the pressure of the peripheral blood, monitoring arterial blood gas 
values and thrombotic prophylaxis. 
In case of 2 patients, with biliary pancreatitis, after several weeks, cholecystectomy was 
performed. 
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Fig. 2. The cause of the acute pancreatitis 
In one patient, after 8 weeks, junction cyst of the pancreas with the jejunum was performed. 
In the group of patients with the mild course, the longest stay amounted was 12 days and 
the shortest 5 days. 
Twenty patients with the severe form were divided into two sub-groups.  
In the sub-group of 7 patients, ERCP with sphincteroctomy was performed. 
However, in one of case after three weeks an operative drainage of the abscess of the 
pancreas was performed. 
In the sub-group of 13 patients with the severe course of acute pancreatitis, surgical 
procedure was required. 
In case of 7 patients, cholecystectomy with the lavage of the peritoneal cavity was 
performed. 
In case of 6 patients, the lavage of the peritoneal cavity with laparostomy was performed; in 
this group, in two cases- lavage was performed twice, in two cases- three times, while two 
other cases- four times. 
In the course of further lavages, pancreatic necrectomy was performed. 
All the patients were receiving antibiotics of a wide spectrum, intravenous liquid-based 
therapy and an analgesic drugs. 
Moreover, the following were applied: gastric suction, and thrombolytic prophylaxis. 
The functioning of the kidneys, the pressure of the peripheral blood and acid-alkaline 
economy were monitored. 
Sixteen patients were fed parenterally with the supplementation of microelements. 
In case of four patients, a nutritional microjejunostomy was making. 
In case of 1 patient, a complication in the form of cerebrovascular accident occurred, while 
in case of 2 patients, the course of acute pancreatitis was made more complicated by atrial 
fibrillation. 
These patients were treated within the framework of Intensive Care Unit. 
After obtaining the stabilization of the blood circulation system, the patients returned to the 
surgical ward. 
In one patient, massive hemorrhage from the upper digestive tract occurred, and, in spite of 
interventional endoscopy, the patient died. 
Two other patients’ death as a result of the complications of multi-organic failure. 
Out of the group of 20 patients with the severe course, 3 persons died, therefore, the 
mortality rate in this group amounted to 15%. 
The longest stay amounted to 57 days, the shortest 7 days. 
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The average time of hospitalization was 8 days for cases with the mild course and 18 days 
for the cases with the severe course (Fig. 3).  
 
 
Fig. 3. The average time of hospitalization 
8.2 Oxidation activity measured by the amount of 8-OhdG in the blood serum in 
patients with the mild and severe pancreatitis 
In both groups of the patients, quantitative marking of 8-OhdG in the blood serum was 
performed. 
As it is made clear by the data presented in Fig. 4, in case of the patients with the mild 
course of acute pancreatitis, the average value of 8-OhdG was decreasing along with the 
time of stay at hospital. 
Therefore, on I day it amounted to, on average, 2.49 ng/ml SD±1,51, on III day 2.13 ng/ml 
SD±1,52, on V day 1.71 ng/ml SD±0,43, and on VII day to 1.59 ng/ml SD±0,29. 
In case of the patients with the severe form of acute pancreatitis, the average value of 8-
OhdG was two times higher and was growing with the time of stay at hospital. 
On I day, the level of 8-OhdG amounted to, on average, 4.77 ng/ml SD±2,65, on III day 5.97 
ng/ml SD±3,01, on V as much as 6.68 ng/ml SD±4,01, and on VII day 6.21 ng/ml SD±3,74, 
Fig. 4. 
In case of the patients, in whom multi-organic complications (the abscesses of the 
peritoneum, circulation-respiratory failure, septic shock, thrombolytic complications) 
occurred, a high concentration of 8-OhdG was noticeable These were patients from the 
group with the severe course of acute pancreatitis.In the group with the severe course of 
acute pancreatitis, the highest concentration of 8-OhdG were observed in case of the patients 
with complications in the form of the abscesses of the peritoneum.  
For a male, aged 63, with the abscess of the peritoneum, value of 8-OhdG on V day of 
hospitalization amounted to 16.5 ng/ml.  
For a male, aged 28, also with the abscess of the peritoneum, value of 9-OhdG on III day 
amounted to 16 ng/ml. 
For a female, aged 69, value 8-OhdG on V day amounted to 15 ng/ml. 
For a female, aged 60, value of 8-OhdG on III day amounted to 9.5 ng/ml. 
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In the group of patients with the severe course with other complications, for example with 
circulation-respiratory failure, the values of 8-OhdG were lower. 
For a male, aged 33, with acute respiratory failure, requiring the use of an endotracheal tube 
– the value of 8-OhdG amounted to 2.8 ng/ml on V Day. 
For a male, aged 70, treated at the Intensive Care Ward with respiratory failure, the value of 
8-OhdG on V day amounted to 3 ng/ml. 
For a male, aged 48, with acute respiratory failure and cardiac failure (rhythm disturbance) 
on III day, the value of 8-OhdG amounted to 7.82 ng/ml. 
A male, aged 70, with circulation-respiratory failure – the value of 8-OhdG on V day 
amounted to 2.8 ng/ml. 
 
 
 
 
Fig. 4. The average values of 8-OhdG in the blood serum in patients with acute pancreatitis. 
8.3 Oxidation activity measured with the amount of 8-OhdG in urine in patients with 
the mild and severe pancreatitis  
In case of the patients with the severe form of acute pancreatitis, the average values of 8-
OhdG were several times higher than in case of the patients with the mild form of acute 
pancreatitis. 
In case of the patients with the mild form of acute pancreatitis, on I day the average value of 
8-OhdG amounted to 2.69 ng/ml SD±1, 30, on III day amounted to 2.14 ng/ml SD±0, 66, on 
V day only as little as 1.87 ng/ml SD±0, 53, and on VII day it amounted to 1.62 ng/ml SD±0, 
47 (Fig. 5). 
 In case of patients with the severe form of acute pancreatitis, the average value of 8-OhdG 
on I day amounted to 7.99 ng/ml SD±9, 75, on III day it increased to 8.68 ng/ml SD±7, 16, on 
V day it amounted to as much 9.51 ng/ml SD±7, 90, on VII day it reached the value of 7.55 
ng/ml SD±4, 31 (Fig. 5). 
0
1
2
3
4
5
6
7
ng
/m
l
I        III         V       VII
severe pancreatitis mild pancreatitis
 
Oxidative Stress and Antioxidative Status in the Acute Pancreatitis 
 
131 
 
Fig. 5. The average values of 8-OhdG in urine in patients with acute pancreatitis. 
8.4 Results of total antioxidation ability in the blood serum in patients with the mild 
and severe pancreatitis 
In case of the patients with the mild form of acute pancreatitis on I day of hospitalization, 
the average total antioxidation activity measured with the TAS, amounted to 1.19 mmol/l 
SD±0, 10, on III day it amounted to respectively 1.26 mmol/l SD±0, 12, on V day it 
insignificantly increased to 1.27 mmol/l SD±0, 10, and on VII day it reached the value of 
1.26 mmol/l SD±0, 14 (Fig.6). In case of the patients with the severe form of acute 
pancreatitis, the average values of TAS amounted respectively to: on I day – 1.27 mmol/l SD 
± 0,21, on III day – 1.27 mmol/l SD ± 0,21, on V day – 1.31 mmol/l SD ±0,16, and on VII day 
– 1.32 mmol/l SD±0,17 (Fig. 6). 
 
 
Fig. 6. The average values of TAS in case of the patients with acute pancreatitis. 
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8.5 Statistical analysis  
Statistical analysis applies to the interpretation of the results of laboratory research and their 
mutual connections with a clinical image in case of the selected group of 40 patients, 
suffering from acute pancreatitis. 
The analysis encompassed the results of the research on oxidation potential, anti-oxidation 
potential, interleukin-6 and the protein of acute phase. In this manner, the values making it 
possible to assess the level of advancement of the disease process and the risk of possible 
complications were obtained. The results of the research are the indicator of the dynamics of 
acute pancreatitis. In the course of the research, the analysis encompassed the influence of 
selected clinical parameters on the dynamics of the inflammatory process, and what was 
attempted, was the interpretation of the correlations between these parameters. These 
parameters were assessed in terms of their usefulness in the diagnostics and prognostics of 
the course of acute pancreatitis. At the separate stages of hospitalization, causal-result 
interdependencies between the researched parameters were determined. A so-called level of 
significance (p) was subjected to analysis. The levels of significance (p) for a group of 
patients with the mild form of pancreatitis are presented in Table 1, while for a group of 
patients with the severe form in Table 2.  
The results of the research were correlated in both of the groups of patients, with the mild 
and severe forms of acute pancreatitis. The analysis of the degree of dependence of 
parameters was presented with the use of correlation co-efficient. Table 3 illustrates the 
correlations for a group of patients with the mild course of acute pancreatitis, while Table 4 
for a group of patients with the severe course. 
 
 8-OhdG I 
8-OhdG 
III 
8-OhdG 
V 
8-OhdG 
VII 
8-OhdG 
I urine 
8-OhdG 
III urine 
8-OhdG 
V urine 
8-OhdG 
VII urine 
8-OhdG 
I  0,0016 0,4371 0,1364 0,0177 0,4419 0,9263 0,9061 
8-OhdG 
III 0,0016  0,2048 0,0859 0,0049 0,0167 0,3057 0,7938 
8-OhdG 
V 0,4371 0,2048  0,0639 0,4399 0,0288 0,3732 0,6942 
8-OhdG 
VII 0,1364 0,0859 0,0639  0,9844 0,4258 0,9106 0,5278 
8-OhdG 
I urine 0,0177 0,0049 0,4399 0,9844  0,0001 0,0564 0,0696 
8-OhdG 
III urine 0,4419 0,0167 0,0288 0,4258 0,0001  0,0013 0,1426 
8-OhdG 
V urine 0,9263 0,3057 0,3732 0,9106 0,0564 0,0013   
8-OhdG 
VII urine 0,9061 0,7938 0,6942 0,5278 0,0696 0,1426 0,0088  
A group of patients with the mild form of pancreatitis.  
Table 1. The levels of significance (p) for intra-group correlations. 
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 8-OhdG I 
8-OhdG 
III 
8-OhdG 
V 
8-OhdG 
VII 
8-OhdG 
I urine 
8-OhdG 
III urine 
8-OhdG 
V urine 
8-OhdG 
VII urine 
8-OhdG 
I  0,0081 0,1213 0,0254 0,0059 0,0044 0,0000 0,0148 
8-OhdG 
III 0,0081  0,0066 0,0345 0,0612 0,0097 0,0032 0,0126 
8-OhdG 
V 0,1213 0,0066  0,0000 0,9842 0,8771 0,2748 0,3124 
8-OhdG 
VII 0,0254 0,0345 0,0000  0,5568 0,9066 0,1522 0,4137 
8-OhdG 
I urine 0,0059 0,0612 0,9842 0,5568  0,0017 0,0002 0,1536 
8-OhdG 
III urine 0,0044 0,0097 0,8771 0,9066 0,0017  0,0002 0,0004 
8-OhdG 
V urine 0,0000 0,0032 0,2748 0,1522 0,0002 0,0002  0,0002 
8-OhdG 
VII urine 0,0148 0,0126 0,3124 0,4137 0,1536 0,0004 0,0002  
A group of patients with the severe form of acute pancreatitis.  
Table 2. The levels of significance (p) for intra-group correlations. 
 
 8-OhdG I 8-OhdG 
III 
8-OhdG 
V 
8-OhdG 
VII 
8-OhdG 
I urine 
8-OhdG 
III urine 
8-OhdG 
V urine 
8-OhdG 
VII urine 
8-OhdG 
I 
1,00 0,74 0,24 0,62 0,55 0,21 -0,03 -0,05 
8-OhdG 
III 
 1,00 0,38 0,69 0,73 0,61 0,34 0,10 
8-OhdG 
V 
  1,00 0,73 -0,26 -0,60 -0,32 -0,17 
8-OhdG 
VII 
   1,00 0,01 -0,36 0,07 -0,29 
8-OhdG 
I urine 
    1,00 0,88 0,65 0,67 
8-OhdG 
III urine 
     1,00 0,84 0,53 
8-OhdG 
V urine 
      1,00 0,92 
8-OhdG 
VII urine 
       1,00 
Marked correlations are significant, with p < 0.05. 
Table 3. Intra-group correlations of a group of patients with the mild form of pancreatitis. 
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 8-OhdG 
I 
8-OhdG 
III 
8-OhdG 
V 
8-OhdG 
VII 
8-OhdG 
I urine 
8-OhdG 
III urine 
8-OhdG 
V urine 
8-OhdG 
VII urine 
8-OhdG 
I 
1,00 0,57 0,36 0,54 0,69 0,67 0,86 0,68 
8-OhdG 
III 
 1,00 0,59 0,51 0,51 0,62 0,71 0,69 
8-OhdG 
V 
  1,00 0,89 0,01 -0,04 0,30 0,32 
8-OhdG 
VII 
   1,00 0,19 0,03 0,42 0,26 
8-OhdG 
I urine 
    1,00 0,76 0,83 0,49 
8-OhdG 
III urine 
     1,00 0,81 0,85 
8-OhdG 
V urine 
      1,00 0,89 
8-OhdG 
VII urine 
       1,00 
         
Marked correlations are significant, with p < 0.05. 
Table 4. Intra-group correlations of a group of patients with the severe form of acute 
pancreatitis. 
9. Discussion  
Acute pancreatitis is a disease of moderate-to-severe or severe course. 
In terms of anatomy, it is characterized by the reversible damage to the pancreas and the 
tissues adjacent to the pancreas in the form of oedema and necrosis, but sometimes by 
multi-organic complications as well. 
Acute pancreatitis still constitutes a major problem for contemporary medicine. 
It results from the fact of diagnosis-related difficulties and from the lack of an effective 
therapy of the severe course of acute pancreatitis. 
The pathogenesis of acute pancreatitis still remains unknown. 
Many researches has proved that the origins of anatomical changes, occurring in the course 
of the pancreatic gland, are connected with micro-circulation disorders. 
What has also been confirmed is the participation of many mediators in the development of 
the changes of this type. 
The direct factors of changes causing acute pancreatitis are: the activation of pancreatic 
enzymes and micro-circulation disorders. 
In the cases of severe acute pancreatitis with multi-organic complications, micro-circulation 
disorders, mainly afflicting the lungs, liver, the digestive tract and the circulation system 
occur, accompanied by the development of Systemic Inflammatory Response Syndrome 
(SIRS) and Multi-Organ Dysfunction Syndrome (MODS). 
The research showed that the increase in the value of 8-OhdG, particularly within the fifth 
days, was connected with the severe pancreatitis with multi-organic complications.  
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The increase in the values, particularly of 8-OhdG, in the serums and urine, in case of the 
individuals with the severe form of acute pancreatitis, may be associated with the spread 
and intensification of inflammatory process, damaging the cellular structures. 
Those results are compatible with the research of (Szulz et al.1999 and of Wereszczyńska-
Siemiątkowska et al 2003, 2004), who emphasize the role of oxidation stress in the processes 
of destruction of factors connected with them in the forecasting of acute pancreatitis. 
8-OhdG is defined as a marker of the living cell DNA damage. 
The reactive form of oxygen, produced in oxidation stress, may attack the biological 
structures of DNA and destroy them, this being the result of the oxidation of chemical 
compounds, contained in it. 
Damage to nucleic bases or breaking up the bounds, connecting nucleotides, occur.  
Lower values of 8-OhdG and reduced dynamics of its increase in the course of disease were 
found in the case of the individuals with the mild form of acute pancreatitis. 
Those results suggest that the values of 8-OhdG reflect the activity of disease process and 
may be useful in the assessment of the severity of disease, as well as in the forecasting in the 
course of treatment. 
The review of the literature (Rahman et al., 2004; Roth et al., 2004; Virlos et al., 2003) shows 
that the perfect antioxidation ability, marked in blood serums, in case of the individuals 
with the severe form of acute pancreatitis, is lowered as compensative mechanisms are 
being exhausted.  
Therefore, TAS, as one of methods of marking the anti-oxidation properties, is a useful 
forecasting marker, and lowering its value may signal transfer from the mild form of acute 
pancreatitis into the severe form. 
Own research provided no evidence for the claim that there were any substantial differences 
in terms of the value of TAS in the case of the individuals with the severe and mild form of 
acute pancreatitis.  
Both in case of the severe and mild form of acute pancreatitis, no TAS growth or TAS fall 
tendency in separate markings of the conducted research was noticed, either. 
Such results, when confronted with the research of others authors (Dziurkowska-Marek et 
al., 2004; Modzelewski, 2005; Rahman et al., 2004), in which lowering of the value of 
antioxidation potential in the individuals with acute pancreatitis – may result from the 
method of marking. 
In own research, the behaviour of the TAS values at similar level in separate markings may 
be connected with the administered treatment, for it is known that some medicines may 
show antioxidation properties. 
According to the research of (Scott et al., 1993), such is the action of vitamin C.  
Anti-oxidation action of beta-carotene, vitamin A (retinol) and vitamin E (tocopherol) was 
confirmed by (Curran et al., 2000) in their work. 
Similar reports were received from (Virlos et al., 2003), researching the properties of vitamin 
C, selenium and acetylcysteine (Dejong et al., 2001). 
In own material, all the patients with the severe pancreatitis, apart from operational 
treatment, required intensive treatment.  
All the patients were provided with extra-intestinal or intra-intestinal feeding (in 4 cases, 
with the use of microjejunostomy) with the supply of elementary diets and of micro- and 
macro-elements.  
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The Vitalipid preparation was administered; this preparation contains, among others, 
vitamin A (retinol) and vitamin E (tocopherol). 
As an additive to industrial diets, enriching intravenous drip, among others, with vitamin C, 
folic acid, biothin and pantothenic acid. 
Oxidation processes exert a destructive influence on many important functions of the 
organism and may constitute an additional, apart from other inflammatory factors, 
property, destroying the cellular and tissue structures of the organism.  
The potential of oxidation activity may, therefore, constitute an indication of intensified 
inflammatory reactivity. 
Antioxidation potential (TAS) may inform about the efficiency of the systems antioxidation 
systems, significant in the neutralization of the intensified oxidation processes. 
Currently, the pharmacological attempts of alleviating the results of acute pancreatitis are 
made (Curran et al., 2000; Vaquero-Raya & Molero-Richard, 2005; Virlos et al., 2003). 
In the light of the most up-to-date knowledge, certain pharmacological impacts provide 
hope for the application of a new, effective strategy, which may significantly improve the 
results of the treatment of the severe pancreatitis. 
The improvement in the blood flow in organs is achieved by means of using isovolemic 
haemo-dilution. 
In this method, intravenous drips, such as 0,9% NaCl, Dextran 40 000, 10% HES and 
albumins, are 
The application of heparin, as an anticoagulation factor, may result in the improvement in 
the blood saturation of organs, too. 
Application of the antagonists of receptors of bradykinin B2 and gabexate mesylate exerts a 
beneficial influence on microcirculation. 
Cleansed beef hemoglobin turned out to be a safe substitute of the blood and to improve, as 
an oxygen carrier, the saturation of the tissues with oxygen (Panek et al., 2007). 
The application of oxidizing agents, so-called plasma oxygen carriers, is currently a new 
strategy in the treatment of the severe pancreatitis. 
Upon the basis of own research, it was determined that the high values of 8-OhdG in the 
serum of peripheral blood and urine alike in case of the patients with acute pancreatitis, 
indicate these tests may reflect the severity of the course of acute pancreatitis, as well as 
serve for predicting the occurrence of multi-organic complications to a degree greater than 
that in case of other biochemical tests. 
10. Conclusion 
1. As performed examinations show, 8-OhdG parameter, marked by means of Elisa 
method in the serum and urine is the sensitive parameter of acute pancreatitis 
inflammatory activity. 
2. High values of 8-OhdG are characteristic for acute pancreatitis with severe course and 
are the indicator of oxidative stress. They inform also about the risk of multiorganic 
complications.    
3. Total antioxidative status (TAS) is similar in both groups of patients and its decrease is 
not statistically significant for the severe form of acute pancreatitis. 
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1. Introduction 
In acute pancreatitis, reductions in blood flow and alterations of microvascular integrity 
resulting in impaired tissue oxygenation play an important part in the progression and 
possibly the initiation of the disease. Independently of the initial noxa, the intra-pancreatic 
activation of trypsinogen to trypsin is the crucial trigger of acute pancreatitis. The central 
events for the further course are the release of local mediators (cytokines, vasoactive 
substances, free oxygen radicals) and subsequently the development of microcirculatory 
disturbances and the activation of leukocytes and their infiltration into the tissue. At 
present, the deterioration of microcirculation is seen as the most important pacemaker in the 
progression to a necrotizing pancreatitis. In addition to its potentiatory role, severe 
pancreatic ischemia can play a pathogenetic role in the initiation of acute pancreatitis. The 
acute edematous pancreatitis is characterized by an increased and homogeneous 
microperfusion. The experimental necrotizing pancreatitis shows a progredient decrease of 
capillary perfusion despite stable macrohemodynamics.  
There is increasing evidence that ischemia alone may be the primary cause of pancreatitis or 
may be the exacerbating promotor for the progression from edematous to necrotizing 
pancreatitis. In clinical studies there was evidence, that ischemia during cardiopulmonary 
bypass triggered acute pancreatitis and acute pancreatitis was found in up to 25% of 
autopsies of patients dying after shock. In animal models severe pancreatitis could be 
induced by obstruction of terminal pancreatic arterioles. The study by Mithöfer et al. [1] 
demonstrates, that temporary hemorrhagic hypotension in rats per se initiates acute 
pancreatitis.  
The hypothesis, that the manifestation of microvascular injury in acute pancreatitis involves 
ischemia/reperfusion(I/R)-associated events, is supported by the study of Menger et al. [2], 
who analyzed the pancreatic microcirculation of rats during postischemic reperfusion by 
use of intravital fluorescence microscopy (Fig. 1, 2). In this investigation, post-ischemic 
reperfusion was characterized by a significant reduction of functional capillary density (no-
reflow) and by a marked increase of the permanently adherent leukocytes in postcapillary 
venules (reflow paradox) (Fig. 3). In addition, the functional and histomorphological 
alterations in this study were similar to the alteration seen in edematous pancreatitis. 
Postischemic activation of leukocytes has been reported to determine the outcome of I/R 
injury. Kusterer et al. [3] have demonstrated that sodium taurocholate-induced pancreatitis 
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is characterized by early arteriolar vasoconstriction with ischemia, followed by arteriolar 
vasodilation with reestablishment of blood flow (reperfusion). Increased leukocyte-
endothelial cell interactions in postcapillary venules - mimicking the I/R event - were 
observed during vasodilation. The concept of I/R-induced pancreatitis is mostly reflected in 
the clinical situation of post-transplant pancreatitis. Experimental studies using the model of 
syngeneic pancreas transplantation in rats show microcirculatory disturbances and cellular 
damages similar to those seen in the beginning of an acute pancreatitis [4]. Pancreatitis after 
hemorrhagic shock or hypotension with hypoxia, but not complete ischemia/anoxia may 
also involve pathomechanisms associated with ischemia/reperfusion. A recent study 
demonstrates, that hemorrhagic hypotension in rats induces intermittent capillary 
perfusion, which is characterized by periods of normal blood flow followed by periods of 
complete cessation of blood flow [5]. This type of regional ischemia and reperfusion may 
contribute to the manifestation of pancreatitis, independent of the etiology.  
2. Cell-cell interactions 
By means of intravital microscopy (Fig. 1-3) in conjunction with technique of selected cell-
labeling, direct impairments of pancreatic microcirculation induced by controlled 
haemorrhage or interruption of arterial blood supply to the pancreas in the early phase of 
acute pancreatitis have been observed [6], suggesting the pancreatic microcirculation being 
highly susceptible to ischemia [7-9]. The nature of blood cell–endothelium, especially 
leukocyte–endothelium, interactions as an early step in the inflammatory response has been 
characterized in experimental pancreas transplantation and in models of I/R-induced acute 
pancreatitis [4, 10].  
 
 
Fig. 1. Processing of intravital microscopy of the rat pancreas.  
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Fig. 2. In-vivo microscopic image of pancreas microcirculation.  
 
 
Fig. 3. In-vivo microscopic image of sticking platelets in a postcapillary venule of a post-
ischemic rat pancreas.  
2.1 Leukocytes 
The neutrophils play a central part in the inflammatory process of acute pancreatitis. Their 
activation and that of the endothelium by cytokines (IL-6, TNFa, IL-8, IL-1b and others) and 
of proinflammatory mediators (platelet-activating factor (PAF), free radicals and others) will 
allow a narrow interaction between them that will result in a significant concentration of 
neutrophils activated in the interstitium [11-14]. This interaction takes place in three parts: a 
weak adhesion of the neutrophils to the endothelium, followed by a stronger adhesion and, 
finally, the neutrophil migration (Fig. 4). Three families of adhesion molecules are 
implicated: selectins, b2-integrins and immunoglobulins (Table 1). The selectins are surface 
glycoproteins implicated in weak adhesion. The L-selectin, expressed by the endothelial 
cells and the neutrophils, plays a part at the beginning of reperfusion. It interacts with the P-
selectin on the neutrophils and a specific ligand present on the membrane of the neutrophil, 
the E-selectin-specific ligand-1 (ESL-1) [15]. Endothelial P-selectin will be expressed later 
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from the Weibel–Palade bodies after activation of the endothelium by reactive oxygen 
species (ROS), hypercalcaemia, complement or thrombin. Its peak of expression occurs 10–
20 min after the beginning of reperfusion [14]. It interacts with P-selectin glycoprotein 
ligand-1 (PSGL-1) expressed by the neutrophils. These interactions are very weak, giving the 
neutrophils a weak, transitory, reversible adhesion known as ‘leukocyte rolling’. This phase 
prepares the neutrophil and the endothelium for the following stage. A more important 
stowing of neutrophils in the endothelium utilizes other leukocyte and endothelium 
proteins that have a stronger affinity for each other. 

Leukocyte adhesion receptor  Endothelial ligand   Function 
 
a4b7 (unactivated)   MadCAM-1    Rolling 
 
a4b1 (unactivated)   VCAM-1    Rolling 
 
PSGL-1                   P-selectin    Capture, Rolling 
 
L-selectin                  P-selectin    Capture 
                                                              Peripheral node                                    Rolling 
                                                              addressin (PNAd) 
                                                              E-selectin 
                                                              MadCAM-1 
a4b7 (activated)                  VCAM-1/MAdCAM-1   Firm adhesion 
 
a4b1 (activated)                  VCAM-1    Firm adhesion 
 
CD11a /CD18   ICAM-1, ICAM-2                 Firm adhesion,  
 (LFA-1)                                                                                                               Emigration 
CD11b/CD18    ICAM-1                  Firm adhesion,  
(Mac-1)                                                                                                                Emigration 
PECAM-1    PECAM-1    Emigration 
Table 1. Leukocyte-endothelium interactions. Adhesion receptors and their ligands on 
activated endothelial cells. Modified from [17]. 
The ROS, PAF and leucotriene (LTB4) stimulate the expression by neutrophils of b2-
integrins from the intracellular granules. This family of membrane proteins consists of 
CD11a/CD18, CD11b/CD18 and CD11c/ CD18 and interacts with the ICAM-1 endothelial 
protein whose expression is enhanced by TNFa and IL-1 [16, 17]. This interaction fastens the 
neutrophil to the surface of the endothelial cell and allows the next stage. ICAM-1 and 
PECAM-1 are adhesion molecules belonging to the superfamily of immunoglobulins which 
take part and orchestrate the transfer of the neutrophils towards the interstitium. The 
leukocyte extravasation utilizes many stages, not all of which are yet clear. Nevertheless, it 
seems that PECAM-1, localized at the level of the intercellular endothelial junctions, is 
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necessary to allow neutrophil migration [18]. This transfer is facilitated by the inflammation 
mediators, the connection of CD11/CD18–ICAM-1 and the ROS making the endothelial 
barrier receptive by decreasing the expression of cadherin and phosphorylation of vascular 
endothelial cadherin and cathenin, components of the intercellular junctions [19, 20]. 
 
 
Fig. 4. Multistep adhesion cascade of leukocyte-endothelium interactions. Modified from 
[183]. 
Arriving at the interstitium, the activated neutrophil will cause considerable damage to a 
tissue, which has already suffered from hypoxia. These lesions are mainly related to the 
massive ROS production, to the release of the contents of the neutrophilic granules and to 
the metabolites of arachidonic acid. The last, metabolized by phospholipase A2, generates 
PAF and LTB4, two powerful chemoattractive components that stimulate the adhesion of 
neutrophils to the endothelium and their degranulation in the interstitium. The neutrophilic 
granules, filled with proteases, collagenases, elastases, lipooxygenases, phospholipases and 
myeloperoxidases, will digest and disorganize the protein network of extracellular matrix 
(Table 2). The proteic network of extracellular matrix is important in healing while being 
used to guide tissue formation. The inflammation induced by reperfusion is a major cause of 
the lesions observed after restoration of blood flow in an ischemic organ. The massive 
production of cytokines, the activation of the complement and a complex choreography of 
the neutrophils are the key factors and are therefore being examined in research to modulate 
the inflammatory reaction.  
2.2 Platelets 
Considerable evidence has accumulated that platelets can also contribute to I/R injury in 
several organs, such as the heart [21], lung [22], and pancreas [23]. Upon activation, platelets 
are able to generate reactive oxygen species and nitric oxide (NO) and can release pro-
inflammatory mediators, such as chemokines, cytokines, growth factors, and cytotoxic 
proteases [24]. Therefore, platelets can potentially contribute to the manifestation of 
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pancreatitis after normothermic I/R injury. In the liver of a rat model, Khandoga et al. [25] 
have demonstrated that platelets interact with the hepatic endothelium after 90 min of warm 
ischemia and 20 min of reperfusion and evoke the development of hepatic microvascular 
and hepatocellular injury. 
 
Leukocytes Platelets
Cytokines/chemokines 
IL-1, IL-2, IL-6, IL-8, IL-12 
IFN-a, IFN-b 
TNF-a, TNF-b 
Transforming growth factor-b 
Monocyte chemotactic factor-1 
 
Reactive oxygen species 
Superoxide 
Hydrogen peroxide 
 
Proteases 
Cathepsin-G 
Elastase 
Collagenase 
 
Oxidases 
Myeloperoxidase 
 
Lipid mediators 
Leukotrienes B4, C4 
Platelet activating factor 
 
Miscellaneous 
Cationic proteins 
Histamine 
VEGF 
Cytokines/chemokines 
IL-1, IL-7, IL-8 
RANTES 
TNF-b 
CD40 ligand 
 
Reactive oxygen species 
Superoxide 
Hydrogen peroxide 
 
Growth factors 
PDGF 
Transforming growth factor-b 
VEGF 
 
Lipid mediators 
Thromboxane A2 
12-HETE 
 
Procoagulants 
Thrombin 
ADT and ATP 
Platelet factor-4 
Polyphosphates 
 
 
Table 2. Activation products released by leukocytes and platelets that may impair 
endothelial barrier function. Modified from [18]. 
Platelet activation was accompanied by leukocyte activation in a study of Hackert et al. [7]. An 
interaction between these two cell types has been demonstrated by different authors in the 
past [26-28]. Among others, P-selectin seems to be one of the most important adhesion 
molecules, which links the inflammatory and procoagulatory cascades and has the potency to 
activate leukocytes and platelets as the cellular elements of either pathway [27-30]. Besides 
their adherence to endothelial cells, activated platelets form stable aggregates with leukocytes. 
This results in a combined inflammatory and coagulatory contribution to thrombus formation 
and is also mediated by P-selectin and beta-integrins [31, 32]. Especially, the formation of 
microthrombotic vessel occlusion with microcirculatory perfusion failure and consequent 
ischemia, hypoxia, and tissue necrosis promote organ damage. 
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2.3 Lymphocytes 
Recent studies have implicated peripheral blood lymphocytes in Ag-independent 
inflammatory-mediated injury following organ reperfusion [33-36]. The contributory role of 
lymphocytes in I/R is likely a multifactorial one.  
Evidence is mounting on the importance of T cells in mediating both short- and long-term 
damage during I/R injury, which in turn could explain why I/R contributes to poor late 
allograft function [37, 38]. The demonstration that systemic immunosuppression (CsA, 
FK506) attenuates hepatocellular injury following I/R implies the involvement of T 
lymphocytes in the pathophysiology of the injury [39, 40], data supported by Shen et al. in 
T-cell-deficient (nude) mice [41, 42], as well as in rats in which treatment with FTY720 
prevented hepatic I/R insult in parallel with massive redistribution of recirculating T cells 
from host peripheral blood into the lymph node compartment [43]. The adherence of 
lymphocytes in hepatic sinusoids occurs early duringreperfusion and impairs liver function 
following prolonged cold ischemic times [44]. Recent data have also shown that circulating 
CD4+ T lymphocytes may act as a cellular mediator in subacute PMN recruitment following 
hepatic I/R injury [38] (Table 3). 
 
Platelet receptors Ligand Function 
 
P-selectin PSGL-1 Rolling, adhesion, RANTES 
deposition 
PSGL-1 
 
P-selectin Rolling, adhesion and P/L 
interactions 
GP1bα vWF 
P-selectin 
Mac-1 
Aggregation, rolling, 
adhesion and P/L 
interactions 
GPIIb/IIIa GPIIb/IIIa 
ICAM-1 
(via fibrinogen) 
av b3 
Mac-1 
Aggregation and adhesion 
JAM-A PSD95/ZO-1 Aggregation and adhesion 
PECAM-1 PECAM-1 Aggregation and adhesion 
Table 3. Platelet–endothelium interactions: Potential molecular determinants. Modified from 
[157] 
JAM-A junctional adhesion molecule-A 
PECAM platelet endothelial cell adhesion molecule-1 
PSGL-1 P-Selectin glycoprotein ligand-1 
vWF von Willebrand factor 
ZO-1 zona occludens protein-1 
3. Adhesion molecules 
A variety of adhesion molecules are implicated in the progression of disease. Intercellular 
adhesion molecule, platelet endothelial cell adhesion molecule 1 and endothelial leukocyte 
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adhesion molecule 1 (ELAM-1) are up-regulated, expression of P- and E-selectin enhanced, 
and leukocytes become CD18 positive in acute pancreatitis [11].  
3.1 Intercellular Adhesion Molecule-1 (ICAM-1)  
ICAM-1, a single-chain transmembrane glycoprotein with a molecular weight of 80-110 
KDa, consists of five Ig-like domains, a hydrophobic transmembrane domain and a short 
cytoplasmic C-terminal domain [45]. Its ligand includes lymphocyte function- associated 
antigen-1 (LFA-1) and macrophage antigen-1 (Mac-1) [46]. ICAM-1 is an immunoglobulin 
molecule mainly expressed in vascular endothelial cells, and plays an important role 
especially in the process of inflammation. Under normal circumstances, it will not be 
expressed or just with low expression in most vessels. However, when its expression 
increased, it can interact with integrin on the surface of granular cells. Therefore, it can cause 
leukocyte migration through capillary endothelial barriers to inflammatory regions, and 
then cause excessive architectonic inflammatory response [47]. Experiments show that 
ICAM-1 high expression may cause leukocyte adhesion through endothelial cells – 
leukocyte interaction, increase capillary permeability, reduce capillary blood flow velocity, 
cause pancreatic microcirculation disorder [48-50]. ICAM-1 expression correlates with 
histological severity and leukocyte infiltration [51], and can be upregulated by trypsin in 
vivo and in vitro [49]. This upregulation is mirrored by increased tissue infiltration of 
leukocytes and increased endothelium-leukocyte interaction. 
Whereas the binding of endothelial ICAM is directly to CD18 on the leukocyte surface, the 
binding of platelets to the endothelium is possible via the following mechanism. I/R leads to 
fibrinogen deposition on microvascular endothelial cells and a corresponding accumulation 
of firmly adherent platelets. Experimental interventions (i.e., anti-fibrinogen antibody or 
ICAM-1 deficiency) that reduce the I/R-induced fibrinogen accumulation also blunt the 
accumulation of adherent platelets in both arterioles and venules, suggesting that the 
binding of fibrinogen to endothelial cell ICAM-1 creates a scaffold on the vessel wall onto 
which platelets can adhere using GPIIb/IIIa [52] (Table 3). 
3.2 Platelet–endothelial cell adhesion molecule (PECAM)-1 
The pancreatic circulation during acute experimental edematous pancreatitis may also be 
influenced by the expression of platelet-endothelial cell adhesion molecule on 
polymorphonuclear leukocytes. PECAM-1 expression was up-regulated in the peripheral 
circulation and down-regulated in the pancreatic microcirculation, suggesting that 
inhibition of PECAM-1 expression may improve the pathological changes associated with 
acute edematous pancreatitis in rats [53, 54]. 
3.3 P-selectin 
P-selectin is normally stored in granular structures of both platelets (α-granules) and 
endothelial cells (Weibel–Palade bodies), from which it can be rapidly mobilized to the cell 
surface upon endothelial cell activation. Some vascular beds (e.g., intestine) exhibit 
significant basal expression of P-selectin [55], with little basal expression on inactivated 
circulating platelets. Several studies have addressed the contributions of platelet vs. 
endothelial cell P-selectin to the platelet adhesion induced by stimuli such as I/R [56, 57], 
[58], endotoxin [59], and TNF-α [60]. In I/R models of platelet adhesion, it appears that 
those models that elicit a rapid adhesion response in both venules and arterioles are entirely 
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dependent on endothelial P-selectin [56], while I/R models exhibiting slow, time-dependent 
platelet adhesion only in venules involve both platelet and endothelial cell P-selectin [57]. A 
blocking mAb directed against PSGL-1, a ligand for P-selectin that is expressed on 
leukocytes and platelets [61], is also effective in attenuating the I/R-induced platelet 
adhesion observed hours after reperfusion, which further supports a role for platelet-
derived P-selectin [57]. 
 
Influenced Paramter  Treatment Effect References 
Leukocytes Neutrophil depletion 
Diannexin 
Tacrolimus  
Anti-fibrinogen antibody 
Erythropoeitin 
+ 
+ 
+ 
[57] 
[42] 
[158, 7] 
[159] 
[160, 161] 
Platelets Platelet depletion, anti-
platelet serum 
+ [162] 
Lymphocytes FTY720 
Tacrolimus 
+ 
+ 
[43, 163, 33] 
[158, 7] 
ICAM-1 Anti-ICAM-1 antibody 
ICAM-1-deficiency 
Phloretin 
Erythropoeitin 
+ 
+ 
+ 
[51, 164, 165]  
[52] 
[166] 
[160, 161] 
P-selectin CP-96,345 
Statins 
+ 
+ 
[167] 
[168-170]  
ET ETA receptor antagonist + [79, 171-173] 
NO L-arginine 
Sodium nitroprusside 
+ [174-176]  
TNF-α Receptor antagonist 
Knockout mice 
Polyclonal antibody 
+ 
+ 
+ 
[177] 
[178] 
[90] 
IL-1 Receptor antagonist 
Knockout mice 
+ 
+ 
[177] 
[178] 
IL-10 IL-10 administration + [108, 109]. 
PAF PAF antagonist + [179], [180], [111] 
Serotonin 5HT2 receptor antagonists + [119], [118] 
Bradykinin Bradykinin B2 receptor 
antagonist 
++ [181], [132] 
TXA2 TXA2 receptor blocker + [182] 
VEGF tyrosinekinase inhibitor 
PTK787/ZK222584 
+ [146] 
COX2 Inhibition, depletion + [136, 137] 
Table 4. Therapeutic approaches to prevent or treat microcirculatory disturbances in acute 
pancreatitis. 
The platelet adhesion elicited by bacterial endotoxin also appears to involve endothelial P-
selectin [59]. However, glycoprotein (GP) Ibα is the platelet ligand that appears to mediate 
this interaction. This glycoprotein and PSGL-1 are two platelet ligands that have been 
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implicated in P-selectin-mediated platelet interactions (primarily rolling) with venular 
endothelial cells. Platelet GPIbα also exhibits the capacity to bind to endothelial cells in a P-
selectin-independent manner. vWF, which is released from Weibel–Palade bodies during 
endothelial cell activation, can bind to GPIbα. vWF–GPIbα interactions have been 
implicated in the platelet recruitment in mouse mesenteric venules stimulated with either 
calcium ionophore, A23187, or histamine [62, 63]. 
4. Vasoactive mediators 
4.1 Endothelin 
Endothelin-1 (ET-1) is a potent vasoconstrictor of the pancreatic microcirculation mainly 
produced by endothelial cells. The intact microvasculature is balanced by the constricting 
action of ET-1 and the dilating features of nitric oxide (NO), made constitutively by 
endothelial nitric oxide synthase (eNOS). It has been shown that ET-1 production is 
controlled at the transcriptional level. Up-regulation of prepro-ET-1 mRNA can be induced 
by numerous factors such as cytokines, angiotensin, thrombin, and TGF- [64]. Released 
from endothelial cells, ET-1 mediates transient vasodilation followed by a profound and 
longlasting vasoconstriction. Furthermore, ET-1 is able to induce an inflammatory response 
in human vascular smooth muscle cells by stimulating the synthesis and release of pro-
inflammatory cytokines such as interleukin-6 [65]. ET-1 does not only mediate local injury, 
but also systemic disease. 
ET affects microcirculation by:  
- constriction of arterioles and venules [66, 67] 
- release of prostaglandine E2, IL-6 and IL-8 from monocytes [68] 
- stimulation of phospholipase A2 [69] 
- reinforced formation of free oxygen radicals in neutrophiles [70] 
- expression of adhesion molecules [71, 72] 
- stimulation of catecholamine release [73] 
Beside its vasoconstrictive effects endothelin as multifunctional cytokine modulates the 
motility and secretion of the intestinum, stimulates mitogenesis and acts as a growth factor.  
Several investigators have shown that the pancreas is especially susceptible to ET-1 [74], 
[75]. The study of Hildebrand et al. showed that the rat pancreatic acini possess ETA and ETB 
receptors [76]. At doses of 100 to 1000 pmol/kg via intravenous injection, endothelins cause 
sustained reduction in pancreatic blood flow in the rabbit and dog of up to 80 % [75, 77]. In a 
study in rats, intravenous infusion of endothelin-1 or alcohol significantly reduced 
pancreatic capillary blood flow. The deterioration of capillary blood flow was more 
pronounced when alcohol and ET-1 were combined [78]. Liu et al. observed a decrease of 
pancreatic blood flow and a reinforcement of morphological changes after application of 
endothelin to rats with cerulein-induced edematous pancreatitis [47]. Foitzik et al. found in 
transgenic rats with an overexpression of endothelin receptors a more severe course of a 
necrotizing pancreatitis, which could be moderated by the application of a selective ETA 
receptor antagonist [79]. Plusczyk et al. showed that topical ET-1 application leads to a 
decrease in blood flow in the pancreas [80]. In intravital microscopy a strong heterogeneity 
of erythrocyte velocity, a decrease in the number of perfused capillaries and a reduction of 
the capillary width were seen. This group suggests that high local ET concentrations can 
cause complex microcirculatory disturbances, leading to acinar cell necrosis and therefore to 
the development of necrotizing pancreatitis [80]. There is some evidence that endothelins 
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also increase pancreatic capillary permeability [74, 81], though this might be explained by 
the resulting portal venous vasoconstriction.  
4.2 Nitric oxide 
Nitric oxide (NO) is synthetized through NO synthases from the amino acid L-arginine. For 
the first time, this pathway was described in endothelial cells [82], but it is also found in 
platelets, macrophages and in cells of the pancreas [68, 69]. NO causes a relaxation of 
vascular smooth muscle cells, depression of platelet aggregation and adhesion and reduces 
the leukocyte activation in vitro [72, 83]. Reduced NO formation reinforces leukocyte 
adhesion and migration [84-87]. These effects are regulated by the activation of the soluble 
guanylatcyclase which leads to increased concentrations of cGMP in the effector cells [86]. 
NO may also act as scavanger of oxygen free radicals [88]. However, also cytotoxic effects 
are described [89]. The overproduction of NO by inducible NO synthetase is an important 
factor in the hemodynamic disturbances of several inflammatory states. 
5. Cytokines 
During acute pancreatitis, some inflammatory cells and pancreatic tissues release 
inflammatory mediators and cytokines, which influence the whole process of inflammation. 
The most important cytokines are tumor necrosis factor-a (TNF-a), interleukins (IL) and 
transforming growth factor (TGF).  
5.1 TNF-α 
Lipsett [90] and Hirota et al. [91] independently proved that the levels of inflammatory 
cytokines always increase during acute pancreatitis and that the degree of the increase is 
closely linked to the severity of the disease. Many other studies have reported that self-
tissue injured with over-activated neutrophil leucocytes is an important causal factor of 
systemic complications [92-94]. One proposal is that the neutrophilic granulocyte may 
generate and release inflammatory cytokines such as TNF-α following inflammatory 
stimulation [95, 96]. TNF-α is an important species of inflammatory cytokines that 
participates in the pathomechanism during pancreatitis. Hughes et al. [97] found that 
injecting TNF-α antibody into rats can markedly improve the state and survival of rats with 
necrotizing pancreatitis, thereby indicating the important role of TNF-α in the onset and 
progression of the disearse. A number of mechanisms have been proposed for TNF-α-
induced pancreatic injury. TNF-α can directly injure pancreatic duct cells and cause 
microthrombus, pancreatic acinus ischemia, hemorrhage, necrosis, inflammation and edema 
[6]. When the quantity of produced TNF-α exceeds that of the tissue TNF receptor, the 
excessive free TNF-α will enter the blood circulation, activate neutrophilic granulocytes and 
cause their aggregatione. It then stimulates the release of cytokines, such as IL-1b, IL-8 and 
IL-6 [98], causing a cytokine cascade reaction that promotes the local and systemic injury. 
The continuous existence of TNF-α may enhance the expression of endothelium adhesion 
molecules, which is necessary for the aggregation of inflammatory cells. Numerous 
granulocytes invade the pancreatic and renal tissues, increase granulocyte phagocytosis and 
degranulation, generate oxygen-derived free radicals, lysosomes, elastin enzyme, among 
others, and cause cell metabolic disturbances and renal failure [99]. 
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5.2 IL-1 
Interleukin (IL) IL-1 is a pro-inflammatory cytokine generated by the pancreas that plays an 
important role in the early stage of severe acute pancreatitis. In a animal model, the IL-1 
receptor antagonist (IL-1r) has been found to decrease case fatality by 30% [100]; in addition, 
the IL-1 receptor can markedly lower the concentrations of IL-6 and TNF-α [101]. Fink et al. 
[102] administered the IL-1 receptor antagonist before inducing the pancreatitis model and 
found that the IL-1 receptor block markedly lowered the release of amylopsin and 
pancreatic necrosis in a dose-dependent manner. 
The generation of IL-1b formed from IL-1 through the mediation of IL-1 convertase (ICE). 
IL-1β and TNF-a have many of the same biological activities, including pyrogen functions, 
the promotion of cell catabolism, the production of protein in the acute reaction period, 
effecting the secretion of PGI2 by epithelial cells and platelet activating factor, among others, 
that will cause the expansion of the inflammation area and increase the levels of 
inflammatory mediators, destructive enzymes and ROS secretion. IL-1b can interact with 
TNF-a to induce or aggravate organ injury. It also has chemotaxis and activating effects on 
granulocyte and can stimulate the production of other inflammatory mediators, such as IL-
8, IL-6 and other inflammatory cytokines, through autocrine or paracrine mechanisms.  
5.3 IL-6 
IL-6 is mainly generated by mononuclear macrophages, which have extensive 
inflammation-promoting effects, such as promoting the activation and proliferation of B 
cells and their final differentiation into plasmocytes, increasing immunoglobulin synthesis, 
promoting T cell differentiation and proliferation, promoting the acute period reaction and 
injuring tissue. The level of IL-6 in the serum can reflect the state of necrotizing acute 
pancreatitis. There are marked differences between acute pancreatitis patients without 
complications and severe acute pancreatitis patients with complications in terms of IL-6 
levels. When present at levels of over 40 µl, IL-6 is considered to be an indication index of 
severe acute pancreatitis [103]. Relevant data show that IL-1 and IL-6 can act on endothelial 
cells, causing them to lower their thrombomodulin activity, aggravate renal ischemia, form 
thrombus [104] and activate inflammatory cells to release NO and ROS to directly cause 
renal injury.  
5.4 IL-8 
IL-8 is a potent neutrophilic granulocyte chemotatic factor and activating factor that is 
mainly generated by neutrophilic granulocytes. Generated by mononuclear/ macrophages 
and endothelial cells, it can activate and induce T and B cell differentiation, enhance NK 
cells for killing target cells, promote phagocytosis and play an important role in tissue injury 
mediated by neutrophilic granulocytes. It is currently believed that most inflammatory 
reactions induced by TNF-a, IL-1 and IL-6 are realized by inducing the generation of 
chemotactic factors, mainly IL-8. Studies have shown that during necrotizing acute 
pancreatitis the levels of IL-6 and IL-8 always increase concurrently and that these positively 
correlate with the state of severe acute pancreatitis [105].  
5.5 Transforming growth factor (TGF) 
Kimura et al. [106] studied the expression of TGF-b1 by means of immune electron 
microscopy and found that a marked effusion of the polymorphonuclear leukocyte and 
deposition of fibronectin and TGF-b1 among pancreatic lobules and inside lobules within 
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12–24 h after inducing pancreatitis. They therefore believed that this kind of change at the 
early stage of pancreatitis is related to the generation of fibronectin and type III collagen in 
the extracellular matrix during the reparative process of pancreatic tissues. Konturek et al. 
[107] proposed that TGF-b can induce non-inflammatory apoptosis to repair injured 
pancreatic tissues. 
5.6 IL-10 
Interleukin-10 (IL-10) is an anti-inflammatory cytokine. Its plasma levels are elevated in 
animal models of endotoxemia and inhibit the release of pro-inflammatory cytokines (i.e. IL-
1β, IL-6 and TNF-α) from monocytes/macrophages thus preventing subsequent tissue 
damage. IL-10 also stimulates production of naturally occurring IL-1 receptor antagonist (IL-
1ra) and release of soluble p75 TNF receptor [108]. IL-10 is believed to have a protective role 
in acute pancreatitis. Administration of IL- 10 in experimental acute pancreatitis reduces the 
local inflammatory response and subsequent mortality [108, 109]. 
 
 
 
 
 
Fig. 5. Interaction between cytokines and oxidative stress in the inflammatory response in 
acute pancreatitis (IL-1β: interleukin-1β; IL-10: interleukin 10; MnSOD: Mn-superoxide 
dismutase; PAP-I: pancreatitis-associated protein I; TNF-: tumor necrosis factor α; NF-kB: 
nuclear factor kappaB; ERK: extracellular signal regulated kinases; JNK: c-jun N-terminal 
kinases; p38: p38 kinase). Modified from [184]. 
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6. Other mediators 
6.1 Platelet activating factor (PAF) 
PAF, 1-O-octadecyl-2-acetyl-sn-glycero-3-phosphocholine, is a potent inflammatory 
mediator produced by endothelial cells, platelets, monocytes, neutrophils, and basophils. It 
is considered to be the key inflammatory mediator in severe acute pancreatitis external 
secretion and local/systemic inflammatory reactions [110]. 
PAF has been shown to be released into the peritoneal fluid as well as the bloodstream and 
the lung after the induction of acute experimental pancreatitis. Locally, PAF acts on 
microvascular diameter, permeability and platelet and leukocyte rolling, adhesion and 
migration through different mechanisms, including synthesis and release of NO and 
arachidonic acid metabolites, and up-regulated expressions of ICAM-1 and CD11/CD18. 
Secondary actions include the elevation of adhesion factor b2-integrin, changes in the 
endothelial cell skeleton, increases in capillary permeability, massive effusion of plasma, 
increase in blood viscosity and a slowdown of blood flow. It also participates in I/R injury 
and stimulates other vasoactive substances, including the generation of cytokine and 
inflammatory mediators. In acute pancreatitis, PAF levels rise due to the cytokine cascade 
reaction activated by elevated levels of TNF-a [98]. On the one hand, PAF promotes 
granulocyte aggregation and aggravates inflammatory reactions; on the other hand, it 
increases capillary permeability and aggravates renal tubule injury. The imbalance between 
PAF and vasoactive substances can initiate a vicious cycle that leads to a series of chain 
reactions and amplifying reactions—the cascade reaction. This reaction can increase tissue 
and organ injury, cause systemic inflammatory reaction syndrome (SIRS) and, eventually, 
multiple organ dysfunction syndrome (MODS) and/or multiple organ failure (MOF), or 
even death [98], [48]. Clinical studies have found that PAF antagonist Lexipafant has clear 
treatment effects on multiple organ failure of severe acute pancreatitis patients and also 
lowers the serum levels of inflammatory mediators such as IL-8 and IL-6 [111]. 
6.2 Activation of complement 
I/R activates the complement and the formation of many inflammatory mediators, 
including the anaphylatoxins C3a, C4a and C5a. These recruit and stimulate the 
inflammatory cells and increase the expression of adhesion molecules such as vascular cell 
adhesion molecule-1 (VCAM-1), ICAM-1, E-selectin and P-selectin on the surface of the 
endothelium and the neutrophils [112, 113]. C5a is a chemotactic factor that directly 
stimulates the synthesis and the leucocyte secretion of cytokines such as IL-1 and 6, the 
monocytes chemo-attractive protein-1 (MCP-1) and TNFa. The iC3b takes part in the 
adhesion of the neutrophils on the endothelium. C5b-9, known as the ‘final cytolytic 
membrane attack complex complement’, is a powerful chemotactic agent, which causes 
direct lesions to the endothelial cells, stimulates the endothelial production of IL-8, MCP-1 
and ROS and inhibits endothelium-dependent vasodilatation [13, 113, 114]. 
6.3 Serotonin 
Platelet serotonin (hydroxytryptamine; p-5HT) is an index of platelet activation [115, 116]. 
Furthermore, the administration of human pancreatic fluid caused the release of 5HT in 
parallel with platelet activation [117]. Several studies showed that the production of 5HT 
can induce further platelet aggregation and 5HT release [118, 119], a positive feedback that 
may lead to thrombus formation [120]. Furthermore, 5HT is also a potent vasoconstrictor 
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[116]. Thus, these proprieties may mean that this bioamine is an aggravating factor for acute 
pancreatitis. The release of serotonin is considered to be the “gold standard” assay for the 
detection of platelet activation [121]. 
6.4 Bradykinin 
The neuropeptide bradykinin is well known for its actions as an endothelium-dependent 
vasodilator. Bradykinin induces relaxation of vascular smooth muscle via stimulation of B2 
receptors, which in turn stimulates constitutively expressed endothelial nitric oxide (NO) 
synthase (eNOS) to produce NO, induces cyclooxygenase-dependent production of 
prostacyclin and other prostanoids, as well as superoxide, activates charybdotoxin-sensitive 
K+ channels, and induces the formation of epoxyeicosatrienoic acids by cytochrome P-450 
epoxygenase [122-124]. In addition to its actions on arterial and arteriolar vascular smooth 
muscle, bradykinin also exerts powerful pro-inflammatory effects in postcapillary venules. 
For example, it generates the release of endothelium-derived mediators from cultured 
endothelial cells that are chemotactic for neutrophils, eosinophils, monocytes, and 
pulmonary alveolar macrophages; induces the expression of endothelial adhesion 
molecules; and provokes leukocyte and platelet adherence to endothelial monolayers and 
postcapillary venules [125-129]. 
The specific mechanisms of bradykinin in the pancreas can be listed as follows: bradykinin 
can promote the synthesis and release of NO, bradykinin influences the pancreatic 
microcirculation by stimulating the formation of reactive oxygen species, PAF, ET, and 
different inflammatory mediators. 
6.5 Thromboxane A2 (TXA2) 
TXA2 is a potent capillary vasoconstrictor substance and platelet aggregation promoter that 
is able to induce platelet release and secretion, cause local and/or systemic disturbance of 
hemorrhage blood coagulation and destroy the cell-protection mechanism [130, 131]. 
Effected by increased phospholipase during acute pancreatitis condition, the cell membrane 
phospholipids decompose arachidonic acid, evoke TXA2 increase, lead to platelet 
aggregation, thrombosis, induce platelet deformation, adhesion, result in coagulation 
dysfunction, precipitate pancreatic ischemia and microcirculation, and increase pancreatic 
pathology injury [132]. In addition, it can promote neutrophil cell activation, release ROS, 
injure capillary endothelial cells, result in increased capillary permeability, and plasma 
extravasation [133]. 
6.6 Cyclooxygenase (COX) 
COX, the key enzyme for prostaglandin synthesis, exists in two isoforms as COX-1 and 
COX-2. COX-1 is constitutively expressed in most tissues and has been suggested to mediate 
the synthesis of prostaglandins required for physiological functions and maintenance of 
organ integrity. COX-2 is undetectable in most tissues in normal condition, but is highly 
inducible by cytokines, mitogens, and endotoxins, and is responsible for an increased 
production of prostaglandins during inflammation [134, 135]. The role of COX-2 in 
pancreatic pathology is unclear. Studies performed by Song et al. [136], and Ethridge et al. 
[137], with mice have shown that pharmacological inhibition of COX-2 or COX-2 gene 
disruption reduces the severity of pancreatitis and pancreatitis-associated lung injury.  
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Furthermore, Foitzik et al. [138], found some beneficial systemic effects of COX-2 inhibition 
on acute pancreatitis, such as an improvement of renal and respiratory function, but they 
have not observed any significant effect of COX-2 inhibition on histological score of 
pancreatic damage or plasma level of trypsinogen activation peptides. Warzecha et al. [135] 
investigated the role of the blockade of COX-1 or COX-2 and found a significantly reduction 
of serum lipase and serum poly-C ribonuclease activity, as well as decreased pancreatic 
edema and inflammatory infiltration in morphological features in animals with cerulein-
induced pancreatitis.  
6.7 Prostaglandin I2 (PGI2) 
PGI2 is also one of the arachidonic acid metabolites with a strong vasodilator effect. The 
main influence on pancreatic microcirculation in pancreatitis can be listed as follows: 
expansion of the pancreatic bed to increase pancreatic blood supply, improvement of 
pancreatic microcirculation, and increase of pancreatic blood flow by inhibiting platelet 
aggregation, adhesion and deformation. Furthermore, PGI2 can also stabilize 
lysosomalmembrane to prevent cytokine release and attenuate inflammatory response [139], 
[140]. 
6.8 Nuclear factor-kappa B (NF-kappa B) 
NF-kappa B is a multi-purpose nuclear transcription factor, mainly involved in the 
regulation of expression referring to immune and inflammatory molecules [141]. Under the 
normal physiological circumstances, the NF-kappa B exists in the cytoplasm of other cells in 
the form of inactivity. When it is activated, it will promote a variety of cytokines gene 
transcription, and it plays an important role in cytokine-mediated infection, inflammation, 
oxidative stress, cell proliferation and apoptosis, the process of microcirculation and so on. 
Shi et al. showed that NF-kappa B activation can aggravate acute pancreatitis 
microcirculation disorder and gradually reduce the amplitude of pancreatic blood flow, and 
slow down blood flow velocity with the gradual increase of NF-kappa B P65 expression. The 
possible acting mechanism of NF-kappa B is that the excessive expression of NF-kappa B 
induces inflammatory cells' excessive secretion of nitric oxide, and then causes dysfunction 
of endothelial cells and smooth muscle cells, and capillary tension disorders, and leads to 
capillary pathological expansion, increase in capillary permeability due to endothelial cell 
injury, and plasma extravasation, which eventually leads to reduction of effective blood 
volume, pancreatic tissue hypoperfusion, and induces increases microcirculation disorder 
[142]. 
6.9 Vascular endothelial growth factor (VEGF) 
VEGFs are endogenous vascular peptides that result in angiogenesis, vasodilatation and 
increased microvascular permeability in vivo [143]. Induction of VEGF mainly occurs in 
response to hypoxia [144]. Warzecha et al. found an increase in the immunohistochemical 
expression of VEGF even in the early course of I/R-induced acute pancreatitis [145]. Using 
the novel tyrosinekinase inhibitor PTK787/ZK222584, von Dobschuetz et al. observed a 
significant decrease of macromolecular permeability and a slightly increased functional 
capillary density with reduced leukocyte–endothelium interactions in the treatment group 
supporting a beneficial effect of this approach [146]. 
 
Microcirculatory Disturbances in the Pathogenesis of Acute Pancreatitis 
 
157 
6.10 Role of endotoxin 
Endotoxin, which is mainly produced by Gram-negative bacteria, is a component of the 
lipopolysaccharide present in cell walls. Clinical studies show that endotoxemia occurs in 
acute pancreatitis and particularly in severe acute pancreatitis, and that it is closely related 
to the onset, progression and complication of multiple organ failure in severe acute 
pancreatitis. Windsor et al.’s [147] study demonstrated the link between endotoxin and the 
state of pancreatitis. Other researchers studying the relation between plasma endotoxin 
levels of acute pancreatitis patients and multiple organ injury have found that endotoxin has 
an important promoting effect during the progression of multiple organ injury. As the most 
potent stimulant of endothelin, endotoxin can elevate the endothelin level in vivo and in 
blood, potently contracting medium-sized arteries and arterioles. Increased endothelin 
levels will also aggravate ischemia in other tissues, enhance bacterial translocation, raise 
blood endotoxin and renin-angiotensin levels and form a vicious cycle chain of tissue 
ischemia and endothelin that aggravates tissue ischemia endlessly [148]. 
6.11 Influence of reactive oxygen species (ROS) 
The ROS is an oxygen-containing chemical group with high chemical reaction activities, 
mainly those involving the peroxide anion-free radical (O2–) and the hydroxy radical (OH ּ◌). 
By causing lipid oxidation, it can increase mucosa permeability, further enhance phagocyte 
activity, generate more ROS and finally cause histiocyte injury. Scott et al. [149] 
demonstrated that in the pathological state, excessive ROS can cause tissue and cell injury. 
ROS can also participate in the formation of acute pancreatitis pancreatic edema and, 
possibly, in pancreatic necrosis and mediate leukocytes and platelets activated by TNF-α in 
all organs to 
6.12 Toll-like receptor-4 (TLR4) 
In the early stage, acute pancreatitis mainly manifests as a chemical inflammation, which is 
a pancreatic nonspecific inflammatory process resulting from the action of a variety of 
factors. This inflammatory process is an inflammatory cascade reaction dominated by the 
body’s innate immune system. Toll-like receptors are a kind of protein that can trigger this 
inflammatory cascade reaction. It is currently thought that TLRs might play a central role in 
the recognition of endogenous or exogenous antigen in the immune system and in the 
initiation of signal transduction in the process of inflammatory reaction during acute 
pancreatitis. Therefore, investigating the tissue-specific expression of TLRs (mainly TLR4) in 
pancreas and exploring their roles have great significance for understanding the 
pathogenesis of acute pancreatitis. A report has indicated that in the early stage of acute 
pancreatitis, the expression levels of TLR4, TNF-α, and IL-6 in pancreas of acute pancreatitis 
patients are significantly higher than those in the control ones, the level of plasma TNF-α in 
acute pancreatitis patients increases subsequently, and the increase of plasma TNF-α level is 
positively correlated with the expression of TLR4, suggesting that the up-regulation of TLR4 
expression on the surface of peripheral blood monocytes in patients with early acute 
pancreatitis might be associated with the activation of the innate immune system in the 
early stage of the disease [150]. Results of animal experiments have shown that TLR4 
messenger RNA is also up-regulated in the pancreas of rats with cerulein-induced 
edematous pancreatitis in the early stage, the serum levels of cytokines such as TNF-α are 
subsequently elevated, and the two phenomena are correlated [151].  
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Some researchers believe that TLR4 may play an important role in the synthesis and release 
of pro-inflammatory cytokines, and the up-regulation of the TLR4 gene may be related with 
the development and progression of organ injury during acute pancreatitis [152, 153]. Some 
studies have indicated that when severe acute pancreatitis is stimulated by LPS, the 
expressions of cytokines and cell adhesion molecules are significantly up-regulated in 
pancreas, thereby promoting the accumulation of excessive neutrophils in inflammatory 
region and leading to the injury of pancreas and other organs [154, 155]. Although it has 
been known that the translocation of intestinal bacteria and endotoxins is a key to secondary 
bacterial infection in necrotic pancreatic tissue, the mechanism of how multiple organ failure 
develops during pancreatitis has not yet been fully clarified [156].  
7. Conclusions 
Recent advances in experimental research have helped witness the pathophysiology of acute 
pancreatitis. The phenomena of microcirculatory changes observed in acute experimental 
pancreatitis during the past few years gradually underlie the disturbance of the local 
microcirculation in acute pancreatitis, but several challenges remain. Still some questions 
remain unexplained concerning the mechanisms: (1) Which is the first event in the 
pathogenesis of acute pancreatitis? (2) Which factor determines the edematous or 
necrotizing pancreatitis in a given experimental or clinical situation? (3) What is the role of 
impaired distribution of blood supply in early steps of acute pancreatitis? The potential 
mediators responsible for the progression of the disease severity and suggestions for 
therapeutic intervention have largely remained subjecting to speculation and debate. 
Further research may help to find sufficient therapeutic approaches, eventually by affecting 
microcirculatory mechanisms, to influence development and progression of this disease. 
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1. Introduction 
Pancreatitis is the most common complication of endoscopic retrograde 
cholangiopancreatography (ERCP) [1–4]. The reported incidence ranges from 1.8% to 7.2% in 
most prospective series [5–9] but can be up to 30%, depending on the criteria used to diagnose 
pancreatitis, the type and duration of patient follow-up, and the type of case mix [10]. More 
commonly, hyperamylasemia occurs in up to 30% of patients undergoing ERCP [11]. 
As the indications for ERCP have increased, a greater focus on recognizing and preventing 
complications has emerged. The recognized complications of ERCP include asymptomatic 
hyperamylasemia, cardiopulmonary depression, hypoxia, aspiration, intestinal perforation, 
bleeding, cholangitis, adverse medication reactions, sepsis, acute pancreatitis, and death. 
Post-ERCP pancreatitis (PEP) remains the leading cause of morbidity and mortality after the 
procedure and is the focus of studies designed to improve procedural outcomes [12,13]. 
Some studies have suggested that the rates of PEP can be reduced, but the incidence of 
pancreatitis remains high particularly in at-risk patient populations. Pancreatitis continues 
to be the major cause of postprocedure morbidity and mortality [14–17]. 
2. Diagnosis of PEP  
PEP was defined initially as the presence of new pancreatic-type abdominal pain associated 
with at least a threefold increase in serum amylase concentration occurring 24 h after an 
ERCP, with pain severe enough to require admission to the hospital or to extend an 
 
Acute Pancreatitis 
 
174 
admitted patient’s length of stay. This definition was developed in 1991 based upon 
approximately 15 000 procedures evaluated during a consensus workshop. The severity of 
PEP was defined according to the length of stay (mild pancreatitis 2–3 d, moderate 
pancreatitis 4–10 d, and severe pancreatitis >10 d, or intensive care admission or local 
complications secondary to pancreatitis) [18]. This consensus definition has not been 
adopted uniformly and many studies published after 1991 have used different criteria to 
define PEP and to classify its severity. Several studies have challenged the serum amylase 
threshold of three times the upper limit of normal, arguing that this definition is not always 
consistent with the clinical and morphological features of pancreatitis [19–25]. Other criteria 
for serum amylase elevation include twice [23–26], four times [6,27,28] and five times 
[20,21,28–30] the upper normal limit. 
There is also heterogeneity in the criteria used to classify the severity of PEP in published 
studies. Some authors have used the Atlanta criteria published in 1993 to define severity 
[31–33]. The Atlanta criteria incorporate systemic complications of PEP by integrating the 
Acute Physiologic and Chronic Health Evaluation (APACHE) II classification and Ranson’s 
criteria to define the severity [33–35]. An APACHE II score of >8 or a Ranson’s score of 3 of 
11 criteria are defined as severe PEP. Some studies have used the APACHE II classification 
alone to grade the severity of PEP [36]. Other studies have used combinations of criteria to 
define the presence and severity of PEP or have established unique definitions [26,31,37–40]. 
The heterogeneity of criteria in the literature on PEP hinders direct comparison of the 
published clinical trials. 
3. Pathophysiology of PEP 
The pathophysiology of PEP is not well understood. Mechanical, hydrostatic, chemical, 
enzymatic, allergic, thermal, cytokine, oxidative, and microbiological factors have all been 
proposed as causes [32,41–46]. Many studies suggest that PEP results from mechanical 
trauma, causing injury to the papilla or pancreatic sphincter and subsequent swelling of 
the pancreatic duct and obstruction to the flow of pancreatic enzymes. This hypothesis 
remains controversial, and no consensus about the pathogenesis of PEP has been 
established. 
The cascade of events leading to acute pancreatitis is characterized by three phases. The first 
phase is characterized by premature activation of trypsin within the pancreatic acinar cells 
[47]. The second phase is characterized by intrapancreatic inflammation. The third phase is 
characterized by extrapancreatic inflammation [47]. Inflammation in the second and third 
phases has been described as a four-step process: (1) activation of inflammatory cells; (2) 
chemoattraction of activated inflammatory cells; (3) activation of adhesion molecules 
causing binding of inflammatory cells to the endothelium; and (4) migration of activated 
inflammatory cells into areas of inflammation [47]. Recent studies have evaluated 
proinflammatory markers (TNF, interleukin-1 (IL-1), IL-6, IL-8, PAF, and IL-10) in the 
setting of PEP [48–51]. Although three randomized controlled trials (RCTs) suggested a 
protective effect of low- or high-dose (4 g/kg or 20 g/kg) IL-10 given intravenously 15–30 
min before ERCP [52], subsequent studies using similar IL-10 protocols did not support 
these findings [53,54]. Although not demonstrated at present, modulation of 
proinflammatory pathways might be an appealing goal for studies evaluating PEP and the 
systemic inflammatory response. 
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4. Procedural-related factors associates with PEP 
Although the triggers of the inflammatory cascade are not well understood, procedural- and 
patient-related factors have been clearly associated with the incidence of PEP. ERCP is the 
most technically difficult endoscopic procedure performed by trainees and experienced 
endoscopists in both inpatient and outpatient settings. Whereas trauma to the duodenum or 
papilla during endoscopy without cannulation rarely causes pancreatitis [55], cannulation of 
the papilla, especially in moderate to difficult cases, is associated with high rates of PEP. 
Procedures involving multiple (>1–4) or failed attempts at cannulation, multiple pancreatic 
injections (2–5), pancreatic acinarization, and prolonged cannulation time (>10 min) are 
associated with PEP. The following factors have also been associated with a higher risk for 
developing PEP: operator experience, ampullary balloon dilation, precut access 
sphincterotomy, endoscopic sphincterotomy (ES), sphincter of Oddi manometry, distal 
common bile duct diameters of 1 cm, presence of a pancreatic stricture, papillectomy, and 
procedures not involving stone removal [45,56–59] (Table 1). 
 
Patient related  
factors 
Young age. 
Female gender. 
Suspected sphincter of Oddi dysfunction. Recurrent 
pancreatitis. 
Prior history of post-ERCP pancreatitis. 
Patients with normal serum bilirubin. 
Procedure related factors 
Multiple pancreatic duct injections. 
Difficult cannulation. 
Pancreatic sphincterotomy. 
Precut access. 
Balloon dilation. 
Operator/technical related 
factors 
Inadequate training and/or experience 
Trainee involvement in procedure 
Table 1. Factors Increasing the Risk of Post-ERCP Pancreatitis. 
4.1 Operator experience 
Although there is no established mandate for the procedure volume to develop competence 
in ERCP, a prospective study published in 1996 evaluated the number of supervised ERCPs 
a physician must perform to achieve procedural competence and reported that at least 180 
procedures are required [60]. In the United States, the American Society for Gastrointestinal 
Endoscopy and the American College of Gastroenterology have published quality indicators 
for ERCP. Competent endoscopists are expected to be able to perform sphincterotomy, clear 
the common bile duct of stones, provide relief of biliary obstruction, and successfully place 
stents for bile leaks in 85% of patients [61]. 
Few studies have been published on operator experience in ERCP, and this issue remains 
controversial. A recent study in Austria showed that a case volume of >50 ERCPs per year 
had higher success and lower overall complication rates [62]. It is generally agreed that the 
case mix at high volume and in academic referral centers may include a larger proportion of 
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difficult and high-risk cases, which may confound the relationship between experience and 
complication rates. Although operator experience is felt to be critical for high-quality 
outcomes, many large prospective and retrospective trials have not shown consistent 
correlations between inexperience and PEP. Higher rates of bleeding have been reported 
after endoscopic sphincterotomy with a mean case volume of <1 per wk [14], and trainee 
involvement was associated with severe or fatal complications in a recent retrospective 
analysis [63]. However, a large prospective trial found that case volume had no effect on the 
incidence of PEP [24]. A prospective study of ERCP in the United Kingdom (UK) in 2007 
based on self-reported surveys demonstrated that 15% of all credentialed endoscopists 
performed <50 ERCPs per year compared with 61% of those in training; 11% of deaths 
occurred after procedures by endoscopists who performed <50 ERCPs per year. Although 
the rates of PEP were low at 1.5%, the success rates for bile duct stone extraction and biliary 
stent placement were 62% and 73%, respectively. The authors concluded that in the UK 
there is a need for fewer operators and greater experience in those performing therapeutic 
endoscopy [64]. In the same year, a study in France showed no risk associated with operator 
inexperience [65]. 
4.2 Cannulation techniques 
Cannulation techniques to access the pancreatic and biliary ducts include the use of a 
sphincterotome or straight or curved catheter with guide wires or contrast injection. When 
an initial attempt at cannulation fails, access may be achieved after placement of a 
pancreatic guide wire or stent to help guide the endoscopist toward the common bile duct 
and away from the pancreatic duct. Precut access papillotomy is used frequently in referral 
centers when conventional approaches fail. Rare or experimental techniques such as the use 
of endoscopic scissors or endoscopic dissection with a cotton swab have been reported but 
are used rarely in clinical practice [66]. 
Compared with a standard catheter, the use of a sphincterotome may decrease the number 
of failed attempts to obtain biliary access, the time required to cannulate the common bile 
duct, and the rate of PEP [67,68]. Selective sphincterotome cannulation with a guide wire 
may reduce the rate of PEP compared with cannulation with contrast injection [67–71]. In 
2008, a large prospective controlled trial randomized 430 patients into sphincterotome plus 
guide wire versus conventional cannulation arms. The series demonstrated a significantly 
higher rate of cannulation with guide wires but failed to show a significant difference in the 
rate of PEP between the two approaches [72]. The authors reported an 8.8%–14.9% increased 
risk of PEP after >4 attempts at the papilla, highlighting the importance of cannulation with 
fewer attempts. These findings are consistent with those of previous studies [7,72]. 
4.3 Pancreatic duct injection  
Multiple pancreatic duct injections (2–5) [6,7,15,24,58] and pancreatic acinarization 
[6,12,15,30] are recognized as risk factors for PEP. Differences in the osmolality and ionicity 
of contrast media have been studied with varying results in terms of impact on PEP 
[25,28,59,73–75]. A recent meta-analysis of 13 RCTs found no significant difference between 
high- and low-osmolality contrast media [75]. Earlier studies suggested that there is a 
decreased risk of PEP with the use of nonionic contrast agents [73], although this has not 
been demonstrated consistently [74]. One large retrospective analysis of 14 331 ERCPs 
suggested that less opacification of the pancreatic duct in the head than in the tail produced 
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significantly lower rates of PEP [59]. Despite the variable findings, clinical trial data suggest 
that hydrostatic pressure may play a role in the development of pancreatitis. 
4.4 Pancreatic duct stenting  
The theory that PEP is caused by pancreatic duct obstruction is supported by most RCTs, 
which show a decreased incidence of pancreatitis in high-risk patients after placement of a 
pancreatic duct stent [76–84]. The three largest published studies to evaluate the rate of 
pancreatitis with pancreatic duct stent placement reported significant decreases, by 10.4%, 
14.8%, and 52.3%, in the rates of PEP in patients treated with stent placement versus those 
without stent placement [78,79,85]. Although pancreatic duct stenting decreases the risk of 
PEP, it has not been shown to prevent it. Despite stent placement, pancreatitis occurs in 
2.0%–14% of patients [78,79,81,83,84], and some studies have failed to demonstrate a 
significant protective effect [59,83,84]. Eight RCTs, multiple prospective uncontrolled 
studies, and five meta-analyses have compared the rates of pancreatitis after ERCP with and 
without prophylactic pancreatic stent placement [86–90]. Prophylactic stent placement 
reduces the incidence of PEP, particularly in high-risk patients, and virtually eliminates the 
risk of severe pancreatitis. 
Many studies have criticized the absence of intent-to-treat analysis (i.e., patients with 
attempted but unsuccessful stent placement were excluded). However, a meta-analysis 
showed that the four RCTs used intent-to-treat principles by assuming that PEP developed 
in patients in whom the attempted prophylactic pancreatic stent placement failed, even 
when the clinical outcome was not stated in the original study. Despite the use of this 
approach, the odds ratio in the stent group was 0.44 compared with the controls and 
differed significantly in favor of stent placement [86]. On the basis of these results, 
prophylactic stent placement can be considered as the single most important advance in the 
past 15 years for the prevention of PEP in high-risk patients. Despite these findings, 
questions remain about when to place a prophylactic pancreatic stent, the type of stent to 
place, and the optimal follow-up period to ensure adequate removal. The incidence of 
adverse events associated with pancreatic stent placement is around 4% and must be 
considered in the decision-making process for the placement of a stent [86,91]. 
4.5 Biliary stone extraction  
In the setting of choledocholithiasis, endoscopic papillary balloon dilatation (EPBD), ES, and 
mechanical lithotripsy are techniques used to extract obstructing stones. Many studies have 
shown an increased rate of PEP with EPBD; the rates range from 4.9–20% with EPBD versus 
0.42–10% with ES [92–95]. Prospective trials support this observation, although it is difficult 
to generalize the findings given the many factors that contribute to procedural 
complications [96–100]. Balloon dilation may also be required in some clinical settings. If a 
patient has had a prior sphincterotomy and has limited remaining tissue for incision, 
balloon dilation may be necessary to enlarge the bile duct insertion and enable stone 
extraction. 
5. Patient-related risk factors associated with PEP 
Given the high risk of PEP in certain populations, identifying a clear indication is critical for 
reducing the complication rate. ERCP is riskiest in patients who need it the least [101,102]. 
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Large prospective trials have demonstrated that being female, being younger than 60–70 
years, and having suspected sphincter of Oddi dysfunction (SOD) or a recurrent or prior 
PEP are associated with a higher risk of PEP [6,9,15,24,45,87,103,104] (Table 1). However, 
there is some variability between studies. For example, one smaller trial suggested an age of 
<50 years as a significant risk factor [104]. A recent large retrospective study of 16 855 
patients reported that the highest rates of PEP occurred in patients with SOD, but the rate 
was not significantly higher in younger patients or in women [63]. Alternatively, a meta-
analysis evaluating five patient-related risk factors demonstrated relative risks of SOD of 
4.09 (95% CI, 1.93–3.12; P<0.001) and of being female of 2.23 (95% CI, 1.75–2.84; P<0.001) 
[87]. One study demonstrated a 10-fold increase in the risk of PEP in patients with SOD 
[105]. Some factors may be protective as well. The absence of chronic pancreatitis [57], 
presence of obesity [106], older age (>80 years) [107], and a history of alcohol consumption 
or cigarette smoking may be associated with a lower risk of PEP [108]. Proper patient 
selection and identification of patients at higher risk are the most effective means for 
reducing the incidence of PEP. 
6. Pharmacological agents evaluated for the prevention or reduction of PEP 
The effects of pharmacological agents on PEP have attracted much interest. Preventing 
cellular injury and pancreatic tissue auto-digestion may involve blocking the premature 
activation of proteolytic enzymes within the acinar cells [14,45,109–116]. Although 
conceptually straightforward, the goal of blocking this activation has been difficult to 
achieve. Multiple trials have been performed with the goal of reducing the incidence or 
severity of PEP. About 34  pharmacological agents and procedures (e.g., topical application 
of pharmacological agents injected or sprayed onto the papilla) have been evaluated for 
their potential to prevent PEP in controlled trials. Most clinical trials have been 
disappointing, and only a minority of studies has demonstrated benefit (Table 2-5) 
[26,29,37,39,40,53,54,58,87,117–175]. 
In two of five prospective trials, allopurinol was shown to decrease the incidence of PEP 
[119,120]. In these trials showing benefits, allopurinol was given in 300 mg or 600 mg doses 
15 h and 3 h before ERCP. When reviewing other studies of allopurinol, these effects were 
not significant in patients dosed on different 4 h and 1 h regimens and with varying dose 
concentrations of allopurinol [121–123]. This suggests that both the dose and timing of 
allopurinol administration are important in reducing the risk of PEP. 
Three meta-analyses have been published using data obtained from four prospective, 
randomized, placebo-controlled studies that compared rectally administered diclofenac or 
indomethacin at a dose of 100 mg versus placebo [124–126]. No statistical heterogeneity was 
detected between the studies. Two RCTs evaluated the effect of rectal administration of 100 
mg diclofenac immediately after the procedure [39,143], and the other two evaluated rectal 
administration of 100 mg indomethacin immediately before the procedure [144,145]. Both 
sets of studies showed similar results. Patients who were considered to be at high risk for 
PEP were included in both studies. Overall, PEP occurred in 20/456 (4.4%) patients in the 
treatment groups versus 57/456 (12.5%) patients in the placebo groups. The estimated 
pooled relative risk was 0.36 (95% CI, 0.22–0.60), and the number needed to treat to prevent 
one episode of PEP was 15. The administration of nonsteroidal anti-inflammatory drugs 
(NSAIDs) was associated with a similar decrease in the incidence of PEP regardless of risk. 
No adverse event attributable to NSAIDs has been reported. A trial evaluating diclofenac 50  
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Table 2. Randomized controlled trails of drugs that decrease inflammation evaluated for 
reduction or prevention of post-ERCP pancreatitis. 
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Table 3. Randomized controlled trails of drugs that interrupt the activity of proteases 
evaluated for reduction or prevention of post-ERCP pancreatitis. 
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Table 4. Randomized controlled trails of inhibitors of pancreatic secretion evaluated for 
reduction or prevention of post-ERCP pancreatitis. 
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Table 5. Randomized controlled trails of drugs that decrease Sphincter of Oddi Pressure and 
miscellaneous drugs evaluated for reduction or prevention of post-ERCP pancreatitis. 
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mg by mouth given 30–90 min before ERCP and up to 4–6 h after ERCP showed no decrease 
in the incidence of PEP [146]. A small clinical trial by Senol and colleagues found no 
significant difference in the incidence of PEP in patients given ERCP with the use of 75 mg 
of diclofenac by the intramuscular route plus intravenous (IV) hydration versus those given 
placebo and IV solutions [147]. According to the European Society of Gastrointestinal 
Endoscopy, no other drug prophylaxis has been proven to be effective against PEP as rectal 
NSAIDs [148]. 
Glyceryl trinitrate [141], hydrocortisone [130], and IL-10 [52] were shown to be beneficial in 
one RCT. However, studies with larger numbers of patients [26,54,140] found no significant 
effects of these treatments. Gabexate [160,161,163], octreotide [150,151], somatostatin 
[171,174], and ulinastatin [167] have all been reported to reduce the incidence of PEP. 
However, studies evaluating each of these agents using similar designs have reported no 
significant reduction in the incidence of PEP. These differences might be explained by 
differences in the selection and number of patients, clinical presentation, and timing of 
administration or dosage of the agents under investigation. 
7. Management of PEP 
Not all patients with pain and hyperamylasemia following ERCP have acute pancreatitis, 
and clinicians may have difficulty establishing the diagnosis. As a result, some patients with 
severe post-ERCP pancreatitis may not be identified in the early stages of their illness when 
aggressive hydration is most important. Some endoscopists may have difficulty 
acknowledging that post-ERCP pancreatitis has occurred, as this requires accepting that 
there has been a complication. A sense of guilt on the part of the clinician performing the 
procedure is understandable. However, delay in either the diagnosis or treatment of post-
ERCP pancreatitis may lead to adverse consequences. 
Post-ERCP pancreatitis should be managed as for other causes of acute pancreatitis. This is 
sometimes complicated by the difficulty distinguishing mild from severe disease in the early 
stages. The elevations in serum amylase and lipase levels do not always correlate with 
disease severity. 
Mild and moderate PEP usually resolve quickly with conservative therapy. Although there 
are no specific guidelines for the treatment of PEP, a recent study found that a protocol-
based management strategy was associated with less severe pancreatitis, shorter length of 
hospital stay, the need for fewer imaging studies, and less use of antibiotics [109,177].  
Practice guidelines for acute pancreatitis treatment are available and may be applicable to 
PEP as well [47]. In patients with persistent or severe PEP, two important markers of 
severity are multisystem organ failure and pancreatic necrosis, both of which require 
aggressive management [18]. Early identification of organ failure, pancreatic necrosis, 
perforation (especially in the setting of endoscopic sphincterotomy), biliary damage/leak 
and pancreatic fluid collections are important clinical branch points that may require more 
intensive intervention. Checking the levels of serum transaminases, amylase, and lipase is 
not routinely recommended after ERCP, but if assessed, postprocedure elevations occur 
often. These elevations are likely to be secondary to intermittent biliary, pancreatic, or 
papillary obstruction. In a recent study, 46% of patients had elevated liver test results after 
ERCP, but only 5.4% had PEP [110]. Asymptomatic elevation of liver markers is not an 
indication for a change in management and a repeat ERCP should be performed only with a 
clear indication. Although the use of enteral feeding during treatment of acute pancreatitis is 
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controversial, patients who are unlikely to resume oral nutrition within 5 days require 
nutritional support, which can be provided via total parenteral nutrition or enteral routes 
[177]. There appear to be some advantages to enteral feeding. A recent study found that 
initiating oral nutrition after mild acute pancreatitis with a low-fat soft diet appeared to be 
safe but did not shorten the length of hospitalization [111]. 
8. Conclusion 
Acute pancreatitis is a well-recognized and frequent complication that can occur in 1%–15% 
of patients undergoing ERCP. Clinical research to prevent PEP using depurate endoscopic 
techniques and pharmacological prophylaxis is intense and so far indicates that the use of 
NSAIDs and pancreatic stenting, coupled with appropriate selection of eligible patients and 
performed by an experienced endoscopist are the most effective preventive measures to 
reduce the incidence and severity this complication. 
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1. Introduction 
Despite the significant development in endoscope technology and in availability of endoscopic 
accessories and the spreading of well structured ERCP training the incidence of ERCP-related 
acute pancreatitis has been little changed in the last three decades. One of the explanations of 
this contradiction may be that post-ERCP pancreatitis occurs nowadays more often in case of 
therapeutic intervention compared to the diagnostic ERCP and the need for solely diagnostic 
ERCP is rapidly declining due to the development of less invasive imaging methods such as 
magnetic resonance cholangiopancreatography (MRCP) and endoscopic ultrasonography 
(EUS). ERCP has become an almost exclusive therapeutic procedure. 
2. Incidence of post-ERCP pancreatitis 
Endoscopic retrograde cholangiopancreatography (ERCP) has the greatest potential for 
complications among the gastrointestinal endoscopic procedures. The most common 
complication is acute pancreatitis with an overall incidence of 2-10 %, which can reach even 
30 % in the presence of certain risk factors. The post-ERCP pancreatitis is most often mild, or 
less commonly moderate, but in about 10% of cases (about 0.4-0.6 % of the procedures 
performed) it is severe and potentially fatal. The mortality rate is about 0.1-0.5 %. 
Furthermore asymptomatic hyperamylasemia occurs in 35-70 % in patients undergoing 
ERCP. The wide interval of the published incidence of pancreatitis can be explained by and, 
depends on the criteria used for diagnosis, the type and duration of follow-up of patients 
involved in the studies, the levels of endoscopic expertise and, the frequency of patients- 
and procedure-related risk factors in the patient population (Cotton et al. 2009).  
3. Definition of post-ERCP pancreatitis 
A transient elevation in the serum amylase concentration without clinical signs of 
pancreatitis is common following ERCP and abdominal pain is also a frequent complaint 
due to distension caused by intestinal retention of air insufflated during the procedure. 
Therefore clear definition is mandatory for exact evaluation of clinical trials, for comparing 
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the results of different publications and for the standardised management in the prevention 
and treatment of ERCP related pancreatitis. 
The current definition is based on an attempt at consensus in 1991 (Cotton et al.). According to 
this proposal post-ERCP pancreatitis was originally defined as „clinical pancreatitis with 
serum amylase at least three times normal at more than 24 hours after the procedure, requiring 
hospital admission or a prolongation of planned admission”. On the basis of this definition the 
widely excepted criteria for the diagnosis of post-ERCP pancreatitis are the followings: 
pancreatic-type abdominal pain and symptoms with onset after ERCP and severe enough to 
require hospital stay or to extend the length of stay of already hospitalised patients, serum 
amylase and/or lipase at least 3 times higher than the upper limit of normal values in 24 hours 
after the procedure, and/or CT/MRI consistent with the diagnosis of acute pancreatitis. 
The severity of attack was graded by the above consensus report as mild, moderate and 
severe. A mild post-ERCP pancreatitis was defined as a need for hospital stay up to 3 days, a 
moderate pancreatitis was defined as a need for hospital stay for 4-10 days, and a severe 
pancreatitis as more than 10 days with a significant complication. The European Society of 
Gastrointestinal Endoscopy (ESGE) guideline recommends a more specific grading system 
of the severity of pancreatitis for the future (Dumonceau et al. 2010). The Atlanta 
classification can also be used for the estimation of severity of the post-ERCP pancreatitis, 
on the basis of the absence or presence of local (documented by CT) or systemic 
complications, independently of the duration of the hospital stay. 
4. Pathophysiology of post-ERCP hyperamylasemia and pancreatitis  
Pathomechanism of post-ERCP pancreatitis is of multifactorial nature, but it has not been 
fully understood yet. It seems to be an inflammatory response to mechanical, hydrostatic, 
thermal, bacterial and chemical insults that results from canulation and other 
instrumentation of the papilla and injection of contrast medium into the pancreatic duct. 
These initiating factors may act independently or in combination. 
Mechanical trauma: repeated cannulation attempts or prolonged manipulation around the 
papillary orifice may cause injury of the pancreatic sphincter or proximal pancreatic duct 
and may lead to mechanical obstruction due to oedema of the pancreatic sphincter or to 
prolonged spasm in patients with sphincter of Oddi hypertension. 
Hydrostatic factor: pressure increase in the pancreatic duct may be related to overinjection of 
contrast medium (parenchymography) or to pancreatic manometry without distal 
aspiration. The consecutive capillary endothelial injury leads to an increase in capillary 
permeability. It has been suggested that this capillary injury might be mediated by oxygen-
derived free radicals. 
Thermal injury: electrocautery current may produce edema of the pancreatic orifice and 
thermal damage of the periampullary acinar cells. Coagulation or blended current causes 
more tissue injury than cutting current. 
Infection: bacterial injury from contaminated endoscope channel or accessories may occur.  
Chemical factor: injection of contrast medium into the pancreatic duct may result in chemical 
injury. High osmolarity contrast agents are thought to play a role in the induction of 
hyperamylasemia, although a meta-analysis (George et al. 2004) could not confirm it. 
Enzymatic factor: intestinal content may activate intrapancreatic proteolytic enzymes. 
The above initiating factors lead to autodigestion due to premature intracellular activation 
of pancreatic proteolytic enzymes, and to release of inflammatory cytokines producing both 
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local and systemic effects (Demols & Deviere 2003, Karne & Gorelick 1999). The severity of 
pancreatitis is determined by the intensity of the inflammatory cascade and systemic 
response. The process itself is believed the same as for other forms of acute pancreatitis.  
5. Risk factors of ERCP related pancreatitis  
Stratification of patients into low or high risk categories is important pre-investigational 
information to take the potential benefit and risk of procedure into account, to consider 
patient referral to a tertiary centre, and for selection of prophylactic measures. A number of 
risk factors acting independently or in combination have been identified. They can be 
categorised as patient related, procedure related, and investigator related risk factors. 
5.1 Patient related risk factors 
A multivariate analysis of prospective studies found as significant patient-related risk 
factors the followings: young age, female gender, suspected sphincter of Oddi dysfunction, 
previous post-ERCP pancreatitis, recurrent acute pancreatitis, and lack of evidence of 
chronic pancreatitis (Freeman & Guda, 2004). The European Society of Gastrointestinal 
Endoscopy (ESGE) guideline further differentiates between definite and likely risk factors 
based on the strength of evidence from prospective studies (Dumonceau et al., 2010) (Table 
1.). These risk factors can act synergistically, putting patients at high risk for post-ERCP 
pancreatitis. 
 
Definite risk factors 
   Suspected sphincter of Oddi dysfunction 
   Female gender 
   Previous pancreatitis 
Likely risk factors 
   Younger age 
   Non-dilated extrahepatic bile ducts 
   Absence of chronic pancreatitis 
   Normal serum bilirubin 
Table 1. Patient-related risk factors of post-ERCP pancreatitis (Adapted from ref. 
Dumonceau et al., 2010) 
The association of these predictors to post-ERCP pancreatitis proved to be the strongest in 
patients with known or suspected sphincter of Oddi dysfunction with a complication rate of 10-
30 %. All of the risk factors are independently important, but they may have a cumulative 
effect. In a prospective multicentre study (Freeman et al. 2001) the highest risk (42%) was 
found in the following combination of the predictors for post-ERCP pancreatitis: female 
patients, normal serum bilirubin level, suspected sphincter of Oddi dysfunction, and 
difficult bile duct cannulation. It can be postulated that a prolonged pancreatic sphincter 
spasm may be an important common factor in the induction of pancreatitis in the group of 
patients with increased risk for post-ERCP pancreatitis, and that this group of patients have 
a lower threshold for developing pancreatitis after ERCP.  
The higher risk in younger age might depend on the lack of age-related atrophy of the 
pancreatic glands and on the higher prevalence of sphincter of Oddi dysfunction in young 
people, predominantly in females. Similarly to the aging, the protective role of chronic 
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pancreatitis can be explained by atrophy and decreased enzymatic activity. Patients with 
normal serum bilirubin and non-dilated stonefree bile ducts reported as predictors for developing 
post-ERCP pancreatitis may also have sphincter of Oddi dysfunction not having been taken 
into consideration in the diagnosis, especially regarding patients complaining also biliary 
pain. A history of acute pancreatitis independently of the etiology is the second most 
important risk factor after sphincter of Oddi dysfunction, and it should be taken into 
consideration before planning an ERCP.  
5.2 Procedure related risk factors 
Procedure-related risk factors are similarly important as patient-related factors in 
determining the incidence and severity of post-ERCP pancreatitis (Fig 1.). Various 
procedures are associated with higher risk of post-ERCP pancreatitis (Table 2.), most of 
them documented by multivariate analyses. For example role of papillectomy has not been 
analysed, but it can be considered as a definitive risk factor on the basis of prospective 
studies. 
 
Definite risk factors 
   Pancreatic duct cannulation and contrast injection 
   Multiple attempts of cannulation 
   Precut sphincterotomy 
   Endoscopic papillectomy 
Other risk factors 
   Balloon dilation of the sphincter 
   Sphincter of Oddi manometry 
   Pancreatic sphincterotomy 
   Pancreatic brush cytology 
   Failure to clear bile duct stones 
   Difficult or failed cannulation 
Table 2. Procedure-related risk factors of post-ERCP pancreatitis 
Repeated attempts at cannulating, also without pancreatic duct contrast injection is associated 
with high incidence of pancreatitis. This fact supports that papillary edema and sphincter 
spasm, rather than hydrostatic ductal and contrast agent injury are the major factors in the 
induction of post-ERCP pancreatitis. The risk rate seems to progressively increase with the 
number of attempts. More than 10 cannulation attempts can increase the risk of pancreatitis 
about 15-fold (Testoni et al. 2010).  
The contrast injection itself can induce pancreatitis due to hydrostatic injury from pancreatic 
duct overfilling, which is the most pronounced in cases of parenchymography. The use of 
lower ionic contrast agents does not result in lower frequency of pancreatitis than that of the 
conventional ones. 
Pre-cut sphincterotomy is associated with a threefold increase of post-procedure pancreatitis, 
however the risk is likely mainly investigator dependent and seems to be lower in experts 
hands. Moreover, early pre-cut may be safer than delayed pre-cut performed after multiple 
cannulation attempts. The overall risk of pancreatitis after pre-cut sphincterotomy is less 
than after repeated attempts at standard cannulation. Out of the two techniques of needle 
knife precut, fistulotomy where the precut is separate from the papillary orifice, seems to be 
accompanied with less pancreatitis than precut starting at the papillary orifice 
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(Mavrodiannis et al. 1999), although high level evidence fails to support the preference of 
fistulotomy.  
 
 
Fig. 1. Endoscopic retrograde cholangiopancreatogram of a young woman with gallbladder 
stones. Non-dilated bile ducts, young age, and female gender represent patient related risk 
factors, and contrast injection into the pancreatic duct a procedure related risk factor for 
post-ERCP pancreatitis 
Pancreatitis occurs after endoscopic papillectomy performed like a snare polypectomy using a 
side-viewing duodenoscope in 15-20 %. Therefore papillectomy (ampullectomy) should 
perform only by well-trained and experienced endoscopists. The incidence and severity of 
this complication can be significantly reduced by prophylactic pancreatic duct stenting 
(Wong, 2004). Pancreatitis caused by stenosis of the pancreatic duct orifice can also be a late 
complication after papillectomy (Norton et al., 2002).  
Biliary sphincterotomy itself is not associated with an increased risk of pancreatitis. 
Currently the use of pure cut current is advisable, because it causes less tissue injury and 
edema than coagulation current. On the contrary to biliary sphincterotomy balloon dilatation 
of the intact biliary sphincter has been associated with a high incidence of pancreatitis, 
therefore its use is not advisable in the presence of patient-related risk factors, especially in 
patients with sphincter of Oddi hypertension. Large diameter biliary stent without 
sphincterotomy can also induce pancreatitis due to compression of the pancreatic sphincter 
(Tarnasky et al., 1997). On the contrary, biliary-stent exchange in sphincterotomised patients 
causes less-frequent pancreatitis compared to other ERCP procedures (Cotton et al. 2008).  
Sphincter of Oddi manometry using standard perfusion catheter is associated with a 
substantial incidence of pancreatitis. The risk can be significantly reduced by using modified 
triple lumen catheter with simultaneous aspiration or by using a microtransducer catheter. 
In two randomised controlled studies the incidence of post-ERCP pancreatitis was found 
using the alternative catheters in comparison with the standard perfusion catheter 3.0% vs. 
23.5 % and 3.1% vs. 13.8 % (Sherman et al. 1990, Wehrmann et al. 2003).  
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Pancreatic sphincterotomy was associated with high risk of pancreatitis in a recent prospective 
multicentre study only in univariate analysis (Testoni et al., 2010), in agreement with some 
earlier reports (Freeman et al., 2001, Cheng et al. 2006). As independent risk factor proved 
have to been only minor papilla sphincterotomy. 
What other procedure risk factors concerns, pancreatic brush cytology can cause pancreatitis 
due to edema in consequence of mechanical trauma of the pancreatic duct. In case of failure to 
clear the bile duct during ERCP residual stones can induce biliary pancreatitis. 
5.3 Investigator related risk factors 
Data about a potential relationship between post-ERCP pancreatitis incidence and 
endoscopist’s experience in the technique defined as annual case volume (the median 
number of ERCPs per endoscopists/year) are conflicting. Endoscopist’s inexperience and 
trainee participation may be associated with a higher incidence as it was shown in some of 
the studies, while others could not confirm it. This might be explained by the fact that in 
high-volume centres there are more patients with high risk for potential post-ERCP 
pancreatitis and larger number of procedures at higher degree of difficulty.  
6. Prophylaxis of ERCP related pancreatitis 
6.1. Mechanical techniques 
6.1.1 Pancreatic stent placement 
The purpose of placing a temporary pancreatic duct stent is to sustain the pancreatic 
outflow in the face of relative obstruction due to edema and sphincter of Oddi spasm caused 
by manipulations of the papilla. A meta-analysis of eight randomized controlled trials 
demonstrated that short term pancreatic stent placement reduces the incidence of post-
ERCP pancreatitis (Mazaki et al 2010) (Fig. 2.). Sofuni et al (2007) found significant benefit of 
stent placement only in patients at high risk for pancreatitis, and it seems to be not cost-
effective in patients at average risk (Das A et al. 2007). Therefore, the use of prophylactic 
pancreatic stenting is generally proposed only for patients who are at high risk for 
developing pancreatitis after ERCP. Similar standpoint is represented also in the 
recommendation of the ESGE guideline (Dumonceau et al. 2010). 
 
 
Fig. 2. The effect of pancreatic stent placement on the incidence of post-ERCP pancreatitis 
according to meta-analysis (Mazaki et al. 2010) 
Post-ERCP 
pancreatitis 
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What kind of plastic stent should be used? 3 mm long 3 -5 Fr straight polyethylene plastic 
stents without internal flanges (for promoting of spontaneous elimination in few days 
following the insertion) and with one or two external flanges (for preventing proximal 
migration) are recommended for prophylactic purpose (Fig.3). Stents of 3-Fr and 5-Fr in 
diameter proved to be similarly effective, but the insertion of 5-Fr stents seems to be easier 
and faster (Zolotarevsky et al. 2011).  
 
 
Fig. 3. Pancreatic stent without internal flanges 
The stent migrates spontaneously into the duodenum within two weeks in most of the cases. 
Within 5 to 10 days after the stent insertion an X-ray control and, when the stent is in place 
yet, endoscopic stent removal is recommended because of the risk of stent-induced damage 
to the pancreatic duct. Adverse events including pancreatitis following stenting of the main 
pancreatic duct occur in 4.2-4.6 %, but the incidence of pancreatitis after failed cannulation 
attempts may reach even 65 % (Freeman et al. 2004). Therefore this is a technique for 
experienced endoscopist.  
6.1.2 Pancreatic guide wire placement for facilitation of bile duct cannulation 
Data about the effectiveness of pancreatic guide wire placement in the prevention of post-
ERCP pancreatitis are still controversial. In patients with difficult bile duct cannulation 
successful biliary cannulation can be achieved by pancreatic guide wire-assisted technique 
in more than 70% of the cases (Dumonceau et al. 2010). If this method is used, a pancreatic 
stent should be placed for prophylaxis of pancreatitis (Fig 4.). For the same reason 
pancreatic stenting can be useful also in cases in which biliary cannulation remains 
unsuccessful. 
6.1.3 Guide wire-assisted deep biliary cannulation 
Insertion of 0.035-inch diameter guide-wire into the papilla directly or advancing the guide-
wire through the sphincterotome inserted into the papilla for deep biliary cannulation 
reduces the risk of post-ERCP pancreatitis due to promotion of selective primary 
cannulation. This method may namely diminish traumatic injury to the pancreatic duct and 
hydrostatic pressure increase associated with injection of contrast material. Therefore, the 
guide wire-assisted technique is advised for deep biliary cannulation by the ESGE guideline 
(Dumonceau et al. 2010). However, in a prospective randomised trial this technique was 
associated with a lower rate of post-ERCP pancreatitis only with the exception of cases 
where the technique was performed in patients with sphincter of Oddi dysfunction or 
where unintentional pancreas guide wire cannulation occurred (Lee et al 2009).  
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Fig. 4. A case of difficult bile duct cannulation. Following pancreatic guide wire-assisted 
technique pancreatic stent was placed for prevention of post-ERCP pancreatitis 
6.2 Pharmacological agents 
Several agents have been tested experimentally and in clinical trials for potential efficacy in 
the prevention of ERCP induced pancreatitis. Chemoprevention studies have targeted the 
following mechanism of action: reduction of pancreatic secretion, prevention of intra-acinar 
trypsinogen activation, interruption of inflammatory cascade, relaxation of sphincter of 
Oddi, and prevention of infection. The majority of the investigated pharmacological agents 
appeared promising in initial randomised single-centre clinical studies however, conflicting 
results were obtained from larger multi-centre trials (Table 3.). 
 
Drug  Efficacy  
Somatostatin  
Octreotide 
Gabexate mesilate 
Ulanistatin 
Nitroglycerin 
Nifedipin 
Lidocain spray 
Epinephrine spray 
Botulinum toxin intrapapillary 
Ceftazidime 
N-acethylcysteine 
Beta-carotene 
Allopurinol 
Glucocorticoids 
Pentoxifylline 
Semapimod  
Acethylhydrolase 
Indomethacin  
Diclofenac  
Conflicting data 
Conflicting data 
Conflicting data 
Conflicting data 
Conflicting data 
No 
No 
No 
No 
Need for more trials  
No 
No 
Conflicting data 
No 
No 
No 
No 
Yes, but need for more trials 
Yes, but need for more trials 
Table 3. Medications tested for prophylaxis of post-ERCP pancreatitis 
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6.2.1 Reduction of pancreatic enzyme secretion  
Somatostatin and its long-acting analogue ocreotide affect the exocrine function of the 
pancreas directly by reducing the secretion of digestive enzymes and indirectly by 
inhibiting the production of secretin and cholecystokinin. According to a meta-analysis 
pooling the data from ten high-quality randomised controlled trials it can be concluded, that 
somatostatin did not influence the overall incidence of post-ERCP pancreatitis (Dumonceau 
et al. 2010). Although a significant risk reduction of post-ERCP pancreatitis was found in 
four randomised controlled trial, when somatostatin was administered in continuous 
infusion for longer than 12 hours, and in two studies, when somatostatin was given as a 
single bolus, the question is yet open, weather using specific dose-schedules somatostatin 
might be more efficacious (Arvanatidis et al. 2004).  
Concerning the long-acting somatostatin analogue ocreotide the same conclusion can be 
drawn based on an ad hoc meta-analysis of eight randomised controlled trials (Dumonceau 
et al. 2010). Octreotide can reduce the ERCP-induced hyperamylasemia, but this effect can 
only be shown, if endoscopic sphincterotomy is simultaneously performed (Tulassay et al. 
1997). Octreotide increases namely the tone of the sphincter of Oddi, and therefore this 
partial beneficial effect of the reduced enzyme secretion may be effective only with 
sphincterotomy together. Some data suggest that the effect of octreotide may be dose-
dependent and more than 0.5 mg of octreotide may be beneficial (Zhang Y et al. 2009), but it 
should yet be clarified in future studies. 
6.2.2 Protease inhibitors 
Antiprotease agents were tested for prophylaxis of post-ERCP pancreatitis with the purpose 
of prevention of intra-acinar trypsinogen activation to trypsin and that of the subsequent 
inflammatory cascade. Gabexate mesilate in six randomised controlled trials, while ulanistatin 
in four randomised controlled trials have been evaluated. Furthermore, the prophylactic 
effect of gabexate with ulanistatin was compared in two clinical trials. The results can be 
summarised by stating that, although there is a small risk reduction, particularly in the 
ulanistatin subgroup, there is no solid evidence that antiprotease drugs significantly 
influence the incidence of post-ERCP pancreatitis. The same conclusion can be drawn from a 
recently published meta-analysis (Seta & Noguchi 2011) on the basis of which it can be 
stated that the primary studies were not of high quality enough to come to the proper 
consequences. Nevertheless, protease inhibitors are costly.  
6.2.3 Sphincter relaxants 
Nitroglycerin (glycerine trinitrate) proved to be effective in some reports, but ineffective in 
others. Based on two meta-analyses (Bang et al. 2009, Shao et al. 2010) of pooled data from 
five randomised controlled trials it can be concluded that nitroglycerin administered orally 
or sublingual may reduce the incidence of post-ERCP pancreatitis, but transdermal 
nitroglycerin is ineffective. The use of nitroglycerin is often associated with transient 
hypotension and headache, therefore the ESGE guideline does not recommend its routine 
use in the prophylaxis of post-ERCP pancreatitis (Dumonceau et al. 2010). 
Nifedipin was also tested, because calcium channel blockers have proved to be effective in 
the prevention of experimental pancreatitis. In clinical trials, however, nifedipin failed to 
show a significant effect in the prevention of post-ERCP pancreatitis (Prat et al. 2002). 
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Other drugs (lidocaine spray, epinephrine spray, Botulinum toxin injected intrapapillary) 
tested with the intention of reducing the sphincter of Oddi pressure failed to show any 
efficacy (Gorelick et al. 2004, Matsushita et al. 2009, Schwartz et al. 2004). 
6.2.4 Antibiotics 
There is only a single study evaluating the ceftazidime for prophylaxis of post-ERCP 
pancreatitis. This antibiotic was given in a dose of 2 g intravenously 30 min prior to the 
investigation and a significant reduction in the incidence of post-ERCP pancreatitis was 
observed (Raty et al. 2001). Further data are necessary to establish the real place of 
antibiotics in the prevention of ERCP-related pancreatitis.  
6.2.5 Antioxidants 
The following antioxidant agents were investigated for prevention of ERCP related 
pancreatitis: N-acetylcysteine (Katsinelos P. et al. 2005), beta-carotene (Lavy et al. 2004) and 
allopurinol. The free radical scavenger N-acetylcysteine and beta-carotene failed to show any 
beneficial effect. Allopurinol is a xanthine oxidase inhibitor and an antioxidant with 
antiapoptotic property. Four randomised clinical trials dealing with its effect in the 
prevention of post-ERCP hyperamylasemia and pancreatitis were published. Three of them 
reported negative outcomes but in two studies allopurinol proved to be effective in the 
reduction of the incidence of hyperamylasemia, and in one of them also in that of acute 
pancreatitis, particularly in patients submitted to high risk procedures (Martinez-Torres et 
al. 2009). Allopurinol was administered orally in a dose of 300 mg at 15 and 3 hours before 
ERCP. 
6.2.6 Antiinflammatory drugs 
Several agents acting by interruption of the inflammatory cascade were tested. 
Glucocorticoids do not reduce the incidence of post-ERCP pancreatitis according to a meta-
analysis based on six randomised controlled trials (Bay et al. 2008). Similarly to 
glucocorticoids pentoxifylline, semapimod, and acethylhydrolase (a recombinant platelet-
activating factor) all proved to be ineffective. Interleukin-10 reduced the incidence and 
severity of post-ERCP pancreatitis in an initial study (Deviere et al. 2001), but further trials 
could not confirm its effectiveness. As suggested by observational and animal studies, 
heparin has also an anti-inflammatory effect, inhibit the activity of pancreatic proteases and 
improves pancreatic circulation, but in clinical randomised controlled trials neither 
unfractionated heparin (Barkay et al. 2008), nor low molecular-weight heparin (Rabenstein T 
et al 2004) proved to be effective in the prophylaxis of post-ERCP pancreatitis. 
Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit phospholipase A2 which has an early 
role in the inflammatory cascade in acute pancreatitis. Inhibition of phospholipase A2 
results in suppression of several important classes of proinflammatory lipids 
(prostaglandins, leukotriens, platelet-activating factor). Furthermore, NSAIDs inhibit 
neutrophyl-endothelial cell attachment. Indomethacin followed by diclofenac is the most 
potent NSAID with regard to phospholipase A2 inhibition. Indomethacin has shown to 
decrease the mortality of experimental pancreatitis in animals (Wildenhain et al 1989). Four 
prospective randomised controlled clinical studies have been published until now that 
compared rectally administered indomethacin or diclofenac vs. placebo (Murray et al. 2003, 
Sotoudehmanesh R et al. 2007, Montano Loza et al. 2007, Koshbaten M et al. 2008) (Fig. 5.). 
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On the basis of three meta-analyses using the data of these studies rectally administered 
indomethacin and diclofenac in a dose of 100 mg proved to be effective in the decrease of 
incidence of post-ERCP pancreatitis (Elmunser et al. 2008, Zheng et al. 2008, Dai et al. 2009). 
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(RCT: randomised controlled trial)  
Fig. 5. Incidence of post-ERCP pancreatitis: rectally administered NSAIDs versus placebo. 
The reduction seems to be similar regardless of the degree of the risk (Zheng et al. 2008). 
Limitation of the original studies is the small number of the trials performed only in three 
countries. Therefore some scepticism related to the clinical efficacy of NSAIDs in the 
prophylaxis of post-ERCP pancreatitis exists, all the more because several agents tested 
before have shown promise in early single-centre studies, but the results were disappointing 
in larger multicentre randomised controlled trials. Furthermore it has to be mentioned that 
diclofenac administered intramuscularly or orally did not proved to be effective in lowering 
the rate of post-ERCP pancreatitis significantly (Cheon et al. 2007, Senol et al 2009). Further 
multicentre controlled studies are awaited for confirmation of the promising results of the 
foregoing trials. Nevertheless NSAIDs in a single dose are relatively safe, cheap, and easy to 
use. Therefore 100 mg of indomethacine or diclofenac administered rectally immediately 
before or after ERCP is routinely recommended. This standpoint is reflected also in the 
ESGE guidelines (Dumonceau et al. 2010). 
6.3 Post-procedure management (Follow-up after ERCP) 
Post-ERCP pancreatitis is an unforeseen complication but it can be predicted by measuring 
the serum amylase concentration at 2-4 hours after the procedure. It should be taken into 
account, however, that hyperamylasemia without pancreatitis following ERCP is well 
recognised and abdominal discomfort for some hours after ERCP due to intestinal 
distension by air insufflated during the investigation is a commonly occurring symptom, in 
particular in patients with functional gastrointestinal dysfunction. It is advisable to restrict 
oral intake of water for four hours and until serum amylase value is available. Serum 
amylase concentration less than 1.5 times the upper limit of normal value almost excludes 
post-ERCP pancreatitis and the patient can be discharged on the day of ERCP. For patients 
with four hours serum amylase levels more than twice the upper limit, with ongoing 
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abdominal pain / tenderness or fever, fasting and parenteral fluid replacement is 
recommended. The same policy is advised in the presence of any risk factor of post-
procedural pancreatitis at least for 24 hour after ERCP. Further management is depending 
on the 24 hour serum amylase level and clinical signs of pancreatitis. 
6.4 Principles of prevention and reduction of severity of ERCP-induced pancreatitis 
Following factors listed below should be considered when indicating and performing ERCP. 
1. Because post-ERCP pancreatitis can be severe, life-threatening or even fatal, careful and 
adequate patient selection is one of the most important and the most effective 
preventive measures. ERCP should not be performed when the indication is not clear or 
the procedure is unlikely to benefit the patient. In borderline indications and when the 
aim of ERCP is solely diagnostic, non-invasive imaging methods, magnetic resonance 
cholangiopancreatography (MRCP) and endoscopic ultrasound should be performed 
first. Endoscopists should always take a risk-benefit analysis with knowledge of the 
identified patient related risk factors, when deciding whether to perform an ERCP. 
2. Referral of patients at high risk for post-ERCP pancreatitis to a great volume specialist 
centre should be considered.  
3. Minimal use of contrast material, avoidance of repeated attempts of pancreatic 
cannulation and use of guide wire to gain access or use of dual wire technique can be 
effective measures for prophylaxis in certain cases. 
4. Risk related ERCP techniques should be avoided when possible. 
5. Pharmacological prophylaxis with periprocedural rectal administration of NSAIDs 
(indomethacine or diclofenac) as a cheap, practical and safe method is routinely 
recommended. 
6. Prophylactic placement of short 5 Fr pancreatic stent without inner flanges should be 
strongly considered for patients at high risk for development of post-ERCP pancreatitis. 
7. Early screening for post-ERCP pancreatitis following the procedure and appropriate 
management is also important for the prevention or for reduction of the severity of 
ERCP-related pancreatitis.  
The recommendations above are in concordance with the European Society of 
Gastrointestinal Endoscopy guideline (Dumonceau et al., 2010). 
7. Therapy of post-ERCP pancreatitis 
The treatment of ERCP related pancreatitis is the same as that of the acute pancreatitis of 
other etiologies and it depends considerably on the severity of the pancreatitis. The therapy 
is mainly supportive including fasting, adequate correction of hypovolemia, and 
maintenance of optimal fluid balance, close monitoring for signs of local and systemic 
complications, and adequate pain control. Patients with mild pancreatitis can generally 
begin oral food intake in few days. The outflow of the pancreatic juice can be tried to 
improve with spasmolytics, nitroglycerin or theophyllin. Morphine should be avoided 
because this drug may produce high outflow resistance due to sphincter of Oddi spasm, but 
pethidine / meperidine are allowed if the patient requires it for pain relief. If the efficacy of 
pethidine / meperidine is insufficient, epidural anesthesia is the best choice or fentanyl can 
be given. In cases of severe pancreatitis early nasojejunal feeding can be crucial for the 
maintenance of integrity of the gut mucosal barrier, hereby preventing bacterial 
translocation into the systemic circulation. Translocated pathogen intestinal flora is namely 
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one of the main sources of septic complications. Enteral feeding with appropriate energy 
intake has also a role in the correction of the nutritional imbalance due to the prolonged 
hypermetabolic state in severe acute pancreatitis. Adequate intravenous substitution is also 
very important, likewise early antibiotic prophylaxis in necrotizing pancreatitis – although 
still controversial, and effective antimicrobial treatment of the inflammatory complications. 
Infected pancreatic necrosis and infected pancreatic and peripancreatic fluid collections 
should be treated by surgery or by endoscopic or CT guided intervention. Treatment of the 
systemic complications has to be managed in an intensive care unit with close monitoring of 
the vital functions. 
8. Conclusion 
Acute pancreatitis is the most common and feared complication of ERCP. Post-ERCP 
pancreatitis is severe and potentially fatal in a significant proportion. The incidence rate has 
been little changed over the last decades despite important advances in endoscope and in 
accessory technology. 
The widely accepted criteria for the diagnosis of post-ERCP pancreatitis are serum 
amylase and/or lipase at least 3 times higher than the upper limit of normal values in 24 
hours after the procedure accompanied by new pancreatic-type abdominal pain and 
symptoms and severe enough to require hospital stay or to extend the length of stay of 
already hospitalised patients, and/or CT/MRI consistent with the diagnosis of acute 
pancreatitis. 
The pathomechanism is not fully understood. It seems to be an inflammatory response to 
mechanical, hydrostatic, enzymatic, thermal, microbiological, and probably chemical 
insults that results from cannulation attempts and contrast material injection into the 
pancreatic duct. 
A number of risk factors for developing pancreatitis after ERCP are known, they can 
categorised as patient related, procedure related, and investigator related risk factors. It is 
essential to identify patients at high risk to avoid unnecessary procedures or adopt 
protective technical or pharmacological measures. If patient related risk factors are present, 
first of all it is advised to consider patient’s referral to a specialist centre, or for selection of 
prophylactic measures. In borderline indications non-invasive imaging methods should be 
preferred. Out of procedure related risk factors papillary edema and sphincter spasm are the 
major factors in the induction of post-ERCP pancreatitis. For minimizing the risk of 
pancreatitis during the procedure the following measures should be kept in mind: 
atraumatic manipulation of the papilla, avoidance of repeated pancreatic duct cannulation 
and contrast injection, avoidance of balloon catheter dilatation of the intact sphincter, 
limited use of precut sphincterotomy and pancreatic sphincterotomy, avoiding placement of 
biliary stent through intact papilla, using soft-tipped guide wire to access bile duct, and 
using pure cut electrosurgical current.  
Despite selecting patients and using protective technical measures post-ERCP pancreatitis 
can occur unexpectedly. Therefore prophylactic pharmacological intervention is routinely 
advised by means of rectal indomethacine or diclofenac immediately before or after the 
procedure. The administration of indomethacine and diclofenac in a single dose is safe, 
cheap, and easy and based on the few randomised controlled trials it seems to be effective in 
the decrease of the incidence of post-ERCP pancreatitis. Further randomised controlled trials 
are needed to prove the real efficacy of NSAIDs in the reduction of severe ERCP related 
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pancreatitis. For high-risk ERCPs prophylactic placement of short pancreatic stent proved to 
be beneficial in experienced hands, therefore its use is recommended for few days in these 
cases. 
Careful follow up, early screening for pancreatitis and appropriate management of the 
complication are crucial for the outcome. The treatment of post-ERCP pancreatitis itself does 
not differ from that of the acute pancreatitis of whatever etiology. 
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1. Introduction 
The impact of nutritional status in acute pancreatitis (AP) has not been fully elucidated, but 
it is probable that severe malnutrition will adversely affect outcomes, as occurs in other 
critical diseases. Malnutrition is known to occur in 50-80% of chronic alcoholics and alcohol 
is a major etiological factor in AP. Morbid obesity is also associated with poorer prognosis 
(Gianotti L et al, 2009). Assessment of the severity of AP, together with the patient´s 
nutritional status is crucial in the decision-making process that determines the need or 
otherwise for nutrition support. Both should be done on admission and at frequent intervals 
thereafter.  
Substrate metabolism in AP is similar to that in response to severe sepsis or trauma. There is 
an increase in protein catabolism, characterized by an inability of exogenous glucose to 
inhibit gluconeogenesis, increased energy expenditure, increased insulin resistance and 
increase dependence of fatty acid oxidation to provide energy substrates. Energy needs may 
differ and change substantially according to the severity and stage of AP, comorbidities, and 
specific complications occurring during the clinical course of AP. 
Assessment criteria that can serve as early predictors of AP severity are often complex and 
not sufficiently accurate. However, several recently described criteria that rely on criteria 
such as the body mass index, physical findings, and simple laboratory measurements could 
prove useful if validated in large prospective studies (Talukdar R  et al,  2009). 
The factors that influence mortality in different degrees of severity of AP are various. 
Etiology, age, sex, race, ethnicity, genetic makeup, severity on admission, and the extent and 
nature of pancreatic necrosis (sterile vs. infected) influence the mortality. Other factors 
include treatment modalities such as administration of prophylactic antibiotics, parenteral 
nutrition (PN) vs. enteral (EN), endoscopic retrograde cholangio pancreatography with 
sphincterotomy, and surgery in selected cases. Epidemiological studies indicate that the 
incidence of AP is increasing along with an increase in obesity, a bad prognostic factor. Since 
Ranson reported early prognostic criteria, a number of attempts have been made to simplify 
or add new clinical or laboratory studies in the early assessment of severity. Obesity, 
hemoconcentration on admission, presence of pleural effusion, increased fasting blood 
sugar, as well as creatinine, elevated C-Reactive Protein in serum, and urinary trypsinogen 
levels are some of the well-documented factors (Pitchumoni CS et al, 2005). 
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We found evidence that some indicators of nutritional status could be of help in trying to 
predict mortality in AP, since nutritional status may be associated with final prognosis. 
Specifically in the case of severe AP, excess body fat, lack of lean body mass, muscle wasting 
and poor immune status seems to be related with poor prognosis (Fuchs-Tarlovsky V et al, 
2010; Fuchs-Tarlovsky V et al, 1997). 
PN in the past has always appeared ideally suited as the preferred route for nutrition 
support over EN in patients with AP. The pathophysiology of the disease process involves a 
catabolic stress state, elevated caloric requirements; reduction in pancreatic stimulation or 
“pancreatic rest” appeared to be needed to allow resolution of inflammation within the 
gland. However, evidence has emerged that other pathophysiologic processes outside the 
pancreas itself may contribute to the stress state seen in these patients. Failure to use the gut 
may actually exacerbate the stress response, prolong the duration and severity of the 
disease, and increase the likelihood of complications (McClave SA et al, 2006; Lugli AK et al, 
2007). 
More recent clinical trials have suggested that EN in comparison to PN may maintain gut 
integrity, reduce intestinal permeability, and down regulate the systemic immune response 
syndrome (SIRS), thereby favorably affecting clinical outcome (Jabbar A et al, 2003). Further 
evidence suggests that not only is the route of feeding a factor in outcome, but specific 
agents in EN or PN (immune-modulating agents) such as probiotics or -3 fish oil may 
influence hospital length of stay (LOS) and rate of complications (Olah A et al, 2002; Lasztity 
N, 2005).  
2. Nutrition assessment in AP 
Severe AP is associated with high mortality. Adequate nutrition support improves clinical 
outcome. Nevertheless, several recent trials have focused primarily on the route of nutrition 
support and neglected the role of nutrition status assessment in tailoring nutrition support 
to individual needs (Lugli AK et al, 2007). 
Definition of an optimal nutritional regimen requires knowledge of energy requirements. 
Because pancreatitis is a serious disease, it is presumed to be associated with marked 
increases in energy expenditure. However, data for measured resting energy expenditure 
(REE) in patients with pancreatitis are limited. In a study aimed to assess the REE of patients 
with pancreatitis, Dickerson et al found a significantly higher value in those patients 
complicated by sepsis than those with pancreatitis alone. Septic patients had the largest 
percentage of hypermetabolic REE, >110% of predicted energy expenditure. They measured 
REE ranged from 77% to 139% of predicted energy expenditure according to Harris-
Benedict equation. The authors concluded that REE is variable in patients with pancreatitis; 
and the Harris-Benedict equation is an unreliable estimate of caloric expenditure. Septic 
complications are associated with hypermetabolism and may be the most important factor 
influencing REE (Dickerson R et al, 1991).   
AP increases the catabolism and proteolysis of skeletal muscle by as much as 80% in 
comparison with normal controls. Further, nitrogen losses have been shown to increase to as 
much as 20 to 40 g/d (Dickerson R, et al 1991). Decreased levels of total plasma proteins and 
rapid turnover proteins and marked decrease of the ratio of branched-chain to aromatic 
amino acid further characterize the hypermetabolic state (Havala T et al 1989; Shaw JHF, 
1986). Significant decrease in plasma essential aminoacids, with marked reductions of 
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almost all amino acids by skeletal muscle mass, have been reported clinically and 
experimentally (Bouffard YH et al. 1989). 
Another study reported the changes in body composition, plasma proteins, and REE during 
14 days of PN in patients with AP. Total body protein (TBP), total body water (TBW), and 
total body fat (TBF) were measured by neutron activation analysis and tritium dilution 
before and after PN. They studied 15 patients with AP, most of them with severe disease. 
The gains in body weight, TBW, TBP, Fat Free Mass, TBF and resting energy expenditure 
after 14 days were not significant. The authors concluded that body composition is 
preserved in AP during 14 days of PN. In patients without sepsis or recent surgery, PN was 
able to significantly increase body protein stores (Chandrasegaram MD et al, 2005). 
We have found that there are some nutritional parameters associated with mortality in AP. 
From the nutritional indicators measured, body fat reserves, renal function, muscle mass 
and immune function were the parameters that associated better with mortality in AP 
(Fuchs-Tarlovsky et al 1997). In another study aimed to validate these findings, we found 
that the group with higher mortality was associated with higher fat reserves, lower immune 
function or lymphocyte count and lower muscle reserves (Fuchs-Tarlovsky et al., 2010). 
3. Pancreatic rest and secretions 
Today, the validity of this concept of “pancreatic rest” is no longer accepted (Petrov MS et 
al, 2008; Ioannidis O et al, 2008; Talukdar R et al, 2009). Efforts to keep up with the increased 
energy demands in the case of AP are thwarted by the adage to put the pancreas at rest and 
the avoidance of pancreatic stimulation via gut luminal nutrition. The “pancreatic rest 
concept” assumes that the pancreatic rest promotes healing, decreases pain, and reduces 
secretion and leakage of the pancreatic juices in pancreas parenchyma and pancreas tissue 
(McClave SA et al, 1997). This concept disregards the presence of basal pancreatic exocrine 
secretion. Protein enzyme output is the responsible component for autodigestion of the 
gland and perpetuation of inflammatory process. Suppression of protein enzymes output 
alone with continued bicarbonate and fluid volume output may therefore be adequate in 
putting the pancreas to rest. 
3.1 Pancreatic secretion 
Pancreatic secretion and gut motility are tightly interwoven. Basal enzyme secretion is 20% 
of maximal enzyme secretion and it is regulated by cholinergic and cholecystokinin (CCK)-
mediated mechanisms. Feeding by mouth increases pancreatic secretion by involving 3 
stimulation levels: cephalic, gastric and intestinal level or phase (Spanier BM et al, 2011). The 
mere sight of food begins the process of pancreatic secretion and prepares the gut for 
digestion. Once the food enters the mouth and is chewed and swallowed there is a strong 
vagal stimulation which fortifies this response. The passage of food into the stomach 
produces mechanical effects, which further amplify the vagal response and, in addition, lead 
to gastric acid secretion. Finally, the movement of food and secretions through the pylorus 
into the duodenum culminates in the maximal stimulatory effect mediated by humoral CCK 
and secretin and also cholinergic excitation.  For many years it was considered that CCK 
was the chief stimulus for pancreatic enzyme secretion but now it is known that the 
response id complex and possibly mediated through cholinergic activation (O’Kaffe SJ et al, 
2006). 
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Further studies have demonstrated that as food progresses through the gastrointestinal (GI) 
tract, there are a series of feedback loops all the way down from the stomach to the colon. 
Passage of food into the jejunum also inhibits gastric emptying and intestinal transit. The 
presence of food in the ileum inhibits jejunal motility, presence of nutrients in the ileum 
inhibits not only pancreatic secretion but also gastric emptying and intestinal transit, and 
finally the transit of digested food into the colon augments the activation of the ileal brake 
(Van Citters GW, 1999). 
The duration of pancreatic enzyme response increases with greater caloric load. The 
pancreatic response is also influenced by the physical properties of the meal: mixed solid-
liquid meals induce a higher response than liquid or homogenized meals with similar 
energy content. In both instances, the rate of gastric emptying and thus duodenal delivery of 
nutrients are the key factors which determine the duration of the pancreatic secretion. The 
proportion of fat, carbohydrate, and protein contents within a meal also influence the 
duration and enzyme composition of the pancreatic response (Spanier BM et al, 2011). 
3.2 Pancreatic secretion with Enteral Nutrition (EN) 
The degree to which the pancreas is stimulated by EN is determined by the site in the GI 
tract at which feeding is infused. Feeding infused into the jejunum beyond the ligament of 
Treitz may bypass the cephalic, gastric, and intestinal phase of stimulation of pancreatic 
secretion, is less likely to stimulate CCK and secretin, and may stimulate inhibiting 
polypeptides (Abou S et al 2002, Russell MK at al, 2004, Scolapio JS et al, 1999). It has been 
demonstrated in human studies during jejunal feeding that the pancreatic enzyme output 
increased significantly over basal levels when it was delivered at the ligament of Treitz, 
whereas there was no significant increase during more distal jejunal feeding, 60 cm beyond 
the ligament of Treitz (Vu MK et al, 1999). 
Also, the composition of the infused feeds is important. There is some evidence to support 
an added benefit of elemental formulae for putting the pancreas to rest compared to 
standard formulae with intact protein or blenderized diets. Elemental diets cause less 
stimulation than standard formulas, because of their low fat content, the presence of free 
amino acids instead of intact proteins which bind to free trypsin in the gut, causing trypsin 
levels to fall, and less acid production from the stomach (Spanier MS et al, 2011). 
4. Nutrition therapy 
Nutrition therapy in the past has been governed by the principle that the gut should be put 
at rest with avoidance of any stimulation of pancreatic exocrine secretion. These concepts 
should now be replaced by the principle that pancreatic stimulation should be reduced to 
basal rates, but that the gut integrity should be maintained and that the stress response 
should be contained the likelihood of multiorgan failure (MOF), nosocomial infections, and 
mortality (McClave SA et al, 1998). 
Usually, the initial treatment of AP consists of a nil per os (NPO) regimen and 
administration of analgesics and ample intravenous fluids (Pandol SJ et al, 2007; Forsmark 
CE et al, 2007). However, within 24-48 hours EN should be initiated. The rationale for a 
period without food intake is the assumption that pancreatic stimulation by enteral feeding 
may aggravate pancreatic inflammation. Moreover, many patients are anorectic and may 
suffer increasing pain sensation when eating and ileus-related nausea and vomiting, and 
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delayed return of appetite (Banks PA et al, 2006; Forsmark CE et al, 2007; Meier R et al, 2005; 
Gianotti L et al, 2009). 
There have been studies regarding PN and PN supplemented with special nutrients. A 
Chinese study by Xian-Li et al evaluated the effects of supplemental parenteral glutamine. 
Forty one patients with severe AP were randomized to receive either PN or PN with 
glutamine. Use of PN with parenteral glutamine was associated with significantly less 
pancreatic infection (0.0% vs 23.8%, p<0.05) and fewer overall complications (20% vs 52%, 
p<0.05) compared to the use of PN alone without supplemental glutamine (Xian-Li H et al, 
2004). 
However today’s data trends more to the use of EN rather than PN as will be discussed 
below. 
4.1 Enteral vs Parenteral Nutrition 
Traditionally, patients with AP were either treated with strict rest or given PN to allow the 
pancreas to “rest” until the serum enzyme levels returned to normal. Unfortunately, some 
disadvantages are associated with the use of PN; one of the most serious is catheter related 
sepsis. Currently, EN is preferred for patients with AP because it is more cost effective than 
PN and results in fewer complications (Siow E, 2008). 
Despite fears that EN may exacerbate AP because of the stimulatory effect of luminal 
nutrients on trypsinogen synthesis, several randomized clinical trials have shown that 
outcome is better and the cost is lower if EN is used instead of PN (McClave SA et al, 1997; 
Abou-Assi S et al, 2002; Kalfarentzos F et al, 1997). EN can improve survival and reduce the 
complications accompanying severe AP. The explanations are: EN avoids PN related 
complications; luminal nutrition maintains intestinal health; enteral aminoacids are more 
effective in supporting splanchnic protein synthesis; EN may prevent the progression of 
MOF (Ionnidis O et al, 2008). 
In addition to its mucosal protective and immunomodulatory effects, EN is the most 
effective way of supporting intestinal metabolism. By down-regulating splachnic cytokine 
production and modulating the acute phase response, EN reduces catabolism and preserves 
protein (Winsdor AC et al, 1998). In addition, EN with a diet enriched with glutamine has 
beneficial effect on recovery of IgG and IgM-proteins with a trend to shorter disease 
duration (Grant J et al, 1984).  
There are some clinical studies that compared the use of PN versus EN in AP; the end points 
analyzed were mortality and complications. From 1996 to 2006 there were 5 studies which 
studied these outcomes; none of the studies yielded evidence of a difference in the mortality 
rates between patients given EN and patients given PN. Louie at al reported no deaths 
among patients given EN and 3 deaths among patients given PN. Those deaths however 
were attributed to complications of pancreatitis rather than to the mode of nutrition (Louie 
BE et al, 2005).  
Most of the randomized clinical studies reviewed reported higher complication rates among 
patients given PN than among the EN groups. Kalfatenzos at al reported significantly lower 
total number of complications for patients given EN compared with the PN group. 
Complications such as sepsis, nosocomial infection, catheter-related infection, and 
hyperglycemia are common findings in all studies, especially in patients who were given 
PN (Kalfarenzos FE et al, 1991). Abou-Assi et al showed a significant difference in rates of 
catheter–related infections between patients given EN and those with PN. The patients with 
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infections eventually required removal of the venous catheter and antibiotic treatment 
(Abou-Assi S et al, 2002). McClave at al. on the other hand, observed equal increases in the 
risk of infectious complications and the incidences of fluid and electrolyte imbalances 
(McClave SA et al, 1997).  
Louie at al found that the mean number of days of elevated blood glucose levels was 2.7 in 
the enteral group and 3.6 in the parenteral group (Louie BE, 2005). In all the above 
mentioned studies, the patients who received EN required fewer days to the start of oral 
diet than did the PN groups. Abou-Assi et al showed significant evidence that the patients 
given EN received 4.1 fewer days of nutritional support than the PN group. After disease 
resolution, 80% of the patients in EN progressed to oral diet without problem, compared 
with 63% in the PN group (Abou-Assi S et al, 2002).  
In addition, all of these clinical trials demonstrated that EN is cheaper than PN. Gupta et al 
provided significant evidence that patients given EN require a shorter length of 
hospitalization than patients given PN (Gupta R et al, 2003). 
In a recent systematic review about EN vs PN in pancreatitis the authors compared the 
effect of PN vs EN in patients with AP. The searches or randomized clinical trials were from 
2000 to 2008. Eight trials with a total of 348 participants were included. Comparing EN to 
PN in AP, the relative risk (RR) for deaths was 0.5 (95% CI 0.28 to 0.91), for MOF was 0.55 
(95% CI 0.37 to 0.81), for systemic infection was 0-39 (95% CI 0.23 to 0.65), for operative 
interventions was 0.44 (95% CI 0.29 to 0.67), for local septic complications was 0.74 (95% CI 
0.40 to 1.35), and for other local complications was 0.70 (95% CI 0.43 to 1.13). Mean LOS was 
reduced by 2.37 days in EN vs PN groups (95% CI - 7.18 to 2.44). Furthermore, a subgroup 
analysis for EN vs PN in patients with severe AP showed a RR for death of 0.18 (95% CI 0.06 
to 0.58) and RR for MOF of 0.46 (95% CI 0.16 to 1.29) (Al-Omran M et al, 2010). 
McClave et al concluded after performing a systematic review of literature comparing EN vs 
PN in AP that EN reduces oxidative stress, hastens resolution of the disease process, and 
costs less. Insufficient data exists to determine whether EN improves outcome over standard 
therapy. However, in those patients requiring surgery for complications of AP, meta-
analysis of 2 trials indicates that provision of EN postoperatively may reduce mortality 
(RR_0.26; 95% CI 0.0-1.09; p=0.06) compared with standard therapy (McClave SA et al, 
2006). 
In patients with AP, EN significantly reduced mortality, MOF, systemic infections, and the 
need for operative interventions compared with those who received PN. In addition, there 
was a trend towards a reduction in LOS. These data suggest that EN should be considered 
the standard of care for patients with AP requiring nutritional support. This 
recommendation is supported by the 2009 American Society for Parenteral and Enteral 
Nutrition (ASPEN) and Society for Critical Care Medicine (SCCM) Guidelines (McClave SA 
et al, 2009). Although hypertriglyceridemia may occasionally be the cause of AP, several 
years of clinical use has shown that PN containing lipid emulsions are safe in this condition 
(Leibowitz AB, 1992). Serum triglyceride levels should be monitored. Addition of heparin to 
PN infusate may decrease triglyceride levels in some patients (Benderly A et al, 1983). Table 
1 summarizes the available information on the special nutrients in enteral feedings. 
4.2 Nasojejunal (NJ) vs Nasogastric feeding (NG) 
NJ feeding tubes are placed blindly at the bedside, expecting spontaneous transpyloric 
migration or by using endoscopic or radiologic control.  
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Reference 
Author, year 
Study design  Type of 
nutrition 
Results 
 
Conclusion  
Abou –Assi  
et al, 2002 
Randomized  
controlled 
comparative 
clinical trial 
EN(NJ) 
 vs. PN 
Duration of feeding was shorter in the 
EN (6.7 vs. 10.8 days, p<0.05) and 
nutrition costs were lower in the EN 
group. Metabolic (p<0.003) and septic 
(p=0.01) complications were lower in 
the EN group. 
EN seems to be safer 
and less expensive 
than PN in AP. 
Kalfarentzos 
F et al, 1997 
Randomized  
controlled 
comparative 
clinical trial 
EN  
vs. PN 
Patients who received EN experienced 
fewer complications (P<0.05) , 
specially septic complications (P<0.01) 
than those receiving PN. PN costs 
were three times higher than EN. 
EN should be used 
preferentially in 
patients with severe 
AP. 
Winsdor AC  
et al, 1998 
Randomized  
controlled 
comparative 
clinical trial 
EN  
vs. PN 
The acute phase response and disease 
severity scores were significantly 
improved following EN (CRP: 156(117-
222) to 84(50-141), p<0.005; APACHE 
II scores 8(6-10) to 6(4- 8), P<0.0001) 
without change in the CT scan scores. 
In the PN group, these parameters did 
not change but there was an increment 
in the EndoCAb antibody levels and 
reduction in the CT scan scores.  EN 
did not show changes in the level 
EndoCAb level but there was an 
increase in the CT scan scores. 
EN moderates the 
acute phase response, 
and improves disease 
severity and clinical 
outcome despite 
unchanged pancreatic 
injury on CT scan.  
EN reduced systemic 
exposure to 
endotoxin and 
reduced oxidative 
stress; it also 
modulates the 
inflammatory and 
sepsis response in PA. 
Luie BE  
et al, 2005 
Randomized  
controlled 
comparative 
clinical trial 
PN vs. 
EN 
Reduction of CRP levels by 50% was 5
days faster with EN than with PN. 
Nutrition support costs were lower in 
the EN group. 
EN shows a trend 
toward faster 
attenuation of 
inflammation, with 
fewer septic 
complications and is 
the preferred therapy 
in terms of cost –
effectiveness. 
Gupta R 
et al, 2003 
Randomized  
controlled 
comparative 
clinical trial 
EN vs. 
PN 
Fatigue improved in groups but faster 
with EN. Oxidative stress was similar 
in both groups. 
There were no significant differences 
in complication rate and LOS was 
shorter in EN group (7(4-14)vs10(7-
26)days; p=0.05) 
The cost in the EN group was 
considerably less than PN. 
EN is safe in severe 
AP. It is as effective as 
PN and may be 
beneficial in the 
clinical course of 
disease. 
Abbreviations: AP= Acute Pancreatitis / EN = Enteral Nutrition / PN = Parenteral Nutrition / LOS = 
Length of Hospital Stay 
Table 1. Comparative studies between EN and PN 
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Eatock at al. performed a randomized controlled study on early NG versus NJ feeding in 
severe AP (Eatock FC et al , 2000;  Eatock FC et al, 2005). They found that NG feedings were 
very well tolerated and recommended that NG feedings should be considered a therapeutic 
option because of its simplicity, obviating the need for endoscopic or radiologic procedures. 
This study had several limitations, one of them being the failure to fluoroscopically confirm 
that the NJ tubes were appropriately positioned in the jejunum. There is no indication 
whether the NJ tubes were placed distal enough (at least 60 cms from the ligament of Treitz) 
to avoid gastric and pancreatic stimulation. The failure to find difference may have been 
related to continued gastric and duodenal stimulation occurring in both groups of patients. 
Similar findings from randomized studies were reported by Eckerwall et al who performed 
a randomized clinical trial to compare the efficacy and safety of early EN via NG tubes with 
PN. The authors reported that early NG EN in patients with severe AP was feasible, and 
resulted in better glucose control. No beneficial effects on the intestinal permeability or on 
the inflammatory response were seen by EN treatment (Eckerwall GE et al, 2006).  
Kumar et al performed a randomized clinical trial to compare early NJ with NG feeding in 
severe AP, and showed that that EN at a slow infusion is well tolerated by both NJ and NG 
routes in patients with severe AP. Neither feedings leads to recurrence or worsening of pain 
in patients with severe AP. They also reported that nutritional parameters remained 
unaffected because of inadequate caloric intake during the first week of feeding (Kumar A et 
al, 2006). 
Vu et al studied the activation of pancreatic secretion in 8 healthy volunteers in response to 
proximal or more distal jejunal delivery of nutrients into the small intestine. The authors 
concluded that continuous feeding into the distal jejunum does not stimulate exocrine 
pancreatic secretion (Vu MK et al, 1999). 
Piciucchi M et al assessed the rate of spontaneous tube migration and to compare the effects 
of naso-intestinal (NI) tube feeding in AP. They defined NI location as those tubes placed 
beyond the ligament of Treitz. The authors showed that spontaneous tube migration to an 
NI site occurred in 10 of 25 or 25% of the patients, while in 15 (60%) EN was started with an 
NG tube. EN through NG or NI were similar in terms of tolerability, safety, clinical goals, 
complications and hospital stay. As a conclusion, EN by NG tubes seem to provide a 
pragmatic alternative opportunity with similar outcomes in AP (Piciucchi M et al, 2010). 
McClave SA et al also commented in their meta-analysis that a wide range of tolerance to 
EN exists, irrespective of known influences such as mode (continuous versus bolus) and 
level of infusion within the GI tract (gastric versus postpyloric) (McClave SA et al, 2006).  
Patients with severe necrotizing pancreatitis may have gastric outlet obstruction or severe 
gastroparesis and many may have to be approached differently. Feeding into the stomach 
may be ineffective and possibly hazardous. Further multicenter randomized trials studies 
are needed to confirm whether NG feeding is a practical and effective form of management 
for patients with severe AP (Ioannidis O et al, 2008). Table 2 summarizes the available 
information on the special nutrients in enteral feedings. 
4.3 When to start nutrition support 
Per oral ingestion of nutrients is often hampered by abdominal pain with food aversion, 
nausea, vomiting, gastric atony, and paralytic ileus or by partial duodenal obstruction from 
pancreatic gland enlargement. The application of early EN may be limited by the severity of 
the pancreatitis attack and the occurrence of ileus (Spanier BWM, et al. 2011). 
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Reference  Study design  Via or 
Enteral 
Feeds  
Results Conclusion  
Eatock FC  
et al, 2005 
Randomized  
controlled 
comparative 
clinical trial 
 
NG vs. NJ Clinical differences 
between the two groups 
were not significant. 
Overall mortality was 
24.5% with five deaths in 
the NG group and seven 
in the NJ group. 
The simpler, cheaper, 
and easier to use NG 
feeding is as good as 
NJ feeding in  patients 
with objectively 
graded severe AP. 
Kumar A  
et al, 2006 
Randomized  
controlled 
comparative 
clinical trial 
NJ vs. NG Group1 (NG): Diarrhea 
occurred in 4 patients and 
there were 5 deaths, 1 
patient underwent 
surgery. 
Group 2(NJ): Diarrhea 
occurred in 3 patients, 
there were 4 deaths, and 2 
patients underwent 
surgery. 
EN at a slow infusion 
is well tolerated by 
both NJ and NG 
routes in patients with 
AP. Neither NJ nor 
NG feeding leads to 
recurrence or 
worsening of pain in 
AP. Nutritional 
parameters remained 
unaffected because of 
inadequate calorie 
intake during the first 
week of feeding. 
 
Piciucchi M  
et al, 2010 
Randomized  
controlled 
comparative 
clinical trial  
NG vs. NJ Spontaneous tube 
migration to NJ site 
occurred in 10/25(40%) 
prospectively enrolled 
severe AP patients; while 
in 15 (60%) nutrition was 
started with a NG tube. 
CT severity index was 
higher in NG tube patients 
than in NI (mean 6.2 vs. 
4.7, P = 0.04).  
Spontaneous distal 
tube migration is 
successful in 40% of 
severe AP patients, 
with higher CT 
severity index 
predicting IG 
retention; in such cases 
EN by NG tubes 
seems to provide a 
pragmatic alternative 
opportunity with 
similar outcomes. 
Abbreviations: AP= Acute Pancreatitis / NJ = Nasojejunal feeding / NG = Nasogastric feeding /IG = 
Intragastric/NI=Nasointestinal 
Table 2. Comparative studies between NJ and NG 
The precise timing for initiating enteral support has not been specifically addressed in the 
pancreatitis population but has been studied to a large extent in the critically ill population. 
EN has been described as a rational and acceptable option of supporting critically ill patients 
after major abdominal surgery, as well as in patients with AP (Windsor AC et al, 1998). 
Early EN starting prior to 48 hours from admission in critically ill patients is associated with 
a significant 24% reduction in infectious complications and 32% reduction in mortality 
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compared with delay feedings started after that point time (McClave SA et al, 2009; Heyland 
DK et al, 2003) 
Olah et al demonstrated that early jejunal feeding with an elemental diet within 48 hours 
after the onset of symptoms when possible, and was more useful and cheaper than PN. They 
concluded that early jejunal feeding reduced septic complications in necrotizing AP in 
combination with adequate antibiotic prophylaxis (Olah A et al, 2002). 
Pupelis G et al performed a randomized clinical trial measuring the feasibility and 
effectiveness of jejunal feeding after surgery due to peritonitis in severe AP. They concluded 
that early jejunal feeding resulted in 3.3% mortality as opposed to 23.3% in the control group 
(p=0.05) and that jejunal feeding is feasible and effective in postoperative treatment of 
patients due to secondary peritonitis because of AP (Pupelis G et al, 2001). Table 3 
summarizes the available information on the special nutrients in enteral feedings. 
 
Author, reference, 
year  
Study design  Time to start 
nutrition 
therapy  
Results Conclusion  
Pupelis G et al, 2001 Randomized  
controlled 
comparative 
clinical trial 
Patients in EN 
group received 
the daily mean 
of 1294.6 (362.6) 
kcal including 
830.6 (372.7) 
kcal enterally, 
versus 472.8 
(155.8) kcal 
daily in the 
control group (P 
< 0.0001). 
 
The first surgical 
intervention resulted in 
3.3% of re-laparotomies 
in EN patients, caused by 
unresolved peritonitis, 
versus 26.7% in the 
control subjects (P = 0.03). 
Recovery of bowel transit 
took significantly less 
time in the EN patients 
(mean: 54.6 h versus 76.8 
h in control subjects, P = 
0.01). EN resulted in 3.3% 
mortality as opposed to 
23.3% in the control 
group (P = 0.05). 
EN is feasible and 
effective in 
postoperative 
treatment of 
patients due to 
secondary 
peritonitis or severe 
pancreatitis. 
Improved bowel 
and peritoneal 
function could be 
the main impact of 
EN. 
 
Oláh et al, 2002 Randomized  
controlled 
comparative 
clinical trial 
1st phase: PN 
was compared 
with early 
(within 24-72 h 
after the onset 
symptoms) EN. 
Septic complications were 
lower in the EN group (P 
= 0.08, chi(2) test) 
The combination of 
early EN and 
selective, adequate 
antibiotic 
prophylaxis may 
prevent multiple 
organ failure in 
patients with AP. 
 
Kalfarentzos, 1991 Randomized  
controlled 
comparative 
clinical trial 
Group1:EN in 
the  first 72 
hours an EN 
later in the 
course of the 
disease  
Group 1: 23% 
complications and 13% 
mortality 
Group 2: 95.6% 
complications rate and 
38% mortality 
P<0.01 
Early EN reduced 
complications rate 
and mortality in AP 
Abbreviations: Se=Selenium / AP= Acute Pancreatitis / EN = Enteral Nutrition 
Table 3. Comparative studies between early and late EN 
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4.4 Types of enteral formula recommended 
A few studies to date compare the results of feeding elemental, semielemental, and 
polymeric diets to patients with AP (Marik PE, 2009 and Talukdar R et al, 2009). Elemental 
formulas are completely predigested and consist of aminoacids, simple sugars, and enough 
fat to prevent essential fatty acid deficiency. Semielemental formulas required less digestion 
than polymeric foods and contain peptides of varying chain length, simple sugars, glucose 
polymer, or starch and fat primarily as medium chain triglycerides. Polymeric feeds contain 
non-hydrolyzed proteins, complex carbohydrates, and longchain triglycerides. Based on the 
assumption that elemental and semielemental formulas cause less pancreatic stimulation 
than standard formulas, most EN studies have used an elemental or semielemental formula. 
Although there is a variety of data on the use of standard enteral formula in such patients 
(Spanier BWM et al, 2011), both Windsor et al and Pupelis et al have shown that polymeric 
formula can be safely fed through jejunal tubes in AP patients (Windsor ACJ, 1998;  Pupelis 
G et al., 2001). 
A few studies have defined the benefits of semielemental versus polymeric formulas in 
severe AP. Cravo et al found a similar tolerance in 102 patients with AP given 
semielemental versus polymeric formulas (Cravo M et al, 1989). In a randomized trial using 
semielemental and polymeric formulas in 30 AP patients, Tiegou et al showed that both 
formulas were well tolerated and well absorbed, but the semielemental group had less 
weight loss and shorter LOS compared with the polymeric group (Tiegou IE, 2006). Petrov 
et al performed an adjusted meta-analysis using 20 randomized controlled trials, including 
1070 patients. None of the studies was associated with a significant difference in feeding 
tolerance when comparing the tolerance and safety of EN formulations in patients with AP. 
The use of a semielemental diet versus polymeric formulation did not show significant 
differences (RR= 0.62). The authors concluded that the use of polymeric compared with 
semielemental formulation, does not lead to a significant higher risk of feeding intolerance, 
infectious complications, or death in AP patients (Petrov MS et al, 2008; Petrov MS et al, 
2009). Table 4 summarizes the available information on the special nutrients in enteral 
feedings. 
It should be remembered that semielemental or elemental diets are sevenfold as expensive 
as polymeric feeds, and in some countries perhaps even more expensive. In summary, the 
evidence base to use just semielemental or elemental formulas becomes less clear (Spanier 
BWM et al, 2011). 
4.5 Use of supplements or special nutrients in Enteral Nutrition 
The routine use of glutamine, immunonutrition, prebiotics and probiotics in AP is not 
supported by large scale clinical studies. Two studies evaluated immune-enhancing 
formulas that contain glutamine, arginine and fibers or glutamine, arginine and -3 fatty 
acids, vitamins, and micronutrients (Hallay J et al, 2001; Pearce CB et al, 2006). Hallay et al 
compared a standard formula with a glutamine-enriched formula on immunologic 
parameters in 16 patients with AP; they found that the recovery of the immunological 
parameters was better and the time of disease recovery was shorter in the glutamine treated 
group. Other authors also reported the beneficial effect of a glutamine-rich multifiber diet as 
compared to a standard fiber diet; the trend of IgG and IgM, as well as visceral proteins 
(prealbumin and Retinol Binding Protein) with shorter disease duration was seen in the 
treatment group (Hallay J et al, 2001).  
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Author, 
reference, 
year  
Study design  Types of formula  Results Conclusion  
Tiegou 
IE, 2006 
Randomized 
comparative 
prospective 
controlled 
clinical trial 
Semi-elemental vs 
polymeric formula. 
 
Tolerance was good in 
both groups (semi-
elemental vs. polymeric: 
VAS, 7.4 +/- 0.6 vs. 7.1 +/- 
0.6 NS; number of stools 
per 24 hours, 1.7 +/- 0.4 vs. 
1.8 +/- 0.4, NS). 
Steatorrhea was lower 
than normal in both 
groups. In the semi-
elemental formula group, 
the hospital LOS was 
shorter (23 +/- 2 vs. 27 +/- 
1, p = .006) and weight loss 
was less marked (1 +/- 1 
vs. 2 +/- 0, p = .01). One 
patient in semi-elemental 
group and 3 patients in 
polymeric group 
developed an infection 
(NS). 
Semi-elemental and 
polymeric nutrition 
are very well 
tolerated in 
patients with AP. 
Nutrition with a 
semi-elemental 
formula supports 
the hypothesis of a 
more favorable 
clinical course than 
nutrition with a 
polymeric formula. 
 
Windsor 
ACJ, 1998 
Randomized  
Clinical trial 
 
Polymeric  formula 
‘’Osmolite’’®,‘’Fresubin’’® 
Following seven days of 
enteral nutritional support 
there was a significant 
reduction in serum CRP 
from 156 (117–222) mg/l to 
84 (50–141) mg/l (p<0.005) 
and APACHE II scores fell 
from 8 (6–10) to 6 (4–8) 
(p<0.0001) in the enterally 
fed group. 
Polymeric formula 
can be safely fed 
through NJ tubes in 
AP patients.              
Enteral feeding in 
acute pancreatitis is 
practical. 
Furthermore is 
both feasible and 
desirable in the 
management of 
patients with acute 
pancreatitis. 
Cravo M 
et al, 1989 
Prospective  Elemental (group 1/  n=47) 
vs  polymeric formula 
(group 2 / n=44) 
 
Mean nutrient intake was 
higher in group II 
(p<0.001): Kcal: 1447+228 
vs 
1161+182; protein: 45+9 vs 
30+8g; fat: 31+10 vs 4+3g. 
Local complications rate 
was similar (17% in group 
I vs 7% in group II) and 
LOS was: In group I -6.6±3 
.2 vs Group II-6.3±2.2d. 
Elemental diets 
offer no advantage 
upon polymeric 
balanced diets. 
 
Abbreviations: NS=Non significant / AP= Acute Pancreatitis / EN=Enteral Nutrition 
/NJ=Nasojejunal/ LOS=Length of hospital stay 
Table 4. Comparative studies between the efficacies of the different types of EN  
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Pearce at al supplemented arginine, glutamine, -3 fatty acids and antioxidants in 31 
patients with severe AP in a randomized control trial; their findings suggest that an increase 
in C-Reactive Protein was found in the supplemented group compared with the control 
group. No significant differences were found in the length of hospital stay. Although a 
lower incidence of pneumonia and MOF, and shorter length of ICU and hospital stay was 
observed in the immunonutrition group, none of these differences reached statistical 
significance (Pearce CB et al, 2006). 
De Beaux et al randomized 14 patients with severe AP to receive standard PN of isocaloric, 
isonitrogenous, glutamine-enriched PN; only 13 patients completed the study. There was a 
trend for the glutamine supplemented group to show improved lymphocyte proliferation, 
increased T-cell DNA synthesis and decrease release of the pro-inflammatory cytokine IL-8 
(De Beaux AC et al, 1998). 
A double blind randomized clinical trial by Olah et al evaluated the effects of probiotics 
added to EN. They proposed that the rapid disappearance of commensal flora in AP, 
combined with overgrowth of potentially pathogenic organisms, provided the rationale for 
probiotic therapy. The authors divided patients into 2 groups; the treatment group, who 
received a preparation containing Lactobacillus plantarum together with a substrate of oat 
fiber for one week by NJ tube; and the control group who received heat inactivated 
Lactobacillus strain preparation. Infected pancreatic necrosis and abscesses occurred in 4% of 
the patients in the treatment group as compared to 30% in the control group (p=0.023). The 
mean hospital LOS was shorter in the treatment group as well (p<0.05) (Olah A et al, 2002). 
Lasztity evaluated whether provision of -3 polyunsaturated fatty acids (-3 PUFA) or fish 
oil could alter the course of disease in AP through modulation of eicosanoid synthesis. 
Supplementation of EN with 3.3 g/d of -3 PUFA for 7 days in the treatment group resulted 
in a significant decrease in hospital LOS (p<0.05) and duration of nutrition therapy (Lasztity 
N, 2005). 
 
Author, 
reference, year  
Study design  Special nutrient 
in formula 
Results Conclusion  
Hallay J  
et al, 2001 
Randomized 
clinical trial 
 
“Stresson “ ® 
Multi Fibre  vs 
“Nutrison” ® 
Fibre 
The treatment with 
glutamine-rich “Stresson“ 
® resulted in significant 
elevations in the serum 
levels of IgG, retinol 
binding protein, compared 
to the effects of Nutrison 
Fibre. In addition, the 
recovery of treated patients 
was significantly shorter in 
the “Stresson” ® Multi 
Fibre group than in the 
“Nutrison “ ® Fibre group. 
The “Stresson” ®  
Multi Fibre nutrient 
treatment of patients 
treated for AP seems 
to have clinical 
benefit based upon 
the fast recovery of 
IgG, IgM proteins 
and the 
immunological 
defense 
mechanisms. 
Pearce CB  
et al, 2006 
Double-blind 
Randomized 
controlled 
trial 
Glutamine, 
arginine, 
tributyrin and 
antioxidants vs  an 
isocaloric 
isonitrogenous 
After 3 days of feeding, in 
the study group 2/15 (13%) 
of patients had reduced 
their CRP by 40 mg/L or 
more. In the control group 
6/16 (38%) of patients had 
reduced their CRP by this 
The cause of the 
unexpectedly higher 
CRP values in the 
study group is 
unclear. 
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Author, 
reference, year  
Study design  Special nutrient 
in formula 
Results Conclusion  
amount. This difference 
was found to be near the 
statistical significant limit 
(P=0.220). 
Oláh A  
et al, 2002 
Randomized 
clinical trial 
 
Group 1: Received 
Lactobacillus 
plantarum 
together with a 
substrate of oat 
fibre. 
Group 2(control): 
Received a 
isonitrogenous 
formula but the 
Lactobacillus was 
inactivated by 
heat. 
Infected pancreatic necrosis 
and abscesses occurred in 1 
of 22 patients in the 
treatment group, compared 
with 7 of 23 in the control 
group (P = 0.023). The 
mean length of stay was 
13.7 days in the treatment 
group versus 21.4 days in 
the control group (p=NS). 
Supplementary L. 
plantarum was 
effective in reducing 
pancreatic sepsis 
and the number of 
surgical 
interventions. 
Lasztity, 2005 Randomized 
clinical trial  
N-3 PUFAs (fish 
oil) enterally 
(3.3g/day for 5-7 
days). 
The n-3 to n-6 LCPUFA 
ratios increased 
significantly in serum lipids 
of the patients receiving 
supplementation. 
 The SOD activity was 
significantly higher at day 3 
in the supplemented group 
(P<0.05). 
The use of enteral 
formula enriched 
with n-3 PUFAs in 
the treatment of AP 
seems to have 
clinical benefits 
based upon the 
shortened time of 
jejunal feeding and 
hospital stay 
Kuklinski B  
et al, 1995 
Randomized 
clinical trial 
Antioxidant 
treatment sodium 
selenite as a water 
soluble redox 
substance 
represented an 
alternative 
With a well-timed selenium 
therapy the rates of 
lethality complications and 
operation dropped 
drastically. Complications 
occurred if the therapy 
began too late (if patients 
were administered too late) 
and in biliary forms. 
An improvement in 
the prognosis of 
acute pancreatitis 
can be achieved if 
antioxidant 
selenium therapy 
with sodium Se is 
introduced in time. 
In rare cases total 
necroses and 
complications in 
organs only 
occurred in those 
patients who were 
admitted to this 
therapy too late. 
Abbreviations: Se=Selenium / AP= Acute Pancreatitis / PUFA = Polyunsaturated fatty acids / SOD= 
Superoxide dismutase 
Table 5. Special Nutrients in Enteral Feeding  
In a study by Kuklinski et al. reduction of plasma selenium levels was noted in patients with 
AP; positive results after the addition of selenium into the intestinal diet of these patients 
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was reported (Kuklinski B et al, 1995). Despite the limited number of reports on this subject, 
the European Society of Parenteral and Enteral Nutrition (ESPEN) Guidelines recommend 
the use of PN with selenium in patients with AP (Meier R et al, 2006). 
In summary, the beneficial effect of EN on patient outcome in AP may be enhanced by 
providing certain supplements. Although adding arginine, glutamine, -3 fatty acids, or 
specific probiotic preparation to the EN in patients with AP may result in reduction of 
hospital LOS, duration of nutrition therapy, or certain complications (when compared with 
the use of EN alone without the supplements), not enough information is available to make 
firm and specific recommendations. The addition of parenteral glutamine to PN should be 
considered in order to shorten hospital LOS and duration of nutrition therapy (when 
compared with PN alone without the supplement (McClave SA et al, 2006). Table 5 
summarizes the available information on the special nutrients in enteral feedings. 
5. Conclusions 
Most patients with AP have mild disease and do not need additional nutrition support 
during admission. According to guidelines, nutritional support is generally indicated if 
patients cannot consume normal food after 5-7 days when it becomes evident that the 
patients will not be able to tolerate oral intake for prolonged period of time (7 days or more) 
(Spanier BM et al, 2011). However, in a malnourished patient, especially if critically ill, 
nutrition therapy in some form must be provided earlier, to avoid caloric deficits. 
Nutrition therapy by enteral route is now the modality of choice for patients with severe AP. 
Recent guidelines have summarized the levels 1 and 2 evidence in support of the preferred 
role of EN according to safety, cost, and ease of administration. Patients with AP should be 
provided EN early because such therapy modulates the stress response, promotes more 
rapid resolution of the disease process, and results in better outcome. EN has beneficial 
influence on the disease course and should be initiated as early as possible (within 48 hours 
of admission). Large multicenter studies are still needed to confirm the safety and 
effectiveness of NG feeding when compared with NJ feeding and to investigate the role of 
early (within 48 hours) versus late nutrition support. When distal jejunal access is not 
possible to attain or maintain, intragastric feeding can be cautiously initiated, following safe 
practice standards. The clinical evidence to use semielemental diets is still weak. Routine use 
of supplementation formulas with glutamine and probiotics or immune-enhancing diets in 
AP cannot be recommended at this time.  
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1. Introduction 
Acute pancreatitis is an inflammatory condition with a variable clinical course from mild to 
the most severe with serious complications that attempt the life of a patient. According to 
the Atlanta classifications the severe acute pancreatitis occurs approximately at 25% of all 
patients with acute pancreatitis and it is associated with 10-20% of mortality. Death of the 
acute pancreatitis patients is often connected of at least one organ. 
There are two phases of the severe acute pancreatitis relating to the mortality. The first 
phase, two weeks after onset of syndrome, is characterized by hypovolemia or even by the 
shock. It is accompanied by the systemic inflammatory responsive syndrome with 
production of inflammatory mediators and cytokines, which cause consecutive injury of 
lungs, livers and cardiovascular system. The multi organ failure is a very common 
appearance in the case of the severe acute pancreatitis and it happens very often even when 
the infection is absent. The second phase of this disease (third-forth week) is characterized 
by the complications caused by the infection of pancreatic necrosis. About 40-70% patients 
with necrotic acute pancreatitis is afflicted by the infection of the pancreatic necrosis, which 
causes the deaths of acute pancreatitis patients (Beger et al., 1997). The extent of the 
pancreatic necrosis and the duration of disease are the risk factors of the local pancreatic 
infection. Its incidence tends to culminate in third week of disease, though it may appear in 
whichever phase of the disease (Büchler et al., 2000). Severe acute pancreatitis requires 
treatment at the hospital, which is developed from personal, professional and technical 
point of view, where is a possibility to do the full diagnosis and therapy and the 
interdivisional cooperation, what is the basic presumption for treatment and diagnosis of 
acute pancreatitis.  
Diagnosis is based upon clinical presentation, laboratory indicates and imaging studies, 
whilst illness severity can be assessed by clinical scoring systems, such as Ranson, Glasgow 
or Apache II criteria, or by radiological assessments such as the computer tomography 
severity index. Mild disease is often self-limiting and inflammation resolves with simple 
medical management. However, a minority of patients (up to 20%) will develop severe 
disease that carries substantial morbidity and mortality.  
Over the past decades, management of severe acute pancreatitis changed from an early 
operative treatment to a more conservative approach. Nowadays there is clearly no more 
doubt that surgery is not the first choice of treatment for patients suffering from severe acute 
 
Acute Pancreatitis 236 
pancreatitis. Surgical debridement is the gold standard in patients with infected pancreatic 
necrosis. By delaying surgery up to the third or fourth week, sufficient debridement can be 
achieved, resulting in low mortality and morbidity rates. Early enteral feeding is preferred 
over total parenteral nutrition as it results in a reduced incidence of infection, length of 
hospital stay and mortality.  
Besides full intensive treatment of acute pancreatitis there is a non changeable role of the 
surgical – operational treatment. Some indications for surgical treatment are no doubtful; 
some of them are the subject of discussion. The documented persistent infected necrosis and 
abscess is clear indication for the surgical treatment. Permanent acute abdomen, especially 
so called intra-abdominal compartment syndrome and persistent or increasing local 
complications (bleeding, ileus, bleeding of gastrointestinal tract, vascular ileus and others) 
are also the definite indication of the surgical intervention. Many authors consider the sterile 
necrosis, which causes the multi organ failure and which does not react to the maximal 
intensive treatment more than 72 hours, as an indicator of the surgical treatment (Götzinger, 
2007). 
The changes in the management of the patients with severe acute pancreatitis in the last 
decade contributed to the decrease of mortality. The aim of this study is to evaluate progress 
in the management of the patients with severe acute pancreatitis, comparing two clinical 
groups of patients.  
2. Changes in the management of treatment in acute pancreatitis patients 
Despite than mortality from severe acute pancreatitis has remarkably decreased (10-20%) 
during the last decades, many questions remain open about the treatment of this disease. 
Published literature on severe acute pancreatitis was reviewed and the decision to change 
the management of the treatment of severe acute pancreatitis has been made, at the First 
Department of Surgery, University Hospital in Košice, Slovakia. The management referred 
to the enteral nutrition, epidural analgesia, antibiotic prophylaxis, delay surgery to the later 
period in the case of infected necrosis.  
2.1 Enteral nutrition 
Enteral nutrition fed by the three-luminal tube applied by fibroscope, checking position by 
the contrast X-ray exam or by enteral nutrition through jejunostomy, in the case of already 
operated patient. 
In 1997, McClave et al. demonstrated that nasojejunal feeding is a safe and beneficial 
method in mild and moderate pancreatitis (McClave et al., 1997). Later on, Nakad et al. 
found that nasojejunal feeding is feasible in severe acute pancreatitis, too (Nakad et al., 
1998). Recently, some questioned whether nasojejunal feeding is the only proper route of 
enteral feeding in acute pancreatitis. The main disadvantage of nasojejunal feeding that it 
requires an endoscopist or radiologist to place the tube in, which may cause some delay in 
starting early enteral feeding (Spanier et al., 2011). Piciucchi et al. have found that enteral 
nutrition administered by nasogastric or nasojejunal tube seems to provide equal safety, 
tolerability and efficacy, even if more results are necessary to validate the routine use of 
nasogastric tubes in severe acute pancreatitis patients (Piciucchi et al., 2010). 
One of the most common complications of enteral feeding is diarrhea, which can be detected 
in 20–30% of all patients. Diarrhea may deteriorate volume depletion and dehydration 
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resulting in further weakening of the general condition of patients who are very sick 
anyway and usually need intensive care management. Wide-spectrum antibiotics, which are 
frequently used in severe acute pancreatitis, can contribute to the development of diarrhea 
as a significant additional factor (Whelan, 2007). It is possible that fiber enteral nutrition 
formulas have some preventive effect against diarrhea though (Elia et al., 2008). This 
observation was supported by a recently published study by Karakan et al. showed that 
prebiotic fiber supplementation reduced complication rate in acute pancreatitis in 
comparison to standard enteral solution (Karakan et al., 2007). A meta-analysis published by 
Petrov and Zagainov, which was based on six randomized control trials comparing enteral 
nutrition with parenteral nutrition, showed that enteral nutrition statistically significantly 
reduced the risk of hyperglycemia (p=0.04) as well as insulin requirement  (p=0.001), so it is 
associated with better blood glucose control in severe acute pancreatitis patients (Petrov & 
Zagainov, 2007). The facts that enteral nutrition is most likely superior to parenteral 
nutrition in preventing septic complications of acute pancreatitis, it may also eliminate some 
complications of parenteral nutrition (catheter sepsis, pneumothorax, and thrombosis), and 
costs only 15% of the cost of total parenteral nutrition, make it an increasingly accepted 
treatment modality (Olah & Romics, 2010).  
Composition of enteral formulas can be classified into three basic categories: polymeric, 
(semi)elemental, and immunoenhanced. While polymeric nutrient comprises non-
hydrolyzed proteins, maltodextrins, oligofructosaccharides and long-chain triglycerides, 
(semi)elemental contains oligopeptides or amino-acids, maltodextrins, and medium and 
long-chain triglycerides. Theoretically, semi elemental nutrients stimulate pancreatic 
secretion in less extent, but enhance bowel absorption and those are tolerated better by 
patients than polymeric ones (Tiengou et al., 2006; Petrov et al., 2009b).  
Immunoenhanced nutrients involve substrates which modulate the activity of the immune 
system. Various immunonutrition formulas felt in this category, such as glutamine, arginine, 
and omega-3 fatty acids as well as enteral nutrients supplemented by probiotics. Recently, a 
meta-analysis compared (semi)elemental and polymeric formulations indirectly, using 10 
randomized controlled trials where parenteral nutrition was the reference treatment (Petrov 
et al., 2009a). The authors, however, could not demonstrate statistically significant difference 
with regard to tolerance of feeding, infectious complications, or mortality in between two 
enteral nutrition formulas (p=0.611). Enteral feeds with immune-enhancing ingredients such 
as glutamine, arginine, nucleotides, and omega-3 fatty acids that modulate the host immune 
and inflammatory response have recently attracted great interest (Bertolini et al., 2007). 
There are promising experimental studies, where supplementation of enteral feed with 
glutamine or omega-3 fatty acids could reduce the severity of experimental acute 
pancreatitis models (Foitzik et al., 2002; Rayes et al., 2009). Adding probiotics to enteral 
nutrients seemed to be a promising alternative for the future. In 10 of the 15 studies, 
probiotics significantly reduced bacterial infection rate compared to control groups. Two 
studies demonstrated a clear positive trend, but no statistical significance was detected 
(Olah & Romics, 2010). Sun et al., in a meta-analysis of four randomized controlled trials 
demonstrated that enteral feeding with probiotic could not reduce the infected necrosis (Sun 
et al., 2009). Eckerwall and Jacobson reported about timing when to resume oral feeding in 
patients with acute pancreatitis (Eckerwall et al., 2006; Jacobson et al., 2007). The usual 
criteria to initiate oral feeding are (1) absence of abdominal pain, (2) absence of nausea and 
vomiting, and return of appetite, and (3) absence of complications.  
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2.2 Antibiotics in acute pancreatitis 
Infection of pancreatic necrosis by enteric bacteria is the most common cause of death in 
patients with necrotizing pancreatitis. Progress in the therapeutic management of this 
disease has led to a decrease in the mortality of patients without infection of pancreatic 
necrosis, which commonly is reported to range between 5% and 15% (Tenner et al., 1997). 
Nevertheless, mortality rates of 20%-30% are reported in patients with infected pancreatic 
necrosis (Büchler et al., 2000). The clinical importance of pancreatic infection has led to the 
idea that the prevention of infected necrosis could be a beneficial approach.  
Antibiotics prophylaxis in severe acute pancreatitis has been a matter of discussion during 
the past years (Büchler et al., 2000; Slavin & Neoptolemos, 2001). Recent clinical studies 
seem to support the notion that early administration of broad-spectrum antibiotics is 
capable of reducing the incidence of infected pancreatic necrosis (Pederzoli et al., 1993; 
Golub et al., 1998; Sharma & Howden, 2001). Two randomized double-blind studies have 
addressed prophylactic antibiotics in patients with acute pancreatitis with prognostically 
severe and severe pancreatitis on imaging (Isenmann et al., 2004; Dellinger et al., 2007). 
These studies have failed to show any benefit from such drugs being routinely prescribed, 
no difference was found in the rate of pancreatic sepsis and mortality despite previous 
smaller non randomized studies suggesting a benefit. On the other hand, antibiotic overuse 
has been associated with up 30% of patients developing necrosis superinfection with 
Candida species which may confer a poorer prognosis (Büchler et al., 2000; Connor et al., 
2004). If antimicrobials are prescribed, the duration should to be limited to 14 days. 
Fourteen trials were included with a total of 841 patients in systematic review and meta-
analysis of antibiotic prophylaxis in severe acute pancreatitis by Wittau et al. The authors 
have investigated that the use of antibiotic prophylaxis was not associated with a 
statistically significant reduction in mortality, in the incidence of infected pancreatic 
necrosis, in the incidence of non-pancreatic infections, and in surgical interventions (Wittau 
et al., 2011).  
2.3 Epidural catheter 
Severe acute pancreatitis is associated with the development of local complications, such as 
pancreatic and peripancreatic necrosis, abscesses or pseudocysts, and systemic 
complications, such as adult respiratory distress syndrome or renal failure with mortality 
rate is close to 15 % (Demirag et al., 2006). The pathophysiology of acute pancreatitis is 
incompletely understood but alteration in the pancreatic microcirculatory blood flow has 
been involved. Thus, a decrease in pancreatic blood flow occurs early in the course of acute 
pancreatitis and has been suggested to play a role in the conversion of edematous to 
necrotizing acute pancreatitis (Klar et al., 1994). The microcirculatory dysfunction includes 
arterial vasoconstriction with hypoperfusion, ischemia-reperfusion injury and obstruction of 
the venous outflow (Klar et al., 1991; Letko et al., 1994; Demirag et al., 2006).  
Besides perfusion abnormalities, acute pancreatitis is also characterized by local and 
systemic inflammatory responses, including leukocyte activation as well as release of free 
radicals and cytokines (Frossard et al., 2001). Many therapeutic agents, such as  dextran, 
heparin, procaine, L-arginine, antioxidants, or cytokine antagonists, have been tested 
experimentally and/or clinically to improve pancreatic tissue perfusion during acute 
pancreatitis, however, no significantly successful result has been achieved (Beger et al., 2001, 
Paszkowski et al., 2001). Epidural anesthesia that is used to induce analgesia in the 
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perioperative period might be an interesting treatment of the microcirculatory blood flow 
abnormalities (Demiraget al., 2006). 
2.4 Type of surgical intervention 
Severe acute pancreatitis is still related to high mortality rates. Over the past decades, 
management of severe acute pancreatitis changed from an early operative treatment to a 
more conservative approach. Surgical debridement is the gold standard in patients with 
infected pancreatic necrosis. However surgical intervention for sterile necrosis is only 
indicated in selected patients if aggressive intensive care is unsuccessful. Patients suspected 
to have infected pancreatic necrosis, should undergo computer tomography-guided or 
ultrasound-guided fine-needle aspiration for verification. By delaying surgery up to the 
third week, sufficient debridement can be achieved by a single operation, resulting in low 
mortality and morbidity rates. 
2.4.1 Operative treatment of pancreatic necrosis 
In patients with infected pancreatic necrosis, surgical necrosectomy is the established gold 
standard, whereas operative treatment of patients with sterile necroses is controversially 
discussed. Surgical debridement of infected pancreatic necrosis is based on two principles 
(Sahora et al., 2009). First, necrotic pancreatic tissue as well as pancreatic ascites is removed 
out of the peritoneal cavity and the lesser sac, to prevent absorption through the thoracic 
duct, which is accused to increase the incidence of systemic complications as development 
of single or multiple organ failure (Mayer et al., 1985). Second, as much as possible viable 
pancreatic tissue should be preserved to insure a good quality of life after recovery (Broome 
et al., 1996). Nowadays mortality in patients with infected pancreatic necrosis is about 10–
30% in specialized centers as a result of right timing and patient selection (Büchler et al., 
2000). Because of improvements in intensive care medicine, today more patients survive the 
first phase of acute pancreatitis, increasing the incidence of infected necrosis (Beger et al., 
1986). Retroperitoneal gas or bacterial culture gained from fine-needle aspiration 
(ultrasound or computer tomography guided) is confirmation for infected pancreatic 
necrosis. Sterile necrosis, in general, is no indication for surgery. Multiple series have shown 
that patients with sterile necrosis can be managed by a conservative approach, but surgery 
might be indicated in case of late complications, disease progression or persistence. In these 
severely ill patients, who develop organ failure without signs of septic complications, the 
indication to surgery must be made individually (Sahora et al., 2009). As in patients with 
infected necrosis, early operation has shown high mortality rates and should also be delayed 
upon the third week (Büchler et al., 2000; Uhl et al., 2002; Hartwig et al., 2002a). 
In the past, early surgical intervention was indicated for patients with severe acute 
pancreatitis, but was lead to mortality rates up to 65% (Smadja & Bismuth, 1986). The aim of 
this intervention was that patients would benefit from the initial removal of necrotic tissue, 
leading to the reduction of multisystemic complications related to enzymes and toxic 
substances (Fernandetz –Cruz et al., 1994). For evaluation of mortality rates, early surgical 
intervention was compared to a more conservative approach. In retrospective study 
performed by Hartwig et al., and in randomized control trial made by Mier et al., was found 
reduction of mortality rates in patients undergoing delayed surgery (Mier et al., 1997; 
Hartwig et al., 2002a).  
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At present, guidelines for the management of surgical treatment of severe acute pancreatitis 
agree that surgical intervention should be delayed as long as 3–4 weeks after onset (Uhl et 
al., 2002; Isaji et al., 2006). By deferring surgery a proper demarcation of pancreatic and 
peripancreatic necrosis can take place. The demarcation of necrotic masses from viable 
tissue enables an easier and safer debridement with a greater likelihood of sparing 
pancreatic tissue and leads to successful surgical control of pancreatic necrosis. Thus the risk 
of bleeding and the surgery-related loss of vital tissue that predisposes to surgery-induced 
endocrine and exocrine pancreatic insufficiency can be minimized by this approach 
(Hartwig et al., 2002b, Bober et al., 2003).  
The aim of any intervention technique is to maximize debridement, preserve as much vital 
pancreatic parenchyma as possible and to secure postoperative drainage of debris and 
exudates (Götzinger et al., 2002). Resection procedures, as partial or total pancreatectomy, 
which also remove vital tissue, have been abandoned, because of impaired quality of life 
and higher mortality and morbidity (Nordback & Auvinen, 1985). Several open and 
minimal invasive techniques have been described, but an ideal method has not yet been 
defined. The surgical procedures including: open necrosectomy with closed continuous 
lavage, open necrosectomy with drainage and relaparotomy on demand, open 
necrosectomy with open packing and planned re-laparotomy. However morbidity (80%), 
including pancreatic, intestinal fistula, stomach outlet stenosis, local bleeding, and incisional 
hernia, is higher in patients undergoing multiple relaparotomies, which are mandatory in 
open packing procedure (Beger et al., 1982; Büchler et al., 2000; Fernandez-del Castilo et 
al.,1998).  
The open approach for the surgical treatment of severe acute pancreatitis including blunt 
debridement is combined with laparostomy for drainage and access for revisions to further 
remove local debris. Operative access is gained by a way of a midline incision. Careful 
exploration is done to assess the extent of pancreatic and extrapancreatic necrosis, including 
a Kocher’s mobilization of the second part of the duodenum. Furthermore the right and the 
left colon are mobilized. It is possible to approach the lesser sac through the gastrohepatic 
omentum or the gastrocolic omentum. If opening of the lesser sac is not possible because of 
a bounded inflammatory process, direct access from the infracolic compartment via the left 
transverse mesocolon is an alternative. The access through the mesocolon also allows drains 
to be placed in a more exact position once the debridement is completed. It is important to 
send fluid collection from the necrotic region for aerobic and anaerobic culture (Sahora, 
2009). After sufficient debridement there remain cavities, which are often stiff and may 
bleed from the granulated surface. In these spaces is necessity to place 4–10 easy flow 
drains, which are brought out through left and or right side placed laparostomas. These 
drains are not removed unless the daily quantum of fluid loss is less than 20 ml. Another 
possibility is to stepwisely remove these drains that will result in a fistula due to a mature 
fistula tract. This fistula will close in a given period (Sahora et al. 2009).  
Today several additional techniques to open surgical necrosectomy have been described. 
Percutaneous drainage, endoscopic techniques, and minimal invasive surgical procedures 
have been described as additive and alternative procedures. Percutaneous computer 
tomography-guided catheter debridement without surgery has been shown to be feasible in 
selected series in more than 50% of the included patients, with infected and sterile necrosis. 
Mortality rates of 12–30%, of patients treated by percutaneous drainage only, have been 
reported, using different access routes and a variety of catheter types (Bruennler et al., 2008; 
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Mortelé et al., 2009). The major reported complications were hemorrhage and injury to 
adjacent organs. The endoscopic drainage of sterile pancreatic necrosis using several 
transgastric and transduodenal catheters combined with a nasopancreatic catheter to lavage 
the necrotic cavity described Baron in 1996 (Baron et al., 1996). Using endoscopic drainage, 
many authors reported a high percentage of patients, who were treated without the need of 
surgery (Baron et al., 2002, Seifert et al., 2009, Seewald, 2005). Recently also minimally 
invasive necrosectomy techniques have been used with some promising results. Different 
approaches are described to access the necrotic mass. Some authors prefer a transabdominal 
access, which offers a good overview but harbors the risk of spreading intra-abdominal 
infection. As an alternative the necrotic focus can be reached through retroperitoneoscopy. 
Bücher et al. reported a group of 8 patients who underwent minimal invasive necrosectomy 
using a single large port, inserted over the percutaneous drainage channel. Complication 
rate was zero and despite one patient only a single session was needed (Bucher et al., 2008). 
Alternatively Parekh describes a laparoscopic hand-assisted method, using 
a transabdominal approach. In this series 19 patients, out of 23, were treated without the 
need of open laparotomy, zero postoperative complications, and a mortality of 10.5% 
(Perehk, 2006).  
In conclusion, comparison of these minimal invasive procedures is almost impossible 
because of inhomogenity of patient selection. Today there are no randomized controlled 
trails comparing open surgery to one of the mentioned methods. Minimal invasive 
procedures may play a role in bridging the time to definite surgery in critically ill patients in 
some well-experienced clinical centers (Sahora et al., 2009). 
2.4.2 Intra-abdominal hypertension 
Intra-abdominal hypertension is increasingly reported in patients with severe acute 
pancreatitis, and is caused by several factors, including visceral edema and ascites 
associated with massive fluid resuscitation, paralytic ileus and retroperitoneal 
inflammation. There is a strong relation with early organ dysfunction and mortality in these 
patients, which makes intra-abdominal hypertension an attractive target for intervention. 
Several reports conclude that this phenomenon occurs within the first 5 days after 
admission, and that the kinetics of inta-abdominal hypertension is important: patients with 
persistent intra-abdominal hypertension seem to be at the highest risk for mortality. Several 
strategies to reduce intra-abdominal pressure have been developed, and given the 
pathophysiology, percutaneous drainage of ascites is a first logical step. However, if 
conservative measures fail to reduce intra-abdominal pressure in a setting with ongoing or 
worsening organ dysfunction, abdominal decompression is recommended.  Intra-abdominal 
hypertension and intra-abdominal compartment syndrome have been described most often 
in patients with abdominal trauma or after emergency abdominal surgical procedures such 
as aortic aneurysm repair (De Waele, 2008). The intra-abdominal hypertension is defined as 
a sustained or repeated pathologic elevation of the intraabdominal pressure above 12mm 
Hg. The intra-abdominal compartment syndrome is described as the sustained elevation of 
intra-abdominal pressure above 20mmHg in combination with newly developed organ 
dysfunction (Malbrain et al., 2006). 
It was shown that intra-abdominal hypertension is associated with higher mortality and 
morbidity rates, and prolonged intensive care unit stay, in comparison to other patients who 
had normal intra-abdominal pressure (Sugrue et al., 1999). Intra-abdominal hypertension has 
been recognized as a cause of organ dysfunction in critically ill patients, including those 
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suffering from severe acute pancreatitis (Balogh et al., 2002). Placement of a urinary catheter 
for the monitoring of intra-abdominal pressure would be necessary in the severe acute 
pancreatitis patients. The symptoms caused by intra-abdominal hypertension in patients with 
acute pancreatitis are not very different from other conditions associated with intra-abdominal 
hypertension. Hemodynamic instability requiring vasoactive drugs, acute renal failure and 
respiratory failure are the most obvious clinical signs and symptoms that have been associated 
with intra-abdominal hypertension.  The association between intra-abdominal hypertension 
and development of organ dysfunction in severe acute pancreatitis is well documented. De 
Waele et al. showed that there was a 95% incidence of respiratory failure, 91% cardiovascular 
and 86% acute renal failure rate in patients with intra-abdominal pressure of 15 mmHg or 
higher (De Waelle et al., 2005).  The development of intra-abdominal hypertension in patients 
with severe acute pancreatitis is evidently an important problem, as it is associated with organ 
dysfunction and mortality. Therefore, intra-abdominal pressure should be measured routinely 
in patients admitted to the intensive care unit with severe acute pancreatitis, and intra-
abdominal pressure should be considered a target for intervention in all patients.  
Decompressive laparotomy has been shown to effectively reduce intra-abdominal pressure 
and reverse the symptoms typically associated with abdominal compartment syndrome (De 
Waelle et al., 2006; Dambrauskas et al., 2009). If decompression is needed more than 2–3 
weeks after the onset of the disease and there is evidence of extensive necrosis on a 
computered tomography scan or established infection of peripancreatic necrosis, it is the 
feasible to perform a necrosectomy in conjunction with the decompressive laparotomy. In 
selected patients with extensive retroperitoneal fluid collections, a lumbotomy may provide 
access to the retroperitoneal space, and allow evacuation of pancreatic necrosis as well. The 
management of the open abdomen following decompression in severe acute pancreatitis is 
challenging. The best currently available technique is the utilization of the vacuum-assisted 
closure technique aiming for gradual closure of the abdominal wall. The use of a vacuum 
assisted closure system guarantees a perfect seal of the peritoneal cavity, avoiding possible 
superinfection of the pancreatic or peripancreatic necrosis.  
Intra-abdominal hypertension seems to have a significant role in contributing to the early 
multi organ dysfunction syndrome, subsequent complications and mortality in severe acute 
pancreatitis. Intra-abdominal pressure monitoring is mandatory for all patients who 
develop organ dysfunction, and intra-abdominal pressure should be a target for 
intervention when intra-abdominal hypertension and organ dysfunction persist. Surgical 
decompression should be considered in all patients with persistent organ dysfunction after 3 
days or later (Sugrue et al., 2007; De Waele, 2008). 
3. Clinical group of patients and the methods 
All patients who were hospitalized due to the acute pancreatitis symptoms in the period 
from January 2003 till December 2008 at the First Department of Surgery, University 
Hospital, in Kosice, were included to this study. Those patients, who were primarily 
hospitalized and treated at other workplaces and were moved to our institute during their 
disease, were excluded from this study.  
The total number of the patients with acute pancreatitis during onset symptoms was 258 
ones. All patients were hospitalized at the Intensive Care Unit, they received the standard 
intensive care (palliation of pain, nasal gastric tube, central vein catheter, urinary bladder 
catheter, intensive monitoring of the basic vital functions, intensive rehydratation treatment, 
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giving the inhibitors of proton pump, low molecular weight heparin, giving the 
prophylactic antibiotic therapy). In the case of biliary acute pancreatitis, mainly joined with 
jaundice, cholangitis or ultrasound suspicion for the presence of the stones in common bile 
duct, the patients were underwent urgent endoscopic retrograde cholangio-
pancreatography during the first 48 hours after onset acute pancreatitis. The distinguishing 
of the mild forms and severe forms of acute pancreatitis were carried out using Ranson 
criteria, APACHE score, the daily follow-up of level C-reactive protein and measurement of 
percentage of involvement of pancreatic tissue by computer tomography severity index 
(Balthazar computer tomography scoring system). The first computer tomography 
examination was carried out first time after 48 hours from the beginning of disease. The 
diagnosis of the infected necrosis we did according to the clinical finding, inflammatory 
markers (white blood cells, C-reactive protein, procalcitonin), and ultrasound and computer 
tomography finding (presence of gas bubbles). 
Patients with multi organ failure were moved from the Intensive Care Unit to be 
hospitalized at the Department of Anesthesiology and Intensive Medicine of our institute.  
The clinical group of hospitalized patients was divided into two subgroups. Group A 
included the patients hospitalized from January 2003 till December 2005. This group of 
patients was evaluated retrospectively. The second Group B included the patients 
hospitalized from January 2006 till December 2008. This group was studied prospectively, 
according to the clinical protocol prepared in advance, which reflected the changes in 
management of the patients with the severe acute pancreatitis after confirmation of necrosis.  
Fisher’s exact and Pearson chi-square tests were used in data analysis. P < 0.05 was 
considered statistically significant. 
3.1 Clinical protocol of changes in management of treatment acute pancreatitis 
patients 
Enteral nutrition fed by the three-luminal tube applied by fibroscope, checking the position 
by the contrast X-rays exam or by enteral nutrition through jejunostomy, in the case of 
already operated patients. Enteral nutrition was applied if no signs of the cardiovascular 
instability were present. We used the enteral nutrition enriched of the glutamine, arginine 
and omega-3 fatty acids and fibres. The dose was gradually increased from 20ml/hour to 
80ml/hour (maximum 1000ml/24 hours). The enteral nutrition was started at seven o´clock 
in the morning and takes 12.5 hours to half past seven in the evening. At night, the enteral 
nutrition was not administrated. The second change includes an application of the epidural 
catheter to palliate the pain and to recovery of intestinal peristaltic. The continual 
measurement of the intra-abdominal pressure with the catheter in urinary bladder was 
used. The changes in the prophylactic application of antibiotics include changing 
III.generation cephalosporin’s which were administered in Group A for imipenem which 
were replaces in Group B. In both groups the prophylactic application lasted maximum 14 
days. Necrosectomy was indicated and performed as late as possible; usually the surgical 
procedure was pushed to the third or fourth week of hospitalization.  
3.2 Results 
Basic characteristic of both subgroup A and B are documented in table 1. It follows less 
frequency in Group A, however the male/female ratio and occurrence of the severe acute 
pancreatitis was similar. The percentage of the patients with necrotic pancreas and the 
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patients, who needed endoscopic retrograde cholangiography procedure, was similar as 
well.  
 
 Group A Group B 
Number of patients 97 161 
Male/Female 53 : 44 90 : 71 
Mild acute pancreatitis 84 (86%) 132 (82%) 
Severe acute pancreatitis 13 (14%) 29 (18%) 
Number of patients + endoscopic 
retrograde 
cholangiopancreatography 
 
34 (35%) 
 
53 (33%) 
Table 1. Groups of patients suffered from acute pancreatitis, group A (2003-2005), group B 
(2006-2008). 
Further we will be concerned only with the patients with severe acute pancreatitis. More 
detailed characteristic of patients with severe acute pancreatitis is documented in table 2. 
 
 Group A Group B 
Number of patients 13 29 
Male/Female 8/5 16/13 
Mean of age 38,5 year 42 year 
Etiology of acute pancreatitis 
Alcohol 
Biliary disease 
Other 
 
7 (54%) 
5 
1 
 
14 (48%) 
12 
3 
Ranson score 3,9 (3-9) 4,0 (2-9) 
Number of patients with computer tomography scan 
necrosis more than 30% 
 
12 (92%) 
 
26 (90%) 
Patients hospitalized at the Department of 
Anesthesiology et Intensive Medicine  
 
6 (46%) 
 
11 (37%) 
Table 2. Group of patients suffered from severe acute pancreatitis 
More detailed description of group of patients with severe acute pancreatitis is documented 
in table 2. In both groups of patients there is a dominance of male and the similar average 
age, Ranson score, as well as a number of patients with necrotic pancreas over than 30%. 
Alcoholic etiology occurred more often in Group A. Also we noticed the higher number of 
patients, who needed hospitalization at the Department of Anesthesiology and Intensive 
Medicine. During the hospitalization, mainly during the period from 72 hours to 7th day, we 
provided intensive treatment in both group of patients, however in some cases in spite of 
our intensive effort, the multi organ failure occurred. In the case of presence of abdominal 
compartment syndrome, we indicated the surgical intervention including intra abdominal 
decompression. Presence of the infected pancreatic necrosis or abscess was a clear indication 
for surgical intervention. Individual indications and the timing of the surgery are presented 
in table 3. 
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 Sterile necrosis + 
multi organ 
failure 
Infected  
necrosis 
Abscess Together Mortality  
 
Time A B A B A B A B A B 
Till 72 hours 1 1     1 1 1 1 
Till 7 days  3 2     3 2 3 1 
After 7 days  1 1    1 1   
After 14 days   1 3   1 3 1 1 
After 21 days   1 4  1 1 5   
Together 4 4 3 7  1 7 12 5 
71% 
3 
25% 
Table 3. Timing of surgery, surgical indication and mortality in group A and group B. 
In Group A, it is shown more often indications to the surgical intervention in the first days 
and weeks of hospitalization period. Comparing Group B, mainly in the case of infected 
necrosis, the surgical operations were pushed to the third or fourth week. This was reflected 
also in the mortality of operated patients, when we recorded 71% mortality in Group A and 
25% of mortality in Group B. The types of surgical procedures are documented in table 4. 
While during the first days we performed only the surgical revision and drainage, or open 
abdomen. In the case of infected necrosis we performed necrosectomy with closed 
continuous lavage. There are also documented the number of patients with reoperations in 
both groups of patients, which is less frequent in Group B.  
 
 Primary surgery Repeated surgery Mortality 
Type of surgery A B A B A B 
Revision, drainage, open 
abdomen, jejunostomy 
2 1 
 
0 
 
0 2 0 
Revision, drainage, 
jejunostomy 
1 
 
4 1 0 0 3 
Necrosectomy, 
continuous lavage 
4 7 2 4 3 0 
Together 7 12 3 (43%) 4  (33%) 5 3 
Table 4. Type of surgical procedures and mortality of patients in group of patients A and B. 
The mortality in both groups of patients is presented in the Table 5. It shows less mortality 
in Group B (18%). Six patients were found with non infected necrosis 46% in Group A (2003-
2005), but seventeen patients were documented with non infected necrosis 58% in Group B 
(2006-2008). 
 
Acute Pancreatitis 246 
 Number of patients Mortality 
 A B A B 
Acute pancreatitis patients  97 161 7 (7.2%) 5 (3.1%) 
Severe acute pancreatitis 
patients 
13 29 7 (53.8%) 5 (18%) 
Severe acute pancreatitis 
patients after surgery 
7 12 5 3 
Severe acute pancreatitis 
patients with non infected 
necrosis 
6 17 2 2 
Table 5. Comparison of mortality of patients in group of patients A and B. 
The comparison of the cause of the death in both groups is presented in table 6. There was 
statistically significant decrease in mortality in group of patients B (p=0.02).While only 2 
patient’s dead for the pancreatic sepsis with multi organ failure, the remainder 10 patient’s 
dead for multi organ failure in first days after the admitting to hospital. 
 
 Group of patients A  
(2003-2005) 
Group of patients B  
(2006-2008) 
 
P 
Number of patients  13 29 - 
Death 7 (54%) 5 (18%) 0.02 
Multi organ failure 6 (85%) 4 (80%) - 
Pancreatic sepsis 1 (15%) 1 (20%) - 
Table 6. Cause of death in both groups of patients A and B. 
4. Discussion 
Despite of the lasting dissatisfaction with the mortality level of the patients with severe 
acute pancreatitis, nevertheless during last decades as a consequence of the positive shift in 
diagnostic methods and treatment of acute pancreatitis, we succeeded to decrease mortality 
of severe acute pancreatitis patients to 10%-20% (Del Campos et al., 1998). During the last 15 
years a big step was done towards the understanding and development of acute pancreatitis 
and at the same time the great progress in the screening methods of pancreas (Uhl et al., 
2002). In line with the other authors opinions (Bank et al., 2002), taking into account own 
experiences, we are convinced that the decrease of the mortality was causes by an early 
recognition of the severe acute severe and setting up the prompt and appropriate treatment, 
by the improvement of the nutritional support, early endoscopic retrograde 
cholangiopancreatography supplied to the accurately indicated patients, and using the 
effective antibiotic treatment.  
The International Association of Pancreatology proposed for acute pancreatitis treatment 
eleven recommendations (Sarr, 2003; Uhl et al., 2002), which created the framework for 
contemporary management of acute pancreatitis. These recommendations are based on the 
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principles of evidence based medicine. However, in many points, there is need of further 
comparative studies was observed.  
Positive trend of the decreasing mortality in the cases of severe acute pancreatitis was 
visible also at our workplace. These results have been already published previously (Bober 
et al., 1995; Bober et al., 2002; Bober et al., 2003). During the period from 2003 to 2005 the 
results overall got worse, when the mortality level of severe acute pancreatitis increased to 
53.8%. After in-depth analysis of the causes of this negative result, the decision to change 
management of the patients with acute pancreatitis was made. The new protocol was 
designed, which contained the change of the management.  
The contemporary standard of management of acute pancreatitis is the intensive 
conservative treatment with possibility of the diagnosis of its complications in the course of 
the therapy (Huťan, 2006). Very important part of the acute treatment is early and adequate 
fluid resuscitation during the first hour after admission in the case of patients with 
cardiovascular instability. When diagnosis of acute pancreatitis is confirmed, the treatment 
in line with a new protocol was applied.  
Many reports were published about the positive influence of the early enteral nutrition in 
the case of severe acute pancreatitis. Cao et al. published the results of meta-analysis, which 
compared the results achieved by the enteral nutrition and total parenteral nutrition in the 
case of severe acute pancreatitis. Patients with enteral nutrition have shown less risk of 
infection, less percentage of pancreatic and peripancreatic necrosis, as well as, less overall 
complications, less often multi organ failure and low mortality (Petrov et al., 2006; Cao et al., 
2008). Application of the three-luminal tube with help of fibroscope was carried out in our 
Group B by own co-workers, who had enough experiences and own endoscopy certificate. 
The application of the gastric aspirate and the enteral nutrition was tolerated well by all 
patients. Some of them perceived the abdominal discomfort and the slight increasing of the 
intra abdominal pressure. In these cases we have temporarily reduced the volume of the 
enteral nutrition.  
The aim of the prophylactic application of antibiotics is to protect the sterile necrotic tissue 
against the development of infection. In general, it is accepted, that 40%-70% necrosis is 
infected. With regard to the high percentage of this infection of pancreatic necrosis and with 
regard to the fact that mortality is higher in the case of infected necrosis than in the case of 
sterile ones, the preventive application of antibiotics prevention, which has to avoid the 
infection of the necrosis. The reason is except an unproved benefit from prevention also its 
possible risks (antibiotic resistance and development of mycotic super infection from 
antibiotics) (Dambraukas et al., 2007; Dellinger et al., 2007; Olejník & Brychta, 2008). At 
present, the routine application of the prophylactic antibiotics to the patients with proven 
necrosis, has many supporters (Xu & Cai, 2008; Rokke et al., 2007; Dambraukas et al., 2007; 
Otto et al., 2006; Uhl et al., 2002). The conclusions of their studies show that antibiotics 
prevention reduces the sepsis and mortality. The recommendation in International 
Association of Pancreatology reports that prophylactic application of broad-spectrum 
antibiotics reduces infection of computer tomography confirmed necrotic acute pancreatitis, 
but it does not improve survival rate. When choosing the antibiotics, it is pointed at the best 
results Imipenem or Meropenem (decrease of necrosis, less necessities to surgical treatment, 
lower mortality) (Carter et al., 2000). Comparing Imipenem and Meropenem, no differences 
in incidence of the septic complications were observed (Heinrich et al., 2006). Preventive 
antibiotics have to be administered during 7-14 days. Longer applications than 14 days is 
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not recommended (Olejník & Brychta, 2008). Regarding the different opinions on the 
antibiotics prophylaxis, it is necessary to take into account the extent of necrosis of the 
pancreas. If the damage is less than 30% of pancreas parenchyma, the risk of infection is 
small (Olejník & Brychta, 2008). Despite of all contra version, many, also prestigious 
workplaces, at present administer the antibiotics prophylaxis in the case of severe acute 
pancreatitis, bearing the risk of contra productive effect. We assigned our workplace to this 
group.  
In the cases of patients with severe acute pancreatitis, it is necessary from the beginning or 
during the treatment, in spite of the intensive conservative one, to consider the indication of 
the surgical treatment. During the initial phase after admission of patients with acute 
pancreatitis the situations appear, when in spite of the precise differential diagnostics (based 
on anamnesis, clinical examination, laboratory tests, ultrasound) these does not bring the 
clear breaking up and the indication of diagnostic exploration can be actual. Computer 
tomography examination can be very helpful in such situations and it can decrease these 
doubt to minimum. Despite of the risk of surgery, the published opinions say, that it is less 
probable, that the diagnostic exploration exacerbated local inflaming process, though it can 
increase the risk of infection of pancreatic necrosis. This risk should be reevaluated in 
situation, when there is no other alternative approach in treatment without surgical 
intervention (Dugernier et al., 2006).  
The indications for surgery which are also now discussed are the patients with sterile 
pancreatic necrosis and multi organ failure, which are non-responsible to the intensive 
treatment more than 72 hours. In the literature, there is a published opinion, that patients 
with high extent of pancreatic necrosis with persistent multi organ failure, in spite of 
maximum intensive care, can have a benefit from surgery. The clinical status has to be 
revaluated daily, because the right timing of surgical intervention is very important. 
Intensive care is suitable until the indications for surgical solution are not fulfilled 
(Götzinger et al., 2002). 
In our group of patients we indicated the surgical treatment for 7 patients in 7 days after 
admission to hospital. In this group of patients, we recorded 86% mortality (in Group A 
100%, in Group B 67%). Some authors recommend surgical intervention to the patients with 
sterile necrosis, whose status is not improved during four weeks of intensive care (Hartwig 
et al., 2002b).  
A right timing of necrosectomy is discussed up till now. Those, who propose an early 
surgery say, that patient benefits from the early removal of the tissue necrosis, as it results to 
the decreasing of the multisystem complications linked with the releasing of enzymes and 
toxic substations. In the past, an early surgical intervention was preferred especially in the 
cases of system functions damage, but it resulted to the high mortality (Götzinger, 2007). 
Götzinger study pointed at the fact that a benefit from the delay of the surgical intervention 
is in the enclosure of demarcation process of dead tissue. This demarcation enables the safe 
and sufficient following debridement, which leads to be successful surgical control of 
pancreatic necrosis in one or more steps. The analysis of the timing showed, that 
necrosectomy performed after three weeks from the beginning of illness is linked with 
higher percentage of success of debridement of pancreatic necrosis, what results to the lower 
number of reoperation and lower mortality. Very early debridement (up to three weeks) 
means an oversize percentage of mortality (Götzinger, 2007). 
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In rare situation, also intra-abdominal hypertension is an indication to decompressive 
laparotomy (Šiller et al., 2007). Intra-abdominal hypertension is caused by paralytic ileus, by 
large inflammation of retroperitoneal tissue, increased vascular permeability and also by 
liquid collections in abdominal cavity. It can be caused also by aggressive liquid hyper 
resuscitation (Dugernier et al., 2006). 
Intra-abdominal hypertension is typical at the beginning of illness and can lead to the intra-
abdominal compartment syndrome (the intra-abdominal pressure is higher than 20mmHg), 
which can make worth organ dysfunctions (Malbrain et al., 2006). 
At present some indications to surgical treatment are apparent and clear. The absolute 
indications to the urgent surgery are necrosis and pancreatic or peripancreatic abscess. 
Infected necrosis begins at 40-50% patients with necrotic acute pancreatitis (Hartwig et al., 
2002b). Infected necrosis means the necrotic area with bacterial contamination in devitalized 
tissue. Necrosis of pancreas and peripancreatic tissue is the risky environment for bacterial 
contamination. The risk of pancreatic infection grows with the volume of devitalized tissue. 
It culminated in the third week from the beginning of the illness. But 25% of patients have 
the infection during first 7 days (Dugernier et al., 2006). 
Although acute pancreatitis is at the beginning a sterile inflammatory disease, which leads 
to multi organ dysfunctional syndrome, so the clinical features are difficult to distinguish 
from severe sepsis. The confirmation of presence of infection is when gas bubbles are found 
on the computer tomography examination, also by the positive cultivation of specimen 
obtained from the necrosis by thin-needle technique. This technique is safe and 90% precise 
(Schmid et al., 1999). 
Bacterial translocation from intestinal lumen (transmurally, by lymphatic and vascular way, 
by ascites) is the main mechanism of the infection transfer to the necrosis during the first 
weeks of the disease. The microbiological examination shows that the origin of infection of 
pancreas is first of all the intestinal infections. Later sources are nosocomial infections of 
staphylococcus and enterococcus, including the multiresistant microorganism and mycotic 
infections (Büchler et al., 2000). At present, the accepted opinion is that necrosectomy has to 
be done as soon as the evidence of the infected necrosis is confirmed (Huťan, 2008).  
The approach of the surgical treatment of necrotic acute pancreatitis has been developed. 
Some of them are obsolete (resection methods), but various techniques of the necrosectomy 
of pancreatic and peripancreatic necrosis remain as dominant approach done by the classic 
open surgery, by laparoscopic retroperitoneal miniinvasive surgery or percutaneous 
necrosectomy. 
Additional techniques (after necrosectomy) are based on knowledge, that during surgical 
intervention it is not possible to remove all necrosis, because demarcation is not complete 
and too radical removal of this necrosis causes rather damage than benefit. On the other 
hand the rest of the necrosis can be a source of the persistent sepsis.  
From the range of additional techniques may be mentioned the conventional surgical 
drainage with closing of the abdominal cavity and with location of the gravity or suck tube 
drains, open abdomen techniques also called laparostomy and at last the closed continuous 
lavage. It is possible to combine to abovementioned additional techniques.  
Own experiences with all additional technique have been published already (Bober et al., 
2003). At present we use all of them, but we prefer the closed continuous lavage technique 
of bursa omentalis and retroperitoneum, as we published in 2003, accepting also results of 
comparative studies (Beger et al., 2002; Branum et al., 1998). 
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Delay of the necrosectomy to the third –fourth week of hospitalization with applying the 
closed continuous lavage we obtained very good results in number of postoperative local 
complications as well as in the need of reoperations and no mortality in this subgroup of 
patients. 
During last year’s many works were published about retroperitoneal necrosectomy (Connor 
et al., 2005; Van Santvoot et al., 2007) laparoscopic assisted percutaneous drainage of 
infected necrosis and peripancreatic abscess (Horvath et al., 2001), laparoscopic 
necrosectomy (Cushieri et al., 2002; Risse et al., 2004; Šutiak et al.,2008). Also other authors 
published the report about very positive results with percutaneous necrosectomy (Bruennler 
et al., 2008; Hartwig et al., 2002a). The benefit of percutaneous necrosectomy is mini invasive 
approach, which does not require total anesthesia, but the disadvantages are: longer time of 
hospitalization, higher doses of X-ray because of repetitive computer tomography controls 
and high percentage of cases, when patients had to perform of laparotomy due to the 
insufficiency of previous one.  
Pancreatic abscess contrary to the infected necrosis is well demarcated collection of purulent 
liquid without solid necrotic material. It is a result of infection, which arises from 
accumulation of liquid collections or from the area of necrosis, which has liquidized in the 
meantime. Comparing with the infected necrosis, the pancreatic abscess appears later (more 
than four weeks from the beginning of a disease) and the prolonged process is typical for it 
(Fernandez Del Castilo et al., 1998). If the pancreatic abscess contains small, solids particles, 
very often it is not suitable to drain it in percutaneous or endoscopic way (Baril et al., 2000; 
Carter et al., 2000). 
The other indication for surgery is the course of severe acute pancreatitis is bleeding. The 
intensive inflammation, large regional necrosis and secondary infection cause arouses of 
great vessels and cause a pseudoaneurysm, which rupture may cause massive hemorrhage 
to gastrointestinal tract, retroperitoneum or abdominal cavity. 
The early diagnosis and following intervention radiology and surgical treatment are 
necessary for bleeding control. Debridement of the infected necrosis is the effective 
management for minimizing the risk of recurrent bleeding. Fortunately, the incidence of the 
hemorrhagic complications of severe acute pancreatitis decreases due to early recognition 
and intensive treatment of these patients (Huťan, 2008).  
5. Conclusion 
Despite the mortality of severe acute pancreatitis decreased after the implementation of new 
diagnostic and medical procedures in last two decade, many questions are still open. Recent 
studies of severe acute pancreatitis were reviewed and the decision to change the 
management of the treatment of severe acute pancreatitis has been made. The management 
referred to the enteral nutrition, epidural analgesia, antibiotic prophylaxis, delay surgery to 
the later period (three-four weeks after onset) in the case of infected necrosis.  
Using enteral nutrition in preventing septic complications of acute pancreatitis seems to be 
better than parenteral nutrition. Epidural anesthesia is used to induce analgesia, to recovery 
of intestinal peristaltic and for improvement of the microcirculation blood flow. The 
continual measurement of the intra-abdominal pressure with the catheter in urinary bladder 
was used. After confirmation of necrosis, the prophylactic application of antibiotics 
including imipenem was used for severe acute pancreatitis patients. The prophylactic 
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application lasted maximum 14 days. By deferring surgery a proper demarcation of 
pancreatic and peripancreatic necrosis can take place. The demarcation of necrotic masses 
from viable tissue enables as easier and safer debridement with a great likelihood of sparing 
pancreatic tissue and leads to successful surgical control of pancreatic necrosis. 
Applying the change of the management of treatment of the patients with the complicated 
form of acute pancreatitis, there were found an interesting results, which could 
recommended to use this management for patients suffered from severe acute pancreatitis.  
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1. Introduction 
Pancreatitis is a common clinical entitiy with multiple contributing etiologies1. Triglyceride 
(TG) levels greater than 1000 mg/dL are seen in a small but significant number of cases of 
acute pancreatitis (AP), with estimates ranging between 1-7% of all cases and perhaps 
slightly higher in patients who present during pregnancy2-4. The clinical presentation of 
hypertriglyceridemic pancreatitis (HTGP) is similar to other causes of acute pancreatitis, but 
some evidence suggests that there may be an increased severity and risk of complications5,6. 
Multiple etiologies of highly elevated TG levels have been implicated, including congenital 
disorders, metabolic perturbations and certain medications but a definitive treatment 
regimen for profoundly elevated serum TG in association with acute, and often severe, 
pancreatitis has yet to be demonstrated7-10.  
Dietary restriction is the cornerstone of therapy. Additional treatment modalities have 
included insulin and heparin to stimulate the synthesis, release and activation of lipoprotein 
lipase (LPL) from capillary endothelial cells to promote TG degradation into free fatty acids 
for further metabolism or storage11. We present a case of HGTP managed with insulin, 
heparin and octreotide with dramatic results; a logarithmic decrease in serum TGL 
magnitude and a significant reduction in the time to resolution as compared with previous 
reports of treatment with insulin and heparin alone. Recent advances in the management of 
HGTP, including proposed mechanisms, will be reviewed. Adjunctive therapies, including 
plasmapheresis and more chronic therapy with lipid lowering agents and dietary 
modification will be discussed.  
2. Case report 
A 51-year-old Hispanic man presented to the emergency department with 2 days of 
epigastric pain radiating to the back. The patient reported one episode of emesis but denied 
fever, chills, dyspnea, diarrhea, or constipation. His past medical history was significant for 
asthma and gastroesophageal reflux disease. Medications included omeprazole daily and as 
needed acetaminophen, ibuprofen, and albuterol. Social history was significant for tobacco 
use, one pack per month, and ethanol use, two cans of beer daily. 
Temperature was 97.6F. Blood pressure was 117/72 mm Hg, heart rate 80 min, regular, and 
respiratory rate was 18/min. Examination of the cardiopulmonary and nervous system was 
unremarkable. The abdomen was diffusely tender without rebound, guarding or 
discoloration. No xanthelasmas, eruptions, arcus, or xanthomas were noted. Relevant 
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laboratory measurements from lipemic serum are listed in Table 1. The urine toxicology 
screen was positive for barbiturates. Cardiac screening (enzymes, electrocardiogram) was 
negative and ultrasound imaging revealed no abnormalities of the gall bladder, common 
bile duct, or pancreas. A CT scan performed on the second hospital day was remarkable for 
peripancreatic fat stranding without necrosis or hemorrhage. 
 
Analyte Reference Range Admission 24 h 48 h 
Amylase 25-125 U/L 80 126 141 
Lipase 23-203 U/L 179 166 96 
Glucose 74-118 mg/dL 100 83 93 
Triglycerides 30-190 mg/dL 20891 1423 355 
Cholesterol 60-160 mg/dL 862 997 594 
Sodium 136-144 mmol/L 111 121 140 
AST <40 IU/L 737 186 74 
ALT <33 IU/L 227 135 39 
Table 1. Laboratory Values at Presentation and While Hospitalized 
The patient was diagnosed with HTGP and initial management included elimination of 
enteral intake, aggressive fluid repletion, and opiate analgesia. Subsequent therapy included 
a continuous insulin infusion, a 10% dextrose infusion titrated to maintain euglycemia, 60 
U/kg unfractionated heparin intravenous (IV) bolus every 4 hours, and 100g octreotide 
bolus subcutaneously every 8 hours. TG fell by 2 orders of magnitude in 2 days, falling from 
21,000 to 355 mg/dL, the rest of the laboratory values were improved (Table 1), and the 
lipemia resolved. The clinical course was uncomplicated and the patient was discharged 
after 4 days.  
3. Clinical presentation of hypertriglyceridemic pancreatitis 
The clinical features of acute HTGP are similar to that of other causes of pancreatitis12. 
Patients may present with sudden and severe epigastric abdominal pain often accompanied 
by anorexia and profound nausea lasting hours to days13. Other less common findings, more 
indicative of chronic hyperlipidemia, include the presence of eruptive xanthomas over the 
extensor surfaces, lipemia retinalis, arcus and hepatospenomeglay due to fatty infiltration of 
the liver.14 Frequently, those presenting with significant TG elevations and pancreatitis have 
an underlying metabolic abnormality in lipid metabolism15,16. Patient presentations where 
HTGP is encountered include poorly controlled diabetics with or without a history of HTG, 
alcoholics with hypertriglyceridemia or lactescent serum on admission, non-diabetic, non-
obese patients with drug or diet-induced HTG and patients presenting with AP without 
secondary risk factors; the first three of these comprise the majority of clinical presentations 
of HTGP12,17,18.  
Following the onset of HTGP, TGL tend to fall rapidly over 72 hours in the fasting state as a 
result of decreased supply and absorption of chylomicrons19. In addition, VLDL secretion 
from the liver is reduced secondary to the administration of hypocaloric intravenous fluids, 
thus leading to a direct reduction in TGL20. 
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4. Lipid physiology 
Lipoproteins are macromolecules containing both organic proteins and bound lipids that are 
found in plasma in varying proportions and can be separated by density via 
ultracentrifugation. In increasing order of density, these separate into layers of 
chylomicrons, very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), 
low density proteins (LDL) and high density lipoprotein (HDL)21. 
 
 
Fig. 1. Fat metabolism 
http://www.britannica.com/bps/media-view/92255/0/0/0 
TG are a major lipid constituent of chylomicrons and VLDL. The former contains Apo B-48 
and is derived from dietary sources while the latter contains Apo B-100 and is liver 
generated22,23. Cholesterol is the primary component of IDL and LDL24. 
Dietary TG are absorbed through the brush border of intestinal enterocytes, incorporated 
into chylomicrons and pass through the basolateral aspect where they enter the lymphatics 
before entering the venous circulation via the thoracic duct, ultimately acquiring 
apolipoprotein C-II, a critical cofactor for lipoprotein lipase (LPL)25.  
 
Acute Pancreatitis 262 
Both chylomicrons and VLDL are transported to muscle and adipose tissue where they are 
metabolized by LPL to meet energy demands or stored for future use26,27. LPL is secreted 
into the venous circulation by parenchymal cells in many tissues, migrates through the 
vasculature and anchors to the capillary endothelium via a heparan sulfate chain. Upon 
activation, it facilitates lipoprotein binding and TG degradation28. This process results in the 
release of fatty acids and acylglycerols which can then be utilized directly by myocytes to 
meet metabolic demands or be reincorporated into triglyceride for storage in adipocytes29.  
5. Diagnosis and laboratory evaluation 
The clinical presentation and course of HTG pancreatitis does not differ greatly from other 
causes of AP30. Lipemic serum, frequently associated with an underlying metabolic 
abnormality or compromising medications, is the single most reliable clue that the 
pancreatitis is associated with or precipitated by hyperlipidemia31. Although the serum 
triglyceride threshold for considering HTGP is generally considered to be in the range of 
1000 mg/dL, the severity, clinical course and complication rate do not correlate with lipid 
levels. In a study of 43 patients with HTGP, no correlation was observed between admission 
HTG and APACHE II score, nor was there a relation between TG level and pancreatic 
inflammatory complications or ultimate patient outcome32.  
Historically, clinicians have relied on increases in levels of serum amylase, and/or lipase to 
secure the diagnosis of acute pancreatitis. Newer diagnostic modalities, such as urine 
trypsinogen, procarboxypeptidase A and carboxypeptidase A, are becoming more available 
and may become more relevant33-35. Some patients with HTG pancreatitis and lipemic serum 
present with spurious laboratory values that can complicate the diagnosis36 but a serum 
lipase sensitivity and specificity of 67% and 97% respectively, argue that this test remains a 
valuable diagnostic tool37. 
6. Pathophysiology of hypertriglyceridemic pancreatitis 
The mechanism by which elevated levels of plasma TG lead to the development of AP is not 
fully understood. It is generally accepted that levels greater than 1000 mg/dL are required to 
precipitate an episode of pancreatitis, but such levels of TG do not always cause HTGP.38 The 
most recent ATP III guidelines suggest that a normal TG level is considered to be less than 150 
mg/dl, while those greater than 500 mg/dl are considered very high39. Pancreatic lipase, a 
digestive enzyme concentrated in the exocrine pancreas which participates in TG degradation, 
may be liberated in AP and act in an unregulated fashion to contribute to tissue breakdown40. 
Additionally, if the local plasma TG level increases beyond the enzymatic capacity of the 
pancreas, free fatty acids begin to accumulate and can lead to injury of pancreatic acinar cells 
and surrounding tissues41,42. Altered pancreatic blood flow, perhaps aggravated by the 
hyperviscosity of chylomicronemia, may also create a more acidic environment in which free 
fatty acids become more toxic to the surrounding tissue43-46. The resultant cellular injury leads 
to further pancreatic inflammation, injury and destruction. 
7. Causes of hypertriglyceridemia 
Primary Causes: Primary causes of HTG consist of a series of genetic disorders leading to 
abnormalities in lipid metabolism and patients presenting with HTG or lipemic serum 
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should be evaluated for Frederickson classification dyslipidemias types I, IV and V as they 
are strongly associated with highly elevated serum TG47,48.  
Secondary Causes: 
Diabetes – Poorly controlled, or uncontrolled, diabetes is a common cause of HTGP49. In type 
1 diabetes mellitus, the paucity of insulin reduces LPL synthesis and thus compromises 
effective TG hydrolysis and release of free fatty acids. The latter are already accumulating in 
the absence of insulin-facilitated storage50,51. Similarly, in type 2 diabetes mellitus, increased 
insulin resistance leads to enhanced production and reduced clearance of TGs52. The causal 
role of diabetic ketoacidosis (DKA) in HTG was evaluated in a prospective study of 100 
patients with DKA, 11 of whom had AP, and of these, HTG was the only attributable cause 
in 4 cases53. Serum TG levels normalized in these patients after control of the acidosis.  
 
Primary HTG 
 Genetic: Frederickson type I, IV, V 
Secondary HTG 
  Diet: alcohol excess, weight gain/obesity 
  Drugs: exogenous estrogens, tamoxifen, retinoids, thiazides, beta blockers, protease 
inhibitors, propofol, parenteral lipid infusions 
  Disorders of Metabolism: Diabetes, pregnancy, chronic renal failure, hypothyroidism, 
porphyria 
*Adapted from Ref 12 
Table 2. Common Etiologies of HTG 
Alcohol – Ethanol compromises fuel and energy metabolism, thereby resulting in decreased 
serum glucose levels with elevated levels of lipids due to increased production and 
decreased utilization of energy sources. Alcohol can aggravate HTG and the liberated free 
fatty acid esters can promote calcium influx which leads to calcium-mediated pancreatic 
necrosis57. Nutritional deficiencies, including hypoglycemia, activated counterregulatory 
mechanisms and reduced cofactor availability reduce or inhibit insulin secretion, thus 
further compromising energy metabolism and exacerbating hyperlipidemia58. 
Medications- Several medications are known to increase plasma TG levels, including 
isotretinoin59, propofol60, protease inhibitors61 and furosemide62. Estrogens and Tamoxifen 
are two well studied drugs in which the tendency to promote HTG and steatohepatitis is 
well described63. 
Estrogen – Exogenous estrogens increase serum TG and fatty acids primarily by reducing 
levels of lipoprotein and hepatic lipases which subsequently decreases clearance and 
aggravates insulin resistance, perhaps by as much as 40%64-66. Goldenberg et al., evaluated 
56 female patients at a Cholesterol Center because of TG >400 mg/dl and/or HTGP, and/or 
failure of TG-lowering therapy. Of that cohort, 17 females (30%) had a history of AP and of 
those, 9 (53%) had taken, or were concurrently taking exogenous steroid hormones67. The 
authors concluded that hormone therapy remain relatively contraindicated with plasma 
TG>300mg/dl and strictly contraindicated when TG greater than >500 mg/dl in order to 
avoid an episode of pancreatitis.  
Tamoxifen – Tamoxifen is a non-steroidal anti-estrogen commonly used in the treatment of 
patients with breast cancer and has shown the ability to decrease LDL and total cholesterol 
levels. There is frequently an increase in VLDL synthesis and subsequent rise in plasma TG 
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levels due to reductions in lipoprotein lipase activity68,69. Elisaf, et al., reported 12 patients 
with serum TG >1000 mg/dl who were observed after administration of 20mg/day of 
tamoxifen70. Four of these patients, two of whom had a personal or family history of 
hyperlipidemia, developed HTGP. This led them to the conclusion that, like synthetic 
estrogens, the tamoxifen-mediated rise in TGs may be either contributory or causative in the 
development of AP.  
Pregnancy – Gestational AP is an uncommon condition, with studies ranging incidence 
between 1 in 3,500-4,000 pregnancies71. Most cases of AP during pregnancy are mild and are 
most often attributable to biliary disease, while severe AP most commonly results from 
hypertriglyceridemia and tends to occur in the second and third trimesters72. During 
pregnancy there is a physiologic increase in plasma lipids. Cholesterol and TG increase due 
to an increased production of VLDL and the decreased actions of LPL and hepatic lipase73.  
HTGP tends to develop in women with an underlying disorder in lipid metabolism, such as 
LPL74 or apolipoprotein C-II deficiency75. Maternal mortality in cases complicated by HGTP 
is estimated to be near 20% and cause of death has been linked to the pancreatitis itself, or, 
rarely, has been associated with HELLP syndrome.76 The mainstay of treatment, as in the 
non-pregnant state, is early recognition and intervention77,78. A major difference in long term 
management is that the use of HMG-CoA reductase inhibitors (statins) is contraindicated in 
pregnancy as they are a teratogenic category X pharmaceutical79.  
 
 Type I Type IV Type V 
Elevated lipoproteins Chylomicrons VLDL VLDL 
Chylomicrons 
Cholesterol Normal Normal or Increased Normal 
Triglycerides +++ ++ +++ 
Plasma appearance † Clear plasma, creamy 
supernatant 
Turbid Turbid plasma, creamy 
supernatant 
Genotype LPL deficiency 
Apo C-II deficiency 
FCH 
Sporadic HTG 
Familial HTG 
Age of onset (primary 
form) 
Infancy or childhood Usually adulthood Usually adulthood 
Xanthomas ‡ Eruptive or tuberous None usually Eruptive or tuberoeruptive 
Other clinical features Recurrent abdominal pain 
Pancreatitis 
Lipemia retinalis 
Hepatosplenomegaly 
Premature CAD 
Pancreatitis 
Obesity 
Glucose intolerance 
Arthritic symptoms 
Gall bladder disease 
Hyperuricemia 
Recurrent abdominal pain 
Pancreatitis 
Lipemia retinalis 
Hepatosplenomegaly 
Peripheral paresthesis 
Glucose intolerance 
Hyperuricemia 
*Adapted from Reference 12 
† Plasma obtained after 12 hours of fasting, left undisturbed in refrigerator overnight 
‡Seen only in a minority of patients, frequency increases as plasma lipid levels rise 
LPL, lipoprotein lipase; HTG, hypertriglyceridemia; Apo C-II, apolipoprotein CII; CAD, coronary 
artery disease; FCH, familial combined hyperlipidemia.  
Table 3. Familial Hyperlipidemias* 
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Hypothyroidism – HTG is common in hypothyroidism, having been reported in up to 35% of 
cases80. Decreased free thyroid hormone increases the synthesis of LPL and decreases 
hepatic lipase activity with a net tendency toward increased plasma TG levels, perhaps 
further complicated by the down-regulation of LDL receptors81-84. One patient with central 
hypothyroidism secondary to a craniopharyngioma developed HTG with a level of (3,300 
mg/dL) which precipitated an episode of AP85. 
8. Treatment 
Initial Management – Initial management of patients presenting with HTGP mirrors that of 
other causes of AP86. Patients should be placed on bowel rest, receive nothing by mouth and 
undergo aggressive fluid resuscitation due to third space losses87. Adequate pain control is 
essential, often through the use of opioid narcotics88-90. Some controversy still remains about 
the potential for medication-induced sphincter of Oddi dysfunction aggravating the clinical 
picture although low dose transdermal fentanyl patches appear do not to compromise 
sphincteric function91,92. Meperidine has been used as an alternative analgesic to treat pain in 
those suffering from acute pancreatitis, but concern for the production of toxic metabolites has 
altered prescribing practices93-95. Enteral nutrition should be resumed as soon as is practical, 
recognizing that the reintroduction of fats, the building blocks of chylomicrons, may be 
deleterious96-100. Assessment of exocrine function prior to refeeding may be prudent, given that 
pancreatic destruction has the potential to compromise secretion of digestive enzymes101. 
Beyond initial management, HTGP therapy must include measures to reduce serum TG, 
both acutely and following the episode to minimize the risk of recurrence102. Laboratory 
tests including liver function tests, glucose, renal function, thyroid stimulating hormone and 
urine protein should be obtained to rule out secondary causes of HTG103. Specific tests 
documenting LPL or Apo C-II deficiency should be obtained if type I hyperlipidemia is 
suspected104-107. No standard treatment guidelines yet exist in the specific treatment of 
HTGP although a rational treatment strategy should include rapidly lowering serum TG, 
blocking the induction of pro-inflammatory mediators that lead to pancreatic destruction 
and reducing the likelihood of recurrence by eliminating offending agents, as is possible, 
and through the use of antihyperlipidemic medications108-111.  
Insulin – Intravenous insulin administration is an effective therapy for patients diagnosed 
with HTG induced pancreatitis, including those with and without diabetes mellitus112,113. 
VLDL is a triglyceride-rich lipid moiety and the use of insulin decreases hepatic production 
of apolipoprotein B-100 rich VLDL1 and intestinal production of VLDL2, rich in apoprotein 
B-48 while also increasing hydrolysis of TG by LPL114,115. Insulin promotes storage of both 
glucose and fatty acids, thus a continuous infusion of insulin should reduce serum levels of 
both of these fuels116,117. Intravenous (IV) insulin may be considered more effective and 
easier to titrate than subcutaneous (SQ) administration based upon absorption and delivery 
kinetics, although both have been used with some success104,118,119. Insulin has been used 
alone, but is commonly used in conjunction with other TG lowering modalities120,121. 
Mikhail et al. reported lowering TG from 7,700 mg/dL to 246 mg/dL in one patient using 
only intravenous insulin at 3-9 units per hour for 4 days while maintaining euglycemia122. In 
the same report, a second patient treated in a similar fashion saw TG levels drop from 10,500 
mg/dL to 656 mg/dL over 4 days using 4 units SQ insulin (Lispro) every four hours.  
Although no standard protocol for insulin administration in the context of HTGP has been 
defined, the authors have achieved success with insulin doses titrated from an initial rate of 
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0.1-0.4 units/kg per hour. Once an effective insulin infusion dose has been achieved, we 
have kept this constant while the dextrose infusion is titrated to maintain euglycemia, 
contrary to what is usually done when insulin is infused. 
Heparin – Heparin is an effective treatment in the management of elevated TG in the 
presence of HTGP123. LPL, the enzyme which hydrolyzes TG rich lipoproteins, is normally 
bound by a heparan sulfate proteoglycan chain to the capillary endothelium124. Heparin, 
when administered in a bolus dose, has a stronger affinity for the LPL binding site than does 
the heparan sulfate, leading it to dissociate from the endothelium tissue into the plasma as a 
heparan-LPL complex.125 This surge of “free” LPL is then able to bind and metabolize 
lipoproteins at an accelerated rate, thus lowering serum TG levels126. Although there is an 
initial rise in available LPL, there is also a peaking of activity, after which, LPL activity 
begins to wane as the enzyme is transported and degraded in the liver127. This heparin-
stimulated increase and then reduction in LPL activity can be minimized by the use of 
intermittent heparin dosing and results in an initial drop in serum TGs, but then followed 
by a gradual increase128,129. This phenomenon tends to be more pronounced with the use of 
LMW heparin, versus un-fractionated heparin, although studies have shown both 
preparations capable of lowering severely elevated TG in the setting of HTGP.130  
Heparin has been used as successful monotherapy in treatment of profound HTG in 
previous studies131-133; however, more dramatic results have been achieved when used in 
combination with other modalities (Table 4). At present, no studies have been conducted as 
to the best route of administration (IV or SQ) or dosage in the treatment of HTGP. It is the 
opinion of the authors that bolus dosing of IV heparin 18 units/kg134 dosed every 4-6 hours 
is more effective than continuous administration.  
 
Patient Trig Level 
(mg/dL) at 
Admission 
IV Insulin U/h: IV Heparin Units;  
SC Octreotide g 
Triglyceride 
Results 
41-year-old 
female ETOH 
abuse 
7037 Insulin 1-5 U/h for 5d; heparin 500-
900 U/h for 3d 
5111 mg/dL 
by day 3 
51-year-old male 
ETOH abuse 
7900 Insulin 12 U/h; heparin 5000 U b.i.d 670 mg/dL by 
day 4 
31-year-old 
female at 30 wk 
gestation 
4445 Insulin 20 U/h; heparin 10,000 U/24h 880 mg/dL by 
day 3 
51-year-old* 
ETOH abuse 
21,000 Insulin 2 U/h minimum; heparin 60 
U/kg every 4h; octreotide 100 g 
subcutaneously every 8 h 
355 mg/dL in 
48 hr 
*Our patient. 
Adapted from Ref 122 
Table 4. Published Reports of Management of Hypertriglyceridemia With IV Insulin and 
Heparin: Comparison to Case Patient 
Octreotide™ – Somatostatins, also called somatotropin release inhibitory factors (SRIFs) are 
cyclic peptide hormones which exist in 2 forms, SRIF14 (14 amino acids) and SRIF28 (28 
amino acids)135, and are synthesized in several sites within the body, including the central 
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nervous system, pituitary, gastrointestinal (GI) tract, liver, pancreas, and urogenital 
system135,136. SRIFs bind to 6 subpopulations of somatostatin receptors (sstrs) (1, 2A, 2B, 3, 4, 
5) located both peripherally and centrally137. The sstr 2B receptor has been demonstrated in 
rodents but not unequivocally in humans138. Binding of somatostatins to each of these 
receptors leads to the inhibition of adenylate cyclase via a pertussis toxin sensitive G-
protein(Gαi) and, at agonist concentrations greater than 1-nM, there is stimulation of 
phospholipase C which increases calcium ion mobilization139. In neuroendocrine cells, sstrs 
2,3,4 and 5 bind to inward rectifying potassium channels140. 
SRIFs inhibit the secretion of several GI tract hormones including insulin, glucagon, gastrin, 
cholecystokinin, vasoactive intestinal peptide and secretin and also inhibit exocrine gastric 
acid, pepsin, pancreatic enzymes, bile and intestinal fluid secretions 141. The pancreas 
expresses sstrs on both acinar cells (sstr4, sstr5)142 and islet cells (sstr1 > sstr5 > sstr2 > sstr3 
> sstr4)143. In rodents, sstr2 in the dorsal vagal complex exerts some control of pancreatic 
exocrine secretion144.  
Octreotide, a somatostatin analog, has particular affinity for types 2A, 2B and somewhat for 
sstr5145. Octreotide has been used in the treatment of pancreatitis with varying degrees of 
success146. The evidence that pancreatic sstrs are down-regulated in acute pancreatitis 
suggests that the mechanisms of action of octreotide therapy may include both receptor and 
non-receptor mediated mechanisms147. Secretion of insulin and glucagon are inhibited by 
agonists of sstr2, sstr5, and sstr1148. Inhibition of glucagon secretion with octreotide therapy 
may potentiate the fatty acid storing action of insulin and lead to a greater reduction of 
serum TG149. Octreotide’s effect on the hypoglycemic counter regulatory system, notably the 
hyperglycemic actions of glucagon, necessitates the co-administration of dextrose and 
frequent monitoring of glucose levels to maintain euglycemia.  
 
Study No. of patients No. of patients with complete recovery (%) Mortality (%) 
Yeh et al. 17 13(76.5) 2 (11.8) 
Kyriakidis et al. 10 9 (90) 1 (10) 
Kadikoylu et al. 7 7 (100) 0 
Lennertz et al. 5 5 (100) 0 
* Adapated from Ref 5 
Table 5. Apheresis in hypertriglyceridemic pancreatitis * 
Plasmapheresis – Although the primary methods of treating HTGP are dietary fat restriction 
and lipid lowering medications, these treatments may be inadequate in the setting of severe 
acute HTGP150,151. Plasmapheresis has been used with some measure of success and is 
thought to work through two mechanisms: the removal of serum TG from the patient’s 
serum and the supplementation of LPL and apolipoprotein found in the fresh frozen plasma 
of the donor plasma152,153. Yeh, et. al found that a single exchange removed 66.3% of TG, 
while a second exchange removed 83.3% of serum TG154. The number of sessions, however, 
did not correlate with clinical outcome. Syed et al., evaluated patients with HTGP receiving 
plasmapheresis and observed an average reduction in TG levels of 89.3% with the first 
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treatment, but found no clear relationship between APACHE II scores or length of hospital 
stay155. 
Plasmapheresis is not without risk, and at this time its use in HTGP remains undefined. 
Potential complications or adverse reactions include allergic reaction and transfusion related 
infections. One patient undergoing plasmapheresis was reported to develop anaphylactoid 
shock154,156. At present the American Society for Apheresis Guidelines of 2007 places apheresis 
in its role for HTGP as a category three due to limited data and conflicting reports157.  
Apheresis Recommendations* 
Category Recommendation 
I First line therapy 
II Second line therapy 
III Specific role not determined 
IV Not recommended 
*Journal of Clinical Apheresis, Special Issue(Vol 25, 2010) 
9. Long-term management 
Diet and General Precautions –Primary causes of hyperlipidemia often require medications 
but, where possible, reducing the impact of secondary causes with therapeutic lifestyle 
changes such as reducing alcohol intake, weight reduction, improved diabetic control and 
discontinuing precipitating medications are all vital steps158. Dietary advice should be 
obtained through a certified nutritionist, but fat consumption should be reduced to 7% of 
total caloric intake, cholesterol limited to 200mg and trans fatty acid intake should be 
limited159. Medium chain TG are an improved source of fat calories as they are absorbed 
directly into portal circulation and do not require chylomicrons for hepatic uptake and 
lower TG levels at the cost of a slightly elevated cholesterol level160. A meta-analysis 
performed by Dattilo and Kris-Etherson observed a strong correlation between weight loss 
and decrease in plasma TG levels.161  
Medications: 
Fibrates - Fibric acid derivatives are a class of medications which bind to peroxisome 
proliferator alpha (PPARα) receptors and are capable of increasing serum HDL while 
simultaneously lowering TG and are an effective adjunct in treating patients with HTGP 
who cannot be managed with diet alone162. They are typically used in treating primary HTG 
and include drugs such as gemfibrozil, bezafibrate and fenofibrate163. Fibrates lower serum 
TG by increasing the levels of LPL and hepatic lipase, reducing levels of Apo CIII, which 
down-regulates LPL activity, and by increasing fatty acid uptake by the liver164,165. Toxicities 
include elevated liver enzyme levels, cholelithithiasis, myalgias and rhabdomyolysis; the 
last two of these are more common when used in patients with impaired renal function166. 
Two cases have been reported where patients developed pancreatitis while taking fibrate or 
fibrate-statin combinations.167, 168 It is unclear whether the cause of the pancreatitis was 
directly related to the drug itself, a failure of treatment or possibly through the formation of 
biliary sludge or gallstone formation.  
Niacin – Niacin, a B vitamin somewhat less potent than the fibric acids, decreases TG levels 
by reducing hepatic secretion of VLDL and TG while raising HDL and lowering LDL levels, 
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an overall positive impact on the lipid profile169. When used as doses of 1,500mg/day, no 
adverse impact on glucose metabolism is seen but significant prostaglandin D2-mediated 
flushing limits the clinical utility of this drug170.  
Statins – HMG-CoA reductase inhibitors (statins) are not the preferred method for lowering 
serum TG as their role in lipid management remains in prevention (primary and secondary) 
of coronary artery disease in the presence of elevated cholesterol, but only mild to moderate 
triglyceride elevations171. Statins are not suitable monotherapy for long-term management of 
HTG, however, they may have some synergistic benefit when combined with fibrates172,173. 
Omega 3 Fatty Acids – Fish oils and omega-3 fatty acids are effective adjuncts to other drug 
therapy as they lead other drug therapy as they lead to a decrease in VLDL and lower 
endogenously derived TG-rich lipoproteins174,175. Active TG lowering molecules in these 
supplements include eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)176. 
Omega-3 fatty acids were studied in a prospective, double-blinded trial and were able to 
lower TG levels, ranging from 500-2,000 mg/dL, by an average of 45%177. The minimum 
effective dose is approximately 1 g/d; however, a dose of 3 to 4 g/d has shown to reduce 
serum TG by 30-50% in hyperlipidemic patients178.  
10. Conclusion  
HTG is a significant cause of AP, with most estimates ranging from 1-7% of all cases. 
Presentation is often similar to other forms of AP, with lipemic serum usually the only 
distinguishing initial sign. Clinicians should routinely test TG levels in patients with 
suspected or confirmed AP, especially those who have a history of diabetes, alcoholism, 
obesity, are taking a known precipitating medication, are pregnant or display normal 
amylase in the presence of elevated lipase.  
To date, there are no official guidelines for the treatment of HTGP, although a number of 
different treatment modalities have been employed to rapidly lower the serum TG, 
including insulin, heparin, fibric acids and omega 3 fatty acids. Plasmapheresis can also 
rapidly lower serum TG levels, but significant potential side effects and lack of rigorous 
proof of efficacy have yet to clarify its role in treatment of HTGP. Long term management 
with diet modification and anti-hyperlipidemic medications such as statins, niacin and 
omega-3 fatty acids are excellent adjuncts in controlling TGs in patients with HTGP and 
preventing potential recurrences.  
We have achieved dramatic effects with the combination of insulin, heparin and octreotide, 
a reduction in TG levels of two orders of magnitude in 48 hours, results unprecedented in 
the literature. These results, while impressive, have yet to be reproduced and one must 
remain appropriately circumspect when interpreting this case report. It is also important to 
note that the positive barbiturate level may have unmasked an inducible porphyria and that 
rapid resolution of HTGP was aided by the removal of this compound from the metabolic 
milieu. No clear treatment algorithm exists for the management of HTGP and well-
designed, controlled, prospective studies are needed to clearly delineate the ideal regimen. 
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1. Introduction 
According to the Atlanta Classification in many cases of acute pancreatitis there are three 
well-defined fluid collections: acute peripancreatic fluid collection (APFC), the so-called 
postnecrotic pancreatic/peripancreatic fluid collection which develops in the region of 
liquified pancreatic necrosis, and the pseudocyst that develops in the late phase of the 
illness. 
In many cases, these anatomic entities can be succesfully treated with radiological 
interventional methods. 
It is difficult to correctly interpret the articles that review the treatment of numerous patients 
because the nomenclature is unclear. The aim of this article is to analyse the indications, 
limits and results of the listed complications treated by percutaneous drainage (PD) which 
aggravate acute pancreatitis on the basis of the literature. 
2. What to drain? 
2.1 Acute peripancreatic fluid collection (APFC) 
According to the Atlanta Classification peripancreatic fluid collection develops in the early 
phase of acute pancreatitis in about 40% of cases. The acute fluid collection usually develops 
around the pancreas but sometimes emerges in the glandular area and does not contain a 
high quantity of necrosis. Not rarely, it spreads into the chest, mediastinum and/or into the 
pararenal area. Several fluid collections can develop at the same time and can shuttle 
together. The rich pancreatic enzyme content of the fluid can indicate communication with 
the pancreatic duct or indicate parenchymal necrosis. They do not have definite walls, and 
are limited by the walls of the surrounding organs. In a significant number of cases (about 
30-50%), spontaneous resolution occurs without surgical or other intervention. If they do not 
show tendency towards resolution, they can become of significant size and cause clinical 
symptoms or complications [5,6,33,44]. 
The most frequent complaints caused by a big, 8-15 cm size acute fluid collection are pain, 
tension, and increasing abdominal pressure which can significantly worsen the efficiency of 
breathing [1,9]. In other cases they can cause compression symptoms (jaundice, duodenal 
obstruction) or bleeding can develop inside of them. Another frequent complication is the 
 
Acute Pancreatitis 
 
280 
superinfection of the fluid that can be confirmed by fine needle aspiration (FNA) 
[1,2,11,19,25,33,37,40,44]. 
The APFC can be visualized by CT scan or ultrasound examination as well. The number of 
acute fluid collections correlate to the severity of the pancreatitis, the length of 
hospitalization and mortality [19]. 
Even today the treatment of acute peripancreatic fluid collections is not totally clear. In a 
small sized fluid collection, conservative treatment (naso-jejunal feeding, the resting of 
pancreas) is usually effective. Fluid evacuation is advisable when it causes severe 
symptoms. In the past only surgical intervention was available. The authors do not 
recommend surgical treatment in the early phase of the illness because of the high morbidity 
and mortality rates. With the development of interventional radiology and manipulative 
laparo-endoscopy there are other possibilities to evacuate these fluid collections without 
operation [1,6,11,14,21,25,35,40,44]. 
For the treatment of sterile fluid collection percutaneous puncture and drainage are widely 
applied. It is disputed whether repeated punctures or drainage is the most suitable for the 
treatment of fluid collections. There are some who are satisfied with the clearing of the fluid 
collection with only one or repeated punctures in sterile cases. However, this is succesful 
only in a few cases and drainage or surgical intervention follows [6,28,40,44]. 
According to those who are pro drainage in the treatment of sterile acute peripancreatic 
fluid collections, drainage can be applied effectively [1,3,4,14,21,25,34,35,40,44]. Acute 
compartment syndrome caused by massive acute peripancreatic fliud collection can be 
treated effectively with PD [9]. In the randomized controlled trial of Zerem et al. they 
commit themselves to drainage treatment [44]. 
Those who are against drainage treatment claim that it is the treatment itself which causes 
the dreadful complication, the infection of the fluid. According to the literature the rate of 
iatrogenous infection is about 8-27% [12,25,28,40]. Walser, Zerem et al. report a very high, 
50% rate of infection which is, in our opinion, the result of the irrigation 2-3 times a day 
[40,44]. To determine the correct rate of iatregenous infections treated without drainage or 
puncture a prospective randomized trial should be performed which is not available at this 
time. 
With regard to the management of infected acute peripancreatic fluid collections, views are 
not as varied in these cases: percutaneous drainage is suggested [1,5,8,18,21,22,25,33,34]. 
Surgery can often be avoided by drainage treatment, and in other cases the intervention is 
suitable for delaying operative treatment. In such cases, when drainage is not effective, 
operation is suggested [5,6,8,18,21,22,25,34,35,44]. 
2.2 Post-necrotic Pancreatic Fluid Collection (PNPFC), Walled-off Pancreatic Necrosis 
(WOPN) 
Necrosis can liquify and can be accompanied by the development of different sizes of fluid 
collections. These cases are equivalent to the pathological entity accepted in the modified 
Atlanta Classification as postnecrotic peripancreatic/pancreatic fluid collection and walled-
off pancreatic necrosis. WOPN can be misdiagnosed by contrast-enhanced CT for 
pseudocyst but MRI, abdominal or endoscopic ultrasound can help with differential 
diagnosis for these are suitable for proving the significant quantity of necrosis in the fluid. 
This differentiation is very important because treatment, especially the minimally invasive 
one, is different because in cases of WOPN the necrotized tissues should be removed. 
PNPFC cases can be sterile and infected as well [5,12,18,22,24,33,34,43].  
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In cases of PNFC puncture and/or drainage is usually not enough, the evacuation of 
necrotic tissues are also necessary and for this reason some authors are explicitely against 
drainage treatment [3,6,22]. According to other authors the evacuation of necrosis and fluid 
collection is possible with the help of irrigation through 14-30 F bore drains. Necrosectomy 
can be performed by using dormia basket. For such treatment more catheters should be 
placed in the cavity [5,10,11,12,18,21,26,29,33,36,38,43]. Bruennel et al. did not find a relation 
between the thickness, or the number of the drains and the effectiveness. With so-called 
’sinus tract endoscopy’ necrectomy can be performed effectively following the dilatation of 
the drain’s channel [23,36,43]. Horvath et al. performed necrosectomy via the channels of the 
drains with a supplementary incision using laparoscopy [16,17]. 
More than 20% of the patients treated with the minimal invasive method recovered without 
operation. An alternative method for the treatment of WOPN is the endoscopic transmural 
necrosectomy and drainage [13,15,27,30,31,41]. Necrosectomy during operation is the 
suitable method in cases of unsuccessfully treated patients [3,6,10,11,12,22,24,26,28, 
33,34,36,43]. 
2.3 Acute pseudocyst 
The acute pseudocyst appears on CT scan as a walled, oval or circle shaped fluid. It often 
develops in the area of an earlier acute fluid collection which did not show any tendency to 
resolution. The frequency of this is about 30-50%. The wall of the pseudocyst contains 
inflammatory tissues but is not covered by epithelium. It develops most frequently in the 
environment of the pancreas but mediastinal or pelvic appearances are also known. About 4 
weeks are needed for the development of the mutation from the beginning of the disease. Its 
content is usually sterile but sometimes bacteria can be detected without any clinical 
manifestation, in other cases it contains pus [5]. 
Almost 50% of acute pseudocysts do not cause any clinical symptoms and show 
spontaneous absorbing susceptibility. Especially smaller pseudocysts that are not bigger 
than 4-6 cm, recover with conservative treatment (eg: naso-jejunal feeding) [18,33,37]. Bigger 
pseudocysts can cause explicit clinical complaints. Compressive symptoms and pain are the 
most frequent among them. As a complication the content can become infected. Air bubbles 
can be seen in it on CT examination. In its cavity pseudoaneurysm can develop which can 
cause fatal bleeding [2,6,11,14,28,33,37]. 
In those cases where compressive or respiratory complications or pain develop, surgery or 
less burdensome percutaneous drainage gives an opportunity for treatment, allowing for 
the descent of the fluid as well as its bacterological examination [3,4,6,8,11,18,24,33,35]. More 
drains can be placed in cases of multiple pseudocysts [11,18,35] 
Operation can be avoided in cases treated this way and drainage can lead to complete 
recovery, in other cases it is suitable for delaying the time of operation [3,4,6,8,11,18,37,43]. 
In those cases where the cyst cavity communicates with the Wirsung ductal system, external 
drainage is not effective. For this reason, the anatomical conditions of the pseudocyst must 
be cleared by ERCP prior to external drainage [18]. In cases when communication is 
detected between the pancreatic duct and the necroma as a well accepted method internal 
endoscopic transluminal drainage (NOTES) and lavage, with endoscopic necrosectomy is 
indicated [13,30]. 
The infected pseudocyst appears as a pancreatic abscess in the late phase of severe acute 
pancreatitis, at least 4 weeks after the beginning of the disease and needs radiologic 
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intervention or surgery in each case. It does not contain a considerable quantity of necrotic 
tissue mass in opposition to the infected liquified necrosis (Post-necrotic Pancreatic Fluid 
Collection, Walled-off Pancreatic Necrosis). On CT scan gas bubbles can be observed 
[1,2,5,6,18,20,29,37,43]. 
Surgery in these cases involves a lower rate of morbidity and mortality than those 
performed in the early phase of pancreatitis. The results are good [20,37]. Percutaneous 
drainage treatment can be applied in cases of pancreatic abscess with good results and it can 
be suggested as the first intervention [4,5,6,8,18,20,29,33,37,38,43]. Drainage can be also 
applied in cases of numerous abscesses. It is important to carry out bacterological analysis 
from each abscess one by one because different types of bacteria can be cultured from them. 
The management must be supplemented with antibiotics [1,4,5,18,20,26]. 
PD has an effectiveness of 31-94% in the treatment of pancreatic abscesses [1,4,5, 
8,18,20,26,33,37,43]. 
3. How to drain? 
For drainage a pig-tail catheter is well accepted. The insertion of the drain can be guided by 
CT or ultrasound and fluoroscopy or without it [5,6,8,10,11,12,18,21,28,32,39,42,44]. The 
catheter with the main wire is led into the fluid collection and following verification of its 
placement the wire is removed (Figure 1-2). The indication of the location and function is 
that a proper quantity of fluid appears. Depending on the quality of the fluid, different size 
of drains should be used. If there is an abscess, the thicker (14-30F), otherwise the thinner (8-
10F), pig-tail catheter is to be used [1,6,8,10,11,12,21,32,36,39]. The drained fluid shlould be 
sent for bacterological analysis in each case. More drains can be inserted at a time if 
necessary [5,8,10,11,12,18,21,32,33,35,39,42,44]. 
The drain is usually placed without active suction. The daily quantity and quality of the 
fluid must be measured and examined. If the sterile fluid becomes thickened or purulent, it 
signifies bacterial infection. If pus appears or the fluid is dense, the irrigation of the cavity is 
also possible [1,10,11,21,42,44]. 
Ultrasound examination is the most suitable for the observation of the size of the fluid 
collection. It is also inexpensive and can also be performed bedside (Figure 3). The cavity 
filled with contrast material can be well demonstrated and is apt for showing fistulae 
[1,6,10,11,42,44]. 
The drain can be removed if the fluid has cleared up, has become „sterile”, the quantity of 
the drained fluid is less than 10-30 ml per day and the cavity has deflated on imaging 
examinations [1,6,10,12,44]. 
More than 20% of patients (20-50%) recover without surgery, by drainage treatment. If the 
drained cavity does not decrease during drainage or the septic state does not show a 
tendency towards resolution, surgical treatment is indicated. In such cases with the 
application of drainage early operation can be avoided [1,4,6,8,10,11,12,21,26,32,35,39,42]. 
Others suggest transluminal endoscopic (NOTES) procedure if percuteanous drainage is 
failed [7,13,15,27,30,31,41] Some authors suggest the combination of external and internal 
drainage with endoscpopic necrosectomy [27,30,]. 
Complications related to percutaneous drainage are rare. In an experienced hand the rate of 
iatrogenic injuries are negligible, less than 2%, generally the injury of the surrounding 
organs, bleeding can be noticed [1,4,11,12,21,32,35,39,44,]. Sometimes the drain can get 
clogged or slip out, then its replacement is required [8,35,42,44]. 
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Fig. 1. Percutaneous CT guided puncture of acute peripancreatic fluid collection  
A late complication of PD is the development of pancreatic fistulae, which may be in 
relation with the skin or gastrointestinal tract and most close spontaneously. The facts that 
influence the effectiveness of PD of infected fluid collections positively are the presence of a 
single fluid collection, the lack of necrosis, the low APACHE-II and Ransome points and the 
lack of failure [8,35,42,44].  
In this chapter the authors suggest reviewing the transmural endoscopic (NOTES) 
necrosectomy as a minimal invasive method. More and more authors in selected patients 
use this method for necrosectomy with a successful rate of 73-92% [2,7,13,15,27,30,31,41]. 
The necrotic cavity can be drained to the stomach or the duodenum. The effectiveness of this 
method can be enhanced with the use of endoscopic ultrasound (ES) [7,13,15,27,30,31,41]. 
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After dilating the puncture chanel to 8-20 mm the necrectomy can be performed with the 
use of baskets, snares, transparent scope caps, nets and/or water jet [7,13,27,30,31,41]. This 
procedure must be repeated till the complete emptying of the necroma [7,13,27,30,31]. After 
the necrectomy it is essential to drain the cavity with pigtail catheters, or stents [13,41]. The 
endoscopic drainage of WOPN decreases the length of hospitalization, the duration of 
external drainage, the number of CT scans [15]. This method is a possible therapy before or 
instead of surgery [2,7,13,27,30,31,41].  
 
 
 
 
Fig. 2. Percutaneous CT-guided drainage of acute peripancreatic fluid collection  
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Fig. 3. Ultrasound wiew of drainaged acute peripancreatic fluid collection 
In conclusion percutaneous drainage plays an important role in the treatment of 
concomitant sterile ad septic fluid collections (APFC, PNPFC, WOPN, acute pseudocyst) in 
severe acute pancreatitis. In well selected cases percutaneous drainage with appropriate 
caliber drains and supplementary therapy in the greater part of cases leads to complete 
recovery. In other cases PD is useful to delay surgery or to avoid early operation. 
4. Abbreviations 
APFC: Acute Peripancreatic Fluid Collection 
PD: Percutaneous Drainage  
FNA: Fine Needle Aspiration 
CT: Computed Tomography 
PNPFC: Post-necrotic Pancreatic Fluid Collection 
WOPN: Walled-off Pancreatic Necrosis 
MRI: Magnetic Resonance Image 
ERCP: Endoscopic Retrograde Cholangio-Panreatographia 
ES: Endoscopic Ultrasound 
NOTES: Natural Orifice Transluminal Endoscopic Surgery 
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